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Abstract
Regenerative Medicine is an emerging biomedical paradigm promising to radically 
change healthcare. For this to happen, basic science breakthroughs must be translated 
into the clinical setting and market. This thesis examines the evolving Regenerative 
Medicine Translation process from the perspective o f UK-based bioentrepreneurs. 
While much is known about the views of scientists, clinicians and industry 
stakeholders, an understanding of what it is to be an RM entrepreneur and company 
founder and often drive the whole process has not been fully explored.
Based on interviews with bioentrepreneurs and other secondary sources this thesis 
explores three main ‘areas’ of the Regenerative Medicine Translation process: Funding, 
Regulation, and cross-disciplinary Collaboration. A variety o f conceptual tools and 
social science analytical motifs are employed to explore the broad range of activities 
and roles undertaken by bioentrepreneurs. The exploration provides an in-depth look 
at individual experiences (at various stages o f the clinical and commercial Translation 
process of their research) and sheds light on factors that influence the Translation 
process and the evolving role of bioentrepreneurs in it.
A main assumption throughout the thesis is that in the nascent field o f Regenerative 
Medicine therapeutics (including cell-based and tissue-based), RM bioentrepreneurs are 
acting as crucial mediators of knowledge across the various scientific, institutional and 
professional domains. Their unique human capital (including scientific, clinical, 
regulatory and, often, business expertise) in combination with their formal 
status/position as founders of commercial entities aiming to commercialise new 
technologies, places them in a unique position between the bench, the clinic, and the 
industry from where they have the potential to elevate the available resources, facilitate 
Translation and promote innovation.
Findings from this investigation address voids in the understanding o f RM Translation 
in the UK, provide insights not available through other types o f stakeholder, and by 
means of lessons learned, potentially can help facilitate a cadre of more successful 
entrepreneurs and hence more successful Translation in the future.
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Chapter 1
The Three Arts o f Translation: 
Funding, Regulation and Collaboration
This chapter begins with the story o f the first stem cell transplant, as narrated by 
Professor Anthony Hollander from Bristol University, one o f the scientists who took 
part in the breakthrough experiment/operation. Professor Anthony Hollander gave his 
presentation titled: ‘Claudia's Trachea: Lessons Learned for Future Regenerative 
Medicine Strategies’ at the London Regenerative Medicine Network1 meeting in 
December 2008. I use the scientist’s descriptions and comments to present the main 
themes o f Funding, Regulation and Collaboration in the realm o f Regenerative 
Medicine Translation and to provide a structure for presenting my empirical data and 
analysis in the three empirical chapters of the thesis (Chapters 4, 5 and 6).
In the second section o f this chapter I briefly explain the rationale for this thesis and 
present the main research questions. The third section comprises the conceptual 
approach and the methodology that I followed, including descriptions o f research 
settings (actors, timelines, and locations), data sources, analysis o f interviews, research 
ethics and limitations of the study. In the final section I provide a brief overview of all 
the thesis chapters.
Claudia’s Trachea: the Challenges from Breakthrough to Routine
I got a phone call from Martin asking, “Would I help?” My first thought 
was — That’s completely crazy. How can one go from the science that’s
1 The London R egen era tive  M ed ic in e  N etw ork  (LRMN) is a 'n o t-for-p ro fit organ isa tion ' th a t w a s  s e t  up in 2 0 0 5  by tw o  
in tern ation a lly  a ck n o w led g ed  lea d ers  in th e  fie ld  o f  s tem  ce lls  and reg en era tiv e  m ed ic in e , Dr. S tep h e n  M inger (King's 
C ollege  London) and P ro fessor  Chris M ason  (U niversity  C o llege  London). The m ain  o b jec tiv e  o f  th e  N etw ork  is to  provid e a 
foru m  for all a s p e c ts  o f  th e  n e w  reg en era tiv e  m ed ic in e  te c h n o lo g ie s  t o  b e  p r esen ted  and  d iscu ssed  by h o ld in g  ev en in g  
m e e tin g s  o n c e  a m o n th , 11  m o n th s  o f  th e  year . A ccord ing to  its w e b s ite , th e  London R egen era tive  M ed ic in e  N etw ork  is th e  
la rgest and  m o st su c cess fu l r e g e n e r a tiv e  m ed ic in e  n etw ork  in th e  UK (if n o t g lobally) w ith  a m em b ersh ip  o f  o v e r  4 ,5 0 0 . 
S p on sorsh ip  h as c o m e  from  various so u r ces  in clud ing th e  London D e v e lo p m e n t A gen cy  (LDA), th e  UK S tem  Cell F ou n d ation , 
lead in g  law  firm Clifford C han ce, as w ell as in d u stry  sp o n so rs . T he N etw ork  h as sh o w c a s e d  m an y  'h igh p rofile  sp e a k e rs  o f  
in tern a tion a l calibre w ith  in ter es ts  and b ack grou nd s from  b asic  sc ie n c e , tran sla tion a l research , clinical sc ie n c es , 
b io tec h n o lo g y , th e  p h arm aceu tica l industry  or regu latory  affairs'. For m o re  in form ation  s e e :  h ttp : / /w w w .lr m n .c o m .
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been done in several different countries and suddenly put it all together 
in a space of a few weeks and get it into a patient? It didn’t seem at all the 
sensible thing that a career scientist like myself would do. Indeed, it could 
have been the end o f my career, I suppose, if it had all gone pear-shaped.
But I quickly realised that, actually, this was a golden opportunity not to 
just have the chance to intervene in the life o f a lady who was at death’s 
door, but also to do what I and many others have been saying in the 
media for years — which is that stem cells can help to save lives, can help 
to really improve the quality of life. And I did realise the importance o f 
that moment and it was kind of a life changing moment for me. “Yes, 
let’s go for it; let’s see what we can do”.
(Anthony Hollander, LRM N M eeting, D ec. 2008)
In the opening quotation, Professor Hollander explains to the audience his first 
reactions and thoughts when Professor Martin Birchall, an otolaryngology surgeon also 
from Bristol University,2 called him on a Sunday afternoon to ask whether he would be 
interested in participating in an international collaborative project involving four 
research teams in three countries.3 Paolo Macchiarini, a surgeon and clinical 
investigator based at the Department o f General Thoracic Surgery, Hospital Clinic in 
Barcelona, had pioneered the research and now the perfect patient on whom to try the 
technique had arrived in his clinic.
In March 2008, Claudia Castillo, a 30-year-old Colombian woman, was admitted to 
hospital in Barcelona suffering from collapsed airways, following a severe case of 
tuberculosis. In such cases of end-stage bronchial disease, the only conventional 
option is to remove the affected lung and airway and perform a transplant (i.e. lungs 
and trachea from a donor4). At present, patients undergoing organ transplants must 
spend the rest o f their lives on powerful drugs to suppress their immune systems. 
These drugs are necessary to avoid donor organ rejection but they can leave organ 
recipients vulnerable to other infections and complications. In order to save Castillo’s 
life and, in addition, avoid the risks o f immunosuppressant drugs, the doctors decided 
to try to tissue engineer a ‘new’ section o f trachea containing the patient’s own cells.
2 M artin Birchall is cu rren tly  P ro fessor  o f  Laryngology and  co n su lta n t laryn golog ist a t  th e  Ear Institu te (UCL) and  th e  Royal 
N ational Throat N o se  and Ear H ospital (RNTNEH).
3 UK (Bristol team ); Italy (Padua te a m , Milan team ); and Spain (B arcelona te a m ).
4 The p roced u re is k now n  as clinical a llografting  and  th e  ce lls /o r g a n s  u sed  are from  a d o n o r  (cad aver).
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Engineering the ‘new trachea’ required an enormous coordinated effort among the 
different teams to ensure all necessary steps are executed and integrated in a timely 
manner. Initially, a scaffold was prepared by Italian scientists in Padua who took a 
section o f trachea from a donor and repeatedly ‘washed’ it to remove all donor cells, 
leaving only a collagen ‘scaffold’. Two types o f cells were needed to line the scaffold 
and make it bio-compatible with the patient: chondrocytes (cartilage cells) derived 
from stem cells from Castillo’s bone marrow that would line the outer surface; and 
epithelial cells, taken from a still healthy part o f her trachea, to line the inner surface of 
the scaffold. These stem cells, from Castillo’s bone marrow and airway, were taken to 
the University of Bristol, and grown to quantities necessary for the procedure. When 
ready, the cells were flown to Barcelona and placed within the decellularised scaffold in 
a bioreactor (developed for this purpose by a team in Milan), effectively making a 
windpipe in the lab. The final construct was cut and bent into the right shape, before 
finally being surgically grafted into Castillo in June 2008 at the Hospital Clinic in 
Barcelona by Professor Paolo Macchiarini who conceived the project.5 No immune 
suppression medication was required because the raw materials came from Castillo 
herself and, within two months o f the operation, Castillo had a normal lung function 
and was able to lead an independent life.
In his presentation, Hollander describes the initial feelings o f caution and uncertainty 
he had over the outcome o f the collaboration, as well as his concerns about the effect 
failure would have on his career (possibly even signalling its end). He refers to the 
‘crazy’ choice he made as a ‘career scientist’ to agree to collaborate. His choice of 
words makes sense if one considers the early stage of these technologies, their novelty, 
and the challenges that would need to be faced in order for such a procedure to 
succeed. Paolo Macchiarini, the surgeon who designed the project, had only previously 
used pig and mouse models to develop and streamline the process in which autologous 
cells are seeded onto a decellularised donor tracheal scaffold and matured in a 
bioreactor. Encouraged by the in vitro generation of short but vital tracheal matrices, 
and by the absence o f an immunological response to allografted and xenografted 
tracheal constructs in animals,6 Macchiarini’s ambitious aim was to bioengineer a 
human trachea and to attempt the application of this technology in a patient with end- 
stage airway disease.
5 T he tran sp lan ta tion  w a s first rep o r ted  in (M acchiarini e t  al., 20 0 8 ).
6 T he pub lication  d escrib ing  th e  su c cess fu l o u tc o m e s  in an im als is (Jungebluth  e t  al., 2 0 0 9 ).
15
This type o f first-in-human (FIH) experimental intervention inevitably presents a series 
o f risks and ethical challenges that if not entirely without precedent, are nonetheless 
distinctive, unfamiliar and unresolved.7 Most o f the risk is traceable to the character 
and degree of uncertainty in these translational interventions including issues of how to 
best predict and measure human response, how to assure safety, and how to manage 
and reduce any untoward outcomes. One has simply to look at the field o f gene 
therapy to realise the degree o f institutional and personal risk that is involved in early 
translational trials.8 Had the participants failed to join up the steps and successfully 
complete the operation, or if indeed Castillo’s body had rejected the transplanted cnew 
organ’, then ‘fingers would have been pointed’.
Indeed, the development o f cell therapies and tissue engineered products has been, and 
continues to be, a long and risky trip, with both failures and successes readily reported 
by the media. Promises and predictions made by enthusiastic and ambitious scientists 
are communicated to the public through ‘hyped’ press releases, often conveying the 
impression that these therapies are safe and immediately available. In Hollander’s own 
words’ ‘it was a golden opportunity [...] to do what I and many others have been 
saying in the media for years’.
However, experts in the field o f regenerative medicine have drawn attention to this 
‘hype’ and have stressed that unrealistic expectations and the premature use of 
technology could put patients at risk and as a result endanger public trust in new 
technology, jeopardising the future of the whole field (Braude et al., 2005; 2009a: 
1011). Social scientists, on the other hand, who have explored these issues in relation 
to stem cell research, stress that ‘it is a mistake to think that we can somehow factor 
out the hype, the media or the work o f the imagination to exaggerate either the 
promises or the risks o f new technology. This is not going to be possible, now or in 
the future, because it is precisely the importance of imagining a future yet-to-be that 
fundamentally defines the whole issue o f the new genetics and society’ (Franklin, 2001:
7 K im m elm an, an A ssistan t P ro fessor  in th e  Social S tu d ies  o f  M ed ic in e  Unit, McGill U niversity  (M on trea l, C anada), has  
exp lored  th e s e  is su e s  ex ten s iv e ly  in his book: G en e  T ran sfer a n d  th e  E thics o f  F irst-in -H um an R esea rch  - L ost in T ran sla tion  
(2 0 1 0 ) . K im m elm an u se s  th e  e x a m p le  o f  g e n e  th erap y  to  ex a m in e  th e  eth ica l and  p olicy  d im en sio n s  o f  te s t in g  n ovel 
in ter v en tio n s  in h um an  b e in g s  for  th e  first t im e . T he b o o k  a rg u es  th a t m an y  eth ica l fram ew ork s d ev ised  for  ran d om ised  
co n tro lled  trials tran sla te  aw kw ard ly  to  early p h a se  h um an  s tu d ie s  o f  n ovel th era p ie s .
8 In 1 9 9 5 , a h igh -level p anel a t th e  NIH fa u lted  th e  g e n e  th era p y  fie ld  for rushing in to  clinical trials (Orkin & M otu lsky, 1 995 ). 
In 2 0 0 5 , a g e n e  th era p y  lead in g  figu re , Jam es W ilson  re ce iv e d  a five -year, F D A -im posed  ban  on  lead in g  clin ical trials. The 
ban fo llo w e d  th e  d ea th  o f  18 -y ea r-o ld  Jesse  G elsin ger w h o  d ied  S e p tem b er  17 , 1 9 9 9 , w h ile  partic ipating  in a trial o f  g e n e  
th era p y  (h ea d ed  by W ilson) a t th e  U niversity o f  P enn sy lvan ia  Institu te for H um an G e n e  T herapy.
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349). Hence, Castillo’s successful transplantation could be seen by the public as 
providing the crucial new evidence that (at least) adult stem cells can offer genuine 
solutions to serious illness, boosting the arguments o f scientists and vindicating the 
decisions o f investors (public and /o r private) to support the Translation of this kind of 
research.
A nother key point to highlight here is that the tracheal transplant was achieved without 
any major formal funding, using only small local funds (Laurance, 2008). In  the quote 
below, Hollander highlights the importance o f a multidisciplinary team for the 
successful operation and points out the difficulty of securing funding for this type of 
high-risk, translational project:
The reason this worked, it all came together, is because we had a 
multidisciplinary team. And that’s a real take home message. We had 
Paolo [Macchiarini], driving things from the surgical point o f view, the 
work on airways he’d been doing, we had Maria Teresa Conconi who 
developed the scaffold decellularisation process, we had our bioreactor 
experts in Milan and we had the Bristol team, myself and Martin 
[Birchall], doing the stem cell biology [...] So this was a multidisciplinary 
team. Scientists who have applied for grants to do this kind o f work will 
know how extremely difficult it is to get pass review panels with this. I 
don’t think we would have got a grant to do this, I don’t think it would 
have passed. And we need to think really hard about that as a country.
How the hell do we get this kind o f multidisciplinary work funded 
properly without scientists from one discipline trashing your grant 
because he or she doesn’t understand the science in another discipline? I 
don’t know what the answer is, but if we are really going to do this sort 
o f thing more frequently we have to resolve that one.
(Anthony Hollander, LRM N M eeting, D ec. 2008)
Multidisciplinarity and the successful integration of the various ‘parts’ o f the project 
were, according to Hollander, key to the success o f the operation and yet, 
paradoxically, what made it hard to fund. Four research teams from three different 
locations/countries, managed by the surgeon and pioneer o f the technique
17
(Macchiarini), integrated their methods, materials and expertise, as well as their small 
sources o f funding, to produce a custom-made product on time. Despite the 
significance that cross-disciplinarity9 seems to hold for this ‘first’ in RM Translation, 
Hollander maintains that this type o f collaborative Translational Research is 
notoriously difficult to fund. He goes on to share his experience (and that o f other 
researchers) o f trying to get this type of research proposal through research evaluation 
panels, saying that it is not unheard o f for reviewers to reject a cross-disciplinary 
research proposal only because they lack the relevant expertise and experience to 
conduct an appropriate evaluation.
Indeed, in the social sciences literature problems with research funding have been 
linked to the research evaluation process. In today’s academia, evaluation is an 
integrated element o f research, with the traditional peer review providing the gold 
standard o f scientific evaluation. ‘The peers are the judges’. However, the fairness of 
the principle of peer reviews has been questioned when it comes to cross-disciplinary 
research (Porter & Rossini, 1985), with authors reporting that funding structures with 
a strong peer review component tend to overfund mainstream research that follows 
established research lines, and peer reviewers to be risk averse and biased against 
speculative, unorthodox and cross-disciplinary research proposals.10
In addition, authors who have explored potential obstructions to cross-disciplinary 
research have emphasised the importance o f ‘mutual knowledge’ between cross- 
disciplinary teams, if they are to succeed in their common endeavour. ‘Insight into the 
basics of methodology, theories, epistemological and historical aspects of the others’ 
disciplinary discourse is essential for understanding and respecting the position of 
collaborators from other fields. Conceptual compatibility is the basis for understanding 
and overcoming negative prejudices and creating respect’ (Aagaard-Hansen & Ouma, 
2002:432).
9 In th e  rest o f  th e  th e s is  th e  term  cross-d iscip linarity  will b e u sed  accord in g  to  R osenfield  (1992 ); th a t is a s a gen era l 
d es ig n a tio n  for  all th e  th r e e  term s  (m ultid iscip linarity, in terdiscip linarity , transdisc ip linarity). R o sen fie ld 's  ta x o n o m y  
d escr ib e s  th r e e  s ta g e s  o f  p rogressive  in tegration  o f  th e  p artic ip atin g d iscip lin es in term s  o f  th e o r ie s , m e th o d o lo g ie s  and  
overall c o n ce p tu a l fram ew ork . S h e su g g e sts  th a t  m u ltid iscip linarity  is p resen t  w h e n  re sea rch ers  'w ork in parallel or 
s eq u e n tia lly  from  d iscip lin ary-sp ecific  b a se s  to  ad d r ess  co m m o n  p rob lem s'. Interdiscip linarity c o n s is ts  o f  'resea rch ers  
w orking jo in tly  but still from  d iscip lin ary-sp ecific  b asis  to  a d d ress  a co m m o n  p rob lem ', w h e r e a s  tran sd isc ip lin arity  co m p rise s  
'r esearch ers  w ork in g jo in tly  u sin g a sh ared  co n ce p tu a l fram ew ork ' th a t d raw s to g e th e r  c o n c e p ts , th eo r ie s , and  a p p r o a ch es  
from  th e  p aren t d isc ip lin es  (R osen fie ld , 19 9 2 ). In ad dition  to  R osenfield , A agaard- H ansen  an d  O um a (2 0 0 2 ) e m p h a s ise  th e  
sign ifican ce o f  th e  t im e  d im en sio n  on  th e  p ro ce ss  o f  p rogressive  in tegra tion  and p ro p o se  th a t  'th is is a gradual p ro ce ss  in 
w hich  th e  research  grou p  little  by little  m o v e s  in th e  d irection  o f  in teg r a tio n — from  m ulti t o  tran sd isc ip lin arity  and  w hich  
ta k es  p la ce  a t d ifferen t p a ces' (A agaard-H ansen  & O um a, 2 0 0 2 :2 0 6 ) .
10 (Bourke & Butler, 1999 ; Horrobin, 1996 ; Langfeldt, 2 0 0 6 ; Travis & Collins, 1991 )
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The same could possibly hold true for the fair and unbiased evaluation of cross- 
disciplinary proposals, something that, according to Hollander, is not really happening 
in the regenerative medicine (RM) field. From his comments it is obvious he considers 
it crucial that reviewers who are given the evaluation responsibility should have, in 
addition to their disciplinary competences, some kind o f personal cross-disciplinary 
experience. This could be either in terms o f double training (i.e. cross-disciplinary 
background) or in terms o f practical involvement in similar projects.11 In Hollander’s 
view, funding agencies/research councils do not seem to have the appropriate 
expertise when it comes to evaluating cross-disciplinary research proposals. 
Hollander’s account o f grant application realities is in sharp contrast to the importance 
governments and their funding agencies place (or desire to be seen to place) on 
funding cross-disciplinary, highly innovative research, with many research councils and 
science administrators publishing guidelines12 on how to facilitate and promote this 
agenda.
Another point to make here is that cross-disciplinary research is often thought o f as 
highly innovative, off-the-beaten track, ground-breaking and thus as a ‘high risk/high 
return’ endeavour that might jeopardise one’s academic and /or clinical career. This is 
especially true for Regenerative Medicine research as it has so far followed some 
controversial research avenues (e.g. hESCs), where the returns have been uncertain, 
distant, and often negative.13 The concept o f risk-taking is thus a necessary element of 
crossing disciplines and exploring new avenues o f research in Regenerative Medicine. 
This approach to conducting research, however, unavoidably clashes with the standard 
pathways laid down for academic careers, mainly confined within disciplines. Academic 
researchers, clinical practitioners and bioengineers, three o f the most important 
professional communities involved in Regenerative Medicine research, are all used to 
accumulating credit and constructing networks within their own disciplines in order to 
further their careers. ‘Trespassing’ into collaboration with other disciplines may be 
seen as a waste o f time and resources that would best be spent in their own ‘area’. Grit 
Laudel (2006a, 2006b), a sociologist from the Australian National University who has
11 (M cN eill e t  al., 20 0 1 )
12 R esearch  C ouncils UK (RCUK), 2006 ; C om m ittee  on  Facilitating Interdiscip linary R esearch  and C o m m ittee  on  S c ien ce , 
2 0 05 ; EURAB, 20 0 4 ; OECD, 1 9 98 ; A cad em y  o f  Finland, 1997 .
13 In February 2 0 0 9 , re sea rch ers  in Israel rep orted  th a t a 1 3 -year-o ld  boy w ith  ataxia te la n g e c ta sia  w h o  had received  
in jec tion s o f  h um an  fo e ta l n eural s te m  ce lls  in to  his brain a s part o f  an ex p er im en ta l tr e a tm e n t p erform ed  in a Russian  
clinic, fou r y ea rs  a fter  th e  tr e a tm e n t  d e v e lo p e d  brain tu m o u rs ap p aren tly  d erived  from  th e  in jec ted  s tem  ce lls . This w a s  th e  
first rep ort o f  a h um an  brain tu m o u r  com p licatin g  neural s te m  cell th era p y  and  co n ce rn s  w e r e  raised  o v er  th e  sa fe ty  o f  th is  
ex p er im en ta l th era p eu tic  ap p roach  (A m ariglio e t  al., 2 009 ).
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investigated how researchers decide whether or not to propose risky research projects 
to sponsors, has found that many investigators will avoid high-risk topics/areas 
because they fear that the risk of failure (to obtain the grant) is too high. Failure to 
secure funding can be seriously detrimental, particularly to early-stage researchers or 
untenured academics. In the case o f Claudia’s trachea, the future o f Birchall and 
Hollander’s research (who were preparing their application to the European Union for 
grants to cover the next phase of the work) was heavily dependent on the outcome o f 
this one operation.
In his discussion o f the risks faced by high-profile, pioneering RM cases, Hollander 
also emphasised the crucial role ‘flexible’ regulation played in the successful realisation 
of the project:
There was a lot of flexibility by the regulators. They worked with us and 
we got the permissions that we needed. I don’t know if we would get that 
again. I actually don’t know if we would have been able to do this 
operation here in the UK. I really just don’t know that. But I simply 
make the point that if we are going to move forward in this field we are 
going to have to take some kind o f risks with the patients on board with 
that. And I hope the regulatory environment, particularly with the new 
legislation14 coming in January, doesn’t prevent that. Because it could kill 
off this whole field and that would be a disaster in my mind. Actually, I 
think it would be unethical if that was the result.
(Anthony Hollander, LRM N M eeting, D ec. 2008)
In this passage, Hollander expresses his concern about the way Translational 
Regenerative Medicine is conducted (or rather not conducted) under the current 
regulatory regime. Although he does acknowledge a degree of flexibility and 
collaboration on the part of Spanish regulators (as Barcelona was the place where the 
actual transplantation procedure was performed), he expresses uncertainty about 
whether this type o f collaborative work involving research and clinical groups from 
different countries would be possible beyond the one-off case, or whether it could be 
eventually undertaken on a more routine basis in the UK. In the trachea project, the
14 H ollander re fers to  th e  E u rop e-w id e ATMP regulation .
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U K ’s involvement was focused on developing the methods for growing human 
epithelial and mesenchymal stem cells (to be differentiated into chondrocytes) and 
carrying out the cell cultures, work belonging more in the realm of basic rather than 
Translational Research, and quite straightforwardly regulated in the UK. However, the 
surgery, which is the more ‘translational part’ of the project as it involved the actual 
application of the therapeutic construct into the patient, was performed in Spain.15
In Hollander’s view, the UK is ‘going to have to take some kind o f risks with the 
patients on board with that’, if it is going to move forward in the RM field. Indeed, 
what Hollander states is the very compelling argument for initiating first-in-human 
(FIH) trials and experimental clinical research in general: it is the results o f these 
investigations that provide pivotal insights and allow the field to advance. In other 
words, only clinical trials will provide the necessary data to move forward and to 
optimise a cell therapy by recognising the best type o f cell as well as the best delivery 
method for each disease.
Decisions to launch first-in-human (FIH) experiments are often marked by 
controversy. In truth, all forms of medical treatment are accompanied by the risk of 
unwanted side effects and cell therapies are no exception. Given the level of 
excitement surrounding Regenerative Medicine therapies, it is also not surprising that 
basic laboratory findings are being thrust forward into translational human studies at 
the earliest possible stage. There is, however, ongoing debate on this issue with many 
authors stating that we should be wary o f prematurely pushing laboratory research into 
clinical practice (Chien, 2004; Wilson, 2009a, 2009b). In a 2009 Science article, James 
Wilson who led the gene therapy clinical trial shadowed in 1999 by the death of Jesse 
Gelsinger, expressed his growing concern that the field o f stem cell research, like that 
o f gene therapy, is getting ahead o f itself. He says, ‘I am concerned that expectations 
for the timeline have outpaced the field’s actual state o f development and threaten to 
undermine its success’ (Wilson, 2009a:727). According to Wilson, the decision to 
initiate FIH is not just about ambitious investigators and desperate patients willing to 
accept greater uncertainty and higher risk, it is also about the fact that these trials make 
use o f scarce social resources and adverse outcomes can ‘initiate a chain o f events that
15 W h ile th e  overall p erfo rm a n ce  o f  Spanish  b iom ed ica l research  still lags b eh in d  th a t o f  th e  m ajor in tern a tion a l p layers, 
clin ical research  fares  rem arkably w ell in m o st co m p a riso n s. For ex a m p le , p ap ers  on  clinical m ed ic in e  by Span ish  au th ors  
in d ex ed  by T h om son  R euters b e tw e e n  2 0 0 3  and 2 0 0 7  received  an avera g e  o f  2 .6 9  c ita tion s p er  p aper, an im p act 11% a b o v e  
th e  w orld  a v er a g e  (Raya & B elm o n te , 2 0 0 9 ).
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would seriously derail a field’16 (2009a:727). Hence a cautious approach to
Translational Research and its risks is justified not only by the duty to protect the
welfare o f the research subjects but also by the desire to safeguard the integrity of the 
broader research enterprise, and to protect the future o f these innovative health 
technologies. Other experts believe that the risk o f exposing patients to possible 
adverse outcomes o f a new RM treatment must be weighed against the risk of 
depriving all patients o f a novel and possibly effective treatment that will alleviate 
suffering and/or prolong life (Master et al., 2007).
Hollander also makes the point that this kind o f collaborative, cross-border
Translational Research is necessary to achieve the promises o f Regenerative Medicine. 
However, he stresses that the future of this type of work is highly dependent on the 
new, EU-wide regulatory regime which came into force in December 200717 and aims 
to initiate harmonisation o f standards for medicinal products (including RM cell based 
and tissue-engineered products/therapies). In Hollander’s view, an unfavourable or 
dysfunctional regulatory landscape could seriously hamper collaborative translational 
efforts — an outcome he describes as disastrous and unethical as, he implies, it will 
severely retard, or even halt, the development of new life-saving options for patients 
such as Castillo, for whom conventional treatments are essentially worthless.
Reviewing Professor Hollander’s presentation as a whole, it is clear that this landmark 
operation presents at least three crucial take-home lessons. First, it saved the life of 
Claudia Castillo, and transformed her existence from being virtually bed-ridden to a fit 
young woman who can resume the active life she once had. Second, it has 
demonstrated what stem cell technology, which has promised much but so far 
delivered little, can really do. And third, it is a remarkable example o f international co­
operation involving expertise from four teams in three countries.
In his 30-minute presentation, Hollander thus underscored what appear to be the three 
most important ‘pillars’ in the Translation of Regenerative Medicine: Funding, 
Regulation and cross-disciplinary Collaboration. My interviewees seem to be in 
agreement with Hollander’s highlights since these three ‘themes’ also resonate
16 A d verse  e v e n ts  can d a m a g e  public an d  in vestor  co n fid en ce , in itia te  c u m b e r so m e  o v er sig h t m ech a n ism s in ord er to  avoid  
fu rth er  p ro b lem s, and a lso  c lo se  o f f  p rom isin g research  a v en u es .
17 ATMP regulation  ca m e  in to  fo rce  in D ecem b er  2 0 0 7  and  b e c a m e  e ffe c t iv e  in D ecem b er  2 0 0 8 .
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repeatedly (along with a variety of other related issues) in the accounts of all 
informants in this study. Drawing on Hollander’s description, I chose to use the 
themes o f funding, regulation and collaboration as the three ‘lenses’ through which my 
informants recount their translational experiences in the Regenerative Medicine field: 
Chapter 4 addresses funding, Chapter 5 regulation and finally, Chapter 6 the theme of 
cross-disciplinary collaboration. The next section briefly presents the rationale of the 
thesis and the main research questions.
Briefly about the Thesis
This thesis examines the changing ‘landscape’ in the Regenerative Medicine research 
Translation process from the perspective o f UK bioentrepreneurs. The thesis aims to 
characterise the varied nature of the contribution of bioentrepreneurs in the 
Regenerative Medicine Translation process and the various mechanisms through which 
it facilitates product innovation.18
While much is known about the views of scientists, clinicians and industry 
stakeholders,19 limited research to date has focused on the experiences of 
bioentrepreneurs and founders in the UK Regenerative Medicine field. Research with 
scientists, clinicians and industry representatives is certainly important for 
understanding the interactions between these groups of stakeholders in relation to the 
context o f the laboratory, the clinic and the market, but an understanding of what it is 
to be an RM entrepreneur and founder and to often ‘drive’ and ‘coordinate’ the whole 
Translation process has not been fully explored.
This research attempts to remedy this missing component by exploring.what it is like 
to experience Regenerative Medicine Translation through this ‘unique’ and ‘critical’ 
position (role). The exploration provides an in-depth look at individual experiences (at 
various stages o f the clinical and commercial Translation process) and sheds light on 
factors that influence the process and the evolving role o f bioentrepreneurs in it. What 
is like to be a Regenerative Medicine entrepreneur in the UK? How do
181 will n o t b e  exam in in g  any p erform an ce im p lica tion s o f  b io en tre p r en eu r  in v o lv e m en t/a c tiv ity .
19 (P lagnol e t  al., 2 0 0 9 ) . For re levan t socia l s tu d ie s  s e e  th e  literatu re  re v iew  o f  th e  socia l s c ie n c e  s tu d ie s  in th e  RM field  
p rov id ed  in C hapter 3.
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bioentrepreneurs conceptualise, describe and make sense o f the Translation
experience?
Entrepreneurs are often the principal investigators (Pis)20 of the basic research being 
carried out and hence the ones responsible for identifying significant findings and 
recognising and evaluating opportunities for potential clinical and commercial
Translation. They are the inventors o f the technology, owners (or co-owners) of the IP 
and are often involved in the subsequent clinical experimentation o f the products. 
They might simply be licensors o f technology or, in some cases, founders o f a spinout 
(or start-up company) and thus responsible for setting up a robust team comprising
various types o f expertise21 that will have a good chance o f ‘seeing’ the
therapy/product to the clinic and or market.
Findings from this investigation address voids in the understanding o f RM Translation 
in the UK, provide insights not available through other types of stakeholder 
participation, and by means of lessons learned, potentially can help facilitate a cadre of 
more successful bioentrepreneurs and hence more successful Translation in the future.
Fourteen entrepreneurs o f various ages, undertaking various combinations o f 
professional roles and based at diverse UK universities, research institutions, or 
corporate firms were interviewed. Data were enriched by commentaries from 
presentations taken from relevant conferences and meetings and from a number o f 
informal conversations, as well as significant background research in the relevant 
academic and policy literatures.
For the purpose of this thesis, I define Regenerative Medicine bioentrepreneurs as 
principal investigators (Pis) in a Regenerative Medicine field who have one or both of 
the following characteristics:
■ They have a patent on an RM invention (whether they have licensed it yet or not)
20 Principal in v estig a to r  (in th e  b iom ed ica l sc ie n c es) is th e  p erson  d es ig n a ted  as taking overall resp on sib ility  w ith in  th e  te a m  
o f  research ers  for  th e  d esig n , co n d u c t and  reportin g o f  th e  stu d y . Principal Investigators are e x p e c te d  to  lead  and  m a n a g e  a 
research  te a m , s ecu re  n ew  research  grants, liaise w ith  sta k eh o ld ers , publish, re sp on d  t o  w ith  in stitu tion a l is s u e s  and  
a g en d a s, and m aintain  and d e v e lo p  th eir  ow n  research  e x p er tise . Frequently  th e y  s im u lta n eo u sly  carry o u t  a ran ge o f  
tea ch in g  and ad m in istra tive  d u tie s  to o  (Pis are a lso  s o m e t im e s  ca lled  R esearch  Leaders).
21 d ep en d in g  on  area o f  research  and p h a se  o f  Translation.
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■ They have founded (or co-founded) an RM company at some point in their career. 
The company can be either an academic spinout or a start-up (corporate)
A main assumption throughout the thesis is that in the nascent field o f Regenerative 
Medicine therapeutics, RM bioentrepreneurs are acting as crucial mediators o f 
knowledge across the various scientific, institutional and professional domains. Their 
unique human capital (including scientific, clinical, regulatory and, often, business 
expertise) in combination with their formal status/position as founders of commercial 
entities aiming to commercialise new technologies, places them in a critical position 
between the bench, the clinic and the industry, from where they have the potential to 
elevate the available resources, facilitate Translation and promote innovation.
My main research questions are the following:
1. H ow  is Translation being conceptualised and practised by bioentrepreneurs 
in the Regenerative M edicine field in the UK?
A. What are the key challenges (problems) that need to be overcome and at which 
stage of the Translation process?
B. How do bioentrepreneurs address each challenge?
2. What are the translational models that bioentrepreneurs identify?
(e.g. funding models, IP models, regulatory governance models, collaboration models)
3. What is the importance o f the bioentrepreneurs’ contribution?
A. What are the resources bioentrepreneurs need to employ (financial, human, etc) 
in order to lead the products/therapies through clinical and commercial 
Translation?
B. D o they relish their ‘coordinating’ role?
To address these research questions, in addition to drawing upon in-depth interviews 
with Regenerative Medicine bioentrepreneurs, I also use relevant documentary sources 
(see following section on Analytical and Methodological approach). Though the focus 
o f the thesis is Translational Regenerative Medicine in the UK and the data collected 
are from and for UK-based research groups, bioentrepreneurs and companies, I also
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examine sources and data from other countries (especially the US) as Regenerative 
Medicine is a ‘global enterprise’ .
The following section provides an explanation o f the methodological and analytical 
(conceptual) approach I chose to follow in this study. More specifically, I begin with a 
description of the data sources I used and methods I employed. Afterwards, I 
introduce the (interview) research setting (actors, timelines and locations), explain the 
reasons behind my choice o f participants and provide a justification o f my grounded 
theory methodology. In the final section I provide a brief description of the analysis of 
the interviews, the ethical considerations and address the possible limitations o f this 
work.
Methodological and Analytical Approach 
Research Design (Data Sources/Methods)
In this section I review and reflect upon the research process and specific sources and 
methods used to capture my data. I continue with an introduction of the research 
setting and afterwards, I explain the main reasons behind my choice o f informants.
For practical reasons, I focussed on three main data sources. These included 
interviews, documentary sources, and fieldwork conferences, meetings and workshops. 
Interviewing was chosen as the most appropriate technique to explore the specific 
research subject. Indeed, RM bioentrepreneurship and the role it seems to play in RM 
Translation is not an ‘endeavour’ that can be explored through academic journals, 
reports and surveys. Bioentrepreneurs, as the designated Translation champions, are 
presumably the best source of information about the phenomenon o f Translation and 
the various challenges that seem to impede RM innovation (the drawback, o f course, 
being the difficulty o f recruiting interviewees). There are abundant documentary 
sources on RM, most o f which are in the public domain. Documentary sources (such 
as legislation documents) provide a fundamental background and structure to the 
study. Finally, the data gathered during relevant conferences, workshops and meetings 
have been a particularly rich and crucial addition, as I had the opportunity to interact 
with diverse stakeholders, many of whom are leading figures in the RM field, thus
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gaining access to opinions and views that I would not have had the opportunity to 
collect otherwise.
Documentary Sources
A wide variety of documentary sources were used. These include regulation sources, 
such as national and international regulatory guidelines, directives and codes of 
conduct (applicable to the UK context);22 commercial sources such as websites23 
(including individual company websites), newsletters, commentaries, press releases and 
position papers on relevant regulation and commercialisation activities. Blog 
commentaries managed by Regenerative Medicine experts have also proven a rich and 
reliable source o f information on the latest development in Regenerative Medicine 
R&D.24 Many o f the participants have also provided me with handouts and company 
leaflets. Scientific sources including scientific journal papers and reviews on specific 
Regenerative Medicine applications (for example skin systems, cardiac repair, etc.) were 
also very useful in gaining familiarity with the field and keeping up to date with the 
latest advances and breakthroughs. Finally, I also reviewed various government reports 
(e.g. the Cooksey Report, Pattison Report, POST publications, etc.), Research 
Councils’ (for example the MRC) publications, and reports based on national, 
European and international studies (surveys) and initiatives.
Fieldwork Conferences/M eetings/W orkshops
In addition to the formal semi-structured interviews, I had a number of informal and 
personal conversations with relevant actors at numerous fieldwork conferences.25 Since
22 T h ese  in clud ed  official p ub lica tion s o f  th e  E uropean  C om m ission  and EU leg isla tion , d irectiv e  and p o licy  d o cu m en ts; MRC, 
EMA (form er  EMEA), HFEA, HTA p ub lication s and  regu latory  g u id a n ce  d o cu m en ts .
23 A w e b s ite /n e w s le t te r  I fo u n d  esp ec ia lly  u sefu l is th e  'Cell Therapy N ew s' 'Cell T herapy N ew s' is a free , w eek ly  e-  
n e w s le t te r  and w e b s ite  portal d ed ica te d  to  provid ing th e  la te st  in form ation  a ffec tin g  ce llu lar th era p ie s . The w e b s ite  portal 
su p p lies  in form ation  a b o u t cell th era p y  p rod u cts, jo b s , e v e n ts , p u b lica tion s, a s so c ia tio n s  and  regu latory  b o d ie s . T he e-  
n e w sle t te r  in corp ora tes  th e  m o s t  re cen t n ew s  from  all areas  o f  th e  fie ld , from  its s c ie n c e , re search , and b u s in e ss  n e w s , to  
its regu la tory  affairs. T he e -n e w s le t te r  is p u b lish ed  o n lin e  w eek ly  and s e n t  to  o v er  1 1 ,0 0 0 +  su b scrib ers globally  
(h ttp : / /w w w .c e llth e r a p y n e w s .c o m ).
24 O n e o f  th e  m o st u se fu l b logs  h as b een  th e  'Cell T herapy Blog' w hich  in clu d es b u s in e ss  n e w s  and analysis  for ex e c u tiv e s  in 
th e  ceil th era p y  and RM industry. The blog  is 'run' by Lee Buckler a fo rm er a tto rn ey  and E xecutive D irector o f  th e  
Intern ation a l S o c ie ty  for  Cellular T h erap y (ISCT) w h o  is n o w  a co n su lta n t on  th e  b u s in e ss  s id e  o f  th e  cell th era p y  and  
r e g en era tiv e  m ed ic in e  s e c to r  (h t tp : / /c e llth e r a p y b lo g .b lo g sp o t .c o m ).
25 For e x a m p le , I a tte n d e d  th e  C o n feren ce  on th e  C om m ercia l Translation  o f  R egen era tive  M ed ic in e  th a t w a s  org a n ised  by 
M arcusE vans on  16  and  17  N o v em b er  2 0 0 7 . During th e  tw o -d a y  c o n fe r e n c e  17  sp e a k e rs  p re se n te d  on  a variety  o f  
co m m erc ia l T ran sla tion -re la ted  th e m e s  including: th e  la te s t  R&D d e v e lo p m e n ts  in th e  fie ld  o f  R eg en era tiv e  M ed icin e , 
em er g in g  regu lation , th e  co m p le x itie s  o f  m an ufacturin g  RM p rod u cts and th e  role o f  a u to m a tio n  in realisin g  th e  com m ercia l 
d rea m , th e  structuring o f  re im b u r se m e n t s tra teg ie s  and  le sso n s  learn ed  from  th e  cu rren t lead in g  c o m p a n ies  in th e  field .
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these conversations were ‘off-the-record’, I have not quoted nor direcdy used the 
comments o f these individuals, but I did use them to inform my analysis. Extensive 
field-notes were also produced based on observation and participation in these 
conversations, as well as my attendance at meetings and conferences. In addition, 
relevant documents were collected in the form of speakers’ presentations, papers, 
company prospectuses and associated materials to generate an extensive database of 
sources relevant to this research. This generated a large amount o f data on industry 
activities, cutting-edge clinical developments and regulatory issues that was not yet in 
the public domain and would not otherwise be available to me. Equally important 
during these meetings, was the opportunity to observe the various actors as they 
mingled and interacted with one another through the different ‘stakeholder’ networks 
and under one or more of their professional roles (e.g. scientist, clinician, business 
entrepreneur, or manufacturer/developer).
In addition to the above data, I recorded and transcribed three presentations from the 
London Regenerative Medicine Network meetings. The presentation details are the 
following (including speaker, title o f presentation and date):
■ Greg Bonfiglio, Founder and Managing Parmer at Proteus Venture Partners, 
‘Commercialising Regenerative Medicine: Moving Great Science from Bench to 
Bedside’, November 2008.
■ G eoff MacKay, President and Chief Executive Officer (CEO) o f Organogenesis, 
‘Applying Living Technology for Soft Tissue Regeneration: Research and 
Development, Manufacturing and Commercialisation’, November 2008.
■ Professor Anthony Hollander, University o f Bristol, ‘Claudia's Trachea: Lessons 
Learned for Future Regenerative Medicine Strategies’, December 2008.
Interviewing (Actors, Timeline, Locations)
Interviews are generally considered to be the most suitable approach when seeking rich 
data illuminating experiences and attitudes. The drawbacks are that interviews are very
P erm ission  w a s  gran ted  to  record  16  (ou t o f  17  p resen ta tio n s) and  th e  re levan t q u e st io n -a n d -a n sw e r  s e s s io n s  th a t  fo llo w e d , 
a s w e ll as th e  final p an e l d iscu ssio n  w hich  la sted  for an  hour. All p artic ip ants had b e e n  m a d e  a w a re  th a t th e  p r esen ta tio n s  
and  d iscu ss io n s  w e r e  b e in g  record ed  and  th a t th e  in form ation  m igh t b e  u sed  la ter on  in p u b lica tion s. All r e co rd ed  m aterial 
w a s tran scrib ed , and  in co m b in a tio n  w ith  c o n fe r e n c e  d o c u m en ta tio n  and in ter v iew  d a ta , w a s  u sed  to  in form  analysis  
(M arcusE vans is an in tern a tion a l b u sin ess  e v e n ts  and  in form ation  co m p a n y  w h ich , in co llab ora tion  w ith  P ro fesso r  Chris 
M ason  (UCL), runs an annual com m ercia lly  fo c u sse d  r e g en era tiv e  m ed ic in e  c o n fe r e n c e  w ith  th e  p artic ip ation  o f  th e  m o s t  
a cc la im ed  a ca d em ics , p ractition ers  and lead in g  c o m p a n ies  in th e  RM fie ld ).
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time consuming to conduct and analyse. The interviews were conducted in two phases: 
the first phase consisted of seven interviews between September and December 2007 
and the second phase consisted o f seven interviews between October and December 
2009. This timing apart from allowing me time to reflect on how to approach the next 
set o f interviews also had other fortuitous advantages (described later).
My purpose in interviewing was to identify individuals, who through personal 
experience were involved in one or more parts o f the RM Translation process, and to 
try and explore the perspectives and experiences regarding this process with them in a 
semi-structured dialogue that was recorded and then transcribed. In most cases, 
interviews developed into a format more typically recognised as a ‘conversation with a 
purpose’ (Burgess, 1988). Interview duration ranged from 60 to 80 minutes and took 
place at times and locations convenient to the interviewees (usually their academic 
office, hospital unit, or company premises).26
All transcripts were anonymised by replacing full names with codified initials. The 
interviewees’ main professional roles (e.g. PI, founder, or clinician) are also mentioned 
under each quote along with the date (year) of the interview. Finally, people’s names 
(e.g. colleagues/collaborators mentioned), company names and products have been 
replaced by simple descriptions such as [Colleague], [Company] and [Product]. A table 
with the coded initials and brief description of the roles o f each interviewee can be 
found at the end of the thesis in the Appendices (Appendix 1, ‘List of Interviewees’).
26 It w ou ld  b e  d ifficult to  o v er e m p h a s ise  th e  c h a llen g es  in volved  in acq u iring in terv iew s w ith  m an y o f  th e  b io en tre p r en eu rs  
in clu d ed  in th is  stud y . B eca u se  o f  th e ir  ex tre m e ly  b usy  sch ed u le s , it w a s  o f te n  d ifficult to  c o n ta c t th e m  at all, n e v e r  m ind  to  
s ecu re  an a p p o in tm e n t. Even o n c e  an a p p o in tm e n t had b een  m a d e  (m o st  o f  th e  t im e  a fter  'in te n se ' an d  long  
co m m u n ica tio n  w ith  th e  in te r v ie w e e 's  secretary ), it w ou ld  o ften  b e  ch a n g ed  a t th e  last m in u te  d u e  to  th e  u n p red ic ta b le  
sch ed u lin g  d e m a n d s  o f  th e  in ter v iew ee . T h ere are n u m ero u s  a n e c d o te s  to  report, including o n e  a b o u t th e  in te r v ie w e e  w h o , 
a fter  fa iling  to  ap p ea r  at th e  sch ed u led  t im e  and p lace  o f  th e  in terv iew , a g re ed  to  rearran ge it for  th e  sa m e  d ay  an d  tim e  
th e  fo llo w in g  w eek . H ow ever, in an a tte m p t to  'sq u eeze ' th e  in terv iew  in to  his sch ed u le , h e  arranged  to  m e e t  m e  in a 
(cardiac) in ten s iv e  care unit in a room  o ccu p ied  by o n e  o f  his c o llea g u es , a f e w  p a tien ts , and a fe w  n urses rea p p ea r in g  every  
f e w  m in u tes  t o  ask  him q u e st io n s . In a n o th e r  c a se , th e  b io en tre p r en eu r  n o t on ly  rearran ged  th e  in terv iew  th r e e  tim e s  
(a lw ays w ith  an e-m ail and five  m in u tes  b e fo re  I arrived at his o ffice ), b u t a lso , w h e n  w e  finally  did m a n a g e  to  b eg in  th e  
in terv iew , h e  d isa p p ea red  in term itten tly  in to  th e  op era tin g  th ea tre . Finally, I ca n n o t b ut sy m p a th ise  w ith  th e  PI w h o , in 
re sp o n se  to  m y re q u est for in terv iew  le tter, w r o te  back stating: T h an k  you  for  you r m e s s a g e . I am  very  sorry b ut I will n ot  
b e  a b le  to  h elp  you  a t th is  t im e . I h ave a c o m p le te ly  full diary for th e  n ex t f e w  m o n th s  -  partly as a resu lt o f  trying to  m e e t  
th e  re q u ir em en ts  o f  th e  n ew  ATMP regu lation s! I h o p e  th a t you  will b e  ab le  to  find th e  in form ation  you  n e e d  e lse w h e r e .  
O n ce again  I am  very sorry. I w ou ld  norm ally  b e  very  happ y  to  h elp  w ith  a p roject such  a s you rs'.
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Interview Responses
A number o f individuals did not respond to request for interviews (despite follow-up 
letters), including five founding directors o f well-known UK academic spinouts. A 
possible explanation is that many o f these biotech entrepreneurs are high-status busy 
individuals, some o f whom have already been interviewed numerous times about 
similar themes, so they felt that they have already contributed their views and chose 
not to take part. On the positive side, their opinions and views on thesis-relevant issues 
are available through a variety of sources, including journal interview articles, editorials, 
commentaries, books, on-line radio interview archives and blogs. I have used these 
materials to the extent feasible to this research and have referenced them 
appropriately.
Actors: Why Focus on Bioentrepreneurs?
My interest in the role o f the RM inventors/bioentrepreneurs was sparked by previous 
research27 during an MSc course where I had the opportunity of interviewing a number 
o f different Regenerative Medicine stakeholders including basic research scientists, 
clinicians, bioentrepreneurs, bioengineers and others. In my experience, the majority o f 
participants from other stakeholder groups, such as clinical researchers and biomedical 
scientists, while knowledgeable and experienced in the own field, are unfamiliar with 
Translation issues outside their ‘area’. For example, basic scientists are well versed in 
the craft from stem cell cultures to the regulation and standards o f fundamental 
laboratory research. They don’t, however, have the contact with clinical centres which 
would inform them about the ‘real’ medical needs, and thus luck knowledge on the 
‘clinical side’. Clinicians, although aware o f the medical needs o f their patients, are 
often unaware of the cutting-edge laboratory-based developments. Both basic 
scientists and clinicians also seem to be unfamiliar with many issues relevant and 
necessary for Translation, such as regulation and IP. When asked about these issues,
271 h a v e  carried  o u t re lev a n t research  in partial fu lfilm en t o f  th e  re q u ir em en ts  for th e  d e g r e e  o f  M Sc in H ealth  M a n a g e m e n t  
(2 0 0 2 -2 0 0 3 )  a t Im perial C ollege B u sin ess S ch ool, London. The stu d y , w hich  is ca lled  'S tem  C ell-B ased  P roducts: From B ench  
to  B ed sid e', w a s  co n d u c ted  b e tw e e n  M ay and S ep te m b e r  2 0 0 3  and  in co llab ora tion  w ith  N ovaT hera, an  Im perial C o llege  
sp in o u t RM com p an y . T he s tu d y  d escr ib es  and a n a ly ses  th e  jou rn ey  o f  n ovel ce ll-b a sed  p rod u cts  b eg in n in g  w ith  th e  
lab oratory  and  en d in g  w ith  th e  m arket, including: in te llec tu a l p rop erty  is su e s , th e  role o f  regu la tory  a g e n c ie s  for  p a tien t  
p ro tectio n  and  public h ea lth , e th ica l and socia l co n s id era tio n s , leg is la tion  in th e  US, UK and o th e r  E uropean  co u n tr ie s . I h a v e  
a lso  carried  o u t  m arket and  c o m p etitio n  an alysis to w a rd s  b u s in e ss  p lan n in g and com m erc ia lisa tio n  o f  a sp e c ific  p rod u ct  
called  N ovaLung. Q u alitative research  m e th o d o lo g y  w a s  u sed  to  p rov id e an o v erv iew  o f  th e  m ark et for  N ovaL ung (at th e  
t im e  o f  research  N ovaLung w a s  a ca n d id a te  p rod uct u n d er d e v e lo p m e n t) .
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which they consider to be ‘outside their area’, the most frequent responses would be 
something along the lines of: ‘I am really not the best person to ask that’.
In contrast, bioentrepreneurs are, in a sense, at the centre o f the sector and are, in a 
way, the protagonists in all the interactions in the changing terrain o f Regenerative 
Medicine. They are, so to speak, the ‘necessary glue’ that will either make or break this 
sector. Their ability to develop new skill sets, to adapt these to rapidly evolving 
conditions, and to communicate their needs, and the needs o f their sector, to a wide 
range of, often scientifically untrained, stakeholders, funders, and policymakers is at a 
premium as this field reaches its ‘tipping point’ (or not). Bioentrepreneurs are often 
principal investigators (Pis), usually heads o f laboratory teams, who have pursued the 
commercialisation o f one or more of their laboratory findings/inventions through 
founding a company. These bioentrepreneurs are, in my experience, the most 
‘knowledgeable’ and informed actors in the process of Translation, with knowledge 
ranging from basic science, regulation, and manufacturing to business, intellectual 
property and financial expertise.
My focus on this unique type of actor is also supported by a recent study that has 
confirmed the importance and centrality of bioentrepreneurs in the RM Translation 
process. In the research study which was funded by the U K  Engineering and Physical 
Sciences Research Council (EPSRC) and titled ‘Enabling the Emergence o f the 
Regenerative Medicine Industry in the UK’, Livesey et al. (2008) made eight principal 
recommendations for government which they consider to be crucial to the long-term 
success of the industry. One of the recommendations states:
Enhance research and training funding in RM to develop ‘polymaths’ 
who can embrace all aspects o f Regenerative Medicine and become the 
entrepreneurial focus for emerging companies
In outlining their recommendation, the authors continue:
The demands o f a multidisciplinary area like Regenerative Medicine are 
very high for those wishing to start and build a company. As well as 
having to have an understanding of the underlying biology, company 
founders will have to become conversant in process engineering,
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complex regulation and new product development for a difficult 
customer. Individuals with these skills are in short supply. The 
funding of doctoral training centres (DTCs) across a number of biology 
and healthcare related areas and in particular the recent £10 million 
funding for two DTCs related to Regenerative Medicine is a strong 
positive move. However, these research focused doctorates are likely to 
complete in 2012 and there is a need for talented personnel on a 
shorter time frame. Therefore we propose a Masters level 
qualification, possibly tied to a translational institute, specifically aimed 
at deepening the technical expertise o f rising stars in the RM  field  
while providing them with the business skills required to start 
and successfully grow  a company, [emphasis added]
From the above excerpts, it is clear that the field o f RM is in need o f these ‘polymaths’. 
The research acknowledges that those who are interested in starting and building an 
RM company as a vehicle to commercially translate their research inventions must 
possess many ‘talents’. Starting with the essential biological knowledge, they must also 
become versed in bioprocess engineering, the ever-changing complex regulatory 
guidelines, and understand the process of ‘new product development’. In addition to 
the scientific and technical expertise, RM polymaths must acquire business skills which 
are essential in order to ‘start and successfully grow a company’. Although the report 
suggests that doctorates and Masters level qualifications focussed on the acquisition of 
those skills would be a viable solution, it also recognises that the ‘there is a need for 
talented personnel on a shorter time frame’.
Indeed, all the participants are principal investigators (Pis) in a field under the 
definition of Regenerative Medicine and have experience of scientific work with one or 
more types o f stem cells (i.e. adult, embryonic, foetal, cord blood), tissue research. 
Three out o f 14 are also clinicians (i.e. clinically trained) while others have headed 
clinical trials (in RM or a relevant field) or have some kind o f clinical involvement 
through clinical collaborations. In fact, all the respondents have mixed roles as they are 
involved in both basic and clinical research in order to achieve the objectives of 
Regenerative Medicine translational research. In addition, all fourteen interviewees 
have, at some point in their career, been involved with the commercial aspects of
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Translational Research in addition to work on their discipline, either by licensing or 
founding a company. Finally, in addition to their academic, clinical and commercial 
expertise, all the participants can be considered as integral members of a diverse but 
close-knit research, policy and industry-shaping community. In other words, these 
actors are positioned at the ‘heart’ or ‘hub’ o f contemporary RM technological 
innovation, characterised by close relationships and transactions between the academic, 
clinical and commercial ‘space’ o f Regenerative Medicine.
In crafting an understanding of the role of the bioentrepreneur in the Translation 
process I use primarily 14 in-depth interviews, which comprise the core dataset o f this 
study. It is also worth mentioning at the outset that although the dataset is 
comparatively small (due to the relatively small population o f potential research 
subjects, their extremely busy schedules, and the consequent difficulty of acquiring 
interviews), this research was intentionally qualitative in focus, and is thus not intended 
as a representative survey or comprehensive overview. It is instead exploratory and 
indicative — seeking primarily to identify key factors influencing the Translation 
process in the context o f Regenerative Medicine, which may in turn serve as a basis for 
further — potentially more representative or quantitative, research.
The following sections introduce the research methodology used for this study and 
how it has guided data collection, analysis and development o f theory (conceptual 
framework). First a brief overview of the process of grounded theory is presented. The 
subsequent sections describe the interview data collection phases. The chapter 
concludes by explicating the analysis approach for the empirical data.
G T Methodology - A Brief Overview
Grounded theory is a qualitative research approach that was collaboratively developed 
by Barney Glasner and Anselm Strauss in the 1960’s in their influential book ‘The 
Discovery o f Grounded Theory: Strategies for qualitative research’ (1967).28 What 
differentiates grounded theory from other qualitative research is that is explicitly 
emergent. In other words, G T methodology advocates creating new theory (consisting
28 'The D iscovery  o f  G roun d ed  T heory' (1 9 6 0 ) articu la tes  th e  au th ors' research  s tr a te g ie s  fo r  s tu d ie s  o f  p a tien ts  dying in 
h osp ita ls .
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of interrelated concepts) based on the data rather than exploring data to test existing 
theories. In treating ‘all as data’ it applies a pragmatic approach, combining qualitative 
and quantitative data and data gathering methods to encourage a rich understanding of 
the situation under study and hence to enable the generation of theory. Interviews are 
typically the main source o f the information the researcher will develop the theory 
from, but can also include other sources of data such as existing research literature and 
quantitative data (e.g. survey data) (Glaser & Strauss, 1967).
As the essential character o f GT lies in the generation o f theory from data by constant 
comparative, qualitative analysis, it is no surprise that it features a circular, interlinked, 
global rather than linear approach to the research process. A grounded theory study 
could be summarised graphically:
Open
Focussed
GT Starting 
P o in t
Interview s
Coding
Develop Theory
Transcribing
M em oing
The GT approach provides a broad framework for the researcher to approach a 
phenom enon/problem  beyond the confines o f predetermined answers and thus 
enables a flexible and detailed in-depth study of issues that is unconstrained by 
predetermined categories of analysis. As a result, GT is particularly appropriate for 
exploratory studies like the one described in this thesis because it does not force the 
content (data) and process of the study into predetermined theories and structures.
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Why Grounded Theory Methodology for this Study?
The decision to use grounded theory methodology was only taken after conducting the 
pilot (interview) study. An initial analysis o f the two pilot interviews showed that it was 
not suitable to base the overall research study on existing theoretical models (as many 
o f them have used either a diverse pool of stakeholders or have concentrated their 
attention on one or two specific aspects o f the phenomenon o f RM Translation). In 
this project the focus needed to be on bioentrepreneurs experiences and views on 
Translation and hence an inductive approach was chosen to explore the subject area 
through the informants’ eyes. The decision to use grounded theory methodology was 
further supported by the dearth o f existing theory regarding RM Translation.
Indeed, the fact that RM Translation is largely unexplored, with a dearth of social 
science studies currently addressing the ‘area’, had implications for the trajectory o f my 
research. More specifically, when I began the research I considered my work as a 
mainly explorative study aiming to understand the phenomenon of Translation. The 
‘emerging’ character o f the project meant that at the beginning I was not completely 
certain which literature would turn out to be the most relevant.
Grounded theory scholars’ have different opinions about the most suitable time at 
which to review the literature. For example, Glaser and Straus (1967) and Glaser 
(1978) recommend reading widely while avoiding the literature that is most closely 
related to the research study (which should be delayed until after completing analysis). 
Their concern is that the researcher will see his/her data through the lens of earlier 
ideas (often known as ‘received theory’).
In this study I have followed the advice o f Charmaz (2006) and carried out an initial 
review o f the literature before the first data collection (pilot interviews) took place. The 
main reason behind this approach was to learn whether any similar research had 
already been conducted in this area and to identify methodological approaches that 
have been followed. As a result, I read widely on the social science of Regenerative 
Medicine and on entrepreneurship which appeared to be the most relevant at that 
point. After I began collecting data (especially after I completed the first round of 
interviews) I was better equipped to pinpoint the literature most closely related to what 
I was discovering about this field from the actors most deeply embedded within it and
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thus identify the theories, frameworks, and conceptual tools that would be most 
appropriate and useful to present and analyse my own data.
Use o f G T Methodology (in this Study)
The data collection and analysis for this study followed a cyclical process typical for 
GT methodology, by using early findings to shape the on-going data collection. The 
pilot study involved two bioentrepreneur interviews. This preliminary data collection 
phase was then followed by seven more in-depth interviews that helped to explore 
issues raised in the pilot study. A second and final round o f interviews (again seven in 
number) was undertaken exactly a year later (see section on ‘Interviewing’ earlier in the 
chapter).
Interviews- Sampling
GT methodology advocates a form of purposive sampling known as ‘theoretical 
sampling’. According to theoretical sampling, participants in a study are selected 
according to criteria specified by the researcher and based on initial findings. In other 
words, early analysis o f data indicates issues that need further exploration and thus the 
sampling process is guided by the ongoing data collection, analysis and theory 
development. Unlike the sampling done in quantitative investigations, theoretical 
sampling cannot be (entirely) planned before embarking on a grounded theory study. 
Instead, the specific sampling decisions should evolve during the research process 
itself.
In beginning the study, there were, however, a number o f sampling matters that I 
could think about and plan. For example:
1 - The group to study was chosen- that is bioentrepreneurs
2- The kinds of data to be used- interviews (mainly).
3- As I was studying an evolving process/phenomenon, I was considered useful 
to follow different individuals at varying points.
In drawing up this initial sample o f participants I sought information from the 
following sources:
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■ Speakers’ lists from past London Regenerative Medicine Network meetings and 
other conferences to identify people active in the areas in which I am interested
■ Professor Chris Mason (UCL), a Regenerative Medicine translational investigator 
who has renowned UK and international expertise in the field (i.e. in both clinical 
and commercial RM Translation)
Once the project was underway, however, many o f the initial decisions about sampling 
had to be changed. The most important deviation from GT methodology in this study 
is that decisions about interviews (bioentrepreneurs and companies) although modified 
according to the evolving theory they were also highly depended upon access.
Despite difficulties in securing interviews, the final list o f potential participants 
included individuals and companies based in various UK universities.29 In addition, the 
firms and research groups behind them represented a wide range o f approaches to 
Regenerative Medicine, including scaffolds, cell therapies, tissue repair, combination 
therapies (i.e. cells and scaffolds combined) and cover a wide range o f therapeutic 
areas, including wound care, ophthalmology, orthopaedics (bone and cartilage), 
aesthetics (skin and hair rejuvenation), production of clinical grade cell lines for 
therapies as well as for the drug discovery and toxicology arena.
Interviews- Preparation
The participants were contacted by an e-mail and the information sent out before the 
interview included a small summary of the project (background and objectives) and a 
description o f the interviewing procedure. The consent form was also attached which 
ensured participants about anonymity and confidentiality o f data collected (see 
Appendix 2).
Interviews- Pilot Study
In order to determine the most important issues o f the Translation process according 
to bioentrepreneurs, preliminary interviews were carried out with two informants. The 
participants were selected based on the researcher’s judgement. This pilot study was (as
29 To p reserv e  an on ym ity  th e  u n iv ersitie s  are n o t n am ed .
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the rest o f the interviews) guided by the ethical principles on research with human 
participants set out by the LSE/ESRC (as described in a later secdon under the 
heading ‘Ethical Considerations’).
The pilot interviews started with the basic research question: ‘W hat is your experience 
with clinical and commercial Translation in the RM field?’ I then encouraged the 
informants to provide open-ended general descriptions o f their work for around 45 
minutes without asking specific questions.30 This increased the likelihood that the data 
primarily reflect the informant’s own experience and priorities and were not (in any 
way) directed from the questions I asked. In this way, these initial interviews gave me 
the opportunity to explore ‘Translation’ over a broad context, to address multiple 
facets o f the issue, and thus to bring to my attention various issues that I had not 
encountered before, giving me the opportunity to build an understanding o f the real 
problems and challenges encountered in this complex and largely unexplored process 
that was led by my informants’ own sense of what mattered most to them.
Development o f Interview Questions
All first round interviewees were asked a similar set o f questions that was developed 
based on findings from the pilot study. According to G T methodology guidelines 
interview questions should give as little guidance as possible in order to allow 
informants to talk about what is of importance to them regarding a given context.
The broad areas explored involved the current state of Regenerative Medicine in the 
UK, the participant’s experience with regulation (e.g. regulatory agency representatives, 
guidelines, etc), experience with intellectual property (IP) (such as patenting and 
licensing of inventions), product/therapy design and development (including 
manufacturing issues), collaborations (between basic research, clinic and 
industry/company), how to get RM into the clinic through setting up an academic 
spinout company (funding issues, entrepreneurial spirit, integration of expertise, 
conflicts of interest issues), relationship with university and academic technology
30 This in terv iew  ap proach  is ca lled  'c o n v e rg en t in terv iew in g '. The c o n v er g en t in terv iew in g  te c h n iq u e , a lth ou gh  it h as m any  
u se s , is m o st  va lu ab le  w h e n  th e  re sea rch er  is in s o m e  d o u b t ab o u t th e  in form ation  w h ich  is t o  b e  co lle c te d . A lso, if th e r e  is 
th e  in ten tio n  to  u se  su rveys to  c o llec t  in form ation , c o n v er g en t in terv iew in g  can h elp  th e  re sea r ch er  d e c id e  w h a t q u e st io n s  
to  ask  in th e  survey. 'C on vergen t in terv iew in g  e n a b le s  research ers  to  d e te r m in e  th e  m o st  im p ortan t a n d /o r  k ey  issu es  
w ith in  a p op u la tion  rather th an  a full list o f  is su e s  in an organ ization  or barriers to  ch a n g e  in a particular co n tex t' (Jep sen  & 
R odw ell, 2 0 0 8 ).
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transfer offices (TTOs).31 The interview questions can be found at the end of the 
thesis in the Appendices (Appendix 3j ‘List o f Interview Questions’).
Following GT methodology all interviews were transcribed and coded (see ‘Data 
Management and Analysis’ below) immediately after they took place. Thus, initials 
findings from coding helped to (re)shape the questions/discussion for the subsequent 
(second round) interviews.
Data Management, Data Analysis and Theory Generation 
For this study only a word processor (Microsoft Word) and pen and paper were used 
to manage the interview data. Interview transcripts were printed in the left hand two- 
thirds o f the page, leaving one third of the page free for note-taking and coding.
Following GT methodology, interview coding was used to capture what was in the 
interview data. Interview coding is the first step o f data analysis and it helps the 
researcher to move away from particular statements (in transcripts) to more abstract 
interpretations of the interview data (Charmaz, 2006).32 After reading the transcripts 
the researcher needs to identify those phenomena/experiences/perspectives important 
to the participant and assign them a conceptual label, known as code. Several codes are 
then grouped into more abstract ‘categories’ which will form the basis o f a new theory. 
In other words, ‘coding is the pivotal link between collecting data and developing an 
emergent theory to explain these data. Through coding you begin to define what is 
happening in the data and begin to grapple with what it means’ (Charmaz, 2006:46).
For the pilot study, open coding was performed using pen and paper (the use of 
qualitative software was judged to be unnecessary in this research project as the 
number of interviews is relatively small). Open coding is the part o f the analysis 
concerned with identifying initial phenomena and producing a list o f themes of
31 I fo u n d  th a t during m y in teraction s w ith  b io en tre p r en eu rs  m y bio logical s c ie n c e s  back grou nd  w a s  very  u se fu l, as I w a s  
a b le  to  fam iliarise m y se lf  w ith  ea ch  in te r v ie w e e 's  (specific) fie ld  o f  research  rea so n a b ly  quickly and did n o t sp en d  t im e  
trying to  grasp  sc ien tific  co m p le x itie s  th a t m igh t h ave ch a llen ged  a 'pure' so c io lo g is t . I w a s  th u s  a b le  to  c o n c e n tr a te  on  th e  
'n o n -sc ien ce ' ch a llen g in g  issu e s  such  a s IP and  regu lation s. H ow ever, in ord er to  avoid  'in fluencin g' th e  in te r v iew ees ' 
r e sp o n se s  (for ex a m p le , by en cou rag in g  th e ir  'a p p etite ' for e lab ora tin g  on  p rod u cts and p r o c e ss e s )  and  risk lo s in g  im p ortan t 
d ata , I d id n o t inform  any o f  m y in te r v ie w e e s  a b o u t m y b ackground.
32 GT m e th o d o lo g y  a d v o ca te s  u sin g severa l cod in g  te c h n iq u e s  to  ex a m in e  in form an t's  a cc o u n ts  a t d iffer en t levels: o p en  
cod in g , fo c u se d  cod in g , axial cod in g  and th eo r e tic a l cod in g . For m o re  d eta ils  on  th e  variou s te c h n iq u e s  s e e  C harm az (20 0 6 ).
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importance to the respondent. The process involved working through each o f the 
transcripts and using line-by-line coding to take note o f themes and phenomena on the 
margins. Codes were attached to participants’ words and statements in the transcript to 
capture what has been said. Some codes were very close to the respondents account 
(such as keywords or phrases, ‘in vivo codes’) while others were more abstract or 
conceptual.
Examples o f ground theory codes, memos and visual representations provide an 
insight into how the final grounded theory categories were developed and how it led to 
the formulation of a substantive theory. In this case, a large number o f initial and 
tentative codes were assigned to each o f the two transcripts. Most o f these codes could 
be grouped into 7 categories: ‘regulation’, ‘funding’, ‘collaborations’, ‘intellectual 
property’, ‘business model’, ‘expertise’, ‘knowledge brokering and commitment’. An 
important part o f the analysis at this stage was to keep track o f how often the codes 
were used in the pilot interviews. These initial codes and the resulting categories later 
guided the development of the final categories (including the ‘core’ category).
In GT methodology it is important to verify all codes and categories that are assigned 
to interview data to ensure that they are applied in a consistent manner (Miles & 
Huberman, 1994). Ideally, a larger number o f interviews would have been included in 
the pilot study in which case I would have the opportunity to open code them and 
compare between assigned codes.
After I had established some strong analytic directions through my initial (line-by-line) 
coding I began using focused coding to synthesize and explain larger segments o f my 
data. Focussed coding involves using the most frequent and /o r earlier codes (from 
open coding pilot interviews) to shift through large amounts o f data from the next two 
interview phases. In other words, ‘focused coding requires decisions about which 
initial codes make the most analytic sense to categorise data incisively and completely’ 
(Charmaz, 2006:57). In short, the process of focussed coding is useful in determining 
the adequacy o f the initial concepts/codes developed by applying them and testing 
them on further interview transcripts.
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In short, my initial codes were modified and verified by being applied to further 
interviews transcripts but stayed alike for the most part. In other word, comparison 
between ‘pilot interview’ codes and ‘first round interviews’ codes has helped to clarify 
whether the codes were reliable and truly represented the empirical data. During the 
extended coding process some categories became more prevalent and some did not 
appear to have the ‘importance’ initially placed on them (mainly through my 
assumptions based on the initial literature review) and became redundant. For example 
the category ‘ethics’ which had been identified in the pilot study was not sufficiendy 
prevalent as previously identified.
The second round o f interviews helped to verify the initial codes further. This time 
focussed coding was adopted which is considered more directed and selective than 
open coding (used in pilot and first round transcripts).
Developing Categories and Memoing
All passages (quotes) that were assigned to a specific code and shared the same (or 
similar) characteristics were grouped together into more abstract categories (which 
could be interlinked and build the basis for a theory). In GT methodology the process 
of coding and developing categories is supported by writing memos. In effect, memos 
are notes kept by the researcher continuously while reading and coding the data in 
order to provide a record o f thought and ideas and enable the researcher to reflect later 
on in the analysis on initial thoughts and hypothesis regarding categories, properties, 
and relationships between categories.
In this study, memoing continued in parallel with data collection, transcription, reading 
and coding. Memos were used to reflect about potential meanings of participants’ 
statements and compare concepts identified in the transcripts to each other (code 
memos) and to the literature (theoretical memos). These memos were later consulted 
when establishing links between categories and ‘building’ the initial theoretical 
framework. The writing o f memos was particularly useful as it allowed me to keep 
track o f thoughts and ideas without the pressure of having to immediately decide 
where (if at all) and how these ideas fitted with the research findings and analysis .This 
system o f coding and memoing was maintained for both rounds o f interviews.
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Sorting
In using GT methodology it is assumed that the theory/theoretical framework is 
concealed in the data ‘waiting to be discovered’. While coding made visible some of its 
components and memoing added the relationships which linked the categories to each 
other it is through the process o f sorting that I structured my ‘theory’. For the actual 
sorting I worked to a large table and grouped the memos on the basis of similar 
categories or properties they addressed. Afterwards, I arranged the groups on the 
‘sorting plane’ so as to reflect the relationships between them. Having done the coding, 
memoing and sorting, I began writing the first draft o f my ‘theory’ by typing up the 
memos and integrating their ‘notes’ into a coherent argument.
Generation ofTheoiy (Substantive V's Formal Theory)
In general, the data was analysed by means o f comparative methods and analytic 
deduction, revealing recurring themes or categories in the transcripts, in the literature 
and in fieldwork notes. The iterative process o f constant comparison, multiple reading, 
coding, memo writing and creating categories and relationships (and further 
abstractions) (Glaser & Strauss, 1967; Strauss & Corbin, 1990) between them resulted 
in the emergence o f the central themes of funding, regulation, collaboration, expertise, 
business models and innovation, and intellectual property. Central to this process is the 
link between bioentrepreneurs and the various stakeholder spheres and that (at least 
for the now) ‘all things in Translation’ occur in relation to them. In addition, each 
category or theme impacts on the others.
After months of analysing, comparing and revisiting the codes and categories and 
examining relevant literature, the research finally came together during the writing of 
the draft emprirical chapters. As the research instrument in G T methodology is the 
researcher (Patton, 1990) the theory that has emerged is not the only possible one. 
What this thesis has tried to capture is the researchers understanding at a particular 
point in time- of specific incidents and the views o f specific individuals regarding those 
incidents.
It is worth noting here that grounded theory may take several forms. One 
differentiation is between substantive and formal theory. ‘Substantive theory is 
developed for a substantive or empirical area o f sociological inquiry such as patient
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care, race relations, professional education, delinquency or research organisations. By 
formal theory, we mean that developed for a formal, or conceptual, area o f sociological 
inquiry, such as stigma, deviant behaviour, formal organisation, socialisation [...] 
rewards systems, or social mobility. Both types of theory may be considered as 
“middle-range”. That is they fall between the “minor hypotheses” o f everyday life and 
the “all-inclusive” grand theories’ (Charmaz, 2006:32 and 33).
This thesis has developed a substantive theory as collection o f data and interpretation 
focus on particular area: the relationship between RM translational research and UK 
bioentrepreneurs experience/perception of the regulatory/economic/and 
collaboration landscape. This thesis does not provide the scope to raise the specific 
substantive theory to a formal theory that would be generalisable across a wider area, 
such as other types of biomedical research (other than RM) or the status o f RM TR in 
other countries.
G T Methodology- Criteria for Success
Glaser (1992) suggests two main criteria for judging the adequacy of the emerging 
theory: one, that it fits the situation; and two, that it works- that is, it helps the people 
in the situation to make sense o f their experience and to manage the situation better.
G T Methodology- Limitations
Like any other research methodology, GT methodology has limitations. Some point 
out that the research can take considerable time and effort (due to the tedious coding 
process and memo writing as part o f the analysis), and it can be difficult to predict the 
end, thus causing budgetary problems (Bartlett & Payne, 1997). Others consider as a 
limitation that the use o f GT methodology to explore and explain a phenomenon 
and /or build a theory is a very subjective process which is highly dependent on the 
researcher’s abilities (his/her ‘theoretical sensitivity’). This study has followed the 
methodological guidance of Strauss and Corbin (1990) and Charmaz (2006) to collect 
and analyse the interview data. Finally, as GT sets out to find what theory accounts for 
the research situations as it is, findings are not generalisable.
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Ethical Considerations
The London School o f Economics and Political Science has a set o f procedures in 
place to review proposed research for ethical accountability. The LSE research ethics 
policy document, which incorporates the minimum requirements as prescribed in the 
ESRC research ethics framework, aims to guide LSE researchers’ thinking on research 
ethics issues and sets out the process for ethical review of research. Where a project is 
identified as involving human subjects all researchers (staff or students) are required to 
complete the Research Ethics review checklist which will determine the level of 
intervention required by the Research Ethics Committee (REC). In the proposal for 
this research to the Department of Sociology, and as part o f my application for 
sponsorship to the Economic and Social Research Council (ESRC), I completed the 
self- assessment checklist and obtained the review and approval of my research 
supervisor and the Department (Sociology). In the subsequent carrying out o f the 
project, I have made no changes to my objectives or methodological approach that 
would in any way modify the original self-assessment.
All the documentary sources used in this thesis are either publicly available or have 
been voluntarily provided by the participants (e.g. company data, leaflets, reports). By 
design, the research is not seeking either sensitive or proprietary information, and 
during the interviews I have not requested, nor have I encountered, ethically sensitive 
data. When and where commercially sensitive information has been mentioned by 
participants in the flow of the interview, it was used to gain further insight into the 
issues under discussion and has not been cited anywhere in the thesis.
In all formal interviews, I have asked permission to record and offered the participants 
the option to review and modify the resulting interview transcript for accuracy of 
information. I have also provided the interviewees with a consent form briefly 
describing the title and purpose of the project, the option to subsequently withdraw 
parts o f or the whole interview, and also guaranteeing confidentiality and 
anonymisation in publications and presentations. Each consent form was signed by me 
and the participant.
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Analysis of Findings
Data collected from documentary sources and fieldwork conferences/meetings/ 
workshops were compared to the grounded theory categories identified in the 
interviews in order to support the analysis o f findings. The findings from empirical 
data were then compared to the reviewed literature (Chapters 4, 5 and 6), which lead to 
conclusions and recommendations (Chapter 7).
Limitations o f Research
The relatively small number o f bioentrepreneur interviews may be considered a 
limitation of the study. However, this may be justified by the fact that the area of 
Regenerative Medicine therapeutics is just emerging in the UK and elsewhere and 
interviewees were selected to represent individuals with renowned national as well as 
international expertise. Secondly, there are only a handful o f UK companies involved 
with clinical Translation of Regenerative Medicine research and even fewer (academic) 
groups/companies with products on the market (i.e. commercial Translation). Finally, 
this is a qualitative constructed grounded theory study; therefore findings are not 
generalisable.
Chapter Summary and Conclusion
This chapter has introduced the three main ‘themes’ of interest (funding, regulation, 
collaboration) and discussed the choice o f grounded theory methodology as a suitable 
research methodology for this study. It is necessary to capture the views of 
bioentrepreneurs, as bioentrepreneurs are critical to the process of Translation and 
they appear to integrate resources and mediate communication between other 
stakeholder groups such as biomedical scientists, clinicians, business people and 
industry representatives.
A grounded theory methodology has been followed and a grounded theory has been 
developed to provide an explanation for the phenomenon under study: the relationship 
between ‘enhanced’ Translation and bioentrepreneurs’ perceptions of funding 
(schemes), regulation (guideline, compliance, harmonisation attempts), and 
collaboration (exploitation and integration of expertise). The emerging theory can be
45
categorised as ‘substantive’ rather than ‘formal’ since the collection o f data and their 
interpretation focus on the explanation o f a particular area (RM Translation through 
the perspective o f bioentrepreneurs).
The chapter has explained in detail each o f the data collection methods (sources and 
phases) including sampling, ethical considerations and methodological limitations. The 
iterative cycle o f data collection and analysis is an essential element of grounded theory 
methodology and has helped to shape the ongoing data collection as well as the 
development o f the final ‘theory’. The last section below offers a brief breakdown o f 
the rest o f the thesis chapters.
Overview o f Chapters
In the section below, I offer a brief breakdown o f the rest o f the thesis chapters.
Chapter Two — Regenerative M edicine and Translational Research
Chapter two is divided into two parts. In the first part (‘Understanding Regenerative 
Medicine’), I trace the emergence o f Regenerative Medicine as the new and exciting 
‘paradigm shift’ in biomedicine, its current status in the UK, as well as its potential to 
revolutionise medical practice as a novel and unique source of healthcare innovation. 
In the second part (‘Understanding Translational Research’), I provide a detailed 
explanation of the phenomenon o f Translation in biomedicine in general and its 
significance. Finally, I introduce the unique combination of these two paradigms — the 
case o f Regenerative Medicine Translational Research (RM TR) which is the central 
focus o f this thesis.
Chapter Three -  The Social Science Perspective
This chapter examines the literature on the social science studies o f Translational 
Regenerative Medicine and positions my research within this general landscape. 
Starting with a brief introduction into the social science studies o f Regenerative 
Medicine in general and an explanation o f the current influx of interest and funding in 
relevant research areas (especially in the UK), I then continue to review in more detail 
those studies that focus on Translational Regenerative Medicine (i.e. social studies o f 
the ‘Bench-to-Bedside’). These studies draw from a wide variety o f sociological
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perspectives (e.g. sociology of expectations, boundary work, etc) and employ different 
theoretical tools and concepts. This chapter establishes the ‘location’ o f my research 
relative to the existing literature and suggests how the thesis will contribute to the 
‘bench-to-bedside’ area of scholarship by developing a richer description o f the 
mechanisms embedded in scientific and technological progress aimed at the 
development and commercialisation o f Regenerative Medicine therapeutics.
Chapters four, five, and six discuss the main empirical findings o f my research.
Chapter Four -  The Art of Funding
As mentioned earlier, funding appears to be one o f the fundamental pillars in 
Translation. In Chapter 4 ,1 present and examine the views of my respondents on the 
funding o f RM Translation in the UK, including issues o f availability and potential 
sources o f capital such as public funds, private venture capital and big pharma industry 
investments. The bioentrepreneurs’ perspective on the continuing search for a ‘viable’ 
business model for RM Translation is also discussed with particular reference to the 
role o f RM intellectual property as a foundation for such a model.
Chapter Five — The Art of Regulation
Chapter 5 explores the views of bioentrepreneurs on the theme o f regulation. Given 
the fact that I have conducted my data collection in two distinct ‘phases’ the data 
includes evidence o f the ‘dynamic’ regulatory landscape and the efforts of my 
respondents (and consequently of other stakeholders) to adjust. I begin by delineating 
the main problems faced and narrated by respondents during the first phase of data 
collection which I term the ‘era of uncertainty’. I then examine the bioentrepreneurs’ 
perspectives on the interaction with regulators and guidelines and discuss their 
perceptions about the effects of compliance on their work and consequently RM 
innovation. In the final part of the chapter, I draw from the empirical data to discuss 
issues that were repeatedly raised in the interviews such as the issue o f animal models, 
the type o f cells used — autologous or allogeneic, and study their significance in the 
process o f Translation.
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Chapter Six -  The Art o f Collaboration
Chapter 6 is in a way a study o f the respondents themselves as I delve into their ‘lived’ 
experience as bioentrepreneurs focussing on the more ‘practical’ activities behind 
Translation. This ‘practical’ side o f the Translation includes the building o f the 
entrepreneurial team, integration of necessary expertise, and the various other 
collaborations that respondents have mentioned. Bioentrepreneurs admit to playing 
the role o f ‘Research Translators’ hence in effect ‘driving’ and coordinating the 
Translation process (both clinical and commercial) which (as claimed by my 
informants) is often paradoxically hampered by the university and research sponsors 
themselves. Drawing from their narratives it appears that, in terms o f competitive 
advantage ‘value’, the most significant type o f collaboration for bioentrepreneurs (and 
their teams) to engage in is collaboration with clinicians. In the final part o f the 
chapter, I examine why clinician feedback is considered invaluable for the 
development of the therapies and I use the data to build a model that allows evaluation 
o f the importance o f three ‘conditions’ in the Translation process: clinical practice, 
product/therapy design, and timing of therapy delivery.
Chapter Seven — T hesis Conclusion
In Chapter 7, I endeavour to bring the entire story together, drawing conclusions 
designed not only to demonstrate the ‘centrality’ and importance of the role o f the 
bioentrepreneur as an actor in the RM Translation, but also the utility o f a variety of 
social theoretic tools to explore and characterise it. I will also draw some tentative 
conclusions from and for all three ‘areas’ under investigation, namely funding, 
regulation, and collaboration and their significance for successful Regenerative 
Medicine innovation. I will finally argue that the bioentrepreneur- focussed perspective 
offered in this thesis provides an important basis for understanding the phenomenon 
of Translation.
48
Chapter 2
Regenerative Medicine and Translational Research 
Introduction
Over the last century, increased demographics and the global epidemic of chronic 
degenerative diseases have put an increasing burden on healthcare systems (Cortese, 
2007; Waldman & Terzic, 2007). According to data from the Merck Institute of Aging 
and Health, ‘The United States is experiencing a longevity revolution and as the baby 
boomers approach retirement age, they are touching off an age wave that will double 
the number of Americans over age 65 to more than 70 million by 2030. Individual life 
expectancy is also increasing and the older population is growing much more rapidly 
than the entire population of the United States’.33 In addition, ‘the average 75-year-old 
suffers from 3 chronic conditions and takes 5 prescription medications’.34 The 
predictions concerning US demographics, along with the high prevalence o f chronic 
disease, are mirrored in most developed countries, including the UK. The expected 
population growth, in combination with the fact that the aging population is 
particularly susceptible to degenerative diseases, equates to added healthcare 
responsibility which will undoubtedly challenge healthcare systems across the globe, 
already stretched by an expansion of expenditure. These continuing rises in healthcare 
costs, in combination with social pressures for better treatments of serious diseases, 
have left many people frustrated by the slow rate at which new basic research 
knowledge translates into new products and therapies in both the pharmaceutical and 
biotechnology industry (Nightingale & Martin, 2004).
The paradoxical situation o f having a successful ‘front end’ o f the product 
development process (i.e. prolific basic research and inventions) followed by a decline 
in the innovative output (i.e. new products and therapies) at the ‘back end’ o f the
33 C en tres for D isea se  C ontrol and  P reven tion , M erk Institu te o f  A ging and  H ealth . The S ta te  o f  A ging and  H ealth in A m erica  
2 0 0 7 . W ash in g ton , D.C.: M erk Institu te o f  Aging and H ealth , 2 0 0 7 . A vailab le at h t tp : //w w w .s ilv e r b o o k .o r g . A ccessed  M arch  
2 0 0 9 .
34 C en tres for D isea se  C ontrol an d  P reven tion , M erck Institu te o f  A ging and  H ealth . T he S ta te  o f  A ging and  H ealth  in 
A m erica  2 0 0 4 . W ash in g ton , D.C.: M erck Institu te o f  A ging and H ealth , 2 0 0 4 . A vailab le a t h t tp ://w w w .s ilv e r b o o k .o r g . 
A ccessed  M arch 2 0 0 9 .
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development process, raises an obvious question: will continued heavy investment in 
basic research lead to the much-needed new therapies, at effective cost levels, across a 
wider range o f diseases and, at the same time, limit the growth of health care spending? 
The answer to this question is starting to become evident in the fairly recent 
emergence o f two major paradigm shifts in biomedicine, namely Regenerative 
Medicine (RM) and Translational Research (TR).
Understanding Regenerative Medicine
Various healthcare programs have been devised and implemented by nations in order 
to address the increasing medical needs and manage the cost of dealing with chronic 
disease. The current standard of care for age-related conditions is largely based on 
palliative therapies and the use of pharmaceutical drugs. With a few exceptions (such 
as antibiotics), most drugs can be divided into two categories: those which provide 
symptomatic relief and those that treat asymptomatic conditions, such as hypertension 
and hyperlipidimia, which are risk factors for other diseases (Sakurada et al., 2008). 
However, there are still many acute or chronic intractable degenerative 
diseases/conditions such as Parkinson’s disease, myocardial ischemia, stroke, diabetes, 
blindness, arthritis and others, for which no adequate treatment is available. In some of 
these cases, it might be possible to address the tissue degeneration or organ 
dysfunction associated with the condition through the transplantation o f donor- 
derived tissues and organs. Transplantation therapies, however, are crucially limited by 
a shortage of transplantable organs, tissues and cells. Even in cases where the organs 
are available, the necessary immunosuppressive medication has many side effects, 
including a reduction in life expectancy of ten years on average (Hollander et al., 
2009).
In short, despite the dedicated efforts to reduce the economic burden on healthcare, 
the situation stands to worsen. A large number o f  conditions have no available drug 
treatments, and even in cases where a pharmacotherapy approach is available, it allows 
patients to survive with a prolonged course o f their disease, thus contributing to the 
expansion o f healthcare expenditure.
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Regenerative Medicine is seen by many to have the potential to address this healthcare 
‘bottleneck’ by ameliorating the disease outcome and reducing the burden of chronic 
therapy. Unlike drugs that ‘work’ by providing symptomatic relief, Regenerative 
Medicine interventions aim to treat the root cause of the disease linked to progressive 
cell destruction and irreversible loss o f tissue function (Daley & Scadden, 2008). In 
other words, instead of simply mitigating the symptoms as traditional
(pharmaco)therapy approaches do, RM aims to repair the underlying pathobiology or 
restore/replace the native cellular architecture and organ function (Waldman et al., 
2007). In short, RM is widely seen as a new transformative paradigm in biomedicine 
which, driven largely by curative objectives, has the potential to reverse the daunting 
forecasts and decrease the burden o f disease which is paid for in both human and 
economic terms.
W hat is Regenerative Medicine?
Regenerative Medicine is a new and rapidly developing interdisciplinary branch of 
medicine, typically characterised by a convergence o f disciplines such as cell biology, 
biochemistry, molecular embryology, immunology, advanced materials science,
engineering and medicine.35 Since the term was first coined, there have been various 
attempts to define the field as well as map its relationship with ‘a good deal of prior 
activity’, especially in the fields o f Tissue Engineering, bone marrow and organ 
transplants, surgical implants (such as artificial hips), and increasingly sophisticated 
biomaterial scaffolds (Mason & Dunnill, 2008). O f the lengthy definitions in the 
scientific literature, the one by Greenwood et al. (2006) is probably the most clear and 
comprehensive:
Regenerative Medicine is an emerging interdisciplinary field of 
research and clinical applications focussed on the repair,
replacement or regeneration o f cells, tissues or organs to restore
impaired function resulting from any cause, including
35 For a d e ta iled  a cco u n t o f  th e  w a y  th e  various d isc ip lin es  th a t cu rren tly  co m p r ise  R egen era tive  M ed icin e  c a m e  to g e th e r  
s e e  th e  s tu d y  by Viola e t  al. (2 0 0 4 ) co n d u c ted  for  th e  N ational S c ien ce  Fou n d ation  (A vailable o n lin e  at 
h t tp : / /w w w .n s f .g o v /p u b s /2 0 0 4 /n s f0 4 5 0 /s ta r t .h tm ) or th e  W orld T e c h n o lo g y  E valuation  C en tre (WTEC) R eport o f  T issue  
Engineering co n d u c ted  by a p a n e l o f  lead ing  U.S. ex p er ts  an d  d escrib in g  th e  research  and d e v e lo p m e n t a ctiv ities  in th e  
U nited  S ta te s , Japan, and  W estern  E urope (M clntire e t  al., 2 0 0 2 ) .
(A vailable o n lin e  at: h t tp : / /w w w .w te c .o r g / lo y o la / te /f in a l /t e _ f in a l .p d f ).
51
congenital defects, disease, trauma, and aging. It uses a 
combination of several technological approaches that moves it 
beyond transplantation and replacement therapies. These 
approaches include, but are not limited to, use o f soluble 
molecules, gene therapy, stem cell transplantation, tissue 
engineering and advanced cell therapy (2006:1497)
Perhaps the simplest definition of Regenerative Medicine has been published in an 
editorial o f the journal Regenerative Medicine by two leading figures in the field, 
University College o f London’s (UCL) Chris Mason and Peter Dunnill. It states: 
‘Regenerative Medicine replaces or regenerates human cells, tissues or organs, to 
restore or establish normal function’ (Mason & Dunnill, 2008:4). According to Mason 
and Dunnill, as the field grows and there is a need to carry governments and public 
opinion along, lengthy definitions are confusing and ‘not the sort o f thing scientists, 
start-ups or advocates can say succincdy when a pharma executive, government 
minister or member of the public asks for clarification’ (Mason & Dunnill, 2008:1). 
Instead, a short and to the point definition can be a starting point and provide clarity 
to the nature o f the field, which is vital for the move toward the industrial context. 
Finally, perhaps the most widely accepted representation o f the field among the UK 
RM community, is depicted in a diagram by Intercytex Chief Scientific Officer D r Paul 
Kemp (see Figure.l). According to this definition, Regenerative Medicine is the 
‘umbrella term’ which embraces cell therapies, tissue engineering, biomaterials36 (e.g. 
matrices/scaffolds) and regeneration stimulating compounds (e.g. growth factors, 
differentiation factors, other key proteins). The final RM product can involve any 
combination o f these components.
36 B iom ateria ls  are m ateria ls  th a t  can in flu en ce , by physical o r  ch em ica l m ea n s , th e  o rg an isa tion , grow th , and d ifferen tia tio n  
o f  ce lls  in th e  p ro ce ss  o f  form in g  th e  d esired  t issu e . A co m p a n y  w ork in g w ith  such  ace llu lar m atrices  is Integra, UK 
(h ttp : / /w w w .in te g r a - ls .c o m ).
| Stem Cells] | Differentiated Cells |
---------- | Matrix | Factors
| “Functional" Cells j /
I I
Products to Regenerate T issues or Organs
Figure. 1. This diagram is taken from Dr Paul Kemp’s presentation at the London 
Regenerative Medicine Network Meeting (June 2007).
As also becomes obvious from Figure. 1, the central focus of Regenerative Medicine is 
human cells, irrespective of the components/combination used. These may be 
somatic, adult stem or embryo-derived cells as well as the recently discovered induced 
pluripotent stem cells (iPS) (Takahashi et al., 2007; Yu et al., 2007), that is cells that 
have been reprogrammed from adult cells and display embryonic-like features 
(pluripotency). Depending on the source of the cells, products and therapies can also 
be autologous or allogeneic. In autologous therapies it is the patients’ own cells that are 
isolated, purified and/or expanded, stored and reintroduced into the patient. This 
means that there are no immune rejection problems or risks of disease transmission, 
but the bioprocessing is complex. In allogeneic therapies, on the other hand, the cells 
are isolated from (related or unrelated) donors, and although these cells allow for easier 
bioprocessing, rejection and the potential for disease transmission are serious hurdles 
to overcome. In addition to having a therapeutic application, RM products can have a 
diagnostic application where the cells or tissue(s) are used as a biosensor or for the 
development and testing of drugs (for example screening for novel drug candidates, 
testing drug metabolism, uptake and toxicity or identifying novel genes as drug 
targets) (Heilman, 2008).
Cell therapy (that is cell suspension, without scaffolding) has been available for several 
decades. Most of this therapy was and continues to be autologous, typified by bone 
marrow transplants. Clinical allogeneic cell therapy currently utilises unrelated bone
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marrow, umbilical-cord blood (Fanning et al., 2008), or mesenchymal stem cell (MSC) 
transplants.
In contrast to cell therapies, which involve delivering ‘doses’ o f cells to patients, 
Tissue Engineering (TE) involves incorporating the cells into a three-dimensional 
structure using a temporary scaffold (for example a tube to create a blood vessel). 
Current autologous approaches to cell-based tissue engineering include: cultured 
autologous epithelial cells from skin such as Epicel® (Genzyme Biosyrgery, 
Cambridge, MA), MySkin (CellTran, UK) and CellSpray® (Avita), as treatments for 
chronic wounds and life-threatening burns; cultured autologous chondrocytes from 
articular cartilage, such as Carticel® (Genzyme BioSurgery, Cambridge, MA) as a 
treatment for focal defects in articular cartilage o f the knee. All the above treatments 
are based on an autologous expansion service approach which carries a number of 
disadvantages, the most critical being the significant turnaround time in providing 
enough product for treatment and the high cost when compared to conventional 
treatments (Daniels & Roberts, 2006). A more attractive approach to developing 
commercially viable products is based on the use of allogeneic cells and involves the 
production of standard ‘off-the-shelf products similar to the ones produced by 
traditional pharmaceutical development. Only few bioengineered live tissue products 
o f this type have emerged in the market, the most famous being Apligraf® 
(Organogenesis, U S/ Novartis, EU), Dermagraft® (Advanced BioHealing, La Jolla, 
CA), and Trancyte® (Smith & Nephew)(Parenteau, 1999).
According to Intercytex’s chief scientific officer D r Paul Kemp, every product already 
on the market or currendy in development can be represented in the ‘whole-cell 
bioprocessing matrix’ comprising of just four quadrants (see Figure.2 below). ‘You can 
either use allogeneic cells or autologous. You can put these in as a single-cell 
suspension or you can make a construct from them. There are four quadrants to this. I 
have asked numerous people within the industry whether there is another segment to 
the field, and there is simply not’ (Kemp, 2006a:2). Kemp also points out that the 
manufacturing facilities for the four types o f product would be very different, as would 
be the cost. From the matrix, it is clear that the cheapest to produce is allogeneic single 
cell suspensions, then allogeneic constructs, followed by autologous single cell 
suspensions and finally autologous constructs, which are the most cosdy (Kemp, 
2006a, 2006b).
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Sin g le cell 
su sp en s io n Construct
A llogeneic 1 2
A utologous 3 4
Figure.2. Each quadrant is numbered according to the cost of each approach to whole­
cell bioprocessing (1: least cosdy, 4: most expensive). Diagram taken from Kemp, P.
(2006) 'Cell therapy- Back on the up-curve', Regenerative Medicine 1(1): 9-14.
In short, RM therapeutics, whether cell therapies or cell-based constructs, are very 
different to the pharmaceutical and biotechnology products. A phrase regularly quoted 
in scientific articles regarding RM product development and manufacturing is that ‘the 
process defines the product’ or ‘the product is the process’. As noted by Nancy 
Parenteau (Parenteau BioConsultants) who has written extensively on the commercial 
development of stem cell therapeutics: ‘Cells, unlike biological molecules and chemical 
entities, are complex, dynamic and interactive and the design of the therapeutic 
product (i.e. its components, how they are derived and processed) becomes particularly 
important. It can mean the difference between an effective product and one that fails 
to meet clinical and regulatory standards’ (Parenteau, 2009:601). Mason and Hoare
(2007) also emphasise the importance of the bioprocess for cell therapies and call for a 
workable and at the same time rigorous regulatory framework. The authors view such a 
regulatory framework as a target inseparable from bioprocess and suggest that 
everyone stands to gain from consistency and harmonisation. The following section 
briefly describes such standardisation and harmonisation attempts.
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Regenerative Medicine Product Regulation
Appropriate regulation o f RM therapeutics is essential to ensure public safety and trust 
while minimising unnecessary barriers to product development. At the moment, RM 
research is entering a critical ‘transition period’ as the first stem-cell based products are 
beginning the process o f seeking approval for testing and marketing (Fox, 2008). In 
July 2010, the US Food and Drug Administration (FDA) cleared Geron Corporation 
(Menlo Park, CA) to proceed with its much heralded GRNOPC1 trial, which would 
have been the first use o f hESCs in humans, thus lifting a hold placed in May 2008 and 
again in early summer o f 2009 (Alper, 2009).37
In the UK, ReNeuron Group Pic has also received approval from the UK Medicines 
and Healthcare Products Regulatory Agency (MHRA) to conduct a first-in-man trial of 
a stem cell therapy to treat stroke (Pilcher, 2009). O ther companies are also at various 
stages o f developing and testing stem cell products (Langreth & Herper, 2008), which 
means that questions about the adequacy o f the regulatory framework applicable to the 
products o f RM cell-based technology are becoming increasingly important.
Weaknesses of the existing regulatory frameworks include a poor fit between 
established product categories (such as drugs, medical devices, biologies) and emerging 
RM technologies, as well as variation between markets/jurisdictions. Since a primary 
goal o f the RM community is the establishment o f a global industry that enables 
companies to manufacture and market products across national borders (Salter, 2009b; 
Salter, 2009c; Salter et al., 2006), a harmonised international regulatory approach is 
crucial.
Currendy, a number of regulatory approaches are being developed in N orth America, 
Europe and the East (Singapore, China, Japan, and India) and several harmonisation 
initiatives already exist. Most notably, the new European Advanced Therapy Medicinal 
Products (ATMP) regulation,38 that became effective from December 2008 and will be 
managed by the European Medicines Agency (EMA). Apart from formal legislation, 
harmonisation may take other forms, ranging from informal cooperation for the
37 At th e  t im e  o f  su b m ission  (S ep tem b er  2 0 1 0 ), G eron 's P h a se  I trial w a s  o n . On 30  July 2 0 1 0 , G eron a n n o u n ced  th a t  th e  
U.S. Food  and  Drug A dm inistration  (FDA) h as n otified  th e  co m p a n y  th a t th e  clinical h old  p laced  on G eron 's Investigation a l 
N ew  Drug (IND) ap plica tion  h as b e e n  lifted .
38 EC. R egulation  (EC) N o 1 3 9 4  o f  th e  E uropean P arliam en t an d  o f  th e  Council on  a d van ced  th era p y  m ed ic in al p rod u cts  and  
a m en d in g  D irective 2 0 0 1 /8 3 /E C  and  R egulation  (EC) N o 7 2 6 /2 0 0 4 , [2007 ] O.J. L 3 2 4 /1 2 1 . A vailab le at: 
h ttp : / /e c .e u r o p a .e u /e n te r p r ise /p h a r m a c e u t ic a ls /a d v th e r a p ie s /a d v a n c e d _ e n .h tm
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development o f common technical requirements or mutual recognition agreements 
(Von Tigerstrom, 2007). Im portant harmonisation attempts have also been undertaken 
at the international level, by the International Society for Stem Cell Research (ISSCR),39 
the International Conference on the Harmonisation o f Technical Requirements for 
Registration o f pharmaceuticals (ICH),40 and also at a more ‘local’ (UK) level, such as 
the PAS8341 and PAS8442 guidance documents, published by the British Standards 
Institute (BSI). A more in-depth explanation o f the RM regulatory landscape is given 
in Chapter 5, where it serves as the background for the analysis of my empirical data 
regarding interviewees’ perceptions on the effect o f regulations on translational 
Regenerative Medicine innovation.
The Regen Industry: the Ups and D ow ns.. .and Ups
The RegenMed (or simply Regen43) industry is the industry which develops, 
manufactures and sells Regenerative Medicine products. Mason and Dunnill (2008) 
note the fact that the Regen industry has to be distinguished from Regenerative 
Medicine in that although centred on human cells, it also draws on other science and 
technology such as biomaterials for Tissue Engineering. The origins o f the Regen 
industry can be traced back to the Tissue Engineering industry, now only a part44 of 
the much broader Regen sector.
When discussing the progress o f Regenerative Medicine industry, field experts (Kemp, 
2006a) draw attention to a cycle that so often characterises novel medical research:
39 T he International S o c ie ty  for S tem  Cell R esearch  (ISSCR) h as p ub lished  tw o  d o c u m e n ts  so  far: G u id elin es for th e  C ond u ct  
o f  H um an Em bryonic S tem  Cell R esearch , V ersion  1: D ecem b er  21  (2 0 0 6 ). A vailab le at:
h ttp ://w w w .isscr .o rg /g u id e lin es/IS S C R h E S C g u id e lin es2 0 0 6 .p d f and G u id elin es for  th e  Clinical T ranslation  o f  S tem  Cells, 
D ecem b er  3 , (2 0 0 8 ). A vailab le at:
h ttp ://w w w .isscr.org/clin ical_trans/pd fs/ISS C R G L C Iin icalT rans.p df
40 A lth ough  th e  ICH h as n o t y e t  fo rm u la ted  an y  g u id e lin e s  sp ec ific  to  s te m  ce ll-b a sed  p rod u cts, a n u m b er  o f  its g u id e lin e s  on  
b io te c h n o lo g y  p rod u cts are re lev a n t to  th is  area . For fu rth er  in form ation  s e e  C atalan o, J. 2 0 0 6  'The International 
C o n feren ce  on  H arm onization  (ICH) and its R elevan ce to  Cell Therapy. ISCT 6th  A nnual S om atic  Cell T h erap y S ym p osiu m  
(h t tp : / /w w w .fd a .g o v /c b e r /g e n e th e r a p y /is c t0 9 2 5 0 6 jc .h tm ) .'
41 PAS83: G u id an ce on  C odes o f  P ractice, S tan d ard ised  M e th o d s  and R egu lation s for  C ell-based  T h erap eu tics, from  Basic 
R esearch  to  Clinical A pp lication . DTI in co llab ora tion  w ith  British S tand ard s Institu te, UK. N o v em b er  (2 0 0 6 ).
42 PAS84: R egen era tive  M ed icin e . G lossary. (2 0 0 6 ). PAS84 p rov id es clear  g u id a n ce  on th e  m ea n in g  o f  term in o lo g y  cu rrently  
u sed  in th e  UK by industry, regu lators, g o v e r n m e n t an d  acad em ia  w ith  th e  aim  o f  h elp in g  th e  k ey  s ta k e h o ld e rs  to  
c o m m u n ic a te  m o re  e ffec tiv e ly  and  a llow  th e  com m erc ia lisa tio n  o f  th e  n ew  te c h n o lo g y  to  ta k e  p lace  m o re  effic ien tly  and  
safe ly .
43 T he sh orth an d  'R egen' has b e e n  u sed  in a sim ilar w a y  to  th e  term s 'Pharm a' and 'B io tech ' a s rou tin ely  u sed  to  d escr ib e  
c o m p a n ie s  in th e  p h arm aceu tica l and b io tec h n o lo g y  s e c to r s , re sp ective ly .
44 R egen  in d u stry  (just like R eg en era tiv e  M ed ic in e) is an u m brella  term  w hich  in co r p o r a tes  cell th era p ie s  and  t is s u e  
e n g in eer in g . The d iffer en ce  b e tw e e n  th e s e  tw o  ty p e s  o f  th era p y  is th a t ce ll th era p ie s , in gen era l, will in vo lve  'd o ses ' o f  ce lls  
to  p a tien ts; t is s u e  en g in ee r in g  in v o lv es  in corporatin g  th e  ce lls  in to a th ree -d im e n s io n a l stru ctu re  using a tem p o ra ry  sca ffo ld , 
for  e x a m p le  a tu b e  to  cr ea te  a v e s s e l (M ason , 2 0 0 5 ).
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initial hype, a subsequent trough of disappointment, and final emergence of viable 
technology.45 This depicdon of the Regenerative Medicine industry is largely based on 
the concept of ‘Gartner Inc.'s Hype Cycle’ which was first coined in 1995 by Gartner.46 
The Gartner Cycle shows the over-enthusiasm (‘hype’) and disappointment that 
typically happens with emerging technologies, as well as the way these technologies 
move beyond the ‘Trough of Disillusionment’ phase to become widely accepted and 
commercially successful.
VISIBILITY
Peak o f Inflated Expectations
Plateau o f Productivity
Slope o f Enlightenm ent
Trough of Disillusionment
TIMETechnology Trigger
Figure.3. shows ‘Gartner’s Hype Cycle of Emerging Technologies’
The first phase of the industry’s development, running from the early 1990s through 
2001, represented a period of considerable excitement, during which research in the 
field was rapidly expanding at the universities and there was also considerable activity 
on the commercial front. The products that made it to the market during that period 
were largely living skin substitutes (Parenteau, 1999) including Apligraf, Dermagraft 
and Trancyte, and were developed by pioneering companies such as Advanced Tissue 
Science and Organogenesis. The second phase, between 2001 and 2002, corresponds 
to the ‘trough of disillusionment’ part of the Hype Cycle, when ‘things went very 
wrong, very quickly’ and several factors combined to make this period ‘the worst of 
times’ for tissue engineering (Lysaght & Hazlehurst, 2004). New products were 
hampered by delays in regulatory and reimbursement approval, and a variety of less- 
than-optimal business management decisions were made that left several of the early
45 P resen ta tion  by G regory A. Bonfiglio, P roteus V en ture Partners, 'V enture Funding for RM C om pan ies', California Institu te  
for R egen era tive  M edicin e ICOC Loan Task Force, January 16, 2 0 0 8 .
46 For further d eta ils  on  Gartner s e e  th e  com p an y h o m ep a g e  available at h ttp ://w w w .g a r tn e r .c o m /
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companies experiencing severe financial problems (Nerem, 2006). December 2002 
marked the end o f the ‘hyped’ and ‘troubled’ periods o f the RM industry, what is now 
known as RegenMed 1.0 and the transition to the third part o f the Curve, the ‘slope of 
enlightment’ towards the plateau o f productivity, widely known as RegenMed 2.0. In 
fact by 2006,
Tissue Engineering had largely been replaced by cell therapy. The focus 
has switched from whole organs grown in the laboratory at uneconomic 
cost to cell therapies where cells alone are surgically implanted to restore 
damaged and diseased organs: in vivo Tissue Engineering. This dramatic 
refocusing occurred because o f a number of major factors but 
principally: the high cost associated with growing whole organs for weeks 
or months in facilities operating according to Good Manufacturing 
Processes (GMP), the complexity o f bioprocessing solid organs, market 
opportunities and stem cells (Mason, 2007: 25).
Finally, in contrast to RegenMed 1.0 companies which were almost all focussed on 
research, RegenMed 2.0 industry1 is almost exclusively focussed on translating science 
into commercial products, thus integrating the science into the healthcare 
system47(Mason, 2007).
Regenerative Medicine in the UK
The U K  is widely recognised as having strong research activity in the Regenerative 
Medicine area, including world class capability in stem cells and Tissue Engineering, 
and is considered to have a leading position (in basic research) relative to most 
Western economies, including the United States. This UK lead is mainly attributed to 
the informed and open approach towards Regenerative Medicine work that combines a 
strong ethical basis with informed regulatory policies, substantial and well directed 
basic research funding, and a strong interest in consulting the public and securing its 
support (Livesey, et al., 2008). The need to maintain this competitive advantage has 
been widely recognised by all stakeholders and is a central theme to almost all recently
47 P resen ta tio n  g iven  by Eric C. Faulkner, Sen ior D irector, US M arket A ccess  & R eim b u rsem en t, 'F inancing for  Cell T herapy  
C om pan ies: Im portance o f  R e im b u rsem en t P lanning for  P roduct S u c cess ', International S ocie ty  for  C ellular T herapy, 18  
M ay 2 0 0 8 , M iam i, Florida.
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published policies regarding current progress and future directions of the Regenerative 
Medicine field.
In March 2005, for example, the U K  Government’s Chancellor of the Exchequer 
Gordon Brown announced the launch of the UK Stem Cell Initiative (UKSCI) during 
his pre-budget statement. The requirement was for the development o f a ten-year 
research and development strategy for UK Stem Cell Research, from 2006 to 2016, 
which will ‘make the UK  the most scientifically and commercially productive location 
for this activity over the coming decade, and which commands the support of public 
and private research funders, practitioners and commercial partners’ (UKSCI Report, 
2005:103). Sir John Pattison was asked to chair the process, together with D r John 
Connolly (Department o f Health, Secretary to the UKSCI) and a high-level advisory 
panel.48 Eight months later, in November 2005, and after a wide consultation with 
universities, research institutions and industry, the Report and Recommendations of 
the UKSCI was published,49 providing the world’s first blueprint for the future of stem 
cell platform technologies and Regenerative Medicine therapies (Mason, 2006). While 
launching the report, Sir Pattison described the challenges facing Regenerative 
Medicine research in the UK and said:
During the pioneering phases of any new medical 
treatments, there are often substantial gaps in our 
knowledge, leading to a perception that the research is 
“high-risk” . This is certainly true for stem cell therapies.
However, we must foster those who pioneer the applied 
aspects o f our strong basic science, if  we are to make 
significant contributions to its global development. It 
is essential, therefore, that the UK is supportive of early 
clinical trials, provided they are of sufficient quality. This 
will help to develop our breadth o f expertise and
48 The p anel in clud ed  P ro fessor  Colin B lak em ore (C hief E xecutive, M edical R esearch  C ouncil), P ro fesso r  Julia G o o d fe llo w  
(C hief E xecutive, B io tech n o lo g y  an d  B iological S c ie n c e s  R esearch  C ouncil), M s Diana G arnham  (C hief E xecutive, A ssocia tion  
o f  M edical R esearch  C harities), P ro fessor  Sir C hristoph er Evans (UK S tem  Cell F ou n d ation ), Dr P e ter  M ou n tford  (C hief 
E xecutive, S tem  Cell S c ie n c es  (UK) Ltd), P ro fessor  Sally D avies (D irector o f  R esearch , D ep artm en t o f  H ealth ), Dr Mark 
W alp ort (D irector, The W ellco m e  Trust), Dr P eter  A rnold (D irector o f  T ech n o logy , Sm ith  and N ephew ,U K ), Dr Fiona W att  
(The A ca d em y  o f  M edical S c ien ces), Lord M ay o f  Oxford (UK S tem  Cell Fou n d ation ).
49 UK S tem  Cell Initiative R eport an d  R eco m m en d a tio n s , N ovem b er  2 0 0 5 . A vailab le o n lin e  at: 
w w w . a d v iso ry b o d ie s . d o h .g o v . u k /u k sc .
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knowledge o f clinical aspects o f stem cell research
[emphasis added]
(UKSCI Press Notice, 1 December, 2005:2)
This call for attention to the ‘applied’ aspects of the Regenerative Medicine science is 
evidence of the policy-makers’ concern that increased support of the science base and 
the creation o f greater capacity for invention alone, are unlikely to secure the 
competitive advantage on the RM world stage. Indeed, in a review of UK health 
research funding, led by Sir David Cooksey and published in December 2006, a gap 
between the pace o f change in basic research and its application to healthcare practice 
was evident (Cooksey, 2006). The review highlighted the fact that although major 
advances in basic science (including Regenerative Medicine science) and patentable 
inventions are self-evident, translating these advances into commercially viable 
innovations remains problematic. In other words, if Regenerative Medicine in the UK 
(and elsewhere) is to have a major effect in the lives o f patients and the economy, it 
must find ways to close this gap between invention and innovation, between basic 
research and clinical practice, and ensure that all scientific breakthroughs happening in 
UK laboratories are swiftly and efficiently translated into healthcare benefits for the 
public.
The following section (‘Understanding Translational Research’) begins with an 
explanation of what Translational Research is and provides a description o f the 
emerging ‘status’ of Translational Research (TR) in biomedicine. I identify and explain 
existing definitions o f Translational Research (including clarification o f which 
definition is being used in the context o f this thesis). The aim o f this section is to 
provide the reader with a brief, but comprehensive introduction to the concept of 
‘Translation’, which is central to this thesis. I continue with an exploration o f the 
literature on the nature o f the Translation process (bidirectional and iterative) as well as 
some of the potential issues and obstacles that have kept positive basic research 
findings from translating into therapies. Gaining an insight into the above issues will 
facilitate the understanding o f the remaining chapters which examine Translation 
through the lens o f Sociology and Science and Technology Studies (STS). Finally, I 
introduce the case o f Translational Research in the Regenerative Medicine (or RM TR) 
which is the focus of this thesis.
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Understanding Translational Research (TR)
The emphasis on ‘translating’ science into practical applications began in 1980 through 
US code legislation. The Stevenson-Wyndler Technology Innovation Act (1980) made 
‘technology transfer’ (i.e. using existing research knowledge to fulfil public and private 
needs) a mission of the federal Government. In addition, the enactment of the Bayh- 
Dole Patent and Trademark Act within the same year, allowed universities to retain 
certain rights to their inventions so as to provide incentives for researchers to create 
products and services that would benefit the public (Sussman et al., 2006). In 
biomedicine, the term Translational Research (Translational Science/ Translational 
Medicine) can be traced back to the early 1990s in the literature describing biology- 
based attempts to find new drugs for cancer. Since then, the concept has found its way 
into the literature concerned with almost all areas o f medicine (e.g. cardiology, 
psychiatry, neurology) and it has been the subject of multiple catchphrases such as ‘lost 
in Translation’, ‘crossing the valley o f death’, ‘bridging the gap’, ‘walking the bridge’, 
and most notably ‘from bench to bedside’. But what exactly is (biomedical) 
Translational Research (TR)?
Until recently, two types of research have dominated the literature, basic research and 
applied research. Basic research has many different meanings and definitions, and 
alternative terms such as ‘fundamental’, ‘curiosity-driven’, ‘blue skies’, ‘autonomous’ 
and ‘researcher-controlled’. Sometimes, authors refer to basic research meaning both 
‘curiosity-driven’ research (undertaken primarily to acquire new knowledge) and 
‘strategic’ research (undertaken with some instrumental application in mind, although 
the precise process or product is not yet known) (Salter & Martin, 2001).
Sociologist Jane Calvert (2006) who has examined the history o f the basic science 
concept, argues that it is a flexible and ambiguous term which, in practice, is used 
selectively by scientists and policy-makers in a variety of contexts so as to protect and 
promote their interests (e.g. to protect their work from demands o f applicability and to 
justify funding). Whatever the term used, though, the popular understanding in 
biomedicine is that basic research is based on a hypothesis about how biology works 
and takes place in a laboratory, while clinical research is applied research, and 
determines whether known biological mechanisms apply to a disease or treatment.
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Nobel Laureates Joseph Goldstein and Michael Brown (1997) have distinguished basic 
research from Disease-Oriented Research (DOR)50 and Patient-Oriented Research 
(POR), describing the latter as ‘being performed by physicians who observe, analyse, 
and manage individual patients. As a rule of thumb, if the investigator shakes hands 
with the patient in the course o f the research, that scientist is performing PO R ’ 
(Goldstein & Brown, 1997:2805 and 2086).
The relationship between basic and applied (including clinical) research has also been 
famously depicted as the ‘Pasteur’s Quadrant’ by Donald Stoke in his 1997 
homonymous book. In the book, the author considers how viewing research as a 
continuum from basic to applied, assumes that progress only builds in one direction, 
when advances in technologies (i.e. technological breakthroughs) can also reverse the 
direction and lead to better understanding of basic research theories.
In recent years, the term Translational Research (TR) or ‘Bench-to-Bedside’ has come 
into use in various disciplines, to describe the not always so distinct borderline 
between the two ends (i.e. basic and applied research) o f the research continuum. 
Different stakeholders have different meanings for Translational Research (TR). For 
some, TR refers to the enterprise o f harnessing knowledge from basic science to 
produce drugs, devices and treatment options for patients. In this case, the endpoint of 
TR is the production o f a promising new treatment that can be used clinically or 
commercially. For others, mainly health services researchers and public health 
investigators who consider health as the primary outcome, TR is about ensuring that 
the knowledge and new treatments/products actually reach the populations for whom 
they are intended, through timely and proper implementation (Woolf, 2008). Referring 
to these different types of TR by, the same name has become a source of some 
confusion in the relevant literatures, and this confusion is discussed later in this 
chapter.
50 G old ste in  and Brow n d e fin e  DOR as 'research  th a t  is ta rg e te d  tow ard  th e  u n d erstan d in g  o f  th e  p a th o g e n e s is  or tr e a tm e n t  
o f  a d is e a s e , b ut d o e s  n o t  require d irect co n ta c t  b e tw e e n  th e  p a tien t and th e  sc ie n tist . It m ay u se  p a tien t m ateria ls  such  as  
cu ltu red  ce lls  or DNA sa m p les , b ut n o t th e  w h o le  p a tien t' (G oldstein  & Brow n, 1 9 9 7 :2 8 0 5  and 2 8 0 6 ).
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Translational Research: a Global Priority?
Currently, Translational Research is considered an integral part o f all aspects of 
biomedical research, a new ‘paradigm shift’ o f the way science is done, and a new 
movement in funding direction. Stephen Curry, a US business consultant for 
translational science and medicine notes: ‘at its core is the identification of a funding 
category for making public money available to facilitate the movement of an idea from 
bench to bedside’ (Curry, 2008). In the United States, for example, Translational 
Research has been recognised as a funding priority in both the Food and Drug 
Administration’s Critical Path Initiative51 (FDA, 2004) and the National Institutes of 
Health’s (NIH) agenda, through the N IH  Roadmap52 (Zerhouni, 2003) and the launch 
of the Clinical and Translational Science Awards (CTSAs) program in 2006 (Zerhouni 
& Alving, 2006). In Canada, research and knowledge Translation are the focus of the 
Canadian Institutes o f Health Research (CIHR) work. The CIHR, which was created in 
2000 and is the government agency responsible for funding heath research in Canada 
has a budget o f $928.6 million (2008-09) and its mandate is:
To excel, according to internationally accepted standards of 
scientific excellence, in the creation of new knowledge and 
its translation into improved health for Canadians, more 
effective health services and products and a strengthened 
Canadian health-care system53 [emphasis added]
In Singapore, the Biomedical Research Council (BMRC) which was established in 
October 2000, has created a number of research consortia54 to coordinate and drive 
Translational Research at the national level, in what are considered strategic thematic 
areas. Similarly, in the EU, Translational Research has become a centrepiece of the 
European Commission’s £6 billion Seventh Framework Programme (FP7) health 
research budget. The FP7 is running from 2007 to 2013 and states:
51 FDA R eport, 'In n ovation  or S tagn ation : C hallen ge and  O p p ortu n ity  on  th e  Critical Path to  N ew  M edical Produ cts', Food  
and  Drug A dm inistration , US D ep a rtm en t o f  H ealth and  H um an S erv ices, M arch 2 0 0 4  an d  u p d a ted  version  2 0 0 6 . A vailable  
at:
h ttp : //w w w .fd a .g o v /S c ie n c e R e se a r c h /S p e c ia lT o p ic s / cr itica lP a th ln itia tive /C ritica lP a th O p p ortu n itiesR ep orts/d efau lt.h tm .
52 For m o re  d eta ils  on  th e  NHI road m ap  see : h ttp ://n ih ro a d m a p .n ih .g o v
53 S ta te m e n t on  w eb s ite :  h t tp :/ /w w w .c ih r -ir s c .g c .c a /e /7 2 6 3 .h tm l (A ccessed  M arch 2 0 0 9 ).
54 T he con sortia  th a t h a v e  b een  s e t  up to  d a te  in clud e, a m o n g  o th ers , th e  S in gap ore S tem  Cell C onsortium  (SSCC) and th e  
Experim ental T h erap eu tics  C en tre (ETC). D etails on  w eb site :
h ttp ://w w w .a -s ta r .ed u .sg /b io m ed ica l_ sc ien ces /1 7 0 -S tra te g ic - ln it ia t iv e s-T ra n s la t io n a l-R e sea r ch .
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Citizens will benefit from European health research since 
its emphasis will be put on: translational research (i.e. the 
translation o f basic discoveries into clinical applications), 
the development and validation o f new therapies, methods 
for health promotion and prevention including the 
promotion o f healthy ageing, diagnostic tools and medical 
technologies, and sustainable and efficient healthcare 
systems.55 [emphasis added]
In the United Kingdom, Translational Research has been prioritised in a 2006 review 
of health research funding which places considerable emphasis on the need to translate 
the results of basic research along the pathway to new innovations, products and 
healthcare services (Cooksey, 2006). The increasing shift in UK biomedicine towards 
translational goals is also evident in the establishment — by the National Institute for 
Health Research (NIHR) — of five biomedical research centres devoted to 
Translational Research at a cost o f £450 over five years (Lord & Trembath, 2007; 
Travis, 2007).
Outside central government, a range o f other organisations also support Translation, 
such as the research councils, mainly the Medical Research Council (MRC) and the 
Biotechnology and Biological Sciences Research Council (BBSRC). Indeed, promoting 
and strengthening Translational Research has become a key priority for the MRC in 
recent years. Following several specific initiatives, as well as the publication of the 
Cooksey Review (2006), members of the MRC community came together in February 
2007, to review the role of the Council in TR and discuss what more is needed to 
support and accelerate the Translation of medical research. During the workshop56 
Professor Blakemore, Chief Executive o f the MRC (at the time), outlined how the 
Council has been shifting its emphasis in funding57 in order to strengthen clinical and 
Translational Research. To achieve this, the MRC has supported a number of 
initiatives58 which included: additional funding for large-scale clinical trials (£9m), for 
experimental research (£15m), biomarkers (£10m), implementation research (£lm ),
55 S ta te m e n t on  w e b s ite  h t tp : / /e c .e u r o p a .e u /r e s e a r c h /fp 7 /in d e x _ e n .c fm ? p g = h ea lth .
S6MRC W ork sh op , 'A cceleratin g th e  T ranslation  o f  M edical R esearch ', 2 0 -2 1  February 2 0 0 7 , Latim er H ou se, Bucks.
57 In 2 0 0 4 -2 0 0 5  ap p rox im ately  80% o f  th e  MRC's research  p ortfo lio  w a s  in b asic  lab oratory  and p o p u la tio n  h ea lth  research .
58 T h ese  in itia tives  h ave b een  p u b lish ed  in th e  2 0 0 6 /0 7 -2 0 0 7 /0 8  MRC D elivery Plan. S ee  
h ttp : / /w w w .m r c .a c .u k /U tilit ie s /D o c u m e n tr e c o r d /in d e x .h tm ?d= M R C 002472 (A ccessed  June 15  20 0 9 ).
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MRC Centres grants (£15m), Clinical Research Training Fellowships awards and 
additional studentships.
MRC Technology which has been set up to support the intramural MRC research 
portfolio so that scientific discoveries are translated into commercial products, has also 
expanded its activities, including the development o f a new, pilot category o f staff 
called ‘Research Translators’. Their role is ‘to facilitate the translation o f research by 
applying their expertise and knowledge o f the Translation process and brokering 
partnerships/collaborations between scientists and other stakeholders in order to 
progress research findings towards development and delivery of new healthcare 
interventions’ (MRC Workshop, 2007:15). Charities such as the Wellcome Trust and 
private foundations and organisations are also investing in Translational Research (e.g. 
Avia Bio Ventures Ltd, UK) (DTI, June 2007).
The shift to a ‘translational agenda’ is thus a noticeable trend in many o f the world’s 
leading industrial nations. In addition to private entities, governments and individual 
states (such as California and New Jersey)59 increasingly want to see a return on the 
very large sums of money they commit to research (Levine, 2006). The long-cherished 
freedom of the research funding agencies to choose their ‘areas’ o f activity has 
disappeared under the pressure of the numerous healthcare challenges, with academics, 
clinicians, and policy-makers realising that the only way to secure strong funding for 
both basic and Translational Research is to produce successful commercial outcomes, 
reduce the currently spiralling healthcare costs and /or have a major impact on patients’ 
quality of life.
Translational Research: Success or Failure?
During the past decade and following the complete sequencing of the human genome 
there has been an exponential growth in basic research aimed at understanding the 
underlying nature o f disease and developing novel forms o f therapy. This has led to 
major scientific accomplishments in diverse fields such as molecular genetics and cell 
biology, and in the development of revolutionary forms o f treatment such as RNA
59 s e e  California P roposition  71: T h e C alifornia S tem  Cell R esearch  and  C ures Act, 2 0 0 4 ; The E con om ic B en efits  o f  th e  N ew  
Jersey  S tem  Cell R esearch  Initiative R eport, S en eca  and Irving, 20 0 5 ; UK S tem  Cell Initiative R eport and  R e co m m en d a tio n s  
(2 0 0 5 ), D ep a rtm en t o f  H ealth , UK.
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interference, gene therapy and stem cells (Chanda & Caldwell, 2003). When 
considering the explosion o f basic science discoveries along with the recent emphasis 
on Translational Research, it is not surprising that there is a high expectation of 
immediate therapeutic benefits in a wide range o f disease states many o f which have no 
current effective treatment (Bubela, 2006; Ioannidis, 2006; Nerem, 2006). However, it 
remains unclear if TR, this new ‘paradigm shift’, has been living up to expectations. 
Indeed, despite the astounding advances that have been accomplished in the 
laboratory, and despite the cross-stakeholder (governments, funding agencies, 
researchers, clinicians, industry, and the public) commitment, the translation of bench 
research findings to clinically relevant and effective therapies has proven neither simple 
nor assured.
Indeed, as the pharmaceutical and biotechnology industry has fallen dramatically short 
o f its own expectations, virtually everyone has been concerned with the so-called 
‘innovation deficit’ or ‘productivity gap’ — that is the reduction of the number o f 
medicines entering the market on a year-by-year basis, as well as the ever-increasing 
R&D expenditure that compounds the issue (Drews, 1998; Drews, 2000). Recent 
research from the multinational management consulting and accounting firm 
Accenture and the Centre for Medicine Research (CRM) International has suggested 
that ‘only 3% of projects aimed at new targets will enter preclinical development 
compared to 17% for projects aimed on established targets’ (Carney, 2005:1011).
This innovation decline, identified in the pharmaceutical and biotech R&D setting, has 
been also evident in the more academic setting, where the translation rate o f major 
basic science promises to clinical applications has been insufficient and disappointing. 
In their 2003 paper, Contopoulos-Ioannidis et al. (2003) have examined what is 
referred to as the ‘rate’ of Translation by looking at how often and how fast original 
basic research findings translate into clinical development and use. To address this 
question, they evaluated a sample of basic research publications in highly cited journals 
that had presented findings showing a clear clinical promise and then studied whether 
the original expectations materialised over a period o f twenty years. Their study 
provided considerable evidence that even the most promising basic science findings 
take a long time to translate into clinical experimentation, with subsequent adoption 
into clinical practice being even rarer.
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But why is the rate of translation so low? Why is it that current developments in basic 
discovery sciences, published in thousands of discipline-specific journals and in 
combination with high levels o f public and private investment, have not been mirrored 
by the same level o f progress in understanding the clinical basis o f disease and 
ultimately the development o f novel effective therapies? The effort to diagnose the 
‘failure o f Translation’ and explain the decline in biomedical innovation has become 
something o f a cottage industry within the literature o f innovation, and it is here where 
the social sciences may be able to make a significant contribution. In order to do so, 
however, it could be useful to first briefly review the Translational Research literature 
in order to pinpoint and clarify the exact meaning and setting o f Translational 
Research that is going to be explored in this thesis.
Definitions and Nomenclature Issues
The question o f how to define Translational Research remains controversial. Many 
academics have voiced concerns that the first challenge of TR is one o f language and 
meaning (Liang, 2003). As the terms Translation and Translational Research, 
‘Knowledge Translation’, ‘Knowledge and Technology Transfer’, ‘Knowledge 
Dissemination’, ‘Diffusion’ and ‘Implementation’ are used interchangeably to mean 
sometimes similar and sometimes different things in the literature, they become a 
source o f confusion. This is especially true for the funding agencies who are in need of 
a consensus terminology in order to recognise the gaps and address them with the 
Translational Research investments (Kerner, 2006).
The distinction between two main types o f TR was articulated for the first time by the 
Institute o f Medicine’s Clinical Research Roundtable.60 This series o f roundtables (first 
convened in June 2000) was attended by a diverse group o f stakeholders involved in 
basic and clinical research and its purpose was to promote dialogue, exchange o f 
experts’ views and collaboration on the issues faced by the ‘Clinical Research 
Enterprise’.61 As a result of these discussions, the Roundtable participants introduced a 
distinction between two types of Translational Research, T1 and T2. In addition, they
60 Clinical R esearch  R oun d tab le h o m e p a g e  availab le at: h t tp : / /w w w .io m .e d u /? id = 1 9 1 7 9  (A ccessed  June 15 , 2 0 0 9 ).
61 The Clinical Investigator W orkforce: Clinical R esearch  R oun d tab le S ym p osiu m  I. N ational A ca d em y  Press: W ash in g ton , DC. 
2 0 0 1 ; Public C o n fid en ce and  In v o lv em en t in Clinical R esearch , Clinical R esearch  R ou n d tab le  S ym p osiu m  II. N ational 
A ca d em y  Press: W ash in g ton , DC. 2001 ; Exploring th e  M ap o f  Clinical R esearch  for th e  co m in g  D ecad e. Clinical R esearch  
R oun d tab le S ym p osiu m  III. N ational A ca d em y  Press: W ash in g ton , DC. 2 0 0 1 .
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identified two major obstacles, or ‘Translational Blocks’, that impede efforts across the 
clinical research continuum to apply science for better human health. ‘Translational 
block 1’ was described as impeding T1 or ‘the transfer o f new understandings of 
disease mechanisms gained in the laboratory into the development o f new methods 
for diagnosis, therapy, and prevention and their first testing in humans’ (Sung et al., 
2003: 1279). The second block ‘affects the translation o f results from clinical studies 
into everyday clinical practice and health decision making’ (Sung, et al., 2003: 1279), 
namely T2.
A more pragmatic definition o f Translational Research based on the fact that different 
stakeholders look at different aspects o f the issue, is supported by Littman et al. (2007), 
who have been looking at Translational Research in the context o f the pharmaceutical 
industry and drug development. For academia, for example, ‘Translational Research 
represents a general desire to test novel ideas generated by basic investigation with the 
hope o f turning them into useful clinical applications. For academic purposes, 
Translational Research also responds to the need o f identifying novel scientific 
hypotheses relevant to human pathology through direct observation o f humans and 
their diseases’ (Littman, et al., 2007: 218). For the people more directly involved in 
clinical practice, such as physicians and patients, Translational Research represents ‘the 
need to accelerate the capture of benefits from research in daily medical practice’ 
(2007:218). And finally, for the commercial sector, ‘Translational Research is a process 
aimed at expediting the development o f known entities, particularly in the early phases, 
and /or identifying ways o f making an early ‘go/no-go’ decision when the cost of 
product development is still relatively contained’ (2007:218).
For this thesis, a limited definition o f Translational Research is used, namely the 
‘bench to bedside’ model o f harnessing knowledge from basic sciences to produce new 
drugs, devices, and other clinical applications for patients. In other words, the end 
point o f Translational Research is the production o f a promising new 
product/treatm ent that can be used clinically or successfully commercialised (‘brought 
to the market’). This definition is conceptually closer to the T1 term described above 
and is best suited to describe the Translational route in Regenerative Medicine and cell- 
based therapeutics (CBTs) field where research is still very much work-in-progress, 
most products/ therapies are still on the basic discovery, early development or clinical
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trials stage and only a relatively small proportion of products have made it to the clinic 
and/or market.
In view o f the fact that there are not many clinically and commercially successful cases 
yet to investigate and from which to draw conclusions, it is not surprising that T2 in 
the Regenerative Medicine field has largely been ignored so far by the scientific and 
health policy research literature. It has, however, been discussed by a substantial body 
of the sociological and STS literature exploring the effects of new technological 
advances on society and debating issues (such as equitable access) that might emerge 
once proof o f principle exists and the first therapeutic products/treatments reach the 
clinic.
To sum up, there are a number of different terms and definitions/meanings of TR that 
correspond to a variety o f points along the research continuum. Establishing which 
term and definition one is using is perhaps the first critical step to take in exploring 
Translational Research as each ‘area’ has its own characteristics (actors, settings, 
timelines) and raises its own set o f issues. Indeed, much of the literature on 
Translational Research has been concerned with the identification of different 
barriers/obstacles for Translational Research across the various ‘areas’ as well as with 
finding ways to better translate basic biomedical achievements into practical benefits. 
Some o f these barriers are explored in the following section.
Barriers to Translational Research
Scientific authors and commentators have identified various reasons for the 
Translation deficit. For example, the inability o f translational investigators to take into 
account the complexity of human physiology and disease surfaces in the Marincola 
(2003) editorial when introducing the journal of Translational Medicine. For Marincola, 
however, the obstacles are as much technical and methodological as they are 
conceptual or disciplinary. He identifies the limitations o f animal models resembling 
human diseases as one o f the most serious hurdles in Translational Medicine. In their 
attempt to facilitate the mathematical prediction o f a given treatment outcome, many 
basic scientists prefer to simplify the biology of the models through standardisation of 
the genetic make-up o f animal and diseases. As a result, the models no longer
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represent the basic essence of human diseases and hence do not work as well in 
humans as they did in the preclinical settings. According to Marincola, Translational 
Medicine is a bidirectional process, from bench to bedside and from bedside to bench, 
but unfortunately, bedside-to-bench efforts are hindered because ‘the scientific aspects 
are poorly understood by full time clinicians and the difficulty o f dealing with humans 
poorly appreciated by basic scientist’ (Marincola, 2003: 1). Rather than overcoming 
these misunderstandings, over-simplified animal models exacerbate them.
Apart from the calls for greater in-vitro and in-vivo connectivity, several other barriers 
are identified in the literature regarding TR. These include economic hurdles (i.e. 
funding o f product development through to profitability), regulatory barriers, 
intellectual property (IP) obstacles, lack o f metrics, and lack of infrastructure and TR 
training (Horig et al., 2005; Mankoff et al., 2004). The following section explores and 
discusses the apparent bidirectional nature of Translational Research and the role it 
plays in innovation.
O n the Complexity and Non-linearity o f Translational Research 
In the previous sections, I have elaborated on the origin, definitions, terms and various 
meanings o f the TR concept. As it is obvious from this review, Translational Research, 
as currently used in biomedicine, refers to a one-way, linear process through which the 
findings of basic science are applied to clinical problems.62 However, this view of 
Translational Research has been increasingly doubted by many, including basic 
scientists and clinicians as well as social scientists, who argue that it portrays patient- 
oriented investigation as a process that is at best simplistic and at worst intellectually 
derivative.
For example, Peter Stacpoole (Professor o f Medicine and Director o f the General 
Clinical Research Centre, University o f Florida) in a commentary in 2001 states that 
the term ‘bench-to-bedside’ evokes a fundamentally misleading and harmful paradigm 
for describing patient-oriented investigation and those who conduct it. Implicit in the
62 Even th e  Pattison  report, w hich  in 2 0 0 5  p rovid ed  an a g en d a  for research  w ith in  th e  UK in th e  fie ld  o f  s te m  ce lls  and  m ore  
broadly RM, a d o p ts  a largely linear m o d el o f  in n ova tion . The d iagram m atic rep resen ta tio n  o f  th e  's tem  cell th era p y  
d e v e lo p m e n t  and p rod u ction  p ro ce ss ' co m p r ise s  o n e -w a y  arrow s d ep ic tin g  th e  m o v e  o f  in n ova tion (s) from  R&D, to  clinical 
research  and  finally to  clinical p ractice  (P attison , 2 0 0 5 ).
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bench-to-bedside notion is, he suggests, the assumption of a linear and unidirectional 
process of biomedical experimentation, by which so-called Translational Research is 
‘necessarily preceded by and dependent on the creativity and hypothesis testing 
percolating up from laboratories conducting basic research’ (Stacpoole, 2001: 616). 
Stacpoole continues by pointing out that biomedical investigation simply does not 
always work that way, and it is often the wonder and curiosity o f observers o f the 
clinical phenomenology o f human disease that ‘ignites the creative spark and inspires 
both clinically and non-clinically trained experimenters to undertake relevant 
hypothesis testing’ (2001:616). In other words, according to Stacpoole, the quest for 
answers oscillates within and between the bench and the clinical arenas, in a process 
that he describes as highly iterative and palindromic.
Elliot Gershon (1998), a Professor o f Psychiatry and Human Genetics at the 
University of Chicago, also criticises the linear model o f TR even further, noting that 
the prevailing directional bias that most important discoveries are made in the 
laboratory and then applied to the clinic, is a costly one. This is because ‘it enshrines an 
antagonistic “two cultures” mentality in the vast segment o f society related to 
biomedicine, and inhibits intellectual voyages o f discovery that do not go in the 
prescribed way, thus inhibiting rather than stimulating scientific progress’ (Gershon, 
1998: 96).
Damian O'Connell and David Roblin (2006) (from pharmaceutical giant Pfizer) also 
emphasise the non-linearity o f Translational Research (within the context o f the 
biopharmaceutical industry and drug development) and highlight the importance o f a 
‘bi-directional dialogue’ between research scientists and clinicians that would ensure 
the timely removal of poor candidate compounds and facilitate the identification and 
acceleration of ‘good’ compounds that fulfil a medical need, hence overcoming the 
pharmaceutical industries R&D attrition where ‘failure is many times more likely than 
success’ (O'Connell & Roblin, 2006: 833).63
63 The FDA e s t im a te s  th a t ju st a 10% im p ro v e m en t in p red ictin g  a p rod u ct's  fa ilure in clinical trials cou ld  sa v e  1 0 0  m illion  
dollars in d e v e lo p m e n t  c o s ts  p er drug. S ee: FDA 2 0 0 4  'Innovation  Stagnation: C hallen ge and  O p p ortu n ity  on  th e  Critical 
Path to  N ew  M edical Products': US D ep a rtm en t o f  H ealth and H um an S erv ices, Food and  Drug A dm inistration .
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From a social science perspective and with a focus on the RM field (and specifically 
HSCs64), Paul Martin, Nik Brown and Alison Kraft (2008) question the imagined 
trajectories o f ‘bench to bedside’ and present an RM reality characterised by rather the 
inverse, namely ‘bedside to bench’. Their analysis, which is based on a detailed 
historical and empirical study of the development of HSCs spanning several decades 
(1950 to the present), explores the way the relationship between the bench and the 
clinic has changed during this period and what implications are there for understanding 
the knowledge production and application, in other words Translation.
The non-linearity o f Translation has also been argued from a business and 
commercialisation perspective. In his book on ‘Commercialising Successful Biomedical 
Technologies: Basic Principles o f the Development o f Drugs, Diagnostics and 
Devices’, Shreefal Mehta65 — a US ‘inventor/researcher-turned-CEO’ — addresses the 
practical limitations of using a linear model (‘a linear roadmap’) to organise the iterative 
and path-dependent process of biomedical product development. Mehta points out 
that ‘the linear roadmap shows the components that must be accessed to build a sound 
commercialisation plan, but the processes are all carried out in parallel, with shifting 
emphasis on each component as one proceeds down the plan’. In short, Mehta points 
out the inevitable fact that feedback from one component will ultimately influence or 
change the understanding of another previously researched component.66
In short, there are compelling arguments to suggest that Translational Research cannot 
be adequately represented by the ‘bench-to-bedside’ concept and has increasingly been 
described as a ‘bench-to-bedside-to-bench-to-industry-to-bench’ process. This iterative 
and complex nature o f Translational Research that emerges from the scientific and 
other literature, is an important concept in this thesis, and I use it in later chapters as a 
background in order to identify and explain innovation in the Regenerative Medicine 
(RM) therapeutics field.
64 H a e m a to p o ie tic  S tem  C ells (HSCs)
65 S hreefa l M ehta  w a s  aw ard ed  th e  N ew  York capital reg ion 's Future B u sin ess L eaders '40  u n d er 40 ' A ward in 2 0 0 6 . He has  
lectu red  at in tern a tion a l c o n fe r e n c e s , b een  q u o te d  in b u s in e ss  and tra d e  m a g a z in e s  (E con om ist, The S c ien tis t, e tc ) , b een  
w id e ly  p u b lish ed  in lead in g  jou rn als such  as N a tu re  B io tech n o lo g y , and  has ta u g h t e x e c u tiv e  m a n a g e m e n t and  
m ultid iscip linary c la sse s  on  co m m ercia lis in g  b io tec h n o lo g y .
66 For ex a m p le , lim ited  a c c e ss  to  IP rights m ay  ch a n g e  m ark et s tra tegy , w hich  in turn  m ay a lter  th e  regu la tory  p a th w a y  
required  to  d e v e lo p  an F D A -approved p roduct.
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Indeed, Regenerative Medicine is considered by many to be a poster child for 
Translational Research. Maienschein et al. (2008), for example, have argued that 
contemporary stem cell research is being shaped by the pressures o f Translation more 
than any other biomedical field, precisely because the research is developing at the 
same time as the demand for results. As the emphasis on harnessing laboratory 
findings has coincided with this ‘new era in biology and medicine’ (Keller, 2005) there 
is in no longer the possibility of what is called ‘pure’ or ‘curiosity-driven’ exploration o f 
stem cell science. As Maienschein et al. (2008) note, by changing our understanding of 
fundamental biological concepts, stem cell research has also changed the expectations 
about what and how fast things can reach the clinic (or the market). As such, ‘stem cell 
research outcomes may well set the agenda for future funding initiatives and change 
the ways in which Translational Research is understood, by both scientists and the 
public’ (Maienschein et al., 2008).
A vital role in this understanding o f Regenerative Medicine is undoubtedly being 
played by the social sciences and the way they are exploring both Regenerative 
Medicine as a new promising treatment paradigm and Translational Research. In the 
next chapter, first I briefly review the social science literature for Regenerative 
Medicine in general and then provide a more detailed review o f the social studies 
which have focussed on the ‘bench-to-bedside’ paradigm of RM and other relevant 
aspects (for example social science research on RM regulation).
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Chapter 3
The Social Science Perspective
Introduction
In this chapter, I provide a review o f the social science literature that is relevant to my 
thesis and that will help the reader to better conceptualise the research problem and 
questions that have been mentioned in the first chapter, as well as understand the 
rationale behind the study and the intended contribution to the knowledge of the 
specific field.
The purpose o f this review is twofold. First, it is to identify sociological work 
concerned with the emerging field o f Regenerative Medicine and identify and present 
some o f the central research streams that have emerged. This part briefly reviews the 
most relevant social science studies that have addressed the RM paradigm including a 
variety of perspectives (e.g. political perspective) and methodological approaches, and 
thus provides the reader with the background to understand my research and puts my 
‘line o f enquiry’ into context. Second, it is to identify the most influential researchers 
and research groups in the (more narrow) field o f RM Translational Research, critically 
describe their work and reflect on the main sociological theories and concepts that 
have been used to examine the paradigm ‘o f bench-to-bedside’. In other words, in this 
part I identify the pieces o f sociological work that are the most relevant to my research, 
explain why this is and finally explain what motivated my research and guided its 
‘structure’.
The review of the literature (in addition to its value in developing my research 
rationale) has also provided me with methodological insights regarding how to ‘go 
about’ exploring the specific part o f the phenomenon (Translation) I was interested in 
and also how to capture the particular perspective on which I wanted to focus.
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Coverage
Deciding how wide to cast the net was a critical step in conducting the review. As an 
initial approach I read widely on the social science o f RM to try and gain an 
understanding o f the central issues that have emerged and the approaches that people 
in the field have taken to explore and address them. The next step was to identify the 
studies that appeared to be the most relevant to what I had already proposed to do and 
use them to justify it, develop it and refine my research design. Once the first empirical 
data had been collected and themes emerged I decided it was essential for the review 
to cover additional areas that although not characterised as directly belonging to the 
‘bed-to- bedside’ sociological research space, they are in many ways relevant and useful 
in its exploration. For example, I have also reviewed sociological research on RM 
regulation and the recent articles analysing and debating the emergence o f an ‘ethos of 
Translation’. Finally, I have read extensively from the entrepreneurship literature and 
have included many references in the empirical chapters. A full review however, is 
beyond the scope of this thesis. I do review and recommend one study that I found 
the most relevant, in terms o f settings, and the most useful, in terms of structure, 
methodology followed and concepts.
Although the above description might give the impression o f a linear and ordered 
process, in reality, the process of reviewing the literature has been continuous and 
iterative throughout the writing of the thesis; as new references were identified and 
retrieved it became necessary to examine some themes in more detail.
Organisation Format
There are many formats in which to organise a review (for example the historical 
format, the conceptual format, and the methodological format) (Hart, 1998). For the 
purposes o f this review the ‘conceptual’ is the most appropriate format as it allows the 
review to be organised according to the various theories, concepts and analytical motifs 
in the literature. A historical and methodological approach cannot be justified because 
of the recent emergence o f the phenomenon (RM in general and the ‘bench to bedside’ 
more specifically) under study and the dearth of social science studies that have 
addressed it (so far).
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Data Collection Method
My data collection process began with an electronic search in social science databases 
(IBSS) and the Internet. Among the search terms used were: Regenerative Medicine, 
Translation, Translational Research, stem cells, cell therapies, cell therapeutics, 
commercialisation, clinical and commercial translation. Electronic searches lead to 
about 40 percent of the articles that eventually comprised my review. The remaining 60 
percent was located by searching the references o f the articles that were retrieved, 
determining which of those were relevant and searching through them too. In order to 
ensure that I included all relevant studies, I also searched for literature reviews that had 
already addressed the same research area and explored related sets o f questions.67
In the next section, I briefly review social science studies that I think are the most 
pivotal in the RM field, this will provide the necessary background for the reader and 
aid their understanding not only o f the research context, but also the analysis and 
discussion in the empirical chapters (Chapters 4, 5 and 6). For reasons o f clarity I have 
classified the reviewed sociological work under a few broad, distinct but interrelated 
streams of research.
Social Science o f Regenerative Medicine
The social sciences have launched a large number o f studies into the sociological 
perspectives of Regenerative Medicine aiming to explore, map, and understand it, 
often help direct its governance and regulation, and ultimately facilitate the 
achievement of its goals.
In the UK and in recognition o f the importance of the social science perspective for 
the developments in Regenerative Medicine, the Economic and Social Research 
Council (ESRC) set up in 2005 (until 2009), the Social Science Stem Cell Initiative 
(SCI) to the value of £ \ . l  million. Through this funding, the SCI sought to build 
research capacity and raise awareness within the UK  social community o f the 
significance of this emerging field. The SCI has supported a substantial number of 
social science projects involving various themes related to stem cell research, including
67 As far as I am  aw are, on ly  o n e  rev iew  o f  so cio log ica l w ork on  Translation h as b e e n  p ub lished  s o  far. S e e  W ain w righ t e t  al. 
(2 0 0 9 ) , w h e r e  so cio log ica l w ork  in th e  RM fie ld  is c a teg o r ised  und er s e v e n  broad  th e m e s . I h a v e  fo u n d  th is  ca teg o r isa tio n  
u sefu l and I am  using a sim ilar form at.
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the issues of stem cell regulation, innovation, materials and research practices 
standardisation, and the dynamics o f expectations and public engagement.
On the whole, the growing (and relevant) social science literature on Regenerative 
Medicine (RM) can be classified as belonging to one (or a combination) of the 
following research streams.68 The streams include:
1. Research on the themes of regulation, legislation, and policy frameworks;
2. Research focusing on the development o f the notion o f ‘tissue 
economies’ and tissue commodification;
3. Sociological research that relates stem cell research to the social world of 
reproductive technologies;
4. Research on the media representation o f the RM field and the 
relationship between the public (perceptions, debates) and ethics;
5. Socio-political perspectives and the theme o f governance (biopolitics);
6. Research on intellectual property issues related to RM.
In the following paragraphs I briefly review what I consider to be the pivotal studies 
and most influential contributions in each stream of research. The aim is provide a 
picture o f the whole field and help the reader to position my own work.
Focussing on the themes o f regulation of Regenerative Medicine, a number o f social 
scientists have examined the regulatory and legislative frameworks for stem cell 
research in various countries, including Germany and the US (Gottweis, 2002), Israel 
(Prainsack, 2006), Singapore (Kian & Leng, 2005), or have written reviews o f various 
national policy frameworks (Liddell & Wallace, 2005), or have explored the 
development o f the policy framework itself (Parry, 2003).
The relationships between regulation and policy formation (from a more empirical 
basis), has been largely explored by Alex Faulkner, Ingrid Geesink, Julie Kent and 
David Fitzpatrick. In their paper Faulkner and colleagues (2008) examine the risks that 
are formulated in the zone o f tissue engineering (TE) and whether those risks are
68 The research  strea m s or 'th e m e s' in RM are th e  sa m e  as th o se  id en tified  in W ain w righ t e t  al. (2 0 0 9 ). H ow ever, in th eir  
2 0 0 9  p ub lication  th e r e  is o n e  s trea m  th a t I will n o t b e  review in g and  in clu d es  th e  m o re  'cultural' p ersp ec tiv e  on  th e  fie ld  o f  
RM.
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reflected in emerging regulatory policy in Europe. According to the authors, scientific 
and industrial actors formulate the risks of TE in three primary frames (technological 
safety risk; therapeutic efficacy risk; and economic risk) and these frames are mobilised 
selectively during the EU process o f regulatory regime building. Additionally, Faulkner 
(2009) presents a detailed account of the debate and development of regulatory policy 
for therapeutic TE in EU policy institutions and stakeholder networks, exploring how 
jurisdiction o f an emergent zone has been formed through such negotiations and thus 
essentially providing a counter-example to the common view that regulation ‘lags 
behind’ innovation.
The same team (Kent et al., 2006) employs the concepts o f ‘biovalue’, ‘biocapital’ and 
‘intercorporeality’ (Waldby, 2002a, 2002b) to examine the significance of autologous 
applications of tissue engineering for the personal identity o f its end users. The authors 
explore the issue in relation to the tissue-engineered autologous chondrocyte 
implantation (ACI) technique. According to Kent et al. (2006), the implications for 
‘self o f autologous ‘self-repair’ technologies such as ACI are very different to that o f 
allogeneic multi-donor/multi-recipient technologies where analytic concepts such as 
biovalue and intercorporeality are much more applicable.
One important stream of research is focussed on the theme o f tissue commodification 
and ‘tissue economies’ (as defined by Catherine Waldby). Waldby (2002b) examines 
social and philosophical implications of stem cell technologies, including 
transformations in the concept of health/healthy body, particularly in the temporality 
of ageing and social indebtedness. Using cord blood banking as a case study, Waldby 
(2006) argues that the technical economy of Regenerative Medicine is not socially 
neutral. Cord blood banking exists in two distinct forms — an allogeneic tissue network 
based on gifting to public cord blood banks and a private autologous cord blood 
account. In her analysis, Waldby suggests that private cord blood banking not only 
does not conform to the logic of gift economies, but also the form of 
possession/property relationship it creates is novel in the contemporary field of 
human tissue biopolitics.
O ther scholars to have contributed significantly in this research stream are David 
Resnik (2002) and Peter Glasner (2005) who have focused on the commercial potential
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of RM and the resulting ethical dimensions. Resnik (2002) draws attention to the shift 
o f the human embryonic debate from fundamental questions such as whether the 
research should be done at all, to what he sees as the next stage of the debate: the 
batde for property rights relating to human embryonic stem cells. Sociologist Peter 
Glasner (2005) from Cardiff University, uses Waldby’s model o f ‘tissue economy’ 
(predicated on the gifting of spare embryos by family members to stem cell 
researchers) to conceptualise the supply chain from stem cells to therapeutic 
applications.
Another stream o f research, explores the relationship o f RM, and specifically human 
stem cell research, with reproductive technologies. Sarah Franklin from the London 
School o f Economics (2006) explores the question of embryo donation to stem cell 
research from the perspective of the increased proximity between stem cell derivation 
and the process of in-vitro fertilisation (TVF). Franklin uses a model of ‘double 
reproductive value’ to explore what forms o f exchange and flow are occurring, and 
how these are defined and negotiated in the context o f a national hES cell 
coordination network o f practitioners (hESCCO).69
Sociological research on media representations and public concerns about embryonic 
stem cells has been carried out by Williams et al. (2003) and Kitzinger and Williams
(2005) who explore how the debate about embryo stem cell research is played out in 
the UK national press and TV news media.
Pivotal studies in the research stream of public debates and ethics include Margaret 
Sleeboom-Faulkner’s (2008) (University of Sussex) examination o f hESC debates in 
Japan. In her study Sleeboom-Faulkner notes that although the debate is considered 
crucial by policy-makers in Japan, it is found to be monopolised by the voices o f a few 
social groups. These social groups either clearly support or oppose hESC research. 
Nevertheless, according to the author, ‘the public debate is carried on mainly by 
political interest groups that amplify and mis-quote the minority voices. These interest 
groups capitalize on the hopes placed on hESC in promoting financial and political 
support, at the same time as they aim to cure disease’ (Sleeboom-Faulkner, 2008: 285).
69 N etw ork  o f  h um an  em b ryon ic  s te m  cell co o rd in a to rs  (hESCCO).
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In a similar vein, Beatrix Rubin (2008) examines how the concept o f ‘therapeutic 
promise’ serves to draw attention to the central role of medical proposal in the 
discourse of hESC research and how it initiates an alliance between bioethics and 
science in an endeavour that both shapes and ensures the continuation of hESC 
research. The author uses the discourse of hESC research as a case study to show ‘how 
proposals for novel therapies have framed and stabilised the initiation, reception, and 
implementation o f a novel biomedical research domain (such as hESC) in the Western 
systems o f science and policy (Rubin, 2008: 25). Evans et al. (2009) use diabetes stem 
cell research as a case study to examine how the hopes and uncertainties associated 
with its complex research agenda are understood by different groups, including 
researchers involved in the work themselves, public supporters, and public opponents 
of the research. In their analysis, they show that the difference in the understanding o f 
the potential o f stem cell research is a result o f the way scientific progress is being 
communicated, both among the experts themselves and from the experts towards the 
public. Kotchetkova et al. (2008) compare focus group data on perceptions of stem 
cell research with survey-based representations o f public opinion.
Patients’ perceptions of embryo donation to stem cell research have been extensively 
explored in the UK and European context. For example, Sarah Parry (2006) from the 
University o f Edinburgh investigates the views of people involved in UK fertility 
programmes who may be approached to donate their embryos for stem cell research. 
She argues that that participants’ views are context-bound, born out o f lived 
experiences both within the clinic and wider society. In particular, Parry argues that 
people’s understandings of embryos as potential lives and the context in which 
embryos are created, have direct implications for their views about donating embryos 
for stem cell research. Haimes and Luce (2006) explore the views and experience of 
people (in the UK and Switzerland) asked to donate embryos for research.
The theme o f patenting and intellectual property regulation in the UK, EU and US has 
also been intensively examined. The majority of the articles address the ethics of 
patenting, with most focussing on the ethics o f patenting human embryonic stem cells 
(Chapman, 2009). David Resnik (2002) considers arguments for and against patenting, 
while others have sought to empirically research the perceived impact o f the patenting 
regime (as well as commercialisation agendas) on the stem cell community (of Canada)
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(Caulfield et al., 2008). Matthew Herder (2006) from Loyola University, Chicago, 
examines US and European patent systems, illustrating discrepancies in the 
patentability o f hESC technologies and identifying potential negative consequences 
associated with efforts to make available hESC research tools for basic research 
purposes while at same time strengthening the position o f certain patent-holders’ 
rights. Herder (2009) also analyses and compares two recent initiatives in the field of 
stem cell research — ‘Stem Cells for Safer Medicines’ (SC4SM) based in the United 
Kingdom and the cross-border Canada—California ‘Cancer Stem Cell Consortium’ 
(CSCC) — in order to examine the reasons why any o f these research initiative elects to 
adopt a particular approach to patenting, licensing, data and materials dissemination.
From a (bio)politics perspective Brian Salter (2007) examines the basis o f the conflict 
in hESC science between patenting and morality at national and international levels, 
and the manifestations o f those tensions in European patenting policy. He argues that 
a new type o f expertise and authority is needed to negotiate the inevitable plurality of 
the economic and cultural moralities that are shaping EU patent policy and discusses 
how bioethics is a promising candidate for this new governance role. In another article, 
Salter (2008) analyses the approach of the emerging economies o f China and India to 
innovation in stem cell science and their distinctive contribution to the dynamics o f the 
global political competition.
In the next section, I examine the work of the most influential researchers and 
research groups in the field of translational Regenerative Medicine. The aim is to 
describe and examine previous research, identify the central issues under investigation 
and explicate the lines of argument most relevant to my work.
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Social Science o f Regenerative Medicine TR
As mentioned in Chapter 1, Translational Research is quickly becoming an integral part 
o f all kinds of biomedical research and has become a funding priority for governments 
and relevant institutions across the globe including the National Institutes of Health 
(NIH) and the California Institute for Regenerative Medicine (CIRM) in the US; the 
Medical Research Council (MRC), Biotechnology and Biological Sciences Research 
Council (BBSRC) and Wellcome Trust in the UK. With the ultimate aim o f taking 
basic scientific discoveries that happen in the lab and converting them into clinical, 
economic and social benefits, translational efforts are under pressure to achieve their 
goal not only promptly but also transparently and under regulatory regimes that 
guarantee that results are safe and ethical to use.
In fact, in recognition o f the important role the social sciences can play in the study of 
Translational Research (especially in the Regenerative Medicine field), special 
fellowships were set up by the UK Economic and Social Research Council (ESRC) to 
support research specifically on the theme of stem cell Translation. Study areas have 
ranged from the IVF—embryo interface and the processes and obstacles o f product 
development, to commercial models and the emerging politics o f a global stem cell 
bioeconomy.
Given the fact that Regenerative Medicine TR (‘bench to bedside’ paradigm) is a 
recently recognised concept/phenom enon (at least in the sense that is currently used 
by all stakeholders), it is no surprise that there are, to date, few sociological studies that 
have thoroughly addressed it. These studies have focussed on a wide variety of aspects 
and issues, have employed an array of concepts (borrowed from different research 
traditions) and have followed various methodological approaches. Overall, I have 
identified four broad ‘research areas’ that are (in terms o f conceptual tools) the most 
useful to my own work. Each of the following sections provides a review o f what I 
identify as the most influential studies in each o f these areas.
A large part of sociological research in RM TR (bench-to-bedside) has been drawing 
on the sociology of expectations in order to explore a range o f questions about the role 
o f expectations in shaping scientific, technological, commercial, and social trajectories 
of stem cell research. The sociology of technological expectations is a relatively new
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field within Science and Technology Studies, that builds on previous work on the 
social shaping of technology (MacKenzie & Wajcman, 1999) and with the general aim 
of examining how expectations of the future and other future-oriented claims 
(promises or ‘visions’) are an important resource in the creation o f new technologies 
(Guise, 1999; Martin, 1995; Van Lente, 1993; Van Lente & Rip, 1998).
A number of studies on expectation dynamics have shown how, especially in the early 
stages o f a technology’s development, expectations play a crucial part in building 
interest, enrolling support and winning legitimacy, defining roles, constructing mutually 
binding obligations, informing agendas and commercial decisions and attracting 
investment (Walsh, 2002). In other words, expectations are thought to be a 
‘constitutive force’ (or ‘performative’) as far as they coordinate actions in the present in 
order to realise a particular future (Borup et al., 2006; Brown et al., 2000). In this sense, 
expectations are considered by many as a particularly important analytical object when 
studying the bench-to-bedside interactions as both stem cell innovation and 
Translation are highly ‘future-orientated’ endeavours in need o f ongoing financial and 
public support during what is a (possibly) long waiting time, before any benefits come 
to be realised.
Over the last five years a series of social science research papers have thoroughly 
examined aspects o f the TR process employing concepts from the sociology of 
expectations and focusing on their ‘performative’ nature. Among the most influential 
groups are social scientists from King’s College who have published widely on the 
subject, focussing on the field of stem cell research and specifically on the area of 
diabetes mellitus. For this group, ‘stem cell science as a potential cure for diabetes, is a 
prime example o f the increasing pressures of linking the bench and the bedside 
through Translational Research’ (Wainwright et al. 2007: 252).
Beginning with their 2006 paper, Steven Wainwright, Clare Williams, Mike Michael, 
Bobbie Farsides and Alan Cribb (2006) explore the views o f biomedical scientists on 
the prospects for and problems of Translational Research in the field o f stem cells and 
specifically in the area of diabetes. The focus of their research is not only on 
institutional influences on the interactions between scientists and clinicians but also on 
stem cell science itself as barrier to developing treatments (both are areas which
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scientists themselves saw as central in relation to stem cell science as a therapy for 
diabetes). Wainwright et al. (2006) draw on interviews and ethnographic work with 
scientists from one leading beta cell70 laboratory in the UK, and their aim is to ‘unpack 
a number of discourses that construct expectations about the trajectory from bench to 
bedside’ (2006:2052). Among their findings is that, as Translational Research is 
becoming increasingly important in the shaping o f basic scientific research, scientists 
seem to perceive that a number o f institutional influences affect their interaction with 
clinicians (who carry out clinical research on the same field). The scientists understand 
these influences to be either in the form of ‘external influences’ (e.g. governmental, 
commercial, and so on) or in terms o f the ‘two cultures’ o f medicine and science, as 
they are perpetuated by important institutional factors — such as the way clinicians and 
scientists are trained and the way medical schools and research communities ‘operate’. 
Despite these ‘negative’ influences, the authors found evidence of willingness to 
‘bridge’ the perceived difference and collaborate in view o f the benefits that would 
arise from successful interaction (collaboration).
The second part of the study investigates the theme o f biomedical science itself as a 
major problem of imagined future stem cell (diabetes) therapies. In this part of their 
investigation, the authors’ findings suggest that ‘scientific’ problems such as controlling 
the behaviour of (embryonic) stem cells, genetically modifying them and translating 
findings from animal models to humans, are perceived as responsible for dampening 
scientists expectations and in some cases even re-directing them to different stem cell 
‘futures’ such as the use o f stem cells as research tools (as opposed to being used as 
therapeutic transplants). Throughout the paper Wainwright and colleagues (2006) 
highlight the ‘performative’ nature of the discourses o f expectations on the prospects 
for the Translation of research from bench to bedside. They conclude that ‘scientists 
weave a complex tapestry of expectations’ and that ‘enactments o f material 
expectations (about research outcomes) are partially structured by expectations about 
institutional (e.g. funders’) expectations about the prospects for stem cell therapy. 
Conversely, institutional expectations about the possibility of collaboration are enabled 
by expectations about the successful manipulation of stem cells. The institutional and 
the material are thereby intimately entwined’ (2006:2-062).
70 Beta ce lls  are in su lin -secretin g  ce lls  th a t are d estro y ed  in d ia b e te s  by th e  p a tien t's  a u to im m u n e  sy ste m .
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Keeping the focus on the ‘performative’ nature of expectations Steven Wainwright, 
Mike Michael and Clare Williams (2008) have explored the role expectations play in the 
possible emergence of a new paradigm of Regenerative Medicine, the ‘disease in a dish’ 
approach to stem cell Translation. As opposed to the ‘cell transplant’ translation model 
(where stem cells themselves comprise the therapy), under the ‘disease in a dish’ 
model, hES cells will be used as tools for investigating the mechanisms of disease as 
well as enabling the development and testing of new drugs. Drawing on the sociology 
o f expectations, and particularly the concept o f ‘expectational capital’, as well as from 
Bourdieu’s ‘habitus’, ‘capital’, and ‘field’ concepts, the authors argue that scientists’ 
persuasive promises are used to advance their interests in the new ‘disease in a dish’ 
approach, hence promoting (and stabilising) it over the option o f the until-recently 
dominant ‘cell transplant’ translation model and its so far ‘unfulfilled expectations’. 
Wainwright and colleagues draw on over sixty interviews with scientists and clinicians 
in leading labs of the UK and US and explore their views on the bench-to-bedside 
interface in the fields o f neuroscience and diabetes. In justifying their theoretical 
approach o f combining the sociology o f expectations with Bourdieu’s concepts the 
authors state: ‘If  Bourdieu can provide a sense o f the structure that characterises the 
field of stem cell research, the sociology of expectations can allow us to show how the 
future of this structure is performed in order to effect change in the present’ (2008: 
960).
O ther scholars have looked at the constitutive character o f expectations with regard to 
the long tradition of clinical innovation associated with the area o f blood stem cells 
(haematopoietic stem cells, HSCs) in order to explore their role in what is truly the first 
and only (so far) routine application o f stem cells in clinical practice. In examining the 
way biological entities like HSCs ‘become the focus and bearers o f future value in 
contemporary global stem cell economies’, Nik Brown, Alison Kraft and Paul Martin 
(2006) have turned to the past to explore the way current expectations o f stem cells are 
historically constituted. Again, drawing on perspectives in the ‘sociology of 
expectations’, the authors chart the ‘promissory pasts’ o f HSCs through four different 
narratives: their place in blood transfusion, their role in bone marrow transplantation, 
their importance in gene therapy, and finally their role in the more recent areas of 
Tissue Engineering and Regenerative Medicine. By tracking the emergence and 
transformation o f the HSC through ‘a long series o f cycles o f hope and
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disappointment’, the authors have shown how past expectations are embedded in 
current networks and knowledge, in the same way that current expectations will be 
constituted in the construction of biological futures.
In another paper, the same team — Paul Martin, Nik Brown and Alison Kraft (2008) — 
question the ‘imagined trajectories of bench to bedside’ in the field o f Regenerative 
Medicine and instead, advocate a Translation model based on the two-way flow of 
knowledge. Drawing on Anderson’s notion o f ‘imagined communities’ (Anderson, 
1983) they develop the concept of ‘communities o f promise’ and employ it to explore 
how clinical developments really emerge. Using HSCs as their case study, they examine 
the changing relationships between the bench and the bedside (i.e. the scientific and 
clinical communities o f promise) over time and conclude that clinical experimentation, 
by ‘feeding back’ into basic laboratory research, facilitates innovation and is an equally 
crucial driver (to basic laboratory work) in the production o f knowledge.
Several scholars have been exploring the role o f expectations in stem cell innovation 
and Translation by focusing on a recently created ‘branch’ o f the stem cell enterprise, 
the banking of cord blood (CB) stem cells. Nik Brown and Alison Kraft (2006), for 
example, have explored the growing phenomenon of cord blood (CB) banking by 
addressing the relationship between what they call ‘imagination’ and ‘materiality’ — in 
other words, the way in which current expectations of a future stem cell revolution are 
embodied (materialised) in the ever-increasing number o f deposited cord blood 
samples. In their attempt to delve into the promissory dynamics o f expectations of CB 
banking, they have employed a variety of concepts that have previously proven useful 
in unpacking the dynamics and sociological examination o f other bio-phenomena (e.g. 
donation, processing and use o f embryos, ova, tissue, etc).
For example, using the concepts of ‘capitalisation’ and ‘biovalue’, Nik Brown and 
Alison Kraft (2006) study the way promises and expectations in the worlds of CB 
banking work to connect the present and future value of this novel type of biological 
investment. Through the lens of the ‘cord blood debate’, which contrasts public 
banking and its ethos o f altruistic donation to private banking as a form of ‘personal 
property/investm ent’, the authors are examining how the futures and expectations 
attached to the banking of cord blood are restructured and the implications this
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restructuring is having or will have for the wider contemporary tissue economies. In 
the words of the authors, ‘capitalisation can be seen to take the form of a shift away 
from the shared public ownership of a collective future resource and towards a greater 
privatisation o f the storage for personal use and also commercial profit’ (2006:318).
According to Brown and Kraft (2006), cord blood services are also part of what has 
been termed ‘the political economy o f hope’, which resolves around the idea o f ‘a 
shared culture o f images and understandings about the promise o f medicine and the 
importance of personal or collective action in the face o f potential pathology’ (Brown 
& Kraft, 2006: 319). As the authors point out, there is a growing concern that in the 
case o f CB banking this ‘action’ (i.e. the decision to bank the cord blood) is in danger 
o f appearing to be more the result o f the emotional manipulation o f parents during the 
anxiety o f childbirth than promotion o f a ‘legitimate precaution against the possibility 
— however unlikely — of the future clinical utility o f banked cord blood’ (2006:320).
Drawing from qualitative interview data Brown and Kraft (2006) also provide evidence 
of how the cord blood industry is interfering with understandings of family, kinship 
and blood ties, as well as ‘new’ parental duties towards an uncertain, risky future. 
Taking advantage of an ‘increasingly geneticised causality o f disease’ the industry is 
seen to manufacture future familial disease risk and then present its services as an 
essential step towards safeguarding the potential treatments. Building on the 
expectations o f future therapeutic potential, the risk of a future disease and kinship 
responsibilities, cord blood banking is promoted as a vital form of ‘insurance’ that 
parents are advised to take to ensure that their child (and perhaps other family 
members) takes advantage o f future medical therapies.
Exploring further the dynamics across public and private CB sectors, and drawing on 
data from a global survey of the cord blood banking industry, Paul Martin, Nik Brown 
and Andrew Turner (2008) provide a detailed analysis o f the construction of 
expectations in each case and the way public and private organisations are trying to 
create value for their prospective customers. According to the authors, public CB 
banking and its support o f present-oriented, evidenced-based existing applications o f 
cord blood stem cells is operating with a body o f claims that can be characterised as a 
‘regime o f truth’. As Martin and colleagues (2008) suggest, public banks ‘refrain from
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mobilising the future in constructing biovalue and stress instead currently proven 
therapeutics within a regime of truth oriented to the moral economy o f altruistic 
mutuality’ (Martin, Brown, & Turner, 2008: 137). In sharp contrast to this ‘regime of 
truth’, stands a body o f both present but mainly future claims that can be characterised 
as the ‘regime o f hope’, under which commercial cord blood banking has been 
operating. Recent findings about the plasticity o f cord blood cells have hinted at a 
change of their role from ‘just an alternative’ to conventional bone marrow transplants 
for children to a potential therapy for a number o f degenerative diseases in both adults 
and children, and have spurred rapid development of the commercial CB sector. While 
distinguishing between the two regimes of value, Martin and colleagues point to the 
entangling o f the two regimes in the case o f private banks that are operating the so- 
called ‘hybrid model’ where the choice between truth and hope, present and future is 
left to the customer.
In addition to their ‘performative’ nature, expectations are also thought to be 
temporally and spatially ‘situated’ (Brown, 2003). More specifically, they appear to have 
a temporal patterning over time, involving stages such as hypes and disappointments, 
and they are also different (at any one time) for the many groups or communities 
involved. In this section, I review a number o f social science studies which have 
analysed Regenerative Medicine Translational Research, by identifying and 
conceptually employing this characteristic o f expectations.
One recent study that addresses Translation this way is Kitzinger’s (2008) study71 
which examines how experts in the field o f stem cell science attempt to set 
expectations and manage disappointment during the innovation process. Focussing on 
the period 2000—2005, the author navigates her analysis from the initial times of 
visionary promises (2000) to the moments of breakthrough offered by a group o f 
Korean scientists (2005), and finally to the 2005-2006 period o f setback and 
disappointment as the Korean achievements were exposed as fraudulent. The work of 
Kitzinger shows that promises/hopes are more than just a ‘tool’ to be used in 
rhetorical representations of the future in order to mobilise resources and win support 
during the early stages o f stem cell innovation process. In short, through the study of 
the Hwang scandal, Kitzinger (2008) illustrates how, even at later stages o f the stem
71 This stu d y  is lo ca ted  w ith in  th e  grow in g  literatu re o f  ex p e c ta tio n s, a s w ell a s w ith in  th e  m ed ia  s tu d ie s  literatu re.
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cell innovation process — and especially during periods o f failure/setback — 
expectations could be readjusted to the new reality and realigned towards a new future, 
so as to rescue hope and support o f the stem cell innovation process as a whole.
Departing from the sociology of expectations but still with the focus on diabetes stem 
cell research, Steven Wainwright and Clare Williams (2008) from King’s College 
develop a ‘geography o f science’ framework as a new way to examine the interactions 
between the bench and the bedside. Their approach is based on David Livingstone’s 
‘geographical perspective’ which they use to explore what they call ‘stem cell 
landscapes in the making’. The authors illustrate some o f the transformations o f the 
places72 o f stem cell science, explore the influence that place/space has on the 
production, shaping, content circulation and consumption o f science, and finally they 
‘deconstruct the stem cell transplant approach to diabetes to illuminate some o f the 
ways in which “space matters” in the field of stem cells and diabetes’ (Wainwright & 
Williams, 2008: 164).
RM Translational Research and Ethics (‘Translational Ethics’)
In recognition of the many challenges that RM Translational Research faces as it 
crosses disciplines and other professional and institutional boundaries, many scholars 
have turned their attention to the ethical issues that are raised across the whole 
continuum of Translation. Given the fact that Translational Research is in need of 
ongoing financial support in order to achieve its goals, these issues must be addressed 
if the process is to secure legitimacy and win the trust and support of policy-makers, 
investors and the public.
Steven Wainwright, Clare Williams, Mike Michael, Bobbie Farsides and Alan Cribb
(2006), for example, have empirically explored the ethical views o f biomedical 
scientists on stem cell research and how these views are grounded in routine practice in 
the laboratory setting. The study focuses on the views of biomedical scientists on the 
(ethical) sources of human embryos and stem cells, scientists’ perceptions of the 
human embryos and stem cells and, finally, scientists’ perceptions o f the current 
regulatory frameworks governing stem cell research. Building on Gieryn’s ‘boundary-
72 Both p h ysica l/m ateria l sp a c e s  and  'disciplinary' sp a c es .
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work’ concept (Gieryn, 1983, 1999), the authors introduce the concept of ‘ethical 
boundary-work’ which they claim is becoming an integral part of the routine practice 
and performance of biomedical science. According to Wainwright and colleagues
(2007), scientists have various practical ways of engaging with the ‘ethics’ o f their work 
in order to conduct themselves in a ‘complicated, political, moral and epistemic 
context. These practical ways (‘practical ethics’) include the use of different sources of 
embryos and stem cells as well as deferring ‘ethical responsibility’ from the ‘space’ o f 
the laboratory to the ‘space’ of public regulatory bodies such the HFEA, the MRC and 
the Tissue Bank. Scientists consider that these regulatory authorities are responsible for 
the constant surveillance of the work being carried out, and for reassuring both the 
scientific community and the public that the research is being conducted legally and to 
high ethical standards. As the authors point out, the notion o f ‘ethical boundary-work’ 
that has been developed in this piece o f research has taken a form quite distinct from 
Gieryn’s original concept, in that instead o f defending scientific expertise by 
demarcating it from non-science, it de-privileges scientists by relocating their ‘ethical 
work’ to ‘outsiders’ (such as the regulatory bodies mentioned above).
The same team (Cribb, Wainwright, Williams, Farsides and Michael, 2008) has also 
examined how the socially produced and institutionally constructed roles/positions of 
the basic scientist and clinician, ‘dictate’ somewhat different ethical positions. 
According to the authors, stem cell experimental Translational Research and treatment 
are an ideal case when exploring what they call the ‘uneven ethical terrain’, as 
Translational Research (TR) by definition involves ‘work done inside and across role 
positions that are constructed within, and defined by the differentiated ethical spaces 
of the scientific and the clinical’ (Cribb et al., 2008: 351). The focus of the study is on 
two ethical issues: the use of experimental therapies and the responsible presentation 
of claims for innovative RM therapies. The authors argue that the normative 
structures73 produced by the institutions, and the organisation of the scientific and the 
clinical, construct different ethical spaces and role positions, leading to what they term 
‘division o f ethical labour’. According to Cribb and colleagues, this ‘division’ turns the 
application of science into a series o f negotiations and collisions between the two 
ethical value fields, and challenges the establishment o f effective collaborative 
relationships that are essential for successful Translational Research.
73 Including ro le-re la ted  g o a ls , ob lig a tio n s  and d isp o sitio n  b e tw e e n  th e  lab s c ie n tis ts  and th e  clin icians.
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In addition to the above studies that draw on empirical work to explore aspects o f the 
Regenerative Medicine Translation, there are several other studies that address the 
same issues albeit in a theoretical way. For example, in addition to the problems that 
arise from the ‘division o f ethics’, there are other challenges that are created by the 
‘homogenisation’ o f the ethics of the field. According to Woods (2008), ‘bringing 
together all aspects of stem cell science under one rubric homogenises the field but 
obscures important moral distinctions between clinical application and experimental 
laboratory science’ (Woods, 2008: 845). Reflecting upon the argument for the use o f 
established but still risky stem cell therapies (e.g. HSC transplantation), Woods points 
out that the same ethical reasoning should not be used for the moral justification o f 
future but still theoretical therapies. In other words, in W oods’ view, the 
consequentialist reasoning in the form o f risk-benefit evaluation that seems so robust 
in the context of an actual clinical application (even ‘risky’ ones) ‘becomes attenuated 
and overshadowed by other important considerations in the more esoteric context of 
hES cell research’ (2008:846), not least because of its still speculative and unproven 
nature.
Exploring the theme o f Translational Research and bioethics, Shapiro and Layde 
(2008) emphasise the importance o f integrating bioethics into each stage of 
translational and clinical research. This is, according to these authors, an essential step 
both for maximising the beneficial impact of scientific advances and for guarding 
against the potential deleterious medical and societal consequences of such advances. 
According to Shapiro and Layde, bioethics has the potential to play a critical role in 
what they identify as a 4-stage Translation process including basic research; preclinical 
studies and first-in-human trials; incorporation of results into clinical and community 
best practices; and finally, the fourth stage of refining best clinical practices. More 
specifically, the authors note that at the earliest stage o f basic research studies, 
bioethics input is critical in addressing issues such as whether to limit certain areas o f 
scientific inquiry, while at the second stage bioethics input is critical for the responsible 
conduct and reporting o f human subjects research, including the management of 
conflict o f interest issues that arise from industry collaborations. Although the authors’ 
discussion and framework have been inspired by the whole spectrum o f the evolving 
discipline of Translation, their conclusions are perfectly suited to the Regenerative 
Medicine field, which could potentially benefit by applying their recommendations for
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assuring appropriate bioethics input is firmly incorporated into scientific agendas and 
Translational science initiatives.
Robert, Maienschein and Laubichler (2006) from the School o f Life Sciences and 
Center for Biology and Society (Arizona State University) call for a more integrated 
approach to bioethics, which they name ‘systems bioethics’. This approach, the authors 
argue, can provide a useful framework to address ethical and policy issues in 
controversial fields where there is significant pressure to generate clinical applications 
fast, as in stem cell research. In contrast to traditional bioethics, which is based on the 
atomistic analysis o f particular aspects of the ethics of genetics, genomics and 
developmental biology, systems bioethics aims to integrate aspects o f  the history and 
philosophy of science, religious studies, experimental and clinical medicine, economics, 
political theory and the social studies o f science (much as systems biology brings 
together different methodologies and experimental approaches, in an integrative way 
to study the complex interactions of living entities). The authors note that although 
this new approach to bioethical enquiry could be applied to other controversial 
research (e.g. gene therapy), it stands to be especially useful in the case o f stem cells 
because stem cells as such ‘are cultivated precisely to change, and therefore must be 
intrinsically dynamic and potentially unpredictable in some ways that may influence our 
decisions about the potential risks and benefits of applications’ (Robert et al., 2006: 
20).
Translational Research and Ethos (‘Translational E thos’)
A different and recent body o f literature that I have found useful for my research is 
that which has debated Maienschein’s notion of the ‘ethos o f Translation’. Jane 
Maienschein, Mary Sunderland, Rachel Ankeny and Jason Scott Robert (2008) argue 
that the widespread push to Translational Research that is being imposed upon the 
biomedical sciences by government, funding agencies, institutions and patient 
advocacy groups, is bringing a new social contract for the way science works in society. 
The authors contrast this new social contract with the traditional social contract for 
science articulated by Vannevar Bush in his Science the Endless Frontier (1945), and which 
is based on the support o f basic science and the assumption that ‘applied’ results will 
inevitably follow. In short, the authors argue that by subscribing to the new social
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contract, accepting the translational imperative and building end goals into the research 
from the start, scientists might unwillingly distort science. Furthering their argument, 
Maienschein and colleagues also suggest that the pressure o f Translation could also 
import a negative effect into the ethical discourses in biomedical science because it ‘is 
taking the Translation as [an] unquestioned desirable goal and trying to make ethics fit’ 
(Maienschein et al. 2008: 50).
Schwab and Satin (2008), however, question the above argument on the potentially 
distorting epistemic fit that accompanies translational demands and suggest that more 
precise conceptions of Translational Research as well as more diverse conceptions o f 
science and bioethical discussion are needed to gain perspective on the potential 
impact o f Translational Research on both science and bioethics. Zubin Master and 
Vural Ozdenir (2008) accept the ‘silent’ emergence o f Maienschein’s ‘translational 
ethos’ and that it may inadvertedly affect certain types o f basic research that do not fall 
under the ‘popular’ Translation trend. However, they also point out that this kind of 
‘promissory practices’ (such as Translation) are not a new phenomenon in the 
biomedical sciences where scientists are subject to hyper-competition and have to 
favour certain types o f research programmes.
Finally, Audrey Chapman (2008), a Professor o f Medical Humanities and Ethics at 
University of Connecticut, offers a completely different view, suggesting that it is more 
likely that the translational imperative will enhance the role o f ethics in medical 
research. In her analysis, she uses the N IH ’s model o f a clinical and Translational 
Research Institute as an example, and notes that in its calls for applications for funding 
it has identified clinical research ethics as a central programme area, hence making 
ethics ‘a partner in training scientists, the research process, the development o f 
therapeutic applications, clinical testing, and the diffusion o f products’ (Chapman, 
2008:65).
RM Translational Research: Regulation and Standards
The themes of RM TR and regulation have been explored in various combinations and 
with a reference to standards, uncertainty, harmonisation, regulatory policy innovation 
and governance. For example, STS scholars Lena Eriksson and Andrew Webster
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(2008) from the University o f York, examine the development of standards in the stem 
cell field, the challenges of stabilising them through collaborative work, and the 
different epistemic values the discovery of various types of standards hold. Their study 
focusses on the international joint effort of the International Stem Cell Initiative (ISCI) 
taking place in various labs across the world to analyse the role that standards play in 
futures o f stem cell research as imagined/constructed by stem cell scientists. As hESC 
research is an international enterprise, standardisation74 is necessary to enhance 
collaboration between different research groups as well as to facilitate the production 
o f comparable data, which will, in turn, speed up the pace o f research and move the 
field closer to the clinical applications (therapies).
According to Eriksson and Webster (2008), the whole imagined landscape of stem cell 
research from the lab to the clinic is characterised by uncertainties which they have 
termed ‘unknowns’. Unknowns are o f three different types, the ‘known unknowns’, the 
‘knowable unknowns’ and the ‘unknown unknowns’ — each located at a different phase 
o f the stem cell research trajectory and posing different types o f challenge and reward. 
The ‘known unknowns’, which are the focus of the IS O ’s work, refer to the 
procedures and substances used in the derivation and maintenance of stem cells, the 
variation o f which could potentially ‘make a material difference’ by changing the 
biological properties o f the cells. In this respect, the known unknowns are, as the 
authors point out, ‘a seemingly stable future soon to be present’ (Eriksson & Webster, 
2008: 58). In other words the scientists do not yet have the answers to their questions 
(on standards for protocols and materials) but they do have a very clear idea o f what 
they are looking for. Despite the fact that the ‘discovery’ o f these ‘known unknowns’ is 
an absolute requirement before the research moves to the next phase, it is apparently 
been considered as of low epistemic value by the scientific community, when 
compared to the ‘knowable unknowns’. The ‘knowable unknowns’ in hESC research 
are the cells lines themselves and the salient scientific questions about their behaviour 
that the scientists are trying to answer. According to Eriksson and Webster (2008), 
these ‘knowable unknowns’ occupy a different layer of futurity on the imagined 
landscape, are of higher epistemic currency, but will only become a reality (a present), 
if the ‘known unknowns’ are stabilised first. The final type o f uncertainties are the
74 This ta sk  o f  s tan d ard isa tion  (w hich  h as b een  a ssu m e d  by th e  Intern ation al S tem  Cell Initiative) a im s to  d e v e lo p  a s e t  o f  
stan d ard ised  criteria for th e  d eriva tion , ch aracterisa tion  and m a in ten a n ce  o f  s tem  cell lin es, th rou gh  a co m p a ra tiv e  s tu d y  o f  
all hESC lines cu rren tly  in u se .
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potential clinical applications of stem cell research, what the authors term ‘unknown 
unknowns’, which are seen as the more distant and more unstable part of the future. In 
the case o f the ‘unknown unknowns’, the discovery payoff might be even higher but 
their high-risk nature means that they are a ‘futurity whose ontological status is very 
uncertain indeed and in contrast to the ‘known unknowns’ it might never come about 
at all’ (2008:64). Webster and Eriksson (2008) also explore the ways in which this 
form o f governance-by-standards approach acts to manage uncertainty in the ‘unstable’ 
regulatory landscape of, initially, ‘basic innovation’ and eventually clinical application 
o f hESC-based therapies.
Another recent piece o f research has also examined the role o f ‘regulatory standards’ in 
shaping and securing a certain future. More specifically, in a recent paper that draws on 
empirical research conducted at the UK Stem Cell Bank, Neil Stephens, Paul Atkinson 
and Peter Glasner (2008) explore the role o f the UK Stem Cell Bank in sustaining stem 
cell hopes and protecting the future vision o f stem cell science. Work with human 
embryonic stem cells (hESCs) is politically controversial and a number o f public 
concerns in relation to the source and use of hESCs could be seen as threatening to 
the present and future o f stem cell science. The fear o f a potential collapse o f public 
support and associated loss o f social legitimacy for stem cell work has led the UK 
Bank to assume a ‘regulatory role’ that involves accrediting the ethical status o f each 
potential donation to the Bank, quality checking donated cells and screening requests 
to access already deposited material. In the authors’ words, the role o f the Bank is 
performed through strategies that ‘involve a complex temporal interplay: securing 
accounts of the past (both technical and social), while validating the regulatory 
legitimacy of the present’ and all this ‘in an effort to shape an imagined future o f safe 
and publicly acceptable stem cell science’ (Stephens et al., 2008: 46). In short, this 
study shows how promises about detailed ethical scrutiny and tight regulation help 
address public fears and solidify social networks that are essential to the work o f the 
Bank.
Linda Hogle (2009) from the University of Wisconsin-Madison also examines attempts 
to develop consensus standards, reference methods and classifications rubrics, but in 
this case the focus is on the field o f tissue engineering (TE) in the US. Hogle (2009) 
analyses the collective formal and informal processes that were employed to determine
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what would count as relevant and objective evidence in the regulation o f human tissue- 
engineered products. According to Hogle, although they were meant to provide 
‘procedural certainty’ and create order, attempts to standardise and classify ambiguous 
products had unintended consequences, including challenges to fundamental 
assumptions about bodily interactions with technologies and reconsiderations o f the 
institutional forms through which medical therapies have long been evaluated. In 
short, Hogle’s work highlights the way political-industrial assemblages participate in 
socially negotiated forms of objectivity and argues that they are inseparable from the 
way new technologies take shape.
Another pivotal study on RM Translation and innovation that is related to the 
regulation o f IP was published in 2009 by Olivia Harvey from the University of New 
South Wales (Sydney). Harvey (2009) examines hESC science in the US with a view to 
understanding the relationship between Translation in hESC science, the overall 
biotechnology innovation system, and how the State might intervene in this process to 
enhance competitive advantage. The main argument put forward by Harvey (2009) is 
that the adoption of the biotech innovation model by hESC research is one o f the 
problems with US hESC research. According to Harvey, the normal processes of 
biotechnology innovation are further complicated in respect to hESC by the 
complications associated with patenting, the special cultural and political sensitivities, 
and finally by the uneven regulatory arrangements across the US that have an impact 
upon the networks and opportunities available to scientists and investors. In other 
words, the biotech innovation model ignores the specificities o f hESC development 
and, at the same time, exacerbates the existing limitations to the long-term success o f 
the hESC research in the US.
The Literature on Entrepreneurs
Over recent years, there has been a dramatic rise in entrepreneurial activity at 
universities (Wright et al., 2007) in the form o f patenting, licensing, research joint 
ventures with private companies and the creation o f spin-outs. The increase in 
entrepreneurial activity in universities has been matched by a concomitant increase in 
scholarly interest in this topic (Rothermael et al., 2007). Academic entrepreneurship is 
an interdisciplinary topic which can be studied using mixed methods (i.e. both
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quantitative and qualitative analysis) and can draw on theories and concepts from 
economics, sociology and management.
The literature on entrepreneurship is large and beyond the scope o f the current thesis. 
However, as the focus of this thesis (informant-wise) is on entrepreneurs — namely 
bioentrepreneurs — I consider it useful to briefly review one study that I found 
‘conceptually’ useful and that could perhaps also be used as an inspiration for future 
research that would integrate theories and perspectives (from the sociology o f 
expectations and entrepreneurship), hence benefiting from and eventually contributing 
to other research traditions.
In general, there is a relative dearth o f studies that have focussed on the resource 
accumulation behaviour reported by nascent entrepreneurs who seek to commercialise 
their research. According to Paul Westhead (Director for the Centre of 
Entrepreneurship, Nottingham University Business School) and Harry Matlay 
(Birmingham University Business School) (2005), attitudinal, resource, operational and 
strategic barriers must be overcome by nascent entrepreneurs who, according to the 
authors, have no assets of business ownership experience to leverage (including 
financial resources, social and business networks) (Westhead & Matlay, 2005).
One o f the few studies (as far as I am aware) that have explored these issues in the 
context of biomedicine is the study of the Medici Fellowship scheme by Simon Mosey, 
Paul Westhead and Andy Lockett. Mosey and colleagues (2007) have explored the 
success of a university technology transfer boosting scheme that was based on the 
introduction of ‘knowledge brokers’ in five research-intensive UK universities. The 
Medici Fellowship scheme was a short-term intervention to address the barriers to the 
Higher Education Institutions’ (HEI) commercialisation process. More specifically, the 
scheme sought to ‘engender a culture change within Biomedical faculty towards the 
commercialisation of their research, to address perceptions o f negative attitudes 
towards commercialisation amongst faculty, and to help academics to accumulate 
resources to support the process of commercialisation’ (Mosey et al. 2007: 364). In 
short, the aim o f the scheme was to broaden the social capital o f academics, which 
could be drawn upon to leverage resources available in practitioner networks (that is 
non-academics such as business individuals, customers and so on). The scheme
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provided training ‘which demystified the “language o f business” [...] ‘experimental 
learning was facilitated, which proactively encourages individuals to deal with the 
opportunities and threats that need to be considered when commercialising an idea 
from a university setting’ and ‘context specific skills were accumulated and the Fellows 
were encouraged to “learn by doing’” (2007:364). According to the authors’ findings, 
‘fellows who accumulated human and social capital were able to act as agents of 
attitudinal change in their host institutions. Although they did not markedly change the 
culture towards commercialisation, they addressed several structural holes by creating 
weak ties with external actors who provided early-stage funding, market and legal 
information and potential customers’ (2007:360). In monitoring the outcomes 
associated with this novel ‘structured training initiative’ that aimed to facilitate 
academic biomedical research Translation, Mosey et al. (2007) were guided by 
theoretical insights from human and social capital theory.
Overall, theoretical perspectives from human and social capital literatures are being 
increasingly used to explore and gain insights into the role of, and the barriers faced by, 
novice entrepreneurs. Thus, future research on the phenomenon of RM Translation 
could benefit greatly from combining what could be termed ‘traditional’ analytical tools 
(for example drawn from the sociology of expectations) with concepts widely used and 
useful in the entrepreneurship literature (and elsewhere), such as social and human 
capital, and social networks.
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The Literature on Sociotechnical Networks, Techno-economic Networks 
(TENs) and Heterogeneous Engineering
This section provides an account o f the key social science literature that this thesis 
aims to make a contribution to and presents the theoretical framework that is used to 
frame the empirical findings o f the research in the conclusion o f the thesis (Chapter 7). 
In designing my empirical study I drew on various ideas and research streams. The 
following paragraphs summarise these research streams and describe the theoretical 
tools and concepts I found useful for investigating the complex nature o f the RM 
Translation process, drawing on work of Thomas Hughes, John Law and Michel 
Callon. All three authors advocate similar approaches to understanding technological 
innovation.
In particular, the historian of technology Thomas Hughes, understands technological 
innovation and stabilisation in terms of a system metaphor and proposes to think of 
technologies as if they were not only material artifacts within a separate technical 
sphere, but sociotechnical systems (Hughes, 1986; Hughes, 1987) . In the systems 
approach, the argument is that ‘those who build artifacts do not concern themselves 
with artifacts alone but must also consider the way in which these artifacts relate to 
social, economic, political and scientific factors. A.U these factors are interrelated and 
all are potentially malleable’ [emphasis in the original] (Law, 1987: 112).
Additionally, in Thomas Hughes’ systems approach ‘innovators are best seen as system 
builders: they juggle a wide range of variables as they attempt to relate the variables in 
an enduring whole. From time to time strategic problems arise that stand in the way of 
the smooth working or extension of the system. Using a military metaphor, Hughes 
talks o f these problems as reverse salients,75 and he shows the way in which 
bioentrepreneurs tend to focus on such problems and juxtapose social, technical, and 
economic variables as they search for a solution’ (Law, 1987: 112).
75 In his sem in a l b ook , N e tw o r k s  o f  p o w e r :  E lectrifica tion  in w e s te rn  s o c ie ty , 1 8 8 0 -1 9 3 0 ,  T h om as H u gh es in tro d u ces  th e  
c o n c e p t in th e  an a lysis  o f  tech n o lo g ica l s y s te m s  w h e reb y  th e  rev erse  sa lie n t  re fers to  a c o m p o n e n t  o f  th e  sy ste m  th a t, d u e  
to  its in su ffic ien t d e v e lo p m e n t, h am p ers th e  p rogress or p rev en ts  fu lfilm en t o f  p o ten tia l d e v e lo p m e n t  o f  th e  c o llec t iv e  
sy ste m . H u gh es' b ook  is a stu d y  o f  Edison and illu strates b o th  th e  sy ste m ic  n atu re  o f  m u ch  tech n o lo g ica l activ ity  and  th e  
im p o rta n ce  o f  th e  c o n c e p t o f  rev erse  sa lien t.
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Sociologist John Law’s own approach- ‘network’ approach76- in turn, borrows much 
from Hughes’ system building perspective. Law, in addition, emphasises that in 
explanations of technological change and innovation the social should not be 
privileged nor be perceived ‘as standing by itself behind the system being build and 
exercising a special influence on its development’. 77 In other words, Law thinks that 
‘the dominant factor in the growth and evolution of the system is a purely contingent 
matter and can only be determined by empirical means’ (1987:113). Indeed, he 
suggests that other factors -natural, economic, or technical may at times explain better 
the final shape o f artifacts in question as well as the social structure that results.
Law also argues that ‘the stability and form o f artifacts should be seen as a function of 
the interaction between heterogeneous elements as these are shaped and assimilated 
into a network’ and that ‘an explanation o f technological forms rests on a study of 
both the conditions and the tactics o f system building’ (Law, 1987: 113). Because the 
tactics depend, as Hughes has suggested, ‘on the interrelation of a range of disparate 
elements o f varying degrees of malleability’ Law calls such activity ‘heterogeneous 
engineering’ and suggests that ‘the product can be seen as a network o f juxtaposed 
components’ [emphasis in the original] (1987:113).
Yet, according to Law, large-scale heterogeneous engineering is not easy. This is 
because the ‘elements in the network are difficult to tame and hold in place [...] 
vigilance and surveillance have to be maintained, or else the elements will fall out of 
the line and the network will start to crumble (1987:114). Hence, ‘system builders seek 
to create a network o f heterogeneous but mutually sustaining elements. They seek to 
dissociate hostile forces and to associate them with their enterprise by transforming 
them’ (1987:121).
To sum up, Thomas Hughes’ system approach emphasizes a comprehensive viewpoint 
highlighting the interaction among heterogeneous parts and John Law’s 
‘heterogeneous engineering’ stresses a holistic viewpoint that allows us to understand
76 Law's 'n etw ork ' ap proach  h as b e e n  d e v e lo p e d  in re la tion  to  seco n d a ry  em pirical m ateria l a b o u t th e  te c h n o lo g y  o f  th e  
f if tee n th  and s ix tee n th  cen tu ry  P o r tu g u ese  m aritim e ex p a n sio n . S e e  Law, J. (1 9 8 7 ). T ech n o logy  and H e te r o g e n e o u s  
E ngineering: T he C ase o f  P o r tu g u ese  Expansion. In T. P. H. W .E. Bijker, and T.J. Pinch (Ed.), The S ocia l C on stru c tion  o f  
T ech n o log ica l S y s te m s:  N e w  D irection s  in th e  S o c io lo g y  a n d  H isto ry  o f  T ech n o logy  (pp. 1 1 1 -1 3 4 ) . C am bridge, MA: MIT.
77 Contrary to  socia l con stru ctiv ism  a p p r o a ch es  w h o  w ork  on  th e  a ssu m p tio n  th a t th e  socia l lies  b eh in d  and  d irects  th e  
g row th  and  stab ilisa tion  o f  artifacts.
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the underlying mechanisms of sociotechnical systems. Both concepts/theories of 
‘sociotechnical network’ and ‘heterogeneous engineering’ easily lend themselves to the 
study o f RM Translation through the perspective o f bioentrepreneurs and their 
academic enterprises. I will consider the Translation o f RM therapeutics (through 
founding o f RM spinouts or start-ups) as an example of what John Law calls a 
‘network’. The ‘core’ of this ‘network’ is formed by the RM under development.
Figure.3 shows the structure o f what I consider ‘sociotechnical network’ in this study. 
The central element consists o f the bioentrepreneur, the company s/he  has founded 
and the therapy/product that is being translated. The five peripheral elements consist 
of the five different ‘spaces’ (stakeholder groups) that are also involved in the process. 
The small (white) circles include the issues that have been mentioned in the narratives 
of the respondents as the most influential factors in the interaction between the two 
‘interacting elements’.
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Figure.3 ‘Sociotechnical Network for RM Translation’
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Several other authors have also used the concept o f ‘heterogeneous engineering’ to 
explore the evolution of sociotechnical systems. For example, in his book ‘Inventing 
Accuracy: a Historical Sociology of Nuclear Missile Guidance’, Donald MacKenzie (1990) 
examines the development o f nuclear missile guidance systems as a historical product 
and social creation.78 MacKenzie’s theoretical model is created in the context of 
discussing nuclear missile guidance and his prime example of successful heterogeneous 
engineering is Charles Draper, Director of the Instrumentation Laboratory at MIT and 
of the key proponents o f inertial missile guidance. He shows how Draper used 
‘heterogeneous engineering’ to successfully develop inertial missile guidance system 
during the Cold War. Using Law’s concept of ‘heterogeneous engineering’ to describe 
the complete ‘set of skills’ that is needed to succeed in promoting a specific 
technology, he states:
‘People had to be engineered too- persuaded to suspend their 
doubts, induced to provide resources, trained and motivated to 
play their parts in a production process unprecedented in its 
demands. Successfully inventing the technology, turned out to be 
heterogeneous, the engineering of the social as well as the 
physical world’ (MacKenzie, 1990: 28).
In other words, the author suggests that for a technology to be successful its 
proponents must create interest for it and obtain resources. Additionally, they must 
create an institutional framework in which progress can be made and at the same time 
train the employees and the public.
Following the 1990 publication of ‘Inventing Accuracy’, MacKenzie produced- a wide 
ranging collection o f his (most recent) previously published work under the title 
‘Knowing Machines: Essays on Technical Change’. In a chapter entitled ‘The 
Charismatic Engineer’, MacKenzie and co-author Boelie Elzen describe the 
‘heterogeneous’ work o f Seymour Gray- the engineer whose name has become 
associated with the invention of the supercomputer. In their discussion o f Cray’s 
work, they introduce the notion of ‘charisma’- a phenomenon, that according to the
78 Previou s s tu d ie s  o f  g u id a n ce  s y ste m s  h ave te n d e d  to  v ie w  th e m  from  th e  tech n o lo g ica l d e term in is tic  p ersp e c t iv e -  th a t is 
th a t idea  th a t g u id a n ce  s y ste m s  ev o lv ed  to  in creasin g  m issile  accuracy, and  th a t th a t n u c lear  s tra teg ie s  are d e te r m in e d  by 
th is  te c h n o lo g y  (M acK enzie re jec ts  th is  v iew ).
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authors, £is little touched upon in the social studies o f technology’ (MacKenzie, 1996: 
135).
The authors interpret Cray’s charisma as a matter of forging a network. In short, they 
describe his continuous efforts to build the world’s fastest computer and in doing so, 
places himself at the intersection o f what could be seen as two contrasting worlds 
(networks). The first is the more stabilised world of previous efforts where customers 
demand hardware modifications, software and end-user support. The second is the 
uncertain journey towards higher speeds during which he constantly has to attempt to 
enrol the technology and hence gain the support o f his colleagues. At every hurdle that 
could hinder his quest for a faster computer, Cray tried to ‘shake o ff  the constraints by 
building networks, forming alliances and placing himself at the front of this network.
In an article he published in 2001,79 John Krige, a historian o f science and Kranzberg 
Professor o f History, Technology and Society at the Georgia Institute o f Technology 
(Atlanta), has also used the concept of ‘heterogeneous engineering’ to describe the 
work o f Carlo Rubio who, together with Simon van der Meer, won the 1984 Nobel 
Prize for physics.80 In their press release the Royal Swedish Academy recognised that 
there was more to this achievement than sheer intellectual insight and technological 
achievement. They write: ‘Such qualities had to be embedded in a technological, 
managerial, institutional and political infrastructure’ (Krige, 2001: 425). In his paper, 
Krige captures the ‘salient’ features o f that infrastructure by suggesting that at least one 
o f the laureates- Carlo Rubio- ‘should be viewed, not only as a physicist, but also as a 
’’heterogeneous engineer”, who succeeded in mobilising the human and material 
resources needed to attain his objectives’ (Krige, 2001:425). In short, Rubbia’s ability 
to mobilise the necessary resources so as to bring that idea to fruition was essential to 
success.
Another research tradition that has been developed to examine the process of 
innovation and diffusion through the various interactions between the world of 
science, technology and the marketplace and which provides useful theoretical tools
79 Krige, J. (2 0 0 1 ). The 1 9 8 4  N obel Physics Prize for  H e te r o g e n e o u s  E ngineering, M in erva  (Vol. 3 9 , pp. 4 2 5 -4 4 3 ):  Springer  
N eth erlan d s.
80 Both Carlo Rubio and S im on van d er  M eer w ere  b ased  a t CERN (th e  European organ isa tion  for N uclear R esearch ) and  w o n  
th e  prize for th e ir  d ec is iv e  co n tr ib u tio n s to  th e  'large p roject' th a t led  to  th e  id en tifica tion  o f  tw o  im p ortan t fu n d a m en ta l 
partic les.
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for the study of RM Translation is that o f techno-economic network (TENs). As 
mentioned at the beginning of the chapter, in addition to Hughes and Law, Michel 
Callon (Centre de Sociologie de l'Innovation, Ecole des Mines de Paris) has also 
explored the heterogeneous processes o f social and technical change, and in particular 
the dynamics of techno-economic networks (TENs).
Callon defines a TEN  as ‘a coordinated set o f heterogeneous actors (public 
laboratories, technical research centres, industrial firm, financial organisations, users 
and public authorities) which participate collectively in the development and diffusion 
o f innovations, and which via numerous interactions, organise the relationships 
between scientifico-technical research and the market’ [...] A network is also not 
limited to just the (heterogeneous) actors who make it up. A whole set of 
intermediaries81 circulates between them’ (Callon et al., 1992: 216). More importantly,
TENs are what Callon calls ‘polycentric’ networks which ‘can be characterised
simultaneously by a great degree o f strategic autonomy for the various
actors/organisations composing it and by mechanisms for integration and 
coordination that enable each actor to profit from the collaborative work with the 
other partners’ (1992:216).
TENs are a useful framework to examine the work o f RM bioentrepreneurs for two 
main reasons: first, unlike Hughes’ and Law’s sociotechnical systems, it has been 
specifically ‘designed’ to include the notion of the market (as one of the three main 
poles o f the network) and second, it suggests the existence o f actors (and thus 
intermediaries) that are ‘not necessarily assignable to a particular category of
organisation or institution’ (Callon et al., 1992: 222). In that sense, the TEN  theory has 
been developed to deal with ‘role’ overlaps as seen in the case o f RM bioentrepreneurs. 
Finally, the distinction between incomplete and chained network, dispersed and 
convergent network, and short and long network is useful when investigating the 
dynamics o f the RM Translation (network(s)).
Another concept that I found useful in the analysis of the RM bioentrepreneur 
sociotechnical network, particularly for explicating the (dynamics of) interaction 
between product developers and clinicians, is that of ‘concurrent engineering’. In their
81 In term ed iaries g ive  m ateria l c o n te n t  to  th e  links u niting  th e  a ctors  and can b e  w ritten  d o cu m en ts , in corp ora ted  skills, 
m o n e y  or m o re  or le ss  d e v e lo p e d  tech n ica l ob jects .
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1997 article on ‘social embedding of new products’, Jasper Deuten from the School of 
Philosophy and Social Sciences, University of Twente and colleagues present a new 
management approach that allows managers within a firm to include, what the authors 
call ‘societal embedding’, in the management of product creation process (PCP). In the 
authors’ words: ‘one need not fatalistically await whatever societal embedding of one’s 
product will result, but can anticipate and actively work towards desirable societal 
embedding. Thus in addition to, and integrated with Product Creation Process (PCP), 
one can think and act in terms of processes that create social embedding, i.e. “societal 
embedding creation processes” (SECP)’ (Deuten et al., 1997: 131).
According to Deuten and colleagues (1997), in sectors like biotechnology, ‘where 
integration in business chains and public acceptability are major issues, firms have 
taken up the challenge of such an integrated management approach (PCP+SECP), 
even if in a partial and not always successful way’ (1997:131). This integrated approach, 
the authors suggest, is already much better than current practices, in which issues of 
societal embedding are bracketed until a late stage in the process (i.e. when potential 
damaging consequences o f innovation cannot be avoided). They state:
Product creation managers will often have a sequential 
approach82 to the environment [...] when management is 
forced, as in biotechnology, to deal with alignments with the 
wider society, this is still taken up in later stages o f the PCP, or 
not all (1997:134).
A principal way, in the authors’ opinion, to manage the uncertain innovation journey 
of a product is to use ‘concurrent engineering’. The term ‘concurrent engineering 
implies intensive interaction between upstream and downstream functions, and 
upstream and downstream are regarded as parallel, rather than sequential processes. 
Furthermore, concurrent engineering implies integration o f functions. Cross-functional 
teams are used to stimulate integration. Concurrent engineering is a reaction to 
changes in business environment (increasing international competition, decreasing
82 The w e b  o f  a lig n m en ts  in w hich  th e  n e w  prod uct is t o  b e  e m b e d d e d  is grad u ally  filled  in. 'In m an y  c a s e s  m a n a g e m e n t o f  
PCP w a n ts  to  clarify th e  fu n ction a l an d  tech n ica l a s p e c ts  o f  th e  n ew  p rod u ct b e fo r e  it m ak es a lig n m en ts  w ith  o th e r  parts o f  
th e  en v ir o n m e n t. [...] in th e  early s ta g e s  a lig n m en ts  w ith  th e  b u sin ess  e n v ir o n m e n t are s e e n  a s th e  m o st re levan t. O nly a fter  
th e  p rod u ct c o n c e p t  is m o re  d e f in ite  d o  links w ith  th e  regu la tion  e n v ir o n m e n t b e c o m e  im p ortan t. A lign m en ts  w ith  th e  
w id er so c ie ty  are on ly  p u t on  th e  a g en d a  in later s ta g e s  o f  th e  PCP, in particular if re s ista n ce  o f  th e  public is e x p e c te d , or  
b e c o m e s  m an ifest' (D eu ten , Rip & Jelsm a, 1 9 9 7 :1 3 4 ).
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product cycles etc.). Managing for societal quality implies that pressures in the 
regulation environment and wider society have to be taken into account as well’ 
(1997:136).
In this thesis, I argue that In the same way that Deuten et al. (1997) view societal 
embedding as a broader notion of success for biotechnology products, 
bioentrepreneurs (in this study) view the ‘clinical embedding’ of RM products. In the 
same way that extended concurrent engineering is introduced by Deuten et al. as a 
management approach to make sure that societal embedding creation processes 
(SECP) are managed as a simultaneous and integral part o f the Product Creation 
Process (PCP) from the start, respondents in this study propose what is, in fact, 
extended concurrent engineering between clinicians and bioentrepreneurs/product 
developers.83
Chapter Conclusion
My research has been motivated by a lack o f information about the ‘world’ of 
bioentrepreneurs and their role in RM Translation, and by the more ‘practical 
concerns’ (barriers, failures, delays) o f the RM Translation process as identified in the 
literature and as I understood them from personal communication with stakeholders 
during conferences and meetings.
So far most of the studies looking at the ‘bed-to-bedside’ paradigm have followed a 
similar structure. For example, they have focussed on a small number of 
questions/themes and have collected data from what would be a large and varied pool 
of RM stakeholders (often including biomedical scientists and /or clinicians and /or 
industry representatives). My study has been structured in very much the opposite way. 
More specifically, I chose my interview informants from just one ‘pool’ of stakeholders 
— namely bioentrepreneurs who hold critical and influential positions — and explore 
how they experience the Translation process and (unlike previous studies) address a 
wide range of themes. In fact the wider-than-normal range o f themes that were
83 Both n o tio n s  a lso  r e so n a te  w ith  G ibb on s e t  a l.'s (1 9 9 4 ) a rgu m en t o f  a m acro level sh ift to w a rd s  a m ore  socia lly  rob u st  
'M od e  2' form  o f  k n o w le d g e  p rod u ction  ch arac terised  by th e  active  in v o lv e m en t o f  m u ltip le  socia l and sc ien tific  grou p s.
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addressed (e.g. funding, regulation, collaboration, IP) is a logical consequence o f the 
multifaceted role of the interviewees and is itself an empirical finding.
As many of the recent studies in the field have drawn on the sociology of expectations 
and related concepts to analyse their findings, I felt slighdy biased and was tempted to 
incorporate it into my analysis. Looking carefully at the data, though, I soon felt I 
could not justify its use satisfactorily, despite sometimes coming across themes and 
issues in the narratives that could have possibly benefited from its use. However, these 
occurrences were limited. One reason for the lack o f such ‘expectations-related 
findings’ might be that bioentrepreneurs are less likely to either understand or 
communicate an ‘overblown’ potential of a technology or be themselves ‘hyped’ about 
either basic scientific breakthroughs or technological developments. Their distinct 
position in the ‘centre’ o f the RM TR field, which involves constant updates about the 
laboratory advances, the clinical setting (and clinical challenges) and the realities o f the 
market, may help to dampen their expectations to a larger degree than is observed in 
other types of stakeholders.
Instead, I have sought to address the lack o f knowledge and the practical concerns that 
I identified in two ways: first by relating the concerns with the rest of the relevant 
sociological research — mainly through the process o f comparing and contrasting — and 
second, by identifying a variety of conceptual tools and analytical motifs that I either 
used in the ‘original version’ or I have moulded them in ways that I thought would 
best serve and advance my analysis. In some cases, and where I thought it would be 
useful in exploring and explaining the phenomenon (RM Translation) as well as the 
data that were coming in, I synthesised terms and concepts afresh.
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Chapter 4
The Art o f Funding
Introduction
The first chapter introduced the story o f the first ever stem cell transplant and 
identified the three most important elements for successful realisation o f such 
pioneering interventions: sufficient Funding, reasonably ‘flexible’ Regulation and 
effective and efficient cross-disciplinary Collaboration. This chapter discusses the first 
of these elements — Funding — and explores the experience and views of UK RM 
bioentrepreneurs about funding in Regenerative Medicine Translation.
The chapter is structured as follows: the first section provides a brief description o f the 
biomedical research funding sources in the UK; this will provide the necessary 
background in order to conceptualise the issues reported by the informants later on. 
The second section examines the perceived lack of public translational funds for RM 
in the UK; the third and fourth sections examine the views o f interviewees on the two 
emerging (alternative) sources o f capital, namely venture capital and biopharmaceutical 
industry investments; finally, the two last sections explore how bioentrepreneurs 
experience and participate in the efforts of the RM industry to identify and /or create a 
‘viable’ and hence fundable business model and their perceptions about the role IPRs 
(patents) appear to play in these efforts.
To begin to appreciate the problem of the so called ‘equity gap’84 that has plagued the 
Translational Research (TR) arena, as much in Regenerative Medicine as in other 
biomedical research fields, it is useful to understand the way medical research is funded 
in the UK. For instance, the overwhelming majority of basic biomedical research has, 
so far, been the preserve o f laboratory-based scientists at universities or other research 
institutions. This type o f research benefits from having a wide variety o f funders and 
funding mechanisms from public sector, charities and occasionally the health industry. 
For example, in terms o f the public sector, the key funders o f basic research are the
84 Ray O akey, D irector o f  t h e  C entre fo r  R esearch  on  E n trep reneursh ip  and Innovation  M a n a g em en t at M a n ch ester  B u sin ess  
Sch ool h as co in ed  th e  term  'eq u ity  gap '. S e e  (O akey, 20 0 3 ).
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Biotechnology and Biological Sciences Research Council (BBSRC) and the Medical 
Research Council (MRC). Very substantial spending in basic biomedical research 
(including Regenerative Medicine basic research), is also undertaken by charities with 
three o f the largest funders being the Wellcome Trust, the British Heart Foundation 
(BHF) and Cancer Research UK. Applied research,85 on the other hand, is primarily 
taking place in clinical settings and involves human volunteers. The main funders of 
UK applied research are the Health Departments o f England, Wales, Scotland and 
Northern Ireland (Cooksey, 2006). This well-established but inflexible UK biomedical 
funding structure is unfortunately detrimental for the emerging paradigm of 
Translational Research which occupies the phase in the research continuum between 
basic and applied research. Translational Research helps turn early-stage innovations into 
therapies or products by advancing the innovation to the point where it becomes 
attractive for others (such as venture capital firms, industry, public—private 
partnerships) to take up the challenge o f developing a product for the market.
Given the increasing emphasis of governments and publics on tangible medical 
breakthroughs that can only happen if the findings from heavily (publicly) funded basic 
research are ‘translated’ to the clinical setting, it is not surprising that the UK 
biomedical funding scheme has been widely criticised. In fact, in a consultation 
meeting for the Cooksey Review86 held at the Royal Society in 2006, it was 
acknowledged that ‘although the BBSRC and the MRC offer some opportunities in 
Translational Research, current funding to help move ideas from the laboratory is 
limited and research councils are still perceived as being weak at supporting 
Translational Research’.87 In short, by not providing enough ‘earmarked’ funds for the 
translational phase, the U K places Translation in, what many respondents and others 
in the field, call the ‘equity gap’ or, how it is often referred to in scientific 
commentaries and literature, the ‘valley o f death’88 (Butler, 2008; Woolf, 2008). The
85 A pplied  research  co v e rs  a w id e  ran ge o f  activ ities  including: research  in to  p rev e n tio n , d e te c t io n , and d ia g n o sis  o f  a 
d isea se; research  for  th e  d e v e lo p m e n t  o f  in terven tion s; th e  s u b s e q u e n t ev a lu a tio n  o f  th o s e  in ter v en tio n s  (a lso  know n as  
H ealth T ech n o lo g y  A sse ssm e n t, HTA); research  in to  th e  m a n a g e m e n t o f  d isea se ; and finally, th e  p rovision  o f  h ea lth  and  
social care  serv ices  (C ooksey, 2 0 0 6 ).
86 In M arch 2 0 0 6 , th e  C hancellor o f  th e  Exchequer and th e  S ecreta r ie s  o f  S ta te  for  H ealth  and T rade and  Industry invited  Sir 
David C ook sey  to  u n d er tak e an in d e p e n d e n t rev iew  to  ad v ise  on  th e  b e s t  d es ig n  and  in stitu tion a l a rra n g em en ts  for th e  
public fu n d in g  o f  h ea lth  research  in th e  UK.
87 C onsu lta tion  M e etin g  fo r  th e  C ook sey  R eport R eview : 'Lost in T ranslation ', th e  Royal S ocie ty , London, 3 1  July 2 0 0 6 .
88 The 'valley  o f  d ea th ' c o n c e p t  is n o t exc lu sive  to  th e  R egen era tive  M ed ic in e  fie ld . It is o fte n  u sed  to  re fer  to  th e  ch asm  th a t  
ex ists  b e tw e e n  b asic  re sea rch ers  and  c lin ic ian s/p h ysic ian s b oth  in term s  o f  co m m u n ica tio n  and  co llab ora tion , a s w ell a s  
fu n d in g -w ise . In th e  literatu re it is a lso  referred  to  as th e  first gap  in T ranslational R esearch  or T ranslation  Gap 1 or G l. TGI 
sp an s key preclin ical an im al s tu d ie s  th rou gh  to  th e  en d  o f  su ccess fu l P h ase  3 trial.
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following section focuses on how interviewees perceive the ‘equity gap’ in RM TR and 
how they think it might be possible to remedy the situation.
Translational Research and its Status o f ‘In-Between’
Asked about the challenges associated with Regenerative Medicine Translation, one of 
the first issues brought up by all interviewees is the apparent ‘funding gap’ that they 
encounter when it comes to translating research findings from the laboratory to the 
clinic and /or market. One interviewee explains:
One o f the biggest challenges is funding o f Translation. Because that’s 
sort o f in the interface between what research councils would do and 
what venture capitalists would do. So Translation suffers from this so- 
called ‘equity gap’. And that’s a very serious issue which the TSB 
[Technology Strategy Board]89 is trying to plug now with serious cash 
injections.90 But you know, in other countries these projects are taken up 
much sooner by venture capital. And in the UK, there is no venture 
capital for Regenerative Medicine and very, very little for biotech in 
general. So this is a big issue for the country. I think the UK has to fix 
that.
(XB, P I/C E O /F ounder o f Start-up, 2009)
XB is the founder and Chief Executive Officer (CEO) o f a non-academic, small 
biotechnology company that has developed and holds exclusive intellectual property 
rights (IPRs) for technologies in the field of Regenerative Medicine and stem cell 
research in particular. At the time o f the interview, XB informed me that his company 
had recently secured a significant investment from a London-based venture capital 
fund that backs fast-growing small and medium-sized companies.91 In describing the 
difficulties o f funding Regenerative Medicine Translational Research (RM TR) in the
89 The T ech n o lo g y  S trategy  Board (TSB) (form erly  part o f  th e  D ep a rtm en t o f  T rade and Industry, DTI) is an ex e c u tiv e  n on-  
d ep a rtm en ta l public b od y  (NDPB), e s ta b lish ed  by th e  G o v ern m en t in 2 0 0 7  and sp o n so r e d  by th e  D ep artm en t for B u sin ess, 
Innovation  and Skills (BIS). The a ctiv ities  o f  th e  T ech n o logy  S tra tegy  Board are jo in tly  su p p o rted  and  fu n d ed  by BIS and  o th er  
g o v er n m en t d ep a r tm en ts , th e  d ev o lv e d  a d m in istra tion s, reg ion a l d e v e lo p m e n t  a g e n c ie s  (RDAs) and  research  cou n cils.
90 For e x a m p le , in N o v em b er  2 0 0 7 , th e  T ech n o logy  S trategy  Board (TSB) a n n o u n ced  a 'Cell T h e r a p / co m p etitio n  fo r  p rojects  
w hich  look  to  tra n s la te  b io sc ie n c e  research  in to  m o re  rob u st m e th o d s  for  r e g en era tiv e  h ea ling .
91 As XB m en tio n e d  th e  VC in v e s tm e n t fo llo w e d  on  a gran t from  th e  DTI's T e c h n o lo g y  P rogram m e (In 2 0 0 4 , th e  UK 
G o v ern m en t esta b lish ed  a 10 -y ea r  in v e s tm e n t fram ew ork  for  s c ie n c e  and in n ova tion  p ro g ra m m es. £ 3 2 0  m illion in grant 
fu nd ing h as b een  ava ilab le  to  UK b u s in e sse s  to  su p p o rt R&D p ro jects  b e tw e e n  2 0 0 5  and  2 0 0 8 ).
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UK, XB emphasises its ‘in-between status’. He explains how Translational Research 
falls outside the remit o f research councils and, at the same time, it is too risky to 
attract funding from venture capitals and industry (pharma/biotech). While discussing 
the hurdles and delays his company faced in raising the necessary capital, he also 
commented on the role o f venture capitalists which, he thinks, is limited in the UK 
compared to other countries.
In addition to the unanimous identification of the ‘equity gap’, the majority o f the 
respondents also gave accounts that portray a confused understanding over which UK 
research council or charity funds what type and stage of research. LM, a principal 
investigator (PI) in the wound-management field who is also the founder o f a spin-out 
company, describes her experience o f trying to fund her team’s translational efforts 
(that is early-stage prototype development o f living skin equivalent (LSE) technology 
and its transfer to the clinical setting).92
I was working with a colleague, Professor [Name], and we were tackling 
the problem of how to get patient skin cells from the laboratory to the 
patient, as fast as possible and as flexible as possible [...] We began doing 
that as a research project and got funding from the BBSRC 
[Biotechnology and Biological Sciences Research Council]. And then we 
got to the point where it [the construct] was working and we tried to get 
further funding. At that point, we applied to the Wellcome Trust and 
they turned down the grant and said: “Well listen, this is not research 
anymore, it is product development” .
(LM, PI/Founder of Spin-out, 2007)
LM explains how she and a colleague carried out basic research for their product 
funded by the Biotechnology and Biological Sciences Research Council (BBSRC), 
traditionally a sponsor for a variety of basic Regenerative Medicine research projects 
(including skin Tissue Engineering). After getting satisfactory results and proving that 
their product ‘was working’, LM and her colleague began their efforts to clinically 
translate it. According to LM, their application, this time to the Wellcome Trust, for 
grant money was quickly rejected as the charity considered the proposed work ‘product
92 LM's co m p a n y  h as at le a st o n e  p rod u ct in th e  m arket ava ilab le  for u se  by clin icians.
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development’, which means it was outside the realm o f ‘research’ and thus ineligible 
for the Wellcome Trust’s ‘research’ grant money.
The Wellcome Trust however, was not the only UK ‘sponsor’ to have displayed such 
‘tunnel vision’ as to what Translational Research really involves. It seems that projects 
that have ceased being hypothesis-based basic research and are trying to move into the 
clinical application phase will not be considered for funding by most UK research 
councils. In the quote below the same bioentrepreneur who was turned down by the 
Wellcome Trust recalls her experience o f applying to the Medical Research Council 
(MRC), again seeking support for translational work.
We have had grants turned down by the MRC [Medical Research 
Council], when we have tried to go to the clinic, because they said “it is 
not hypothesis driven”. With a colleague o f mine in London, D r [Name], 
we applied for a couple o f grants (MRC grants] and each was turned 
down. One [reviewer] said that it was not scientific enough. My colleague 
was going to translate cells through to cornea, clinically, and ours was for 
vitiligo93 patients. They said it was not hypothesis driven. And this is not 
what we need for the UK to really pull things together. So there needs to 
be an understanding of what Translational Research is. In research 
councils there is a certain amount of snobbishness. They would be 
happier to look at blue sky stuff, cute science. I f  you write a good grant 
in these areas your chances of getting it funded are good. If  you say: 
“actually we’ve done all o f these bits and now we really need to go to the 
patient”, your chances of getting it funded are very low. So that is a big 
gap. [...] We have scientists who are capable o f pulling together things 
that will work, but to try and find a funding route for that is difficult.
And really we need to be able to fund this small-scale, proof-of-concept 
[phase], prior to commercialisation.
(LM, PI/Founder of Spin-out, 2007)
LM explains how her grant application was rejected by the MRC reviewers for not 
being ‘scientific enough’. A colleague of hers in London, also interested in translating
93 Vitiligo is a ch ron ic d isord er th a t  c a u ses  d ep ig m en ta tio n  o f  p a tch es  o f  skin. It o ccu rs  w h e n  m e la n o c y te s , th e  ce lls  
r e sp o n sib le  for skin p ig m en ta tio n , d ie  or are u n ab le  to  fu n ction .
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her findings to the clinical setting, was treated to the same response by the MRC. LM’s 
frustration on the subject is clear and she blames the research councils and charities for 
not understanding what Translational Research really is. She also mentions the 
snobbishness of reviewers and their bias towards basic research that produces pure 
‘Big Science’. To an extent, her narrative echoes Professor Hollander’s statement in 
Chapter 1, where he highlights the difficulty of having cross-disciplinary Translational 
Research funded. As far as LM is concerned, applications for ‘safe’, bench-based and 
blue-sky research have higher chances of being successful than risky, clinical research 
involving human subjects.
Another bioentrepreneur expresses the same feeling of sponsor — and grant-related 
uncertainty when it comes to applying for Translational Research funding. This 
informant reflects on the funding ‘intricacies’ o f trying to deliver clinical-grade human 
stem cells.
Then you have to put in all the aspects o f how you are going to deliver 
clinical-grade cells, what way you are going to manufacture them, where 
are you going to get support for that. Which isn’t cutting-edge research, 
it’s fairly mundane, but it takes a lot o f time and you have to then comply 
with all the compliance and validation and everything. So it is expensive 
to set up and the route for something like the MRC is quite difficult. 
Because you couldn’t apply for a project grant for that. A project grant is 
mainly for basic research and this is not basic research, it is applied 
research. It is not so easy to see how you can get funding for it. I am 
never quite sure whether it should be academics who do that or 
companies, or a bit of both. I think the thing is that embryonic stem cells 
have come very much from an academic background.. .so it is one of 
those areas.
(GL, P i/C lin ical involvem ent/Co-Founder o f Spin-out, 2007)
Clinical grade cell production, like the one undertaken by GL’s team, necessitates 
adhering to current good manufacturing practices (cGMP)94 to ensure the delivery of a
94 C urrent G ood  M anufacturing P ractice (cGMP) is a quality  a ssu ra n ce  sy ste m  u sed  in th e  p h arm aceu tica l industry. It en su r es  
th a t th e  en d  p rod uct m e e ts  p r e se t  sp ec ifica tion s. GMP co v ers  m an ufacturin g  and  te s t in g  o f  th e  final p rod uct. It a lso  
requ ires traceab ility  o f  raw  m ateria ls  and th a t  p rod uction  fo llo w s  va lid a ted  stand ard  op era tin g  p ro ce d u re s  (SOPs).
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cell product/therapy that is safe, reproducible, and efficient. As the cell therapy 
production encompasses purification, manipulation, culture, characterisation, and 
delivery o f cells, all parts o f the production process must be defined and quality 
controlled.95 Therefore, for academic centres, spin-outs and private companies who are 
moving towards exploiting the full potential of cells, needs arise for the development 
of the infrastructure necessary to support these investigations. Careful consideration of 
the design and building o f the infrastructure is not only significant in terms o f the large 
capital investment involved but, more importandy, in terms of the facility’s role in 
achieving regulatory compliance.96
A common belief among stakeholders in the RM field is that the knowledge-base for 
new developments in Regenerative Medicine and stem cell research generally resides in 
the academic community and in small biotechnology companies with a substantial 
research capacity or those well connected to academic research groups (e.g. spin­
outs).97 This is also clearly acknowledged in GL’s phrase ‘I think the thing is that 
embryonic stem cells have come very much from an academic background...so it is 
one o f those areas...’. Still, despite academia’s ‘competitive advantage’ provided by 
‘cutting-edge’ knowledge and ‘know-how’, the lack of appropriate funding means that 
the academic community is less prepared for the expensive and highly regulated 
aspects o f product development, particularly those related to RM manufacturing. As 
GL explains, building and maintenance of such infrastructure and complying with the 
regulations is expensive, takes time and is not in the realm of what the research 
councils would normally fund.
ZL below, stresses the importance of securing ‘good preclinical data’ and the ‘catch-22’ 
of achieving proof-of-principle: animal studies are expensive to run, but it is very 
challenging to raise external financial support without them (and their positive results). 
They [funding problems] are pretty large. One is funding the animal 
studies to get proof-of-principle, which are expensive and take time. If 
they are successful, then it is really setting up the preliminary clinical trials 
which are also going to be very expensive. And there is a sort of funding
95 For a d e ta iled  d escrip tion  on  th e  p rod u ction  o f  clinical hESCs s e e  (U nger e t  al., 2 0 0 8 ).
96 An article d escrib ing  in d eta il th e  regu latory  en v ir o n m e n t surrounding th e  in frastru ctu re su p p o rt for cell th era p y  and  
practical a sp e c ts  for d esign  co n sid era tio n  is (D ietz e t  al., 2 0 0 7 ).
97 This b e lie f  h as a lso  b e e n  con firm ed  at co n v er sa tio n s  I had w ith  various R egen era tive  M ed ic in e  s ta k e h o ld e rs  including  
clin icians, industry  p e o p le  and b iom ed ica l re search ers .
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gap. It takes time to get those animal studies completed so, in the 
meantime, the main challenge is really supporting them until you can get 
good [animal trial] results. Because getting investment in that early stage 
is really difficult.
(ZL, PI/C lin ician /L icensor o f RM technology, 2007)
In commenting on the high ‘burn rate’ of capital while waiting for the necessary 
preclinical (animal) data and regulatory approval to proceed, ZL underlined how the 
lack o f funding (for time-consuming and expensive animal studies) makes survival 
particularly difficult for any corporate company with limited financial flexibility 
(McKernan et al., 2010), and even more so for small academic spin-outs.
Since the publication o f the Cooksey Review in 2006 and the identification of 
Translational Research funding problems and shortages (in life sciences in general), 
more initiatives and publicly-funded schemes98 have been set up including: the NHS 
Innovation Hubs;99 Regional Development Agencies;100 the creation of the new virtual 
office for Life Sciences within the Department for Innovation, Universities and Skills 
(DIUS) to address key issues affecting the biotechnology, pharmaceutical and medical 
devices sectors. More specifically for RM Translational Research, the Medical Research 
Council announced a new translational stem cell research programme aiming to fund 
Translational Research to the tune o f £10 million per year by 2010/2011, in addition 
to the establishment of the MRC Technology (i.e. the ‘commercialisation arm’ of the 
MRC); the Technology Strategy Board announced a ‘Cell Therapy’ competition with 
the focus on creating better ‘methods’ and cell therapy production processes. Charities 
have also introduced Translation-specific awards, such as the Wellcome Trust 
Translation Awards and the Wellcome Strategic Translation Awards;101 this is 
response-mode funding, designed to bridge the funding gap in the commercialisation 
of new technologies in the biomedical arena. According to the Award’s application
98 For a list o f  th e  p ub licly -fu n d ed  s c h e m e s  in th e  UK g o  th e  fo llow in g  w eb site :
h ttp ://w w w .h m l-  tr e a s u r y .g o v .u k /d /co o k sey _ re v iew _ b a ck g ro u n d _ p a p er_ ex a m p le s_ p u b lic ly _ fu n d ed _ sch em es .p d f
99 C om m ercia lisa tion  o f  in n o v a tio n s arising from  w ith in  th e  NHS is m an aged  by th e  Inn ovation  Hubs in England, m o s t  o f  
w hich  are fu n d ed  by th e  D ep a rtm en t for  Innovation , U niversity and Skills (DIUS) and  O ffice o f  S c ie n c e  and  T ech n o lo g y  (OST), 
via th e  Public S ecto r  R esearch  E xploitation  (PSRE) sc h e m e , and by th e  D ep a rtm en t o f  H ealth  (DH).
100 For m o re  in form ation  on  E ngland's R egional D ev e lo p m en t A g en c ie s  s e e :  C ook sey , 2 0 0 6 .
h ttp : / /w w w .e n g la n d sr d a s .c o m /v is it_ r d a s . For m ore  in form ation  on S co tlan d 's RDAS (S cottish  Enterprise and  H ighlands and  
Islands E nterprise (HIE)) s e e :  h t tp : / /w w w .sc o tt ish -e n te r p r ise .c o m  and h ttp : / /w w w .h ie .c o .u k  resp ectiv e ly .
101 For m o re  in form ation  see :
h ttp ://w w w .w e llco m e .a c .u k /F u n d in g /T ec h n o lo g y -tr a n sfer /A w a r d s /T r a n s la tio n -A w a rd s/in d ex .h tm  and  
h ttp ://w w w .w e llco m e .a c .u k /F u n d in g /T ec h n o lo g y -tr a n sfer /A w a r d s /S tra teg ic -T ra n s la tio n -A w a r d s /in d e x .h tm
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guidelines ‘projects must address an unmet need in healthcare or in applied medical 
research, offer a potential new solution, and have a realistic expectation that the 
innovation will be developed further by the market’.
Despite officially ‘dedicating’ part o f their funds for Translational Research (TR), it 
appears that neither research councils nor charities have convinced the translational 
investigators and bioentrepreneurs. In the following excerpt, a bioentrepreneur 
specifically criticises the Medical Research Council’s (MRC) funding scheme, and 
argues that what it seeks to fund is not ‘real’ Translation, but ‘reverse’ Translation.
The MRC tend to consider ‘reverse’ Translation more than Translation.
So they are more interested in the samples coming from patients who are 
receiving these products going back into basic research to find out 
something more about the process, rather than funding the actual 
research Translation itself. So I think that’s the biggest challenge.
Kaftantzi: What about the MRC Translational Stem Cell Research 
Committee (TSCRC) awards?
Yes, they call them Translational Awards, but what the MRC has 
traditionally funded as a ‘translational project’ is ‘reverse’ Translation. So 
the people who sit on the awarding committees are all basic scientists.
And they all want access to materials from patients who’ve been treated 
for something. They don’t want to pay for the conduct o f the trial, the 
fact that you need regulatory affairs officers, you need CROs [Contract 
Research Organisations],102 etc. Several of us have stood up at meetings 
and decried this. Whenever we have a large enough audience we make a 
fuss about it.
(LK, PI/Founder of Start-up, 2009)
102 C ontract R esearch  O rganisation , a lso  called  a Clinical R esearch  O rganisation , (CRO) is a serv ice  organ isa tion  th a t  p rov id es  
su p p ort to  th e  p h arm aceu tica l and b io tec h n o lo g y  in d u stries. CROs o ffer  c lien ts  a w id e  ran ge o f  'o u tso u r ced ' p harm aceu tica l 
research  serv ices  to  aid in th e  drug and m ed ical d ev ic e  research  and d e v e lo p m e n t  p ro cess . S erv ices o ffere d  by CROs 
include: p rod u ct d e v e lo p m e n t, form u la tion  and m an ufacturin g; clinical trial m a n a g e m e n t (preclin ical th rou gh  P h ase  IV); 
preclin ical, to x ic o lo g y , and  clinical lab oratory serv ices  for p ro cess in g  trial sam p les; d ata  m a n a g e m e n t, b io sta tis tics  and  
m ed ica l w riting serv ices  for  p rep aration  o f  an FDA N ew  Drug A pplication  (NDA); regu latory  affairs sup p ort; and m an y  o th er  
c o m p le m en ta r y  serv ices . CROs ran ge from  large, in tern ation a l full serv ice  org a n isa tio n s to  sm all, n ich e sp e c ia lty  grou p s and  
can o ffer  th e ir  c lien ts  th e  e x p er ien ce  o f  m ovin g  a n ew  drug or d ev ic e  from  its c o n ce p tio n  to  FDA m ark eting approval 
w ith o u t th e  drug sp o n so r  having to  m aintain  sta ff  for  th e s e  serv ices .
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LK cites the MRC award strategy as a failure of the translational funding system in the 
UK and explains that the biomedical community avoids acknowledging the problem, 
perhaps in part, because the system as it stands, supports ‘superb basic science’ and the 
majority o f people who sit on the award committees (deciding on the fate o f the funds) 
are basic scientists. In LK’s opinion, basic scientists are mainly interested in getting 
access to the clinical samples in an attempt to gain insights into the ‘performance’ of 
the product (cells) that may help refine the experiment in its next iteration. In other 
words, what LK implies, is that basic scientists have few incentives to move out of 
their comfort zone and get involved with expensive human trials and all the associated 
complex regulatory, manufacturing, and even intellectual property issues. LK sounds 
sensitive to the need for reform, and mentions how he and few of his colleagues 
repeatedly try to attract attention to this problem.
LK’s account supports the image o f a basic biomedical research enterprise which has 
evolved its own dynamic and it is favoured (or in a way favours itself through the 
composition of the awarding committee) by research council funding. His account 
resonates well with Professor Hollander’s point in Chapter 1, regarding peer review 
evaluation for funding and the preference for research projects that are closer to the 
evaluators’ own discipline and, generally, o f ‘low risk’. This view is also supported by 
Young and colleagues (2008) who argue that peer review o f journal articles is one 
subtle way this funding attitude is perpetuated. Their work suggests that the incentive 
structure built around the impact and citations, favours reiteration of popular work, 
that is, more and more detailed mouse experiments, and that it can be difficult and 
dangerous for a career to move into a new arena, especially when human study is 
expensive of time and money.
LK’s critique of the MRC Translational Awards also questions the recently emerging 
discourse of biomedical ‘Knowledge Translation’.103 The proponents o f this position 
describe a shift away from unidirectional research findings utilisation in the clinical 
setting toward more interactive models of knowledge transfer. The shift began when a 
growing number of scholars in biomedical, clinical and social sciences have noted that 
models involving linear, unidirectional and passive flow o f information from research 
laboratories to clinical settings have not properly addressed the gap between research
103 As d escrib ed  in C hapter 2, in th e  s ec t io n  titled  'On th e  C om plexity  and N on-L inearity o f  TR'.
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and practice (Jacobson et al., 2003). The failings o f previous models led some 
researchers to advocate broad and interactive models o f knowledge (and research) 
Translation. The discourse, although relevant to all biomedical research (Baumbusch et 
al., 2008; Ledford, 2008; Nussenblatt et al., 2010; Stacpoole, 2001), in recent years, has 
taken centre-stage in the Regenerative Medicine therapeutics field.104 This is mainly due 
to the unique characteristics o f cells as ‘drugs’ and ‘therapeutics’ and the prerequisite to 
‘watch’ them work in vivo to be certain o f their safety and effectiveness.
Key to this interactive model of Knowledge Translation (KT), as envisaged for the 
Regenerative Medicine field, is the concept of ‘reverse’ Translation (mentioned by 
interviewee LK). Under the notion o f reverse Translation, successful clinical trials, 
unexpected clinical responses, and even failed trials, can all stimulate new hypotheses 
and inspire new avenues of basic research. According to a recent editorial by Mason 
and Manzotti (2010), Translation is a cyclical process and reverse Translation is 
undoubtedly a very important part o f it. According to the authors, ‘the resulting clinical 
data must be fed back to the basic scientists in order to generate new hypotheses for 
the next round o f research and Translation — a continuous revolving cycle fostering 
advances in both basic discovery and routine clinical practice’ (Mason & Manzotti, 
2010: 153).
The theme of ‘bidirectionality’, specifically in the field o f Regenerative Medicine 
Translation and through the lens o f STS, has also recently been explored by 
sociologists Paul Martin (Nottingham), Nik Brown and Alison Kraft (York) (2008). 
Using the development (over a 50-year period) o f haematopoietic stem cells (HSCs) as 
their case study, Martin et al. (2008) examine the changing relationship between basic 
science and the clinical research community. Drawing from the sociology of 
expectations and concepts such as ‘imagined communities’ (Anderson, 1983), they 
develop the concept of ‘communities o f promises’105 (formed around emerging 
technologies) and use them to question the, up until recently, popular unidirectional 
and linear model of knowledge production and innovation in biomedicine, suitably 
referred to as the ‘bench-to-bedside’ model. Their analysis, which is in agreement with 
an increasing number of scientific commentaries, concludes that clinical
104 (M ason  & M an zotti, 2 0 1 0 ).
105 In th is  ca se , b asic s c ie n c e  c o m m u n itie s  and  clinical com m u n itie s.
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experimentation is as important for innovation as science is, thus supporting a 
dynamic, two-way innovation model for Regenerative Medicine.
W ithout rejecting the reverse Translation notion and the significance of the 
bidirectional flow o f information it represents, LK is one o f three bioentrepreneurs 
challenging the idea that reverse Translation is, as he states, ‘everything’. Having 
experienced first-hand the MRC’s ‘funding preferences’, he calls for a balance between 
the two types of Translation. Although he seems to appreciate the benefits of feeding 
clinical data and materials back to basic scientists, he emphasises the equal importance 
o f pressing ahead with clinical trials (for example, Phases I, II and III), as well as 
dealing with manufacturing and regulatory issues, things that are often ‘overlooked’ by 
the MRC and its funding strategy.
Continuing with the theme o f public funding, three bioentrepreneurs were keen to 
offer their views on how the situation might improve for RM Translational Research. 
For example, LM below, explains how ‘joined-up thinking’106 (on the part o f research 
councils and the NHS) could facilitate potential collaborations between biomedical 
researchers and clinical practitioners and boost clinical Translation, through allowing 
the combination and /or sharing of their resources and funds.
We need more joined-up thinking on how we fund Translational 
Research. Because my way of looking at it, is this: many o f the patients 
that we are using skin for — and there are colleagues who are using 
cartilage, etc — they are NHS patients who have the problems. So chronic 
non-healing ulcers, major burns etc, etc. We have clinical staff that treats 
those patients under the NHS and they often wish they had something 
else they could give the patients like cultured cells or chondrocytes. Many 
o f those NHS staff also need to do research to progress their careers.
And we also have research council funding. Now many o f the research
106 The 'jo in ed -u p  th inking' ap proach  a d v o ca ted  by b io en tre p r en eu rs  is partly fu lfilled  by t h e  e s ta b lish m e n t in January 2 0 0 7  
o f  th e  O ffice for S trateg ic C o-ord in ation  o f  H ealth R esearch  (OSCHR). T he e s ta b lish m e n t o f  th e  OSCHR w a s  a key  
r e co m m en d a tio n  in th e  C ook sey  2 0 0 6  R eview , and its aim  w a s  to  'tak e an o v er v iew  o f  th e  b u d getary  division  and research  
s tr a teg ie s  o f  b o th  th e  MRC and the-NIHR'. In o th er  w ord s, th e  OSCHR w a s  e s ta b lish ed  to  unify, d istr ib u te  and con tro l clinical 
research  fu n d s  from  th e  D ep a rtm en t o f  H ealth (d elivered  th rou gh  th e  NIHR) and th e  D ep a rtm en t for  Innovation , 
U n iversities  and  Skills (d elivered  th rou gh  th e  MRC), and h e n c e  e s tab lish  a m o re  c o h e r e n t  s tra teg ic  ap proach  to  funding, 
esp ec ia lly  fo cu ssin g  on  th e  c a se  o f  T ranslational R esearch . The OSCHR p u b lish ed  its first p rogress  report in N o v em b er  2 0 0 8 . 
T he report can b e  a c c e sse d  at:
h ttp ://w w w .n ih r .a c .u k /f ile s /p d fs /O S C H R _ P ro g ress_ R e p o r t_ 1 8 .ll.0 8 .p d f
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councils will not fund clinical research. And the NHS has got very litde 
research funds. But it has got the problem of the patients and it has got 
the clinical staff and the willingness to do research. So the only way I 
have managed to move into the clinic is by pulling those together, using 
very litde money. Now what we really need, is more joined-up thinking 
between the NHS research budget holders and the research councils.
And there needs to be recognition that having money earmarked for 
getting stuff into the clinic safely, small-scale pilot studies, not 
commercial, is one o f the most creative things the UK could do. Because 
we have all the skill sets to do that, but we have barriers at every stage.
(LM, PI/Founder of Spin-out, 2007)
As LM emphasises in this passage, ‘combined’ (council and NHS) and ‘earmarked’ 
funds for Translational Research would help create a sustainable, seamless process 
between basic researchers in academic departments and surgeons/clinicians that 
promotes collaborations and accelerates innovations. The clinical environment has 
traditionally not been very supportive of Translational Research. As a result o f limited 
time to devote to research (due to teaching and clinical responsibilities), small budgets 
and lack of readily available resources to test technologies and develop product 
prototypes, it is no surprise that creative approaches to address crucial improvements 
in patient care do not often progress out of the idea stage. O n the other hand, 
academic scientists who have the time and resources to conduct research, have limited 
experience in a clinical environment and often lack the understanding of which 
medical problems really need addressing and how the clinical setting places constraints 
on potential solutions.
The need for ‘joined-up thinking’ has also been identified by another interviewee, LK, 
who advocates for more financial support (again combined between research councils 
and NHS) for principal investigators to perform first-in-human (FIH) experimental 
trials.
I think the MRC and the NHS research funds should be focussed more 
towards Translational Research, and by that I mean first-in-man 
Translational Research [...] I think we need to encourage academics to
122
do more than one-off first-in-man, and provide them with the facilities.
At the moment the concept is that you have this brilliant idea...so for 
example if we take my product, [Product], I would have treated three 
patients, and shown that the cells engrafted, that the patients didn’t die 
and that there was reduction in tumour. I would then stop everything and 
look for a commercial partner to pick it up and run with it. And I’d walk 
away from it. Because as an academic this is what I am supposed to do. 
Because I need to get one decent paper in one big journal, and then 
move on into something new.
(LK, P i/C lin ica l involvem ent/Founder o f Start-up, 2009)
Here LK talks about the tendency of RM investigators to end their research work at 
the FIH  stage, if not earlier at the animal studies. He identifies two main problems 
behind this tendency. First, most o f the investigators have neither the necessary 
facilities nor the funds to perform this kind o f trial. Second, he believes it is the 
academic publications and career rewards ‘culture’ that sustain the above strategy. 
According to LK, academics need to publish a certain number o f papers in certain 
high-impact journals, so they are ‘better o ff  halting research before the FIH stage and 
looking for commercial partners to carry them out instead, while they pursue 
something new. Commenting further, he explains how his ‘ethos’ — that is, to change 
clinical practice — requires that he does things differently from ‘normal’ academics:
Now my ethos is that I want to change clinical practice. So I want to run 
a fifteen-patient Phase-I trial and then a Phase-II trial or Phase-III. And 
that is completely outside most universities’ ethos and most university 
researchers.
FIH experimental trials will usually include few people (perhaps 1-3) and, if successful, 
investigators could move to a Phase I trial including around 10-15 volunteers. As 
pointed out by LK, Phase I (and Phase II and III) trials are ‘completely outside most 
university ethos and most university researchers’. LK continues, explaining the reason 
behind the reluctance o f sponsors (public and private) to fund clinical trials, especially 
in academia:
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I think there is a problem with getting funding for Phase I/Phase II trials 
in academia. They are expensive compared to most academic products 
that one puts forward and they are high risk. They also don’t tend to get 
publications in high-impact journals because they are clinical trials. So 
consequently it’s not something that is readily funded by the MRC or any 
o f the research councils. And I think there is a big gap there between the 
basic research and the true Translational Research.
[...] So there needs to be understanding that academics need not just the 
money to do it, but they need to be reviewed in a different way in terms 
o f their career structure, their returns to government or how ‘academic’ 
you are. It shouldn’t be whether you got a paper in Nature Medicine this 
month or next month. It should be over a series o f deliverables.
[...] And we need to have the capacity, either in partnership with industry 
or on our own to manufacture RM products for up to fifteen patients at 
a trial. N ot one or two [patients] in a very inadequate space.
(LK, P i/C lin ica l involvem ent/Founder o f Start-up, 2009)
Phase I clinical trials are considered ‘high risk’ both ethically and financially. This 
means that, even if successful, they will not secure the much needed high-impact 
publications that would justify a research council’s investment and, perhaps even more 
importantly, capture the ‘academic’ credits for Pis, as required by the current career 
progression system. Yet, concentrating on publications so as to satisfy their ‘reviewers’ 
is clearly distracting and discouraging RM bioentrepreneurs from engaging with 
‘serious’ Translation, which LK considers to be past the proof-of-principle and FIH 
stage. He also advocates better support of the manufacturing process in order for Pis 
to be able to progress from three patients to around fifteen.
The changes that LK proposes are large and challenging for the system and even if 
decisions are made to implement them (or something similar) it will no doubt take 
time. However, the pace o f the RM breakthroughs at the bench does not seem to be 
slowing down so the need for principal investigators to bravely turn into 
bioentrepreneurs and drive the process, often completely unassisted, is clearly there 
and it is huge. As LK admits though: ‘the complexity o f taking the fantastically, wizzy
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cell therapy product that you’ve invented and putting it into a small manufacturing 
entity is completely beyond most academics, they don’t understand it’.
LK’s insightful commentary is very useful in understanding how a start-up 
bioentrepreneur thinks o f other bioentrepreneurs (specifically those involved with 
academic spin-outs) and ‘normal’ P i’s, relative to clinical and commercial Translation. 
As LK suggests, what distinguishes him from investigators who have no interest in 
moving Translation beyond the first-in-man stage and those who will ‘simply’ 
(unprepared and unskilled) spin out a company, is a different ‘ethos’. It is from this 
‘ethos’ that stems the ‘desire to change clinical practice’ and the only way to achieve 
that is to strive and get one’s research to as advanced a stage as possible, towards being 
a ‘real technology’ with a ‘real benefit’.
The concept of ‘translational ethos’ has been recently in the forefront o f Regenerative 
Medicine debates. Maienschein et al. (2008) have written about this ethos in the 
context o f stem cell research which they claim has ‘superseded genomics as the 
translational object o f choice’ (Maienschein, et al., 2008: 43). Referring to the 
‘translational ethos’, the authors express concern about the appearance o f a ‘new social 
contract for the way science works in society’. According to this contract: ‘Instead of 
implicit promissory results scientists must promise specific results up front. Moreover, 
they must produce results sooner rather than later and more specifically targeted for 
particular ends rather than the general good. Finally, there is now far more guidance 
from public investors. The result is an ethos of Translation’ (2008:43).
Maienschein et al. (2008) critically interrogate this translational imperative and the 
pressure that comes with it to ask particular kinds o f questions (and reach particular 
kinds o f results), and wonder whether this imperative is undercutting scientists’ abilities 
to engage in other kinds of research. The authors are concerned that ‘public, political, 
and industrial demands, particularly with regard to what the products o f the research 
should be, shape the landscape within which the research trajectory is determined, and 
that landscape is dominated by various demands for translation’ (2008:49) and claim 
that today’s Translational Research ‘builds certain (and- sometimes dubious) end goals 
into the research from the start’ (2008:49).
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Maienschein et al.’s (2008) analysis o f the effects o f the translational ethos on 
bioentrepreneurs suggests that they are driving the clinical and commercial Translation 
process so that it conforms to the external demands o f others such as sponsors and /or 
the market. LK’s account, however, could not be further from this speculation. The 
impression given by LK’s narrative is that he is ‘driving’ the Translation process against 
all odds. In other words, the route he has chosen — a decision he attributes to his 
‘ethos’ — is clearly the difficult one, ‘against the current’. Instead o f conforming to the 
lack of sufficient financial and infrastructure support (for clinical trials) and to the 
academic evaluation system like his colleagues, LK chooses to pursue Phase-I clinical 
trials which will bring him closer to external funding and perhaps the successful 
Translation o f his work.
Summary
It is undoubtedly the case that many bioentrepreneurs interviewed for this study 
perceive a profound lack of funding in UK RM TR.107 All the interviewees, without 
exception, reported difficulty in securing funds which is not credited to competition, 
but instead to an apparent ‘mismatch’ between the translational work principal 
investigators claim to carry out and the kinds of projects research councils and 
charities are ‘interested’ in sponsoring. The consensus among the bioentrepreneurs I 
interviewed is that UK research councils (which handle the bulk o f public funds for 
universities and research institutions) and UK charities, often favour basic ‘scientific’ 
research at the expense o f Translational Research. Yet the ‘favouring’ and continual 
expansion of basic research has been criticised before, with critics stating: ‘the problem 
may be that Big Science is inappropriate for generating medical progress. The 
dominant research paradigm has been termed the ‘basic to applied’ model, and is 
(roughly) the assumption that expanding ‘basic’ medical research leads predictably to 
an increasing frequency o f ‘applied’ clinical breakthroughs. The continuing failure to 
sustain therapeutic progress is making it increasingly apparent that these assumptions 
are, at best, only partially valid’ (Charlton & Andras, 2005: 54).
Another theme to emerge in the discussion concerning public funding o f Translation, 
is ‘bidirectionallity’. Although most of the respondents with whom I had the
107 In truth , th e  d earth  o f  'tran sla tion a l cap ital' d oes, n o t s e e m  t o  b e sp ec ific  to  R egen era tive  M ed ic in e , b u t th e  fa ct th a t all 
m y in form an ts  are part o f  th e  RM parad igm  d o e s  n o t a llow  for gen era lisa tio n .
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opportunity to talk described ‘bidirectionality’ in an inherendy ‘positive light’, some 
bioentrepreneurs argue that the focus on the bedside-to-bench knowledge Translation 
that takes advantage of clinical feedback has led to the overlooking o f important 
‘forward-looking’ translational activities (such FIH, and Phase I, II, III clinical trials) 
and their requirements, such as regulatory and business expertise. Together, then, 
critics of the Translation process identify both ‘internal’ and ‘external’ factors that may 
be impeding more successful Translation, and more financial support for this sector.
Two of the respondents were keen to propose a solution to the dearth o f translational 
public funds (due to their misdirection) by advocating a ‘joined-up’ thinking (and 
subsequently funding) approach between the research councils and the NHS, the main 
sponsors o f basic and applied research respectively. By combining the financial 
resources o f the two ends of the research continuum (basic and applied), much as they 
combine their expertise, research councils and the NHS could possibly serve the 
‘funding needs’ o f Translation. With this proposal in mind, this chapter now turns to 
the views of bioentrepreneurs on the role o f venture capital in Regenerative Medicine 
Translation in the UK.
Venture Capital: The ‘Later-Stage’ Attitude
From the bioentrepreneurs’ accounts so far, it is clear that the strategies and schemes 
that have been set up by the UK Government have not managed to bear enough o f 
the risk of early-stage investment in Regenerative Medicine Translation. As mentioned 
earlier, new high-technology business ventures such as Regenerative Medicine start-up 
firms can have very high capital requirements (e.g. GMP facilities), returns are often 
much delayed compared to other more established science and technology areas, and 
bioentrepreneurs often have few or no assets available beyond their own knowledge 
capital. This situation leaves few choices if principal investigators want to transform 
their research into clinical applications. They are dependent upon ‘risk’ capital 
provided by venture capitalists or investments from industry (especially from large, 
established pharmaceutical firms).
In the absence of adequate public funding, successful identification o f potential private 
sponsors is crucial, and yet is not the same as actually securing the funds, as many spin­
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out founders know too well. Indeed, it is common knowledge within the community 
of start-up bioentrepreneurs interviewed for this study that venture capital groups, as 
well as big pharma, have largely held back from investing in companies focussed on 
Regenerative Medicine (Parson, 2008). In this section, my focus is the 
bioentrepreneurs’ experience of engaging with venture capital while trying to raise 
funds for Translation. The next section includes a discussion of informants’ views on 
the emerging role of industry in the Translational Regenerative Medicine field.
Asked about alternative sources of funds, all bioentrepreneurs interviewed for this 
study expressed dismay at how venture capital is operating in the UK. According to 
the interviewee below, the reason why venture capital is not a good candidate for 
filling the ‘equity gap’ is that most venture capitalists prefer to enter the process further 
‘downstream’, ideally after proof-of-principle has been achieved in the clinic. This 
‘later-stage’ attitude and the problem it poses for Translation funding is evident in the 
following quote by LM:
It [UK Government] needs to seriously put research funding into 
translational work and not just talk about it. Because a common, 
common problem is that when you go for commercial money for a 
company they always wish you were further down the line and you were 
actually “caught” into the clinic. [...] It is actually very difficult for 
academic researchers to fund Translational research.
(LM, P I /  Founder o f Spin-out, 2007)
The level o f technology development that the venture capitalist community is typically 
looking for, is also pinpointed below, by Greg Bonfiglio, during a presentation at a 
London Regenerative Medicine Network meeting in November 2008. Bonfiglio is the 
founder and Managing Parmer o f Proteus Venture Partners (Palo Alto, California), a 
venture fund focussing solely on stem cell and Regenerative Medicine companies. He 
has extensive experience in the commercialisation of Regenerative Medicine research 
and is considered an international leader in the field.
We are trying to find a post where the core technology, the core concept 
has already been established. And by that, do I mean: do you have to be
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in the FDA? No. Do you have to be working your FDA program up?
No. But you do need to know what your technology is and you need to 
have some sense o f what are the most appropriate therapeutic 
applications for it. It needs animal data. You need to have enough data to 
gather so you can talk intelligently with the FDA in one o f those pre- 
IN D  [Investigational New Drug] application meetings. If  you are not 
there, you are probably not going to attract venture capital money. 
Because you are just too early. You could attract money from angel 
investors or friends and family, which is how you should be doing it, or 
grant money. But you are probably not going to attract the interest of 
most venture capital funds.
(Greg Bonfiglio, LRM N M eeting, 2008)
A company’s life cycle may be divided into different phases based on the time of 
maturity involved (European Venture Capital Association, 2006). The seed phase 
comprises the establishment of the company, during which the technology and 
business model are developed. This initial phase would normally involve a modest 
capital requirement, and is often financed either by friends, family and /or the so-called 
business angels108 (sometimes referred to as ‘angel investors’). Once the core 
technology and business models have been developed, then the company is said to 
move into the ‘start-up’ phase. During the start-up phase the technology should be 
verified, the product is considered to be in a ‘prelaunch’ state, and the organisation/ 
company will normally be built up with business expertise. The start-up phase is the 
most capital intensive, and the need arises for external, professional funders such as 
venture capitalists to join financially, or perhaps even take an active role in the business 
(Dobloug, 2008).
Commenting on behalf o f his venture capital firm regarding Regenerative Medicine 
companies and their expectations of VC support, Bonfiglio points out that the 
product/therapy under development does not necessarily need to have FDA-approved 
data for safety and efficacy. It is, however, necessary for the research teams/companies
108 The term  'b u s in ess  a n ge ls ' w a s  co in ed  to  d escr ib e  th e  a ctiv itie s  o f  individual in v esto rs  w h o  sp e c ia lise  in provid ing fin an ce  
to  n ew  start-u p s and ea r ly -s ta g e  firm s in return for an (o ften  su b stan tia l) eq u ity  sta k e . B u sin ess an g e ls  are, typ ically , 
w ea lth y  ind iv iduals, o fte n  w ith  sign ificant p rev iou s m an ageria l or en trep ren eu r ia l ex p e r ie n c e . T hey d iffer from  v en tu re  
cap ita lists  in g en er a lly  b e in g  s o le  in vestors , o fte n  reliant on  th e ir  ow n  fin a n ce , ra th er  th an  m an ag in g  a fund; it is, h o w e v er ,  
b eco m in g  in creasin g ly  c o m m o n  for  b u sin ess  a n g e ls  to  cr ea te  grou p s and  o rg a n ise  th e m s e lv e s  in n etw o rk s and sy n d ica tes  in 
ord er to  search  for and  m ak e in v es tm en ts . D efin ition  sou rced  from  Sainsbury R ev iew  (Sainsbury, 20 0 7 : 83).
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to have key pre-clinical (animal studies) data and to have a solid knowledge o f the 
product and all its potential therapeutic applications — preferably more than one (as a 
strategy to maximise the chances o f success). According to Bonfiglio, only if these 
conditions are met is the technology considered ‘de-risked’ to the point where it is 
potentially attractive to venture capitalists.
Another risk factor is described by the interviewee below, who perceives the absence 
o f venture capital in the RM field to be the result of the way RM companies have 
secured funding in the past, which, he implies, has led to failure o f the ventures and 
has also generated distrust between the venture capitalists and the current Regenerative 
Medicine (RM) research and development community.
For us, as academics — and I feel very strongly — that Regenerative 
Medicine is a very high-risk field. And as weVe seen, there’ve been lots of 
train crashes with Regenerative Medicine companies and I think that, 
largely because they started too soon, they raced off on a field of 
euphoria, obtained funding from wherever, and then not delivered. And 
then the problem is this is still a very academic field. The success we are 
having with our [Product Name] is [because] the academic proof-of- 
principle was done before the company picked it up.
[...] There is a famous phrase that: “Venture capital should not be 
adventure capital”. Most o f these [academic RM spin-outs] have been 
complete adventures.
(LK, P i/C lin ica l involvem ent/Founder o f Start-up, 2009)
LK admits that Regenerative Medicine is still a very academic and high-risk field. By 
this, he means that cell therapies under development -  like the already existing cell 
therapies (largely from bone marrow), have been generally, so far, relying on academic- 
based clinical trials the cost of which is large for either academia (spin-outs) or start­
ups to bear. Yet, according to LK, most o f the Regenerative Medicine spin-outs so far 
have sought venture capital and/or industry funding too soon, before establishing 
proof-of-principle for their technologies. He mentions the company he founded — a 
non-academic firm — and highlights the fact that the product technology was acquired
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for further development by a biotechnology company, after proof-of-concept had 
been achieved.
The importance o f venture capital in relation to the development o f entrepreneurship 
and innovation has long been reported in the social literature. But why is it so difficult 
for biotech companies, and specifically Regenerative Medicine companies, to raise 
adequate funding from private equity sources, such as venture capital? A surfeit of 
scientific/technical, ethical, legal and political problems make Regenerative Medicine 
companies a difficult pitch to venture capitalists. Indeed, as Regenerative Medicine 
research (including hESCs, iPS and other types of cells) is a relatively new area of 
endeavour, academic groups and companies developing these kinds of products face 
several types of risk, including technological risk, manufacturing risk, regulatory risk, 
and risk o f failure in proceeding through clinical trials (Giebel, 2005).109
A final type o f risk, and no doubt a distinctive risk factor for ‘emerging’ technologies, 
is the timeline for investor exit.110 The intrinsic uncertainty o f the lengthy development 
process o f an innovative health technology challenges the flow of supporting finance 
in such a high-risk field (Perin, 2005).111 The concentration of key patents into the 
hands o f few commercial entities, in addition to the unclear, non-harmonised IP 
landscape might also help to dampen investor enthusiasm. This factor has been 
exacerbated by increasing global financial insecurity, a generalised risk factor that has 
hit the whole biotech sector hard as venture capital dries up (Browning, 2009). 
According to Ernst and Young the crisis has reduced venture capital to $16 billion in 
2008, a 46% decrease compared with 2007 (Ernst&Young, 2007, 2009).
Thus, with less money to ‘go round’, it is no surprise that venture capitalists are 
becoming increasingly risk averse. As a result, biotech and regenerative companies are 
having to adjust to a situation where low-risk projects are favoured over high-risk ones, 
and the high-risk ones will probably have to be delayed and will require government or
109 G iebel is a V en tu re  P artner at SV Life S c ien ces , a v en tu re  cap ital firm  fo c u se d  on  h ea lth ca re  in vestin g . He w a s  co fo u n d e r  
and  form erly  CEO o f  C ythera Inc., a h u m an  em b ryon ic  s tem  cell com p an y .
110 V en ture cap ita lists  in b io tech  in g en era l h a v e  a t im e  horizon  o f  a b o u t th r e e  y ea rs  for  a particular in v e s tm e n t-n o w h e r e  
n ear th e  te n  or tw e lv e  years  m o st c o m p a n ie s  ta k e  to  g e t  th eir  first drug on  th e  m ark et. In ad d ition , b ec a u se  th e y  n e e d  to  
spread  th e ir  risks, n o t ev e n  th e  largest fu n d s can afford to  sink a vast sum  in to  an y  o n e  start-u p . A ccord ing to  d ata  from  th e  
N ational V en tu re  Capital A ssocia tion  on fu nd  in v estm en t p o lic ies , th e  a v er a g e  in v e s tm e n t in a b io tec h  firm is a b o u t $3  
m illion . T he a v er a g e  m axim u m  is $ 2 0  m illion  (P isan o, 2 0 0 6 a , 2 0 0 6 b ).
111 Nicola Perin (June 2 0 0 5 ) , The G lobal C om m ercia lisa tion  o f  UK S tem  Cell R esearch . A rep ort p rep ared  a s part o f  an 
in ternsh ip  w ith  th e  B io tech n o lo g y  T eam  at UK Trade and  In vestm en t (DTI).
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charity support in order to progress (Karberg, 2009). A t the moment, however, it 
seems that none o f the research councils112 are very keen to bear the risk to adequately 
support this part of the Translation phase. Nevertheless, throwing, high-risk projects 
overboard may not suffice, and the whole dependence on venture capital and risk- 
averse research council funding may have to change. Finding new sources o f long-term 
financing for translating research into therapeutics will be essential for maintaining 
innovation. An example of such a source could be large pharmaceutical or 
biotechnology firms looking to get involved with the new and promising Regenerative 
Medicine technologies, a scenario which is discussed in the next section.
Summary
Most bioentrepreneurs seem to have a realistic understanding about a company’s 
potential to attract venture capital money. It clearly depends on the stage of the 
research, and all the bioentrepreneurs I spoke to have had quite a lot of contact with 
both venture capitalist firms or have attended relevant workshops and conferences. 
They are also aware that the ‘capital problem’ is typically even greater than normal in 
the Regenerative Medicine field where there is high knowledge intensity (with new 
scientific breakthroughs revealed every day — able to completely obliviate previous 
techniques and materials) and where neither the product nor the potential 
manufacturing process has been tested in market. In short, bioentrepreneurs perceive 
venture capital as perhaps the least possible funding option and instead are directing 
their efforts to sources that seem more ‘accessible’ such as Regional Development 
Agencies, as mentioned by many respondents.
In the next section, I build a picture of how bioentrepreneurs look at the role big 
pharma has played so far in terms of investment in the regenerative therapeutics field, 
and if and how this role has evolved. Where does a founder’s choice for business 
model (commercialisation route) depend? How does the choice of business model and 
research agenda influence industry’s investment decisions? And how industry 
investment strategies, in turn, affect a principal investigator’s (basic and translational) 
research agendas?
112 R esearch  cou n cils, ev e n  w h e n  th e y  are k een , o fte n  require m u ltip le rou n d s o f  gran t a p p lica tion s t o  e n a b le  a n ovel 
p rod uct to  reach  a m atu re s ta g e  th a t  is a ttractive  for private in v estm en t.
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Big Pharma: From ‘Simply Watching’ to ‘Taking an Interest’
Given the current financial crisis and the fact that both public and venture capital 
funding appear to be problematic for Translational RM, many companies who are 
running low on cash are seeking funding from non-traditional sources such as big 
pharma. The ‘non-traditional’ characterisation stems from the fact that normally 
RegenMed companies with their R&D pipelines would be considered a threat to 
pharma, as RegenMed products have the potential to cure diseases, which was 
previously unthinkable. Big pharma, on the other hand, is in need o f ‘new growth 
engines’ for their business and RegenMed companies and spin-outs could help fill this 
gap. Up to 2007 when I conducted the first half on the interviews, investments in the 
clinical and commercial Translation of Regenerative Medicine therapeutics had been 
modest. Since 2007 however, big pharma has been aggressively investing in the 
RegenMed space. For example, in 2008 Novartis and Roche invested in Cellerix in 
Spain, Johnson & Johnson invested in Tengion, Pfizer invested S3 million in Eyecyte. 
Large established biotech and medical devices companies have also made deals with 
RegenMed firms such as Genzyme with Osiris, Novo Nordisk with Cellartis, and G E 
Healthcare with Geron and Cytori (Smith, 2009).
In this section, I present the views of UK bioentrepreneurs on pharma and its role in 
the RM Translation field. What do they think about big pharma’s initial hesitance, its 
current changed ‘funding attitude’ and how their own translational work is influenced 
by the changing landscape.
In the following quote, the informant reveals the ‘watch-and-wait’ attitude portrayed 
by the pharmaceutical industry towards investment in the regenerative therapeutics 
field. Interestingly, the informant describes the ‘challenging’ business model (involving 
venture capital) her company has followed to develop their pipeline and compares it to 
one where a ‘big pharma company’ is involved.
That’s another one of the problems. I think it is very difficult for the RM 
companies to identify a model that works well. The model that we 
followed is a challenging one. That is, develop your first product, get it 
out into the market and start making revenue while trying to get enough 
venture capital funding to develop the next products coming through.
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You could say that a better model, in theory it sounds easier, is if you 
developed a technology that you sold on to bigger companies. There the 
problem is, I will say in all honesty, we have very few big companies in 
the UK who are seriously interested in the Regenerative Medicine area. I 
think the majority are still sitting on their hands and watching. They go to 
the meetings to find out what goes on, but they are not buying.
(LM, PI/Founder of Spin-out, 2007)
The appeal of having a big pharmaceutical (or biotech/medical device) company 
involved in a RegenMed company’s technology commercialisation pathway is shared 
by all informants. Technology is licensed or acquired, usually in a one-off deal with the 
pharma company, and the academic or corporate (research) team can either move on 
into something different or can continue working with the ‘parent’ company on the 
same technology, though this time with newfound resources (financial, regulatory, 
business, possibly infrastructure — things that are simply non-existent in small start-up 
firms). In contrast to this ‘easier model’ as described by LM, venture capital 
involvement means that the company must go through rounds of raising investment, 
the difficulty o f which has been discussed in the previous section. Later on, LM also 
made a reference to the Smith & Nephew113 case, in which the corresponding company 
attempted to enter the Tissue Engineering market ‘a couple of times and failed to 
break out. They ended up saying it was too expensive and too difficult’. It is difficult to 
say, though, how much past failures like the Smith & Nephew case have actually 
influenced the current risk-averse attitude shown until recently by pharma, and how 
much it is simply the ‘uncertain nature’ of RM therapeutics that has kept big pharma 
away.
The next quotation sheds a bit more light on the current ‘state o f affairs’ between 
pharma and RegenMed companies, albeit from the bioentrepreneur perspective.
I think it has been particularly difficult for Translation because the people 
who have the largest amounts o f money are not seeing a good business 
model in some o f these cells. For bone marrow cells, for example, where 
you are injecting the cells back to the same people: it is difficult for a
113 It m u st b e  n o ted , h o w e v er , th a t  Sm ith  & N ep h e w  is a m edical d ev ic e  com p an y  and  n o t a p h arm aceu tica l com p an y .
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drug company to see where they can make the money on that. It is a little 
bit easier with the stem cells and the patches but there are patent issues in 
Europe. You are not supposed to patent hESCs, so they can’t have that 
as their business model. So I think they are struggling to find the business 
model. And for cardiac, in particular, I mean for the bone marrow trials, 
which are relatively straightforward, it’s about £10,000 per patient. Now 
most of the trials for drugs are looking at thousands of patients, not 
hundreds o f patients. So you need the power o f the trials, so it is getting 
somebody to pay for those big trials.
(RG, PI, 2009)
RG is an academic principal investigator (PI) working in the area of cardiac 
Regenerative Medicine. In her narrative above, she points out the difficulty for 
investors, including large pharmaceutical companies who have the most to spend, in 
identifying RM Translation as a profitable business. As with any other area of biotech, 
in Regenerative Medicine investors need to be able to calculate and manage the risk 
involved in their investment decisions. In other words, a Regenerative Medicine 
company’s business model must address the issue o f risk stacking (i.e. how much risk 
can the company offset before success becomes completely improbable). Yet at the 
moment in RM, the high level of uncertainty that characterises the innovation path 
from biomedical science to its therapeutic applications means that there is no 
acceptable commercial model on which investors can draw when making their 
judgements, and ‘the technological novelty of the field challenges the skills and 
inventiveness of the business community as much as those o f science’ (Salter, 2009a: 
405). In short, the fact that tissue engineering and cell therapy development processes 
are far removed from current R&D expertise and the established business model 
which pharma has been following so far is, according to RG, the reason behind their 
hesitance to invest.
Now, in RG ’s broader field (i.e. cardiac disease), the development o f an effective stem 
cell therapy will offer hope to patients with cardiac disease who have otherwise limited 
options.114 Along with the new hope for the ‘difficult to treat’ cases, the potential o f
114 Current tr e a tm e n t o p tio n s  in clu d e h eart tran sp lan ta tion , drug th era p ie s , or  s o m e  ty p e  o f  m ed ica l d ev ic e . In fact, o ften  
th e s e  th r e e  ty p es  o f  th era p y  are c o m p le m en ta r y , each  ad d ressin g  a particular fe a tu r e  o f  h eart d is e a s e , w ith  th e  tr e a tm e n t  
e sca la tin g  and b eco m in g  m o re  invasive as th e  h eart fa ilure w o rsen s. D esp ite  having p roved  to  im p rove th e  fu n ction  o f  a
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stem cell therapy, however, has created a new situation (compared to previous 
therapeutic development processes). For example, small molecules such as beta 
blockers or calcium antagonists were developed with funding from the pharmaceutical 
company that owned the intellectual property in the molecule. As RG points out, 
autologous bone marrow cells themselves, however, have no value as intellectual 
property so their commercialisation as such is not possible. Cardiac patches115 on the 
other hand, she presumes, might be easier to consider as products, as their design is 
closer to the concept of constructs/medical devices. Yet again, pharma considers them 
problematic for investment as the IP patent landscape in Europe is still filled with 
uncertainty. Therefore, according to RG, pharma (and commercial sources in general) 
are unlikely to fund expensive clinical trials unless ownership becomes more 
transparent and secure.116 Without the ‘power o f the trials’ the chances for product 
commercialisation significantly decrease.117
The following respondent uncovers a similar understanding of the reasons behind 
pharma’s attitude towards (not supporting) Regenerative Medicine Translation. Unlike 
RG, however, he makes no mention o f IP concerns, emphasising instead the ‘lack o f 
fit’ between RM and the pharma business model.
I think the problem with most Regenerative Medicines is th a t...I know 
that Geron will say in every meeting — “one-offs, patient-specific 
products are not ever going to fly”. That’s rubbish. It is just a business 
model that has not been considered by big pharma because it is so far 
outside their expertise. And what they are familiar with is 
pharmaceuticals based on another white pill-type programme. And that’s 
not the way we are going to go with this, we are running out o f other 
white pills basically. I think if big pharma [companies] are going to 
survive they will have to embrace some of this. There are some good
d a m a g ed  h eart, n o n e  o f  th e s e  cu rrently  ava ilab le tr e a tm e n t  co m b in a tio n s  h as d em o n str a ted  an ability to  re g e n e r a te  th e  
cardiac m u sc le s  w ith in  th e  scarred  reg ion s o f  th e  in farcted  heart.
115 E n gin eered  'cell p a tch es' w hich  com p rise  o f  ce lls  s e e d e d  on  a b iom ater ia l th a t can b e  u sed  to  a d h e re  and  
r e p la c e /r e g e n e r a te  th e  'd ead ' area o f  th e  h eart. In th is  ap proach  th e  p ossib ility  is b ein g  exp lored  th a t  m ateria ls  m ay  n o t  
s im p ly  act a s a su p p ort for  th e  d eliv ered  cell im p lan ts, but m ay  a lso  add  v a lu e  by ch an gin g  for  e x a m p le  cell survival, cell 
in tegra tion  or by p rev en tio n  o f  m ech an ica l or e lectr ica l rem od ellin g  o f  th e  fa iling  h eart. A lth ough  th is  te c h n iq u e s  s h o w s  
p ro m ise , research  is still n e e d e d  to  d e term in e  su ita b le  cell so u rce , b io m ater ia ls  and op tim a l im p lan ta tion  t im e  p o st­
in fraction .
116 For in sta n ce , if th e  tr e a tm e n t p ro ce ss  is co m b in ed  w ith  a p a te n ta b le  p rep aration  or d elivery  sy ste m .
117 Clinical trials are g en era lly  v ie w e d  as a sign th a t  a co m p a n y  has p ro g ressed  to  th e  n ex t s ta g e  and  in v esto rs  usually  
p erce iv e  it as very im p ortan t va lid ation  o f  a tec h n o lo g y  and te a m . In d eed , v en tu re  in v esto rs  o fte n  m ea su re  a sm all b io tech  
co m p a n y 's  suitability  for in v e s tm e n t b a se d  on  th e  e s t im a te d  t im e  to  th e  clin ic. (P aren teau  B ioC on su ltants, N o D ate).
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models o f...fo r example, things like Regenerative Medicine structures, 
three-dimensional structures, constructs that can be manufactured which 
then can be seeded with cell therapies.
(LK, P i/C lin ical involvem ent/Founder of Start-up, 2009)
As LK points out, the preference of the industry for allogeneic (off-the-shelf) products 
in part explains its ‘aversion’ towards autologous, patient-specific therapies. For the 
time being, Regenerative Medicine start-ups and small biotechs looking for funds 
might be making themselves more ‘attractive’ to potential investors, he implies, if they 
choose to focus on the development of universal, allogeneic products. LK clearly 
suggests that this difference in preference stems from the fact that allogeneic products 
resemble the development and production of pharmaceuticals. This resemblance, he 
claims, makes them better candidates to integrate into the pharma industry which has 
built its technological capabilities and fortunes in a highly specialised and expensive 
research and development trajectory.
Nevertheless, the situation might be about to change drastically as pharmaceutical 
innovation in R&D has been experiencing a steep decline in the last decade and the 
sector is accused of not coming up with the expected innovations. As LK notes, big 
pharma is running out of small white pills. In fact, fully integrated drug discovery 
companies are increasingly being confronted by disruptive life-science technologies 
coming from both public sector research organisations and small-medium 
biotechnology companies. In other words, as big pharma companies struggle to cope 
with the innovation deficit, rising R&D costs and cost containment pressures, small 
RM companies are providing new hope for the healthcare industry’s pipelines. As LK 
implies, the pressure from the various technological and commercial challenges, as well 
as the social pressure for the Translation of science into the most effective and 
beneficial clinical products, will make pharmaceutical companies reconsider the ‘white 
pill’ approach. The respondent is using the pill metaphor to give emphasis, in a way, to 
the difference in the two therapeutic approaches. One approach involves a white pill, 
universal and mass produced; the other a cell solution (or construct), customised and 
individually prepared.
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The image/metaphor o f the pill is a very common metaphor that is used in reference 
to the pharmaceutical industry and the nature o f its R&D.118 In fact, medical and 
healthcare discourse is full of metaphors that help to articulate the unique features of 
diseases, medical interventions, relationships, treatments, and so on. For example, 
‘magic bullets’ for antibiotics, the ‘Holy Grail’ for various treatments. A metaphor 
specific to the RM field has been proposed by Burns (2009): the stem cell ‘superhero’. 
Burns uses the concept/m etaphor o f ‘superheroes’ to capture what is unique about 
stem cell therapies because he claims old metaphors such as magic bullets, holy grails 
and miracle cures do not capture ‘the new conceptual paradigm that supports the 
notion o f stem cell cure’ (Burns, 2009: 428).
The conceptual distinction between a ‘Holy Grail’ pharmaceutical treatment and the 
‘heroic’ stem cell cure features widely in the social sciences. Pharma’s favourite 
‘treatment’ rationale is serviced by its familiar small-molecule ‘blockbuster’ therapies 
that have so far dominated the healthcare industry. The vast majority o f these products 
are currently being developed in-house and are small-molecule, prolonged treatments 
in complex, but high value, therapeutic areas such as oncology, cardiovascular, and 
those concerned with the central nervous system and depression. In contrast, the 
objective o f novel therapeutics such as (stem) cell therapies is to provide a ‘one-off 
treatment’ that will ideally lead to cure. According to social scientist James Mittra 
(Innogen ESRC Centre, Edinburgh) (2005), who has been studying the pharma and 
biotech industry extensively, although traditional big pharma companies do currently 
appear to prefer treatment to cure (that is pills to cell therapies), in the long term, 
change will be inevitable. In Mittra’s words: ‘to develop a cure for diabetes, heart 
disease or cancer would represent a fundamental change to its [pharma’s] traditional 
business model and could potentially render existing high-value therapies redundant. 
To invest money and resources into a paradigm of prevention and cure big pharma 
companies would have to perceive either realistic commercial benefits, or potentially 
significant losses accruing from a failure to adapt and change’ (Mittra, 2005: 33). This 
view seems to agree with LK’s prediction that ‘if they [big pharma companies] are 
going to survive, they will have to embrace some of this [cell therapeutics]’.
118 For ex a m p le , th e  im age o f  th e  'pill' is reca lled  in th e  title  o f  a b ook  by Merrill G oozner: The $ 8 0 0  Million Pill: T he Truth 
b eh in d  th e  C ost o f  N ew  Drugs. In his b ook , G oozn er exp lores  th e  p ro ce ss  o f  drug d e v e lo p m e n t  using c a s e  s tu d ie s  th a t  
reco u n t th e  d iscovery , d e v e lo p m e n t  and ev e n tu a l co m m ercia lisa tion  o f  a n u m b er  o f  s ign ificant drugs; $ 8 0 0  m illion  is th e  
a v er a g e  c o s t  o f  each  n ew  d iscovery .
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In his commentary, LK also mentions the ’opinion’ o f Geron, an internationally 
famous, California-based, biotech company119 which, in his view, exemplifies the way 
most large biotech and pharma firms ‘think’. G eron’s lead product candidate is 
GRNOPC1. The immune-privileged characteristics o f the hESC-derived cells used in 
it, provide the rationale for GRNOPC1 to be developed as an off-the-shelf, allogeneic 
cell therapy, which according to LK is closer to the drug development process and 
thus likely to attract the interest o f large pharmaceutical firms. In May 2009, two 
months after President Obama lifted the restriction banning federal funding of 
research using embryonic stem cells, Geron did indeed ‘attract attention’. But it was 
not the attention o f a pharma company and not for the development o f therapeutics. 
Instead, Geron teamed up with G E Healthcare, a 17 billion dollar unit o f General 
Electric Company headquartered in the UK. The aim o f the partnership is to use an 
existing batch o f Geron’s stem cells to develop sample human cells that drug 
companies could use to test the toxicity o f new drugs early in the development 
process, before they are ready for animal testing or human clinical trials.120
In general, the commercial use o f human embryonic stem cells as tools for drug 
discovery and development is considered more imminent than the ‘traditional’ cell 
replacement model. According to this translational model (and its corresponding 
business model), physiologically relevant human cells (derived from human embryonic 
stem cells) are used as the basis for creating novel and improved in vitro disease models. 
The hope is that using these models in drug R&D will lead to better precision and 
more cost-effective assays, ultimately leading to lower attrition rates and safer new 
drugs, as well as reducing the need for in vivo experimentation (Sartipy et al., 2007).
In their examination of this new paradigm of Regenerative Medicine which they call 
the ‘disease in a dish’ approach to stem cell Translation — sociologists Steven 
Wainwright, Mike Michael and Clare Williams (2008) confirm that, indeed, potential 
transplant therapies are not a priority for pharma for two reasons. One of the reasons
119 G eron C orporation  is in vestiga tin g  w h e th e r  h um an  em b ryon ic  s te m  ce lls  can b e u sed  sa fe ly  to  repair n erv e  tis su e  in 
p a tien ts  w ith  spinal cord injuries. Its lead  p rod u ct GRNOPC1 h as su r m o u n ted  n u m e ro u s  h u rd les b e fo re  finally receiv ing th e  
'go  ah ea d ' from  th e  FDA as  th e  w orld 's  first hESCs clinical trial. On 3 0  July 2 0 1 0 , G eron  a n n o u n ced  th a t th e  US Food and  
Drug A dm inistration  (FDA) has n otified  th e  co m p a n y  th a t th e  clin ical hold  p la ced  on  G eron 's Investigation a l N ew  Drug (IND) 
ap plication  h as b een  lifted  and th e  com p an y 's  P h ase  I clinical trial o f  GRNOPC1 in p a tien ts  w ith  a c u te  spinal cord injury m ay  
p ro ce ed .
(h ttp : / /w w w .g e r o n .c o m /m e d ia /p r e ssv ie w .a sp x ? id = 1 2 2 9 )(A c c e sse d  A u gu st 2 0 1 0 ) .
120 'GE te a m s  up w ith  G eron for S tem  Cell R esearch ' by S co tt M alon e . R eu ters N ew s (w w w .r e u te r s .c o m )
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echoes RG ’s account: cell therapies are out of pharma’s ‘comfort zone’ which 
comprises expertise in translating small molecules to the clinic. The other, is that 
pharma is reluctant to be associated with the ‘controversial hESCs, since it might 
negatively affect their share price. In addition, Wainwright et al. (2008) argue that 
experts (scientists and clinicians) in the stem cell field use persuasive promises in order 
to advance their interests in the new ‘disease in a dish’ approach to stem cell 
Translation, hence promoting it over the traditional and ‘failed’ ‘cell transplant’ 
approach.
The recent interest displayed by big pharma has been noted by many experts, not least 
by venture capitalists, who have been assigned to keep a watchful eye over the future 
of the sector in order to spot potential threats and opportunities. Gregory Bonfiglio, 
Managing Director o f Proteus Venture Capital, believes that the ‘change of mind’ 
displayed by pharmaceutical giants like Pfizer, is saying a lot about the future o f the 
industry and the role that big pharma is planning to play:
Pfizer is a watershed event for the industry because it’s a very clear 
stake in the ground by big pharma that “We believe in this technology, 
we can build a franchise around it”. And consider what Pfizer is.
Within the next year they are going to lose 2 billion dollars o f revenue.
We are talking about laying off massive numbers o f people, 25-30,000 
people, shutting down major parts o f their operation. Where are they 
focussing their energy? Regenerative Medicines. To people watching 
the field that says a lot about where they think this field is going. And 
it’s not just Pfizer. GSK just put 25 million dollars into the Harvard 
Stem Cell Institute. Novartis has got a program m e...I think this 
technology is the future and they [pharma firms] are now beginning to 
recognise it.
(Greg Bonfiglio, LRM N M eeting, 2009)
As mentioned at the beginning o f this section, in the past big pharma has shied away 
from investing in stem cell technologies, but according to respondents’ accounts and 
other experts, Pfizer’s move confirms that attitudes are gradually starting to change. 
Several pharmaceutical companies have started to take notice of research advances in
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the Regenerative Medicine field and their proximity to reaching the market. In 2008, 
UK-based GlaxoSmithKline signed a $25 million five-year deal with Harvard Stem Cell 
Institute with the initial aim o f harnessing stem cell technology for drug screening 
(Alamo-Bethencourt, 2008). The venture funds o f Switzerland-based Novartis and 
Roche helped bankroll Cellerix, a Madrid-based company testing stem cells from fat to 
treat rare skin conditions. Roche has also began a collaboration with a Wisconsin stem 
cell company, Cellular Dynamics International, to use cardiac cells (derived from 
embryonic stem cells) to test drug candidates for toxicity. G E Healthcare has also 
recently entered into a global exclusive licence and alliance agreement with Geron 
Corporation and Cytori Therapeutics (Baker, 2010; Ledford, 2008; Winter, 2009).121
Alain Vertes, Global Alliance Director of Roche, believes that this emerging trend of 
pharma companies to partner with RM firms is due to the fact that the field of 
regenerative cell-based therapies is now reaching ‘critical maturity’.122 By this, he means 
that the mechanistic fundamentals of these new therapies — safety and efficacy — are 
now sufficiently well understood to allow the design of appropriate research and 
development strategies. This is also supported by the numerous123 clinical trials that 
have been launched by the biotechnology industry in order to test the 
regenerative/curative potential o f autologous or allogeneic cell preparations in a variety 
of diseases (Carpenter et al., 2009; Giordano et al., 2007). According to Vertes, this 
observation o f ‘critical maturity’ in the field o f RM, constitutes a ‘tipping point’, since 
the potential for radical innovation that live stem cell therapeutics represent could now 
be efficiently integrated within large pharmaceutical companies. In the author’s own 
words: ‘early adoption of live stem cell therapeutics by large pharmaceutical companies 
will enable them to apply their core strengths and success factors to the development 
o f these novel therapeutics, thus providing not only competitive edge to the early 
entrants as they build internal resources, expertise and field awareness, but providing 
also an important thrust forward to the entire arena as these companies leverage their
121 M ost o f  t h e s e  co lla b o ra tio n s b e tw e e n  big pharm a and RM b io tec h , h o w e v er , s to p  sh ort, for th e  m o m e n t, o f  using ce lls  
directly  for th era p y  and  in stea d  co n c e n tr a te  on  d ev e lo p in g  drug screen in g  and  o th er  research  to o ls . The e x c e p tio n s  are  
Joh nson  & Joh n son  w h o  h as in v ested  in N o vocell's  th era p eu tic  p roject, and  Osiris T h erap eu tic s  w hich  d o m in a tes  th e  ad ult 
s te m  cell sp a c e  and h as b een  paid $ 1 3 0  m illion upfront (w ith  a n o th e r  $ 1 .2  billion to  b e paid in p o ten tia l m ile s to n e s)  by th e  
b io tech  G en zym e, for  t h e  d e v e lo p m e n t  o f  tw o  la te -sta g e  adult s te m  cell t r e a tm e n ts  (P rochym al and  C hon d rogen ).
122 V ertes (2 0 1 0 ) u se s  th e  annual n u m b er o f  sc ien tific  p u b lica tion s in a g iven  te c h n o lo g y  -  (SC: all s te m  cells; mAb  
(m o n o clo n a l an tib od ies); MSCs (M esen ch ym al S tem  Cells), e tc . -  and its grow th  rate, a s in d icators o f  th e  sc ien tific  m aturity  
o f  a g iven  fie ld . A fter a fie ld  has reach ed  m aturity, V ertes su g g e sts  th a t in crem en ta l in n ova tion  rather th an  d isruptive  
in n ovation  is likely to  occu r (V ertes, 2 0 1 0 ).
123 T h ere are o v er  8 0 0  clinical trials o n g o in g  u n d er a b ro a d -b a sed  d efin ition  o f  CBTs (C ell-Based T h erap eu tics) (M cA llister e t  
al., 2 0 0 8 ).
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scale, global presence, long-term vision, and deep clinical development expertise’ 
(Vertes, 2010: 156).
The result is perceived by some industry commentators as a ‘win-win’ situation. Regen 
companies often struggle with product development and commercialisation, given the 
lack o f money (especially after the recent fall-out in the economy) and their relative 
inexperience with clinical development, regulatory affairs and commercialisation. Large 
pharma, on the other hand, is in need of a new platform that can bring innovative 
products down the pipelines and drive revenue growth (given the number of products 
going off-patents in the next few years)(Smith, 2009).
Summary
Until recently, bioentrepreneurs have perceived big pharma as an unlikely sponsor. 
Those interviewees working with embryonic stem cells have mentioned intellectual 
property issues as a ‘thorn’ in investing strategies. Bioentrepreneurs working on 
autologous cell therapies based on the service model (instead of allogeneic products) 
believe the logistics, costs and financial returns o f such a therapeutic approach are 
unlikely to be attractive to the pharma industry. Finally, all interviewees admitted that 
they are witnessing some very important developments, although not in therapeutics. 
Large pharmaceutical companies are showing interest in the ‘safe’ translational model 
based on using stem cells as tools in the drug discovery process. The move of the 
pharma industry to embrace Regenerative Medicine technologies, even if it is through 
the ‘disease in a dish’ approach, is considered by bioentrepreneurs and other experts in 
the field as unavoidable, given the low productivity of pharma’s R&D and the 
promising results o f RM research.
In the next section, I present empirical data on the various ways UK bioentrepreneurs 
are dealing with the lack of funding identified in the three previous sections of this 
chapter and their struggle to identify or create a ‘viable’ business model — the ‘ticket’ 
for securing financial support and forwarding their products to market.
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In Search o f a ‘Viable’ Business Model
Everyone involved with the Regenerative Medicine sector, including all my informants, 
is well aware of the high-profile failures o f the ‘first wave’ of Tissue Engineering 
companies and of the difficulties the industry124 has been facing in obtaining 
reasonable returns on investments. Regenerative Medicine therapeutics, including 
tissue-engineered products and cell therapies, are based on intrinsically complex 
(scientifically and technically) processes and it is difficult to define exactly what is the 
product that is being sold. In fact, in order to show how markedly different RM 
products are from pharmaceutical and biotechnological products, and the importance 
o f bioprocessing for the final ‘result’ a key phrase is often used: ‘the product is the 
process’.125
Professor David Williams, Director of the UK Centre for Tissue Engineering at the 
University of Liverpool, has commented on the difficulty of defining, costing and 
subsequendy commercialising the resulting products. His concerns and comments are 
referring to tissue-engineered products, but they are equally true for most (if not all) 
Regenerative Medicine therapeutics. He states:
If tissue engineering is all about persuading the body to heal itself, where 
is the product? How is this process regulated and how do we charge for 
this persuasion process in the commercial world? [...] Is the scaffold the 
product, or the growth factor? The bioreactor, or the construct? None of 
these makes commercial sense. A few grams o f a scaffold made o f a 
commodity polymer or ceramic can hardly be sold for thousands of 
euros, and can you really ask a patient to buy back a piece o f their own 
dssue in the form o f a construct? (Williams, 2005: 8 and 9)
According to David Williams (2005) it is essential to find business models for the field 
in order to speed its realisation as a commercially viable sector. In this section, I 
present the views and perceptions of interviewees as they navigate the ‘daunting
124 T he p rev iou sly  T issu e E ngineering (TE) industry is n o w  part o f  th e  b road er R egen era tive  M ed ic in e  in d u stry  ca lled  
R egen M ed .
125 The im p lication s o f  th e  'p rod u ct is th e  p ro cess ' co n ce p tu a lisa tio n  for  th e  regu la tion  o f  ce ll-b a sed  p rod u cts  and  th era p ie s  
are d iscu ssed  in d eta il in C hapter 5.
143
waters’ o f business models. Their experiences seem to be highly dependent on the type 
o f therapy they are developing and the type o f company they are involved with.
It is interesting to mention here that two o f the participants were not comfortable 
talking about business models as they perceived the information to be o f a confidential 
nature. Despite reassuring them about confidentiality and complete anonymity, they 
still chose not to discuss the theme in the detail I would have liked, so I had to limit 
myself to relevant information that they ‘let slip’ while talking about other closely 
related issues.
Interviewee XB talks about the business model followed by his company:
We develop platform technologies at this point. We have two different 
platform technologies, both focus on stem cells. For the longer-term 
business model, on the therapeutic side, the decision was to go for small 
molecule therapeutics that cause regeneration. And that differentiates us 
from all the other stem cell companies, except maybe from one or two 
now entering the same arena. But it is difficult to stay away from the cell
therapy, I think, particularly in the UK, because a lot of the incentives
that are being offered to companies in the Regenerative Medicine field 
are specifically for cell therapy.. .so we may have to revisit that.
(XB, P I/C E O /F ounder of Start-up, 2009)
XB, a founder and chief scientific officer (CSO) o f a (non-academic) RM start-up, 
explains that his company has been focussing on platform stem cell technologies and 
that his team has created a technology that is able to identify small molecules that act
on cells to regenerate them. The research, as XB points out, has been carried out in
collaboration with a large pharmaceutical company and, as he claims, there are not 
many companies that operate in the same ‘area’. He finally explains that although this 
is a ‘viable’ business model at the moment, his company may ‘have to revisit’ the idea 
o f developing cell therapies, as their development seems to be favoured by UK public 
funders.
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Another interviewee, GL (an academic founder), gives his own explanation for the 
choice o f business model:
[Company] ’s model is still cell therapy rather than using tools for drug 
discovery. The reason for that is, really, from an investment point o f view 
it [developing therapies] is risky but it has bigger returns in the end.
(GL, P i/C lin ica l involvem ent/Founder o f Spin-out, 2007)
GL explains that his company has chosen to focus on the therapeutics field, instead o f 
pursuing the ‘drug discovery’ business model, in which stem cell lines are sold to 
institutions and private companies for testing the effectiveness and toxicity of drugs. 
He explains that the reason behind the choice is the potential for bigger returns, 
although he is aware of the increased risk in terms o f attracting (the often risk-averse) 
investment, and surviving the failures, delays, costs and uncertainties o f the field. 
Asked whether he and his co-founder are planning to ‘experiment’ with any other 
business model in the (near or far) future he says:
We are sort o f looking at that. But the problem is that with a small 
company you can become very diffused if you are looking at tools as 
well. And you end up not doing any of that properly, so in a way you 
have to be focussed. I mean, in a way, it’d be nice to support everything 
by tools but that is also tricky for that reason [becoming diffused]. So we 
are not very big, we are just trying to get to the next stage.
(GL, PI/C linical involvem ent/Founder o f Spin-out, 2007)
Although GL admits that their research and, consequently, their business strategy is 
not ‘fixed’ and they are ‘open’ to other commercial Translation models, he stresses the 
fact that the company is a small academic spin-out. This suggests that although, ideally, 
it would be useful to concurrently develop and commercialise ‘drug discovery’ tools 
along with cell therapeutics, in order to secure profits and help fund their long-term 
clinical product development, realistically it is difficult (if not impossible) to do so 
because the company is too small to diversify. He points out that if a small company 
like theirs ‘spreads’ its R&D agenda and hence its resources (financial, human, etc.) 
towards too many goals, it runs the risk o f ‘not doing any of that properly’. Thus, and
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is so often the case, although the financing of a longer-term translational goal by a 
shorter-term one might be desirable, it is not feasible due to challenges o f scale.
A very different perspective is provided by PK who is involved with a medium sized 
RM start-up. According to PK, his company is prepared to follow a variety of 
‘complementary’ business avenues in order to financially sustain an innovative research 
and development trajectory and a ‘rich’ product pipeline. PK comments:
And there isn’t one model, it’s a whole mixed bag from one end of the 
spectrum, making something and selling it yourself, to the other end of 
the spectrum, doing a bit of research and then selling the data. And 
there’s everything in between, you know, taking it to certain stages. And 
what we are probably going to follow, and probably everyone else I 
think, is a mixture [of business models]. You will do some of it [R&D] all 
[by] yourself — hopefully in some products in some regions — and you will 
license out some technologies from riskier products in other regions, and 
everything in between. So the same product could be treated differently 
in different regions. For example, you could sell it yourself in your home 
territory [UK] or in Europe say. You could have a distribution agreement 
in which it’s purely distributed in somewhere like America, and you could 
have a licensing agreement in Asia where your licensing partner’s got to 
get it through their regulatory system.
(PK, P I/C SO /F ounder of Start-up, 2007)
PK  suggests that, eventually, the majority of RM R&D groups and companies will have 
to follow a ‘mixture’ of business models in order to survive. This means that although 
some o f the products will follow the traditional route o f being developed and sold by 
the same firm, other products — usually the ‘risky’ ones — could be licensed out to other 
companies at various stages o f their development. Indeed, ‘mixed bag’ 
commercialisation strategies, like the one described by PK, are often employed by 
biotech companies as a way to gain quick returns on investment from short-term 
projects. In the case o f RM start-up firms, such ‘short-term’ strategies could involve 
development of cell lines (‘bio-tools’) or culture media, and be o f assistance in funding 
longer-term R&D projects such as the development o f cell therapeutics. Interestingly,
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PK associates a product’s ‘commercial viability’ with regulation, by emphasising that 
for certain regions (markets) where the regulatory system is ‘unknown’, it is more 
advisable to license the product so then it is the licensing partner that has to ‘get it 
through their regulatory system’.
In general, during the majority o f the interviews and as business models were discussed 
by bioentrepreneurs, their comments gave the impression o f flexible, ‘uncertain 
structures’ that they could easily change given an adequate reason, whether it is access 
to additional financial resources, a ‘valuable’ collaboration opportunity, a profitable 
deal or sometimes as a desperate last move for economic survival.
In the following quote, LK describes the type o f business model he thinks will 
dominate the RM field in the future:
My vision is that we will have a small number of service companies that 
will be able to get cells from individual patients on behalf o f healthcare 
providers, either manipulating the cells, or put them on the scaffolds they 
buy from somewhere else, or into devices they buy from industry, to 
make these products available to patients. But I think we are going to be 
faced a lot with patient-specific products. And I don’t think we should 
shy away from that, if there is a model for delivering those [patient- 
specific products]. And I am working with a number o f US companies 
on patient-specific products, so I don’t think there is a major problem 
there. Our [Product] has been hugely popular. The American company 
[Name o f Company] bought the patent for that. And [Company] have 
raised an enormous amount of money on the back o f our Phase I/Phase 
II trial. The investors have not been big pharma, but once you start 
seeing the sort o f results we are seeing, I think they will be looking at 
ways of picking that up. In the same way that Pfizer RM has been set up, 
as part of Pfizer.
(LK, P i/C lin ical involvem ent/Founder o f Start-up, 2009)
LK believes that the future of commercial Regenerative Medicine will not be based on 
selling a product but will have to be based on the provision o f a complete service, with
147
the focus on autologous, patient-specific treatments. These treatments might be cell 
therapies, tissue-engineered applications or combinations of cells and medical device, 
but they will all be process driven and will be provided by established service 
centres/companies. LK also gives the example o f one product that has been developed 
by his research team, through a company he co-founded, and has been licensed to a 
clinical-stage biopharmaceutical company which ‘shepherds promising therapies 
through the drug development process’. The product/therapy is based on a three-step 
process during which cells are harvested from a patient, processed accordingly, and 
then reintroduced back into the patient. LK also expresses his certainty that once the 
clinical outcomes prove good enough and satisfactory returns on investment realised, 
then big pharmaceutical firms will start showing more interest. His mentions the case 
o f pharmaceutical giant Pfizer which decided to expand its interest in stem cell 
business and, in the beginning o f 2009, launched a new dedicated R&D unit — Pfizer 
Regenerative Medicine.126
The concept for the provision o f a full service has been quite popular in the RM field 
especially in Europe (Bock et al., 2003). O ther authors have also proposed models 
where the service involves the whole process from cell sourcing to the final treatment 
of the patient, with David Williams, Director of the UK Centre for Tissue Engineering 
at the University of Liverpool, suggesting that ‘it should be possible for one service 
facility to cover a wide range o f conditions, meeting the requirements for economy-of- 
scale’ (Williams, 2005: 9). Greg Bonfiglio, Managing Parmer o f Proteus Venture 
Partners, who is considered a leading authority in RM commercial Translation, is also 
confident about managing to ‘build’ a successful business model around the provision 
of autologous cell therapy services, as opposed to the dominant view of selling an 
allogeneic product.
There’s been a lot of debate as the industry is maturing and we are now 
thinking more seriously about commercialisation issues; there’s been a lot 
o f debate whether you can build a business around autologous cells. I
126 Pfizer's R egen era tive  M ed icin e  P rogram m e has b een  s e t  up to  look for sm all m o le c u le s  th a t are a b le  to  a lter  cell fa te  and  
d ifferen tia tion  during n e u r o g e n e s is  in th e  brain. T he N ew  Y ork-based co m p a n y  p lan n ed  to  sp en d  m o re  th an  $ 1 0 0  m illion on  
th e  n e w  in itiative, w hich  a im ed  to  e m p lo y  70  research ers  b a sed  a t tw o  facilities , in C am bridge, M a ssa ch u setts , and  
C am bridge, UK. The UK grou p  fo c u s e s  on  neural and  sen so r y  d isord ers, w h e r e a s  th e  US te a m  co n c e n tr a te s  on  en d o cr in e  
and cardiac research . In -h ou se  research ers  w ork w ith  b o th  em b ryon ic  an d  ad ult s te m  ce lls . It is u se fu l to  n o te  th o u g h  th a t, 
so  far, Pfizer RM unit is fo c u se d  exc lu sive ly  on  using s te m  cells  t o  d e v e lo p  n ew  m e d ic in es  and  n o t th era p eu tic s.
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believe that you can. Fundamentally the challenge around autologous 
cells is that it is a service product, a service business, it doesn’t scale, cost 
o f goods is very high, and your manufacturing lot is one. Because you are 
building cells for the individual. You are not building cells in a bottle 
which you can sell to millions of people. You take cells from one 
individual and put them back into that individual. Can you build a 
business model around that? A lot o f people have said “No, you can’t” . I 
don’t believe that. I think you can.
(Greg Bonfiglio, Proteus Venture Capital, LRM N, 2009)
It is interesting to record a different view as expressed in a presentation at the London 
Regenerative Medicine Network meeting, by G eoff MacKay, President and CEO at 
Organogenesis Inc. since 2003. Organogenesis Inc. (Canton, Massachusetts) is a 
Regenerative Medicine company that focuses on developing cell therapies that induce 
soft tissue regeneration for multiple applications. The company’s flagship product is 
Apligraf, a human skin equivalent containing living allogeneic cells. Unlike 
technologies where autologous cells are cultured to provide an epidermal layer, 
Apligraf is available without the delay involved in culturing autologous cells and avoids 
the need for skin grafting and consequent creation o f donor/patient wound sites. 
Asked by a member of the audience whether the company is thinking of entering the 
autologous cell therapies field, G eoff MacKay replied:
W e’ve debated this. I think regardless o f which way the field goes a 
company, in my opinion, has to commit, and you kind of have to commit 
early. Because the ‘animal’ that we’ve built is an allogeneic company. And 
so where immunology precludes us from going, we don’t go. So there are 
a number o f applications where having an allogeneic delivery might not 
be appropriate but in the field of wound healing, I think that is perfectly 
appropriate. Our thinking is, you know some o f the comments about 
tumourogenicity, we sort o f view the optimal target product profile in 
this field as — if you can deliver allogeneic cells to kick-start a wound and 
then eventually leave, then you have no oncogenicity issues to even talk 
about [...] What we want it [Apligraf] to do is: we want to put it there, do 
its job, stimulate, transfer a chronic wound into an acute [wound], and
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then go away. And as long as it does that, we are happy. So if there are 
autologous strategies that can increase the efficacious or the safety 
profile, then we’d be in a conundrum. Because we sort o f build this 
whole manufacturing suite to be allogeneic. And its our belief that in this 
particular area an autologous strategy wouldn’t work.
(Geoff McKay, Organogenesis, LRM N, 2009)
MacKay’s account is a testament to the close relationship between the RM product 
under development, the ‘building’ (infrastructure) of the company and, most 
importantly, the potential (of the product) for integration within the healthcare system. 
As MacKay explains, Organogenesis is a company ‘built for a purpose’: to produce 
products that induce soft tissue regeneration. Normally, allogeneic donor-derived cell 
therapies require immunologic compatibility between donor and recipient (patient), 
condemning them to have limited commercial potential. Apligraf, however, belongs to 
a number of products whose development is based on cell types that do not appear to 
give rise to an immune response. As MacKay points out, this is the main reason the 
company is focussing on Apligraf and ‘steers away’ from ‘immunologically’ 
problematic areas. Allogeneic products have also very different manufacturing 
requirements to autologous therapies. In fact, allogeneic (universal) products are 
usually amenable to bulk manufacturing and can take advantage o f technology used to 
produce biotechnology products. It thus makes sense that the company infrastructure 
depends on the product and the processing that it requires.
Another important point in MacKay’s description is the relationship revealed between 
the therapeutic area, type of product, and potential for integration into the healthcare 
system.
If  you are going to cure diabetes we’ll build hospitals for you. But if you 
are going to close a chronic wound, the healthcare system isn’t going to 
change around you. You have to change around the healthcare system 
and that gets you back to allogeneic cells.
(Geoff McKay, Organogenesis, LRM N, 2009)
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In general there is a reluctance to pay for expensive treatments when much less 
expensive treatments exist, even if they provide inferior benefits (Williams, 2005). 
Therefore, the commercial success (or not) of a product, in this case Apligraf, depends 
on the costs of development and production and on the willingness of the healthcare 
system to pay for these services. As implied by MacKay, the fact that Apligraf is one o f 
many options for patients in the wound management field is in a way imposing the 
only profitable model to follow and that is the allogeneic business model. In the last 
quote below, MacKay highlights the importance o f keeping the R&D of the company 
focussed in the emerging and volatile field of RM:
Although we do have some process patents on how to amplify and 
manage the cells in the cell banks, really, the majority o f the IP 
[intellectual property] is on the 3D construct. [...] We call it a technology 
platform simply because, as you can imagine, it can be customised to a 
number of different applications, and like a lot o f RM companies we can 
err on the side of being greedy. We can try to look at what to do and, on 
a white board, you can probably think o f thirty applications [of the 
product] [...] but then we don’t think that we will be able to execute 
them all properly [...] what we try to do is to focus, and we put a few 
filters on our business. The first filter is soft tissue. So, using these 
allogeneic cells, the primary focus of the company is wound healing with 
our flagship [product] being Apligraf.
(Geoff McKay, Organogenesis, at LRM N M eeting, 2009)
Again, it is interesting that despite leading a large and established international 
company, MacKay’s account echoes that of GL, who is talking on behalf o f a small 
academic spin-out. Both MacKay and GL perceive the concurrent development of 
multiple applications as ‘risky’ in terms o f ‘stretching’ resources and not being able to 
execute each and every application ‘properly’.
Summary
There is an understanding in the RM bioentrepreneur community that there must a 
clear commercialisation route and a robust business model behind any cell therapy
151
approach in order for Translation to succeed and returns on investment to be realised. 
According to many authors (including the statements o f interviewees in the previous 
sections on pharma involvement) the industry is still struggling with the identification 
o f a business model that makes economic sense, and the debate is still raging whether a 
personalised, serviced-based (autologous) or an ‘off-the-shelf (allogeneic) type of 
therapy will dominate the RM market. In this section, I highlighted challenges related 
to choice of cell therapy approach and related business model(s). My aim was to show 
how bioentrepreneurs perceive business models in RM, what are the most important 
factors for them to consider, and on what basis they make their strategic decisions 
concerning which research agenda and business models to follow. Indeed, several of 
the informants reveal a preference for the cell therapy development. Among the 
reasons that they give is the potential for larger financial returns and the apparent 
preference of public funders for cell therapeutics (as opposed to stem cell-based tools 
for drug discovery research).
There is also no consensus within the community o f informants over the need to focus 
a company’s R&D. A number of interviewees and other experts (such as 
Organogenesis’ Geoff MacKay) underscore the importance of concentrating financial 
and human resources on a single product. Others are advocating a ‘mixture’ of 
business models in order to increase returns and hence the chances o f the company’s 
survival. Although it is difficult to say which strategy is best overall, it is safe to assume 
that RM bioentrepreneurs are following whichever they think fits best with the type of 
product under development, the scale of their activities and their financial situation.
Intellectual Property as a Foundation for Business
Many respondents mentioned difficulties associated with IP rights, ownership and the 
freedom to operate in the intellectual space, and argued that it is not always clear who 
owns the final product. This uncertainty around intellectual property creates problems 
for principal investigators at various stages of the Translation process, including when 
they are ‘pitching’ candidate pipelines to investors. Below, US-based venture capitalist 
Greg Bonfiglio explains the importance o f protecting IP rights (usually patents) for 
attracting venture capital (VC) financing.
152
A t a minimum you need to be able to establish that you have freedom to 
operate. No venture capitalist is going to invest in a company only to find 
themselves embroiled in an IP lawsuit. You can worry about building 
your bigger fence or your walls later, but you have to show freedom to 
operate otherwise you are not going to get their (i.e. VCs’) attention.
(Greg Bonfiglio, Founder and M anaging Director o f Proteus 
Venture Capital, LRM N, 2008)
According to Bonfiglio, for a regenerative company (whether academic spin-out or 
corporate start-up) to draw investment it must have a business plan that both outlines 
a credible IP strategy capable of protecting the company’s products through issued 
patents127 and at the same time gives the company freedom to operate with regard to 
the product development process. Freedom to operate, which Bonfiglio suggests 
would be the first concern to address, requires a detailed analysis o f all o f the IP in the 
field o f Regenerative Medicine, and a detailed identification of what would interfere 
not only with the company’s freedom to operate in the present but also its ability to 
patent products in the future.128 In the words o f another venture capitalist, Lutz 
Giebel, a venture partner at SV Life Sciences and former founder and CEO of Cythera 
Inc. (a human embryonic stem cell company): ‘for a new stem cell enterprise to get off 
the ground, a well-thought licensing129 and cross-licensing strategy is a must’ (Giebel, 
2005: 799).
Indeed, all the spin-out companies that the interviewees have founded are based on 
some form of intellectual property, either in the form o f a filed or granted patent or 
know-how. For the majority of these companies the tangible product has yet to appear
127 'A p a ten t is a form  o f  in te llec tu a l prop erty  right (IPR) w hich  co n fers  on  th e  h o ld er  th e  right to  e x c lu d e  o th e r s  from  
m aking, using, or com m ercia lis in g  a p a ten ted  in ven tion  w ith o u t prior p erm iss ion  from  th e  in v e n to r /p a te n te e . T he m o st  
im p ortan t part o f  th e  p a ten t is a list o f  cla im s, w hich  are carefully  w ritten  d escr ip tio n s  o f  th e  in ven tion  th a t a lso  d e fin e  th e  
lim its o f  th e  ap p lica tion . T here are  tw o  ty p e s  o f  claim s: p rod uct (or 'c o m p o sitio n  o f  m atter') c la im s and p r o c e ss  cla im s. Of 
th e  tw o , th e  fo rm er  are gen era lly  m o re  p ow erfu l b e c a u se  th e y  co v er  th e  m a tter  itse lf  regard less o f  h o w  it is m a d e , o b ta in ed  
or u sed '. D efin ition  so u rced  from  (Loring & C am pbell, 2 0 0 6 ).
128 P a ten t law s can h elp  p ro m o te  th e  p rogress o f  s c ie n c e  and te ch n o lo g y , by p ro tectin g  th e  financia l in ter es ts  o f  in v en to rs  or  
co m p a n ie s  and  th u s  a llow ing  th e m  to  m ak e th eir  k n o w le d g e  availab le to  th e  public. In ad dition  to  th is  o p e n n e s s  w h ich  can  
fa c ilita te  co llab ora tion  and tru st a m o n g  sc ie n tists , th e r e  are a lso  s o m e  e c o n o m ic  b e n e fits  a s p a ten ts  o ffer  in ce n tiv es  to  
resea rch ers  and  sp o n so rs  (esp ec ia lly  com m ercia l sp o n so rs) to  co n d u c t and fin a n ce  re search , by a llow in g  th e m  to  p rofit from  
it. In fact, p a te n ts  g ran ted  by n ation a l a n d /o r  in tern ation a l p a ten t a g e n c ie s  such  as th e  U nited  S ta te s  P a ten t and  T radem ark  
O ffice (PTO) and  th e  European P a ten t O ffice (EPO) resp ective ly , 'p ro tect' an  in ven tion  for  a sp ec ified  p eriod  (u su ally  2 0  
years), k eep in g  p o ten tia l co m p e tito r s  o u t  o f  a n ich e m ark et w h ile  th e  in ven tor(s) reap  th e  rew ard s o f  th e  in n o v a tio n . In 
o th er  w o rd s, IP su p p o rts  fu tu re  re v e n u e  strea m s and er e c ts  barriers t o  c o m p etitio n .
129 T he co n v en tio n a l ro u te  to  m ark et for  u n iversity  in te llec tu a l p rop erty  (IP) h as b e e n  th rou gh  licen sin g th e  rights to  u se  
tech n o lo g ica l d isco v er ie s  con tro lled  by u n iversity -ow n ed  p a ten ts.
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and the economic value is embedded in the potential application of knowledge.130 Thus 
evaluating these intangible assets (patents) can be an important incentive for positive 
early-stage investment decisions. As Brian Salter (2007) from King’s College clarifies 
in his study of the relationship between patenting human stem cell science and cultural 
politics in Europe, ’the economic significance of patents is further enhanced by the 
need for new forms o f knowledge to compete for attention in an increasingly global 
venture capital market with its own clear demands: investors, often institutional 
investors, make their decision in the light of the patents held by companies. For 
capitalisation of new knowledge to occur, then, investors need to be reassured that the 
value o f the knowledge, as opposed to the value o f the eventual product, is in the 
hands of the company concerned. Investors are likely to be particularly sensitive to the 
patenting issue in high risk areas such as early-stage development of health 
biotechnologies where the science is very new and the potential therapies very distant’ 
(Salter, 2007: 302). In other words, a stem cell company’s quality o f protected IP is 
intimately tied up with the company’s perceived value to investors, partners, and /o r 
acquirers (Barrett & Crawford, 2002).
There are other authors, however, who argue that the biotechnology innovation 
system, based on VC-led exploitation of intellectual property, does not seem to be 
functioning in the case o f US hESC research (nor in European hESC research for that 
matter). According to Olivia Harvey (2009) from the University o f South Wales 
(Sydney), the uncertainty surrounding stem cell patenting in US, European, and Asian 
markets is the reason why the traditional approach o f raising finance based on securing 
intellectual property and selling it on for maximum profits appears to be problematic 
for the stem cell field.
Venture capitalists are trained to ‘watch’ the field (in this case Regenerative Medicine 
academic research), recognise opportunities and pursue investments. In contrast, 
bioentrepreneurs usually come from a life sciences background and are heavily 
immersed in basic and often clinical research. Surprisingly, however, they did not fall 
short on IP knowledge and ‘how to go about’ IP rights. GL’s comment below is short 
and straight to the point:
130 S o m e  o f  th e  co m p a n ie s , h o w e v er , d o  h a v e  p rod u cts on th e  m arket.
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I think you need to patent to protect and also to provide room to work 
in a certain area.
(GL, P i/C lin ica l involvement/Co-founder o f Spin-out, 2007)
In addition to the concerns raised over freedom (or lack of freedom) to operate in the 
field and the consequences for the progress of basic research, interviewees expressed 
concerns over the potential exploitation of generated IP and the ownership o f future 
products. The quote below belongs to a principal investigator who is also co-founder 
o f a Regenerative Medicine academic spin-out.
I f  we are talking about developing a product, then in business circles you 
need to establish who owns the product. And it is not enough to just say 
that X and Y funded the product and kind o f leave it hanging as to who 
owns it.
(NC, PI/C SO /C o-founder of Spin-out, 2007)
One o f the company’s chief aims is to commercialise initially research-grade, and 
subsequently clinical-grade human embryonic stem (hES) cell lines. Research-grade 
lines can be used in basic Regenerative Medicine research while clinical-grade lines can 
be used for the development of clinical applications in humans or drug discovery tools. 
NC underscores the necessity o f establishing ownership during the development o f 
any such product. His comments echo Bonfiglio’s advice on the importance o f 
securing freedom to operate by ‘building fences’ to protect, and thus exploit, the 
company’s innovations. In other words, intellectual property ownership is very 
important to successful innovation models (‘Pharma’, ‘Biotech’ and ‘RegenMed’) and is 
a driving force behind private investment. Investors are looking to capture some or all 
of the economic value associated with an innovation, and intellectual property rights — 
mainly patents — are an important method.
For example, QN reflects on the importance of IP and technology transfer for the 
university, and praises the strategy that has been put in place in order to achieve the 
best possible results.
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One of the things we do really well here is IP, SMEs, spin-out activity, 
licensing, patenting. The University is really good at that. Behind 
Stanford and Cambridge we are the third best at capital actual realisation 
o f SMEs [small and medium enterprises]. We have a strategy and panels 
in place to help drive that programme. And it [IP] is something that is 
discussed very early on. I t’s expensive so you can’t afford to just let it 
drift.
(Q N , PI/Founder of Spin-out, 2009)
Q N ’s increased ‘IP awareness’ stems from the fact that apart from his role as principal 
investigator and co-founder of a spin-out, he is also a leading member o f the 
university’s technology transfer board/committee, which is responsible for the 
commercialisation of life science innovations as well as technologies from other 
academic departments including engineering and physics.
Another founder o f a spin-out talks about the approach she follows with the IP o f her 
team’s work:
I think it [patenting] is a very, very valuable thing to do. As an academic 
researcher I would always think about patenting my research. Even when 
I did not have a company involvement, I would always think when we 
were close to something interesting: “Is that something we should 
patent?” . And many times we decide not to go there because we wouldn’t 
think it would be too interesting. If we thought it was interesting, we 
would then go into the University [Technology Transfer Office (TTO)] 
and get them to look at it [the candidate IP].
(LM, PI/Founder of Spin-out, 2007)
For LM, IP awareness seems to have started long before the establishment o f her 
company. She explains how she deals with ‘interesting’ and ‘patentable’ findings and 
how she might rely on further expert advice form the university’s technology transfer 
office before taking the final decision whether to pursue a patent or not.
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Below, are the comments on IP from the only person (out o f the 14 interviewed) who 
is not involved with a company, although she did think about the possibility o f creating 
a company after ‘intense pressure from the University’. RG describes the way she 
views intellectual property in relation to her work and how that relates to the work o f 
others.
But I would most likely hand it o n ...I  would hand on the intellectual 
property that I have generated. Most likely I would not make any 
money out of it myself, and it would be simply that the work that I 
have done feeds into the choice o f cell, growth medium, scaffold and
how they are combined. So mine would be part o f a much larger
intellectual effort to understand what’s the best way to deliver that 
[product] to the heart [...] I wanted to get patents on things but the 
TTO didn’t agree with me. So I didn’t get anything from that. And 
[there are] other things I know I am never going to get any money 
from and I want to just do, in terms o f patents they [University and 
TTO] are very fussy about the IP then.
(RG, PI, 2009)
RG is an academic principal investigator working on an off-the-shelf product for
cardiac regeneration and she is also very involved in clinical work. Earlier in the
interview, she talked about her aversion to spin-out companies because of colleagues’ 
accounts of the difficulties associated with being involved in the commercialisation o f 
their inventions. O n one hand, she seems quite firm in her choice to ‘hand on’ the 
intellectual property her team generates, that is to license it to someone (to use it 
and /o r develop it further), and on the other hand, she seems uncertain about making a 
personal profit. She implies that if there is any money to be made it will, in all 
probability, go to the university. However, she is aware that her work, possibly in the 
form o f a publication, will ‘feed into’ the work o f other laboratory and clinical teams.
RG ’s knowledge o f IP seems somewhat hazy and uncertain compared to the definite 
answers the rest o f the interviewees gave. It would be safe, I think, to assume that the 
‘negative’ experiences of other PIs-turned-bioentrepreneurs have influenced her 
attitude on ‘spinning-out’, and perhaps in turn, deprived her of the further IP
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knowledge she would have acquired had she gone ahead and founded a spin-out. RG 
is also one of two interviewees to perceive IP as potentially crippling her R&D. In the 
quote below, she reflects on how ‘external’ IPRs might potentially delay or completely 
block the progress of her research.
I think it [IP] inhibits it [research] actually. The patent that’s the most 
nuisance to us is the Geron patent on cardiac myocytes. Although we do 
have a non-profit-making collaborative agreement with them, so we are 
fine with that, but we see that their patent -  if they chose to apply it — 
could inhibit the field gready.
(RG, PI, 2009)
As a research scientist working in the field of cardiac regeneration, RG describes the 
‘Geron patent’ on cardiac myocytes as causing the ‘most nuisance’. Her account is 
consistent with the feeling of threat described by many researchers who are working 
on certain types of hESCs. This threat, although ‘potential’ (as it has not been realised 
yet at least to its ‘full extent’) seems to be big enough to make these investigators feel 
that IP might actually ‘inhibit innovation’ in their field. Even though at the time of the 
interview RG admits to having a non-profit agreement in place that appears to allow 
the smooth operation o f laboratory and product development research, it is clear that 
she still worries about any future changes in the IP landscape that would endanger the 
continuity of her team’s work. Her concerns are not unreasonable, as in the US 
licensing is not compulsory, which means that patent holders have the choice of 
licensing on their own terms or even not to license at all.
Access to hESCs is presently mediated by a political, legal and economic infrastructure 
assembled on the foundation of thee seminal US patents131 (Rabin, 2005). The patents, 
also known as the WARF patents, have been assigned by their inventor, James 
Thomson, to the Wisconsin Alumni Research Foundation (WARF) (Madison, US) and 
are unique in the sense that the patents have claims on the hESCs themselves and not 
just on the method o f deriving them. According to Jeanne Loring (founding Director, 
Center for Regenerative Medicine, Scripps Research Institute, Lajolla, CA) and
131 B e tw een  1 9 9 8  and 2 0 0 6 , th e  U niversity o f  W iscon sin -M ad ison  w a s  aw ard ed  th ree  US p a ten ts: US P aten t N os. 5 ,8 4 3 ,7 8 0 ;  
6 ,2 0 0 ,8 0 6 ;  and 7 ,0 2 9 ,9 1 3 . B efore a m e n d m e n t and re -exam in ation , th e s e  p a ten ts  to g e th e r  c o v e red  th e  en tir e ty  o f  all s te m  
cells , n o  m a tter  h o w  th e  ce lls  w e r e  d erived .
158
Campbell (based at McDermott, Will & Emery, LLP, Washington, DC), by patenting 
ES cells, ‘WARF has the right to exclude everyone else in the United States from 
making, using, selling, offering for sale, or importing any ES cells covered by the 
claims until 2015. The right of exclusivity is rooted in the US Constitution and was 
intended to benefit society by encouraging innovation while discouraging secrecy on 
the part of the inventors’ (Loring & Campbell, 2006: 1716).
RG’s view is shared by many in the field as the WARF patents and their exclusive 
licensing have been the subject of much controversy132 in the literature (Rabin, 2005; 
Regalado & Hamilton, 2006; Taymor et al., 2006).133 The main criticism is that, 
although embryonic stem cells are precisely the type of broadly applicable enabling 
technology that, as general matter, should be licensed non-exclusively in the interest o f 
promoting future research and product development, the Wisconsin Alumni Research 
Foundation (WARF) chose to license exclusively some of the most critical commercial 
rights under the patent (Rai & Eisenberg, 2003). In short, WARF signed a worldwide 
commercial license with Geron (who funded James Thom son’ original research on 
embryonic stem cells) giving it exclusive rights to its patented method for isolating 
primate and human ES cells and for three134 cell lines developed from them: neural 
cells, cardiomyocytes and pancreatic islet cells (it also gave Geron non-exclusive rights 
to develop products and commercialise research products based on other cell 
types) (Pollack, 2002).
Thus, in order to work with these embryonic stem cell technologies, academic 
researchers and commercial companies must negotiate with Geron and agree to 
sharing profits from their applications. N ot surprisingly, the W ARF-Geron licensing 
strategy (and as a result the patenting strategy) led to series o f re-examinations and 
litigations (Fitt, 2009) and prompted intense criticism which stands today. For 
example, Fiona Murray from the Sloan School of Management, who has published 
widely on science commercialisation, IP, innovation and entrepreneurship (particularly 
in the areas o f genomics and Regenerative Medicine) writes: ‘Human embryonic stem 
cells with their potential both for expanding our understanding of biology and for
132 A n oth er  rea so n  w h y  th e  WARF p a ten ts  are con troversia l has to  d o  w ith  th e  m oral and cultural s ign ifican ce  a tta ch ed  to  
th e  h um an  em b ry o . This part o f  th e  con troversy  is b ey o n d  th e  s c o p e  o f  th is  th es is . For articles a d d ressin g  th e  e th ic s  o f  
p a ten tin g  hES cells  s e e  (C hapm an, 2 0 0 9 ) and (Salter, 2 0 0 7 ).
133 A n on ym ou s. (2 0 0 7 ). Burning brid ges. N ature B io tech n o logy , 25 (1 ), 2.
134 T he initial n u m b er  o f  cell ty p e s  und er th e  exc lu sive  licen se  w a s  six, b u t  a fter in te n se  criticism  from  th e  m ed ia  and  
p ressu re  from  th e  NIH, WARF su e d  G eron and m a n a g ed  to  red u ce  th e  cell ty p e s  to  th ree .
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commercial use, represent a classic example of knowledge that should be accessible to 
both academia and industry. Although it ought to be possible to create a stem cell 
market that provides rapid, unconditional access to academic researchers and more 
circumscribed access to commercial scientists, along with higher prices and profit 
sharing, the University of Wisconsin has instead imposed terms and conditions on 
academic researchers that, I believe, represent an encroachment o f private sector 
barriers on the free exchange of ideas’ (Murray, 2007: 2342).
The following respondent revealed a more defiant attitude toward this situation, 
implicidy proposing that the EU establish an alternative to the US patent system:
In Europe you are not allowed to patent an embryonic stem cell. So we 
don’t care about Geron. But for the US market it is an issue. We£ve 
reached our own deals with Kangs College London and University of 
Sheffield to access their cell lines and use them commercially, and while 
we are doing that in Europe we don’t need any further licences.
(XB, P I/C E O /F ounder o f Start-up, 2009)
XB is aware of the IP issues but because o f the already decided market for his 
company’s products, he does not appear to be as concerned as RG. He confirms 
having secured an agreement with the relevant authorities in the UK in order to work 
lawfully with the necessary cells/lines. The company’s future products, he says, are 
going to be legal as long as they are marketed in the EU. So far, the US is the only 
country to have allowed hESCs to be so broadly patented, and as a result patents rights 
can only be enforced in the US. However, ‘hESCs and any derivatives/products made 
in another country, immediately become subject to the US patent law if they are 
imported into the United States’ (Loring & Campbell, 2006: 1716). Unlike the US 
Patent and Trademark Office which has granted many patents, including patents on 
culture methods, differentiated cells derived from hESCs cells, and even hESCs per se, 
the European Patent Office (EPO) has not granted a single patent that makes direct 
hESCs claims (Porter et al., 2006).
In short, not all respondents have the same awareness regarding IP rights. There seems 
to be a connection between IP awareness, the professional roles held by the
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respondents, the type of product they are developing and also the university where 
those respondents are based. People who have founded companies are very aware of 
the IP ‘nuts and bolts’, and the majority admitted they were keen to spot any 
opportunity and look into it, perhaps even seek the advice of the university’s 
technology transfer office (TTO). The bioentrepreneur who was also member o f the 
university’s commercialisation committee, displayed, not surprisingly, the highest 
awareness of all the informants, and was very keen to discuss ‘IP opportunities’. 
Informants were also familiar with the potentially ‘threatening’ patenting strategies of 
others that could seriously affect their ability to do research, and the two people with 
products nearing the market were very familiar with the limitations and ‘freedoms’ of 
their potential market’s IP landscape.
The cost associated with patenting was also discussed by almost all interviewees. 
Individual international patents can run into the thousands o f pounds and returns will 
only be realised if the patent is licensed or, in case of a company (spin-out or start-up), 
if the product is successfully developed and commercialised. One informant, GL, 
comments:
The problem with patenting is that it costs a lot of money. So [Company] 
had to make decisions on which patents it is definitely going to hold on 
to and which others it might have to drop because o f the cost o f putting 
applications through.
(GL, P i/C lin ica l involvem ent/Co-founder o f Spin-out, 2007)
Below, LM talks about the need of small and cash-starved spin-outs to make important 
decisions on which patents they are going to pursue and which they will just have to 
forgo.
From a company perspective the issues are slightly different. I f  you were 
a company with plenty of money to spend you would patent a lot more 
things than you would as an academic. Because quite quickly it comes 
down to money, not lack o f ideas. But you haven’t got the money. You 
may set up quite a few patents that couple of years down the line when
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they become expensive you may have to let them go down. Scientifically 
they may be fine, but you just can’t keep them going commercially.
[...]So a university can’t afford to follow through on patents. They can 
generally just get you to the patent filing, but if  you haven’t been able to 
find the funding — which usually means a commercial interest — to 
support the patent a few years down the line, then you have to let it go 
down. I don’t really know on the academic front whether UK universities 
are less able to support patents than, say, American or other European, 
but that might be the case. Small spin-outs will lose out on patenting 
opportunities as they haven’t got the cash.
(LM, PI/Founder of Spin-out, 2007)
LM’s comments confirm, once again, the significance o f IP for attracting funding and 
how the cost o f patenting can burden small firms. As she explains, big companies in 
the field have better chance o f protecting their ideas simply because they can afford to 
do it. For academic spin-outs or small corporate start-ups on the other hand, it is more 
difficult. Capital in small firms is scarce and hence the need arises to prioritise between 
which patents are absolutely crucial and which could be ‘left out’ from the firm’s 
patent portfolio. The university will usually help with the initial patent filling 
application but then external financing is essential in order to continue supporting the 
patents. In short, LM, from her firm-founding experience, captures the difference 
between big and small firms and suggests that the latter are clearly disadvantaged when 
it comes to protecting their IP as they ‘haven’t got the cash’.
A few informants mentioned patent pooling as a ‘desirable’ way to facilitate access to 
IP and reduce cost and inefficiencies. NC gives his view below:
I would be in favour of the concept o f patent pooling where the 
technology is an underpinning technology that would be used by many.
There are aspects associated, say, with cell culture generally — to maintain 
the cells or devices to facilitate their expansion, purification, 
differentiation — one could rightly put under the banner o f being suitable 
to be collected as a pool so that, you know, private entities can 
reasonably access that to [be able to] work. And that just benefits
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everyone. By contrast, I think there are other technologies which, the 
closer they are to actually creating a tangible product that could plug into 
other technologies, [for which] the proper thing is to provide some type 
o f protection in exchange for the investment that has been made to 
develop them. Bottom-line, none of this technology gets to the bedside 
unless there is private investment. So we need to strike a balance [on] 
how we get there.
(NC, P I/C SO /F ounder of Spin-out, 2007)
It is often the case that patents in biomedicine, perhaps even more so in Regenerative 
Medicine, cover complementary technologies. For example: a product, a method of 
obtaining or manufacturing the product, and a method of using/delivering the 
product. In such cases where complementary technologies are owned by different 
patentees, in order to use the technology (and avoid infringement), one is required to 
obtain licenses from each patent owner (Esmond et al., 2006). This can be confusing, 
time consuming and expensive.135 So instead o f struggling with the ‘foggy5 and 
‘dispersed5 IP landscape, complementary technologies can be ‘integrated5 through the 
structuring and implementation of patent pools. A patent pool is an arrangement in 
which one or more patent owners agree to license certain of their patents to one 
another and /or third parties (Ebersole et al., 2005). NC suggests structuring and 
implementing patent pools for what he calls ‘underpinning technologies5 that could be 
used freely by many, while reserving the ‘normal5 patenting for cases where there is a 
tangible product.
Summary
Several respondents mentioned difficulties associated with IPRs, ownership and the 
freedom to operate. Properly evaluating and protecting the ‘intangible5 IP assets is, 
according to the interviewees, of paramount importance for small ‘high-tech5 and 
early-stage companies such as the RM spin-outs and small start-ups that dominate the 
UK RegenMed industry, as they can represent an attractive investment opportunity for 
external sponsors.
135 A n oth er  re lev a n t con cern  is th a t  if o n e  o f  p a ten t h o ld er  d ec id e s  n o t to  licen se  at all (or req u ires an u n rea so n a b ly  high  
price), th e n  th is  will b lock  th e  p ro g ress  o f  re search  and h in d er la ter d isco v er ie s . This is e sp ec ia lly  tru e  for  'b reakth rou gh ' 
p a ten ts  w ith  very  broad  c la im s th a t th rea t to  d o m in a te  m arkets.
163
Another point that has emerged in this section is that IP awareness varies among 
bioentrepreneurs, and it appears to be associated with a bioentrepreneur’s combination 
of roles as well as the type(s) of products s/he is developing. For example, individuals 
working on hESCs are wary of any potential future changes in the WARF IP policies 
and are concerned about the effects these changes could have on the progress o f their 
own research. Furthermore, interviewees whose products are nearing 
commercialisation are familiar with the ‘legal’ complications that might arise while 
promoting their products in different markets (countries).
Finally, the high cost o f patent applications has been repeatedly cited as the main 
reason for bioentrepreneurs not pursuing all the patents that would be ‘advisable’ to 
pursue. As many informants explained, applying for patents is perhaps easier in the 
case o f medium sized start-ups who have the financial resources to ‘follow patents 
though’, as opposed to ‘cash-starved’ spin-outs (or small start-ups) that are instead 
‘forced’ to prioritise their IP and only ‘protect’ what they consider absolutely necessary.
Chapter Conclusion
In this chapter, I have attempted to chart some o f the key factors identified by the 
participants in this study, concerning the funding o f UK’s Regenerative Medicine 
Translational Research. This chapter thus outlines the significant obstacles to 
successful Translation as they are perceived and experienced by a ‘critical’ and ‘central’ 
group of actors, namely RM bioentrepreneurs in the UK.
In the first section o f this chapter, I examined how bioentrepreneurs experience the 
lack of translational funds: to what do they attribute this shortfall for what is widely 
perceived to be one of the highest priority arenas o f biomedical innovation? How in 
their opinion might the situation be rectified?
The account I have offered has drawn on the testimonies o f bioentrepreneurs who 
have had their applications to fund translational projects repeatedly rejected by 
research councils and charities, despite these sponsors advocating a commitment to 
Translational Research in the UK. Judging from the investigators’ accounts, the 
funding pathways are unclear and strewn with obstacles. While funding for hypothesis-
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based, basic research seems easier to secure, projects that are pursuing high-risk 
Translational Research are perceived as difficult to fund. Even in cases o f earmarked 
funds such as the MRC translational awards, the emphasis on the practice of reverse 
Translation is perceived as favouring, once again, basic research. Recommendations to 
rectify the situation include combining the two main streams o f public funding for 
basic and applied research (i.e. research council and NHS funds) to promote 
integration of skills and collaboration between basic scientists and clinicians, thus 
facilitating Translational Research.
In the second and third sections, I considered the views and experiences o f 
bioentrepreneurs with the only two other alternatives sources o f funds (in the absence 
o f public funding), namely venture capital or support from industry (pharma/ biotech 
investments). As I have shown, venture capital was characterised as a ‘later-stage’ 
source with most bioentrepreneurs reluctant to pursue it. There is also evidence that 
relates this reluctance to past, rushed and disorganised attempts o f colleagues to spin­
out VC-backed companies that eventually led to failures and have ‘troubled’ the VC 
community.
Like venture capital, until recently, big pharma involvement was also perceived as 
improbable and fraught with difficulties. The main reason behind this perception, 
according to bioentrepreneurs, is that large established pharma firms have traditionally 
been operating a business model based on small molecule production, a type of 
product that differs markedly from the development and production o f cell 
therapeutics. However, a recent increase in interest, evident through the 
announcement o f partnerships, investments and other direct activities in the field o f 
RM, have led bioentrepreneurs to believe that industry funding is becoming an 
increasing possibility. With the focus o f pharma on the development o f drug discovery 
tools instead o f cell therapeutics, however, many investigators seem willing to 
reconsider research agendas and ‘reconstruct’ business models in order to become 
more ‘attractive’ (possibly to the detriment of cell therapy development approaches).
In the fourth section, I explored how bioentrepreneurs understand and conceptualise 
the much-debated ‘viable’ RM business model in order to attract the attention o f the 
various funders. As Translation struggles from the lack of public funding, increasingly
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conservative venture capitalists and ‘cautious’, ‘risk-averse’ industry, bioentrepreneurs 
try to push forward untested forms o f therapy that everyone knows will be expensive 
to produce and implement. From the data, it is evident that the main ‘problem’ with 
identifying a profitable business model is the diversity o f products, processes and 
therapeutic areas that UK bioentrepreneurs work on. This makes the existence o f one 
‘ideal’ model improbable. It is notable that in the case o f Apligraf as described by 
MacKay the successful business model operated by Organogenesis is based on the 
absence of immunogenicity in the case o f the specific cells used (which supports the 
rationale of an off-the-self product) and the cost and effectiveness of other 
competitive therapies on offer for the same condition.
In the final section I examined intellectual property and the importance 
bioentrepreneurs attribute to it as a foundation for creating a ‘translational’ business. 
Clarity o f ownership and freedom to operate are the two most important features o f IP 
identified by bioentrepreneurs. In general IP awareness varies among investigators and 
is also relevant to their own scientific activities.136 There is also evidence that 
bioentrepreneurs perceive the cost o f IP as limiting, with two informants proposing 
patent pooling as a way to reduce costs.
As a whole, these observations contradict Jane Maienschein and colleagues’ (2008) 
portrayal of a bioentrepreneurial drive to Translation that is potentially restricting basic 
research agendas. To the contrary, as mentioned above, it appears to many UK 
bioentrepreneurs that basic research is easier to fund than Translation. At the same 
time, Translation still ‘looks like’ basic research to big pharma and to many venture 
capitalists.
As a result, and in a manner that is consistent with the following chapters, the picture 
that emerges o f both small-scale and successful ‘breakthrough’ bioentrepreneurs in the 
RM area is that they face a series o f funding challenges that require them constantly to 
balance conflicting agendas. Because o f their small scale they must be rigorously 
focussed on a limited — or even a single — R&D trajectory, and yet they must be 
flexible enough to change and adapt — often quickly — to new opportunities that arise. 
At the same time, in order to finance their research and product development, they
136 A ctiv ities m igh t in clu d e a variety  o f  p ro fess io n a l ro les, ty p e s  o f  ce lls /p r o d u c ts  th e y  w ork  w ith , m ark ets th e y  are pursu ing.
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have to simultaneously be monitoring on several different fronts. They must be 
working both toward their clinical ‘catch’, and backwards to protect a patent trail 
behind them. They must be focussed on an immediate, local market, and yet also bear 
in mind the need potentially to expand that market considerably in the future. Above 
all, they must be monitoring — in addition to funding opportunities and strategies — the 
co-dependent changes affecting regulation and cross-disciplinary (local, national and 
international) collaborations. It is to these two areas that the next chapters now turn.
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Chapter 5
The Art o f Regulation
Introduction
Regenerative Medicine science and technology is highly varied and complex in terms of 
the different materials used and their potential therapeutic applications. The variety of 
emerging technologies being developed, coupled with their ‘novel’ and ‘uncertain’ 
nature and the pressure for Translation, pose a significant challenge for institutions 
responsible for their regulation and governance, as well as innovators and other key 
stakeholders. Indeed, quite different approaches have been taken by policy and 
regulatory authorities in national and international contexts.
So far, the largest part o f the (scientific, legal and social science) literature has focussed 
on what is called ‘upstream’ regulation — that is regulation of fundamental Regenerative 
Medicine research. It is important to emphasise here that my focus in this chapter (and 
thesis in general) is on ‘downstream regulation’ — that is regulation during product 
(prototype) development and during the critical step o f beginning clinical 
experimentation (in humans).
As half of the interviews were conducted in late 2007, before the seminal ATMP 
regulation came into force,137 and half were conducted between October and 
December 2009, when the implementation of the ATMP regulation was ‘in full swing’, 
I had the chance to see how the experience of the field is changing — from confusion 
and widespread uncertainty to the flexible and highly variable interpretation of the 
long-awaited ‘new regulation’.
In this chapter, I explore the experience of UK bioentrepreneurs in dealing with 
‘downstream’ regulation of novel Regenerative Medicine therapeutics in the context of 
uncertainty. The following section briefly describes the product/therapy classificatory 
categories and the evolving regulatory landscape before and during the period of data
137 The A dvan ced  Therapy M edicinal Products (ATMP) R egulation  ca m e  in to  fo rce  in D e c em b er  2 0 0 7  and b e c a m e  e ffe c t iv e  in 
D ecem b er  2 0 0 8 .
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collection. In other words, it provides the context for understanding the implications 
o f regulation for bioentrepreneurs’ attempts at Translation. Section 2 examines how 
bioentrepreneurs deal with uncertainty over potential regulatory routes and regulatory 
agency oversight. Section 3 explores the collaboration between regulators and 
bioentrepreneurs, focussing in particular on the claims o f interviewees about helping to 
shape emerging regulation. In section 4, the bioentrepreneurs’ efforts to comply with 
regulatory guidelines, the ‘cost’ of compliance, as well as the informants’ views on the 
transition to a whole new ‘promising’ and ‘long-awaited’ regulatory infrastructure are 
discussed and analysed. Finally, section 5, considers the challenges bioentrepreneurs 
face depending on the nature of their products (i.e. autologous or allogeneic) and the 
relationship between regulation, product testing and the (unconvincing) ‘truth’ o f the 
animal models.
Classifying Therapeutics: From the Existing to the Novel 
According to the legal framework that exists in most developed countries, the 
regulatory route that a medical product follows, from the laboratory up until its 
approval for clinical trials and marketing authorisation, will depend on how the 
product is classified under the relevant legislation. The traditional categories o f 
therapeutic products include drugs (medicines or medicinal products), medical devices, 
and, in some jurisdictions, biological products (biologies).
In general, before a new medical product can be released, it has to be approved for 
market release by the relevant Regulatory Authority. In the US, for example, the Food 
and Drug Administration (FDA) is the regulatory body responsible for overseeing 
healthcare products. In the UK, it is the Medicines and Healthcare Products 
Regulatory Agency (MHRA) — a government body which was set up in 2003 to bring 
together the functions o f the Medicines Control Agency (MCA) and the Medical 
Devices Agency (MDA). So not surprisingly, until recently, medical products were 
regulated either as medicinal products (such as drugs) or medical devices (for example 
pacemakers).
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However, with the emergence of advanced therapy products (that is gene therapy, cell- 
based and tissue-engineered products), the crucial question was posed (in the EU):138 
should they be required to meet the criteria of the Medicinal Product Directive (MPD) 
or the less demanding139 Medical Devices Directive (MDD)? The majority o f 
Regenerative Medicine products, however, fell between these two categories. It soon 
became obvious that neither of the two product types was a good fit for the ‘emerging’ 
technologies and it might be necessary to produce new European legislation to 
adequately cover them.
Because o f their borderline nature, cell and tissue-based products raised a number o f 
concerns for the regulators, most importandy the risk o f contamination and disease 
transmission. The fact that many o f these products contain viable cells means that they 
cannot be sterilised using conventional sterilisation techniques, hence the need arises 
to ‘quality assure’ the whole production process from the provenance of the raw 
materials to the point of product application. In the presence of such risks and 
concerns and in the absence o f appropriate and Europe-wide legislation, several 
countries started developing their own approaches to regulation. The resulting 
regulatory divergence and market fragmentation across Member States has not only 
hampered the development of the TE and subsequently Regenerative Medicine 
industry (RegenMed), but also made availability of existing products in different 
European countries very patchy.
In response to the various voices and calls for review of the regulatory system and its 
harmonisation, in 2002, the European Commission (Directorate General Enterprise) 
launched a public consultation to assess the need for a legislative framework for 
human tissue engineering and tissue-engineered products. The consultation brought to 
light the numerous difficulties in categorising new products and highlighted a broad 
consensus (in particular amongst industry and governments) in favour o f a detailed,
138 In co n tra st to  th e  EU, in th e  US, th e  FDA had a n tic ip a ted  th e  n e e d  for n e w  regu latory  p a th w ays th a t are a b le  to  d eal w ith  
prod u cts th a t in vo lve  living ce lls  and  are d ifferen t from  co n v en tio n a l p h arm aceu tica ls  and  m ed ica l d ev ic e s . C o n seq u en tly , it 
s e t  up n ew  'regu la tory  rou tes' for  th e  so  ca lled  'b io log ies' and 'hybrid' (com b in a tion ) p rod u cts, in clud in g ce ll-b a sed  
th era p ie s  and  t is su e -e n g in e e r e d  p rod u cts. In 1 9 9 7 , th e  FDA re lea sed  th e  P rop osed  A pproach  to  R egulation  o f  Cellular and  
T issu e-B ased  P rodu cts w ith  th e  a im  o f  estab lish in g  a n ew , c o m p reh en s iv e  regu la tion . T he regu latory  stru ctu re o f  th e  
'P rop osed  A pproach' is tie red  and  risk-based  in th a t p rod u cts th o u g h t to  p resen t g rea ter  risk r e ce iv e  m o re  regu la tory  
oversigh t, requ ire m o re  e x te n s iv e  con tro ls  in m an ufacturin g  and  clinical s tu d ie s , an d  m o re  rigorous p rod u ct  
ch aracterisa tion . P rodu cts th o u g h t to  p resen t le ss  risk are str in gen tly  regu la ted , b ut le ss  so  th an  h igher-risk  p rod ucts.
139 R egulating a p rod u ct u n d er th e  m ed ica l d e v ic e s  regu la tion s is g en era lly  co n s id ered  le ss  b u r d e n so m e  b e c a u se , unlike  
m ed ic in es , m ed ical d ev ic e s  are n o t au tom atica lly  su b jec t to  a clinical trial. This is b e c a u s e  it is o f te n  im practical and  
u n n ec essa r y  to  t e s t  th e m  in th is  w a y  and sa fe ty  and p erform an ce  can b e  b a sed  on  lab oratory te s ts .
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harmonised EU regulatory framework that will specifically and comprehensively 
address both the existing and any future advanced therapy products. In particular, 
participants stressed the need for the new initiative to include these products which at 
the time of the consultation period (2002-2004) did not fall clearly or entirely within 
the scope of existing legislation. These included products derived from genes and cells 
which have had a poor working definition (mostly classified as pharmaceuticals) and 
tissue-engineered products (TEPs)140 that were not explicidy covered by the existing 
legal framework and fell in a regulatory gap somewhere in between Directive 
93 /42 /E E C  on Medical Devices and Directive 2001/8 3 /E C  on Medicinal Products. 
The consultation paper states:
At present, the lack o f a comprehensive, clear and uniform regulatory 
framework creates legal uncertainties and leads to a fragmentation o f the 
tissue engineering market: similar products are regulated differendy in the 
various Member States, different safety requirements may apply and 
patients can be denied access to products which are readily available in 
other countries.
(European Commission Consultation Paper, 2004: 3)141
Responding to industry concerns over lack o f harmonisation in the cell-based and 
tissue-based therapeutics arena, the European Commission142 began its first step 
towards addressing the situation by developing a new core regulation — Regulation 
(EC) No 1394/2007143 — the Advanced Therapy Medicinal Products regulation (in this 
thesis referred to as ‘ATMP regulation’). According to the regulation, an Advanced 
Therapy Medicinal Product (ATMP) is defined as ‘a gene therapy, somatic cell therapy 
or tissue engineered product (TEP) (or combinations thereof), that claims to have a
140 G en e  th era p y  and so m a tic  cell th era p y  p rod u cts had prev iously  b een  in clu d ed  in an a m e n d e d  a n n ex  to  th e  m ain  D irective  
on  M edicinal P rodu cts (2 0 0 1 /8 3 /E C ), b ut th e  ATMP regulation  (1 3 9 4 /2 0 0 7 )  is th e  first in stru m en t to  sp ecifica lly  cover  
T issu e-E n gin eered  P rodu cts (TEPs).
141 P roposal for  a H arm onised  R egu latory Fram ew ork on  H um an t is su e  E n gin eered  Produ cts, E uropean C om m ission , DG 
E nterprise C onsu lta tion  Paper, B russels, 6 April 2 0 0 4 . A vailab le at:
h ttp ://e c .e u r o p a .e u /h e a lth /f i le s /a d v th e r a p ie s /d o c s /c o n su lta t io n _ p a p e r -2 0 0 8 -0 7 -2 2 _ e n .p d f  
(A ccessed  in June 2 0 1 0 ).
142 A n u m b er o f  in tern ation a l in itia tives  such  as th e  International S o c ie ty  for  S tem  Cell R esearch  (ISSCR) and  th e  
International S tem  Cell Forum  are a lso  w orking on  h arm on isa tion  p r o c e sse s . T h ese  in itia tives m ain ly  w ork  to w a rd s  th e  
h arm on isa tion  o f  tech n ica l stan d ard s and  sa fe ty  req u irem en ts  a s a w a y  to  h elp  in tern a tion a l co llab ora tion  d e s p ite  th e  
'regu la tory  patch w ork' p r esen ted  by n ation a l research  p o lic ies. The m ajority o f  th e s e  h arm on isa tion  a tte m p ts  a re  fo cu sed  
on  d ev e lo p in g  sc ien tific  and  eth ica l stan d ard s and p ractices fo r  th e  co n d u c t and  g o v er n a n ce  o f  b asic R eg en era tiv e  M ed icin e  
research . T he e x c ep tio n  is th e  r e le a se  in 2 0 0 8  o f  th e  by ISSCR o f  th e  G u id elin es for th e  Clinical T ranslation  o f  S tem  Cells.
143 EC, R egulation  (EC) N o 1 3 9 4  o f  th e  E uropean P arliam ent and  o f  th e  Council on  a d van ced  th era p y  m ed ic in a l p ro d u cts  and  
a m en d in g  D irective 2 0 0 1 /8 3 /E C  an d  R egulation  (EC) No 7 2 6 /2 0 0 4 , [2007 ] O.J. L 3 2 4 /1 2 1 .
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medicinal function’. By clearly defining these three groups of products and laying 
down ‘specific rules concerning the authorisation, supervision and pharmaco-vigilance 
o f advanced therapy medicinal products’, the new regulation aims to provide clarity to 
stakeholders (oversight agencies, regulators, academics and companies that work in the 
area) on issues related to approvals, labelling, monitoring, and risk management; ensure 
a high level o f health protection; provide legal certainty, harmonise market access and 
improve availability for European patients, as well as foster competitiveness with 
pharmaceutical and biotechnology industry outside the EU. In short, the regulation 
which entered into force in December 2007 and became effective in December 2008, 
requires anybody wishing to market an ATMP within the EU to seek authorisation 
from the EMA (European Medicines Agency, formerly EMEA) and lays the 
foundation for a harmonised regulatory regime applicable for all Member States in the 
European community.
It is useful to also clarify here the relationship between the ATMP regulation and the 
EU Tissue and Cells Directive (EU TCD). In the UK, use o f human cells and tissue is 
regulated by the Human Tissue Authority (HTA) under the EU TCD, the first attempt 
to establish a harmonised approach to the regulation o f tissues and cells across 
Europe. The EU TCD is made up o f three Directives: the parent Directive 
(2004/23/EC) which provides the framework legislation and two technical Directives 
(2006/17/EC and 2006/86/EC), which provide the detailed requirements o f the EU 
TCD. The Directives set a benchmark for the standards144 that must be met when 
carrying out any activity involving tissues and cells for human application (patient 
treatment). The three Directives were fully implemented into UK law on 5 July 
2007,145 via the Human Tissue Regulations 2007 (also known as the Quality and Safety 
for Human Application or Q&S Regulations).
In 2007, the Human Tissue Authority’s (HTA) remit was extended by the Q&S 
Regulations to include the regulation of procurement, testing, processing, storage,
144 The EU T issu e and Cells D irective s e t s  o u t  th e  stan d ard s for  th e  q ua lity  and  sa fe ty  o f  th e  d o n a tio n , p ro cu rem en t, te s tin g ,  
p rocessin g , p reserv a tio n , s to ra g e  and  sa fe ty  o f  h um an  t is s u e s  and ce lls . It co v e rs  t is s u e s  such  a s  b o n e  m arrow , sp erm , eg g s ,  
em b ry o s, um bilical cord b lood , b o n e  and h eart v a lves. It ex c lu d e s  b lo o d , b lood  p rod u cts and organ s, w hich  are co v e red  by 
o th e r  E uropean  leg isla tion .
145 The D irective ca m e  in to  fo rce  in April 2 0 0 4  and w a s  to  b e fully im p le m en ted  in to UK law  by 7 April 2 0 0 6 . The co m p le tio n  
o f  th e  im p le m en ta tio n  p ro ce ss , h o w e v er , w a s  d e la y e d , d u e  to  th e  fa c t th a t  th e  D irective w a s  d e p e n d e n t  on  tw o  tech n ica l 
D irectives w h ich  w e r e  still b e in g  d rafted  by th e  la te  su m m e r  o f  2 0 0 6 . At th e  tim e , th e  UK D ep a rtm en t o f  H ealth  (DoH) 
d ec id e d  to  tra n sp o se  th e  D irective (and its tw o  acco m p a n y in g  tech n ica l D irectives) th rou gh  tw o  s e ts  o f  R egu lation s th a t will 
am en d  th e  H um an T issu e A ct 2 0 0 4  and th e  H um an Fertilisation and E m b ryology A ct 1 9 9 0 .
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distribution and im port/export of tissues and cells for human application 
(establishments where these activities are carried out would normally need a license). 
The HTA is still (since 1997) the body responsible for ensuring that human cells or 
tissue used in ATMPs are donated, procured, and tested in an appropriate manner. 
However, the subsequent stages o f clinical research involving ATMPs, including the 
manufacture, storage and distribution o f products would be regulated (and licensed) by 
the MHRA.
Summary
In this section, I have provided an overview o f the changing regulatory landscape in 
the field of Regenerative Medicine and the challenges that the ‘emerging technologies’ 
have posed to both developers/companies and regulators. Indeed, the majority o f RM 
products contain living cells and thus do not fit in the category o f medicinal products 
and cannot be regulated as a medical device either. However, with the increasing 
presence of these combination RM products in the EU R&D agendas, most Member 
States proceeded to develop and adopt variable national policies in order to fill the 
perceived gap between medical devices and drugs. The main reason behind the policies 
was to address important safety issues including the risk o f infection, risk of cancer 
formation and rejection risk. It soon became apparent though, that the resulting 
‘patchwork’ o f national guidelines made the development o f ‘advanced products’ for 
the common EU market difficult. After a long process o f negotiations and drafting, 
the EU introduced its new ATMP regulation which became effective in December 
2008 and covers all products under the ATMP definition.
In this transition phase (roughly between 2003 to date [2010]), from the old, 
inadequate regulation to the novel ATMP guidelines (and their ‘in-progress’ 
implementation), it is particularly important that people involved with the development 
of such ‘advanced therapies’, be able to adapt to the fragmented situation while also 
preparing for future requirements. It is in the next section that I examine this ability of 
UK bioentrepreneurs by focussing on the way my respondents perceive and deal with 
the regulatory uncertainty during the clinical translation of their research findings. The 
majority of interviewees admit to feelings o f uncertainty and frustration over the
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classification of their products as well as confusion over disparities and overlaps in the 
regulatory oversight o f the relevant regulatory authorities.
The Era o f Uncertainty
As noted at the beginning o f this chapter, half o f the interviews were conducted 
between October and December 2007, just before the ATMP regulation came into 
force (December 2007). This first wave o f interviews suggested that all the informants 
were confused and dismayed about product/therapy classification, regulatory agency 
jurisdiction and responsibilities. At the same time, the interviewees also shared a 
somewhat conservative optimism with regard to the upcoming regulation (ATMP).
When asked about the challenges of working with regulators and classifying their 
products for regulatory purposes, most o f  the interviewees had a version of the view 
that is nicely illustrated by RB’s answer below:
They have to put you into one box or another. And the box is medicine 
or device. And everybody knows that for the majority o f these [novel 
Regenerative Medicine products] neither o f those categories are a good 
fit.
(RB, PI/Founder o f Spin-out, 2007)
This perception of ‘category confusion’ is characteristic of the EU context where, as 
mentioned earlier, tissue-engineered (hybrid/combination) products should be ‘made 
to fit’ into one of the two existing categories: drug or device (Faulkner et al., 2003). 
LM, a principal investigator (PI) in the wound care field and founder o f a Regenerative 
Medicine spin-out, also conveys the uncertainty o f bioentrepreneurs over 
commercialisation and regulatory strategies for the regenerative therapeutics field.
Everybody waits for everybody else to make a decision. So when you 
write a grant they will say “How are you going to commercialise this?
What regulatory route you are going to take?” And you think “I wish I 
knew”. So it is not a culture in which it is easy to move things forward 
clinically. (LM, PI/Founder of Spin-out, 2007)
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The above extract confirms not only the tight relationship between regulation and the 
commercialisation trajectory but, more importantly, the significance o f ‘early on’ 
product classification for a research project’s ‘financial viability’. Under the pressure 
for Translation and ‘outcomes’, most (translational) grant applications in the UK 
require applicants to include this kind of information in their application form, but as 
LM admits, the overall culture is not being very accommodating. What she really 
implies is that at an early Translation phase neither the regulators nor the potential 
funders are being helpful as ‘everybody waits for everybody else to make a decision’.
As an example, below is part of the application guidelines for those seeking to apply 
for the Wellcome Trust Translation Awards which ‘are response-mode funding 
designed to bridge the funding gap in the commercialisation o f new technologies in the 
biomedical area’:146
Commercialisation Strategy
What are the strategy and plans for attainment o f a commercial exit, and 
how will they be implemented? What is the rationale behind this route?
W hat are the outputs going to be (e.g. platform technology description, 
product descriptions)? Are there any clinical, manufacturing, regulatory 
or marketing issues known that may affect the ability to deliver the 
product to market?
Current or Downstream Regulatory Considerations or Risks
Evidence that the regulatory requirements are known and being
accounted for in the product development
(Wellcome Trust Translation Awards, Application Guidelines)147
It is clear from the type of information required by the application form, that the bar 
for funding is very high. With both public and private investors looking for rapid 
liquidity to arise from successful clinical and commercial projects, issues such as 
commercialisation and regulatory strategy are deemed critically important and the need
146 C and id ate P rojects for  th e  W ellco m e  Trust T ranslation A w ards m u st ad d r ess  an u n m e t n e e d  in h ea lth care  or in ap plied  
m ed ica l research , o ffer  a p o ten tia l n ew  so lu tio n , and h a v e  a realistic ex p e c ta t io n  th a t th e  in n ova tion  will b e  d e v e lo p e d  
fu rth er by th e  m arket. M ore in form ation  is available at:
h ttp ://w w w .w e llco m e .a c .u k /F u n d in g /T ec h n o lo g y -tr a n sfer /A w a r d s /T r a n s la tio n -A w a rd s/in d ex .h tm
147 T he A pplication  G u id elin es d o c u m e n t is availab le at:
h ttp ://w w w .w e llco m e .a c .u k /F u n d in g /T ec h n o lo g y -tr a n sfer /A w a r d s /T r a n s la tio n -A w a rd s/in d ex .h tm  
(A ccessed  M ay 2 0 1 0 ).
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to be considered early in a project’s life is proved by their inclusion in the grant 
application forms.
To understand bioentrepreneurs’ frustration with the ‘confusing’ classificatory and 
regulatory regimes, it is necessary to explain that how a product gets classified (under 
the ‘two tier’ system) has crucial implications for its whole journey from the laboratory 
to the clinic and market. For example, products that are classified as medical devices 
and are reviewed as such will have to satisfy the safety and efficacy requirements of the 
Medical Devices Directive (EC Directive 93/42/EEC ). These requirements are 
generally considered less burdensome that the ones required by the Medicinal Products 
Directive (Directive 2001/83 /E C ), are less expensive to satisfy (in terms o f developing 
and manufacturing the product) and thus lead to a quicker and ‘easier’ regulatory 
approval.148 As seen in more detail later on, the categorisation of a product can also be 
very significant for its financial ‘survival’ (and hence the survival o f the company) as 
investors will, in most cases, choose to invest in products that will ‘sail through’ the 
regulatory approval process as quickly as possible. Swift regulatory approval means 
that products will reach the market sooner and start bringing in the rapid return-on- 
investment that motivates most (if not all) sponsors.
This preference for a ‘simple’ product profile shown by both sponsors and developers, 
however, seems to be limited to the regulatory (approval) arena. As Linda Hogle (2009) 
suggests: ‘to meet the expectations in all [...] arenas [i.e. public and private payers and 
clinicians], producers might want to position their products differently for regulatory 
purposes than for marketing or other purposes. They seek the fastest, least 
burdensome and lowest cost regulatory route, while for marketability they claim unique 
product properties in order to receive a higher reimbursement rate code and to be 
adopted by clinicians wanting improvements over existing treatments’ (Hogle, 2009: 
722). This ‘audience-tailored’ characterisation o f products is based on what Hogle 
describes as a certain amount of ‘interpretative flexibility’ applied to all product-related 
knowledge and data produced.
148 It is c la im ed  th a t 'th e  q u ick est and  le a st co stly  regu la tory  p a th w a y  is a d ev ice ' and it h as b e e n  e s t im a te d  th a t 'o n c e  
p rod u cts h ave u n d er g o n e  d e v e lo p m e n t and  are ready  for th e ir  key preclin ical an im al s tu d ie s , it is likely to  ta k e  5 years and  
$ 3 0 - $ 2 0 0  m illion as a d ev ic e , and 8  years and  $ 5 0 - $ 3 0 0  m illion as a b io log ic  or drug' (H unziker e t  al., 2006 : 3 3 5 4 ).
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LM’s description o f how she managed to have her product approved in the UK by the 
Medicines and Healthcare Products Agency (MHRA) provides a useful illustration of 
how tissue-engineered and other novel regenerative therapeutics have been ‘dis- 
serviced’ by the ‘old’, two-pillar classification system. LM credits early communication 
and collaboration with the regulatory authority for eventually managing to ‘bring’ the 
product to the clinical setting, despite the blurred regulatory landscape.
Kaftantzi: So how was [Product Name] approved?
That was an interesting one! We had meetings with the MHRA. We went 
and presented our work to them. And we showed them that it was 
autologous keratinocytes on an inert polymer-type carrier. Now, if it were 
the carrier alone, it would have been a device. But it isn’t [alone]. The 
carrier alone doesn’t work. It is the carrier with cells. So they looked at 
what we are doing, we showed them that it worked clinically. Then they 
wrote back to us saying they had reviewed it internally, this was in 2002- 
2003. They wrote us a letter back and said that they had looked at it, and 
that in their opinion it was not a device and it was not a medicine. But, 
providing it was autologous and we did it from clean rooms under 
protocols approved by them, we could continue supplying it and selling it 
to patients. So really, it was the fact that it was autologous and that we 
were working within the framework at that time — which was clean 
rooms — approved by them.
(LM, PI/Founder o f Spin-out, 2007)
LM’s product comprises a synthetic carrier (scaffold) which is seeded with the patient’s 
cells (keratinocytes) and cultured in vitro. The entire entity is then grafted onto the 
patient (on a skin ulcer or burn) where biomolecules in the product actively recruit the 
patient’s own cells to the site to initiate wound-healing processes. In other words, the 
product includes a scaffold, which means it has structural components like a device, it 
contains living cells like a biological, and it delivers molecules at the site of ‘damage’ 
like a drug.149 The complexity of both the product and the actual healing process is an
149 A sim ilar prod uct to  th e  o n e  d ev e lo p e d  by M N 's co m p a n y  and  cu rrently  p r e se n t  in th e  in tern a tion a l m ark et is 
D erm agraft. D erm agraft has fa m o u sly  su ffered  from  in c o n s is ten c ie s  in th e  regu la tory  and  m ark etin g  ap p roach  d u e  to  th e
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indication o f the difficulties biomedical researchers, clinicians, and regulators face 
when they seek to categorise these types o f therapy.
LM’s account o f how her company’s flagship product was approved in the UK, 
exemplifies the way cell-based and tissue-engineered products have been allowed to 
reach the UK market before the development of Europe-wide (or even UK-wide) 
‘appropriate regulation’. As long as products were safe and effective, that is they 
‘worked clinically’, as stated by LM, then they could be manufactured in approved 
facilities and under established protocols and be offered to patients. Autologous, though, 
is a key word and its importance in manufacturing and, consequently, regulation will be 
analysed later in the chapter.
Despite having success with that particular product and ‘getting it through the 
regulatory haze’, LM sounds frustrated and blames the luck of ‘universal’ regulations 
for ‘arbitrary’ classification performed by regulators which, she implies, is not 
beneficial for the field.
It’s actually very, very difficult to get a regulatory opinion on where your 
product falls and you will find identical products have been given 
different opinions even in the UK and that’s very, very frustrating! They 
are dealt on a case-by-case basis, which I think is fine, but it’s a bit 
arbitrary at the moment.
(LM, PI/Founder of Spin-out, 2007)
LM’s comments suggest that product developers, companies and, most importantly, 
sponsors are losing trust in the system as ‘similar’ products, after having been judged 
on a case-by-case basis, are being directed to follow quite ‘dissimilar’ regulatory 
approval routes. NC, principal investigator and founder o f a spin-out focussing on the 
production o f research and clinical hESC lines, shares this view and emphasises the 
need for regulatory harmonisation across Europe:
You could say that a harmonised market, no matter what the decision, 
will be easier to deal with than different decisions in different countries. I
hybrid n ature a s  a kind o f  d ev ic e /b io lo g ic . For m o re  in form ation  on  th e  d e v e lo p m e n t  h istory  o f  D erm agraft s e e  (Stuart, 
2008 ).
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think that the one thing that the commercial environment can’t cope with 
is uncertainty. So uncertainty in the regulatory environment is possibly 
the worst thing.
(NC, PI/Founder o f Spin-out, 2007)
Now, judging from the answers and narratives o f all my (first wave) informants, 
uncertainty over product classification and regulatory route is intimately linked to 
uncertainty over which UK regulatory authority governs which type of 
product/therapy and which part o f the product development process. The following is 
a quote from a principal investigator who is also a spin-out company’s founding 
director and largely involved in reproductive clinical work.
The regulatory aspect is not very clear at the moment with hESCs. I do 
not think that’s really held [Spin-out Company] up because it is not in a 
position [to commercialise a product yet]. But it has held up the 
[Academic Research Centre] to which [Spin-out Company] contracts to. 
Because, for instance, for the clinical development o f clinical grade cells 
we have been in limbo, not knowing [...] The uncertainty surrounds 
which regulatory authority is actually regulating development o f clinical 
grade hESCs. I was at a meeting the other day and it is still not clear 
whether it is going to be the HTA or the MHRA really. And which 
Directive it will come under exactly. The HFEA are also involved but 
really they are only interested in the embryo. Once you destroy the 
embryo to make the embryonic stem cell lines they are not interested. So 
that bit [embryo research] is fairly well controlled. The bit after that is 
problematic. The HTA and the MHRA are involved but the 
interpretation o f what your cells are [i.e. research or clinical grade] has a 
big influence on which Directive you are going for.
(GL, P i/C lin ical involvem ent/Founder o f Spin-out, 2007)
GL’s research group is working on the area o f the derivation and differentiation of 
human embryonic stem cells (hESCs). Apart from research work on the differentiation 
of hESCs to specific cells (such as insulin secreting cells), the Research Centre is also 
working on the derivation o f clinical-grade human embryonic stem cell (hESC) lines
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that can be used by other researchers as tools for research, For this ‘clinical-grade’ 
work, the group is in possession o f a clean room facility so that the generation of 
human ES cell lines can meet the standards for clinical treatment (i.e. Good 
Manufacturing Practice, GMP).
W hen asked to explain ‘which agency governs what part o f the Research Centre’s and 
subsequently the company’s work’, GL, admitted that ‘it is not clear’. Regulating the 
development of clinical-grade cell lines appeared to be especially problematic, with GL 
describing how they have been ‘in limbo’ lately, ‘not knowing’ how and from whom 
their ‘clinical-grade’ work ought to be regulated. He mentions his participation in a 
meeting and points to the general feeling of confusion matched by other colleagues 
attending. Although GL is clearly uncertain about the role o f the HTA and the MHRA 
in the development o f the ‘clinical-grade’ lines, he seems to have a clear view o f the 
role and responsibilities o f the third regulatory authority he mentioned — the HFEA. 
The HFEA (along with the HTA) is one o f the UK’s competent authorities for the EU 
Tissue and Cells Directive (EU TCD) and licenses and monitors centres that conduct 
in vitro fertilisation, donor insemination and embryo research.150 GL confidently 
explains that ‘really they are only interested in the embryo’ and ‘once you destroy the 
embryo to make the embryonic stem cell lines they are not interested’. Overall GL 
perceives the oversight work and responsibilities o f the HFEA clear-cut and ‘fairly well 
controlled’, emphasising the overlap and ambiguity that characterises the rest o f the 
production process.
Similar comments are made by another interviewee, who also works on the production 
of clinical-grade human embryonic stem cells. His company too is interested in selling 
clinical-grade hESC lines as tools for other laboratories and companies. In addition to 
criticising the confusion over ‘who governs what’, he mentions the need for the 
creation of a clear, harmonised, structure that ‘recognises’ and covers the type o f work 
that his company is already doing (research-grade derivation), as well as the new 
aspects that they are starting to focus on (clinical-grade derivation).
150 The o th er  c o m p e te n t  au th or ity , HTA, regu la tes  th e  rem oval, s to ra g e , u se  and d isp osa l o f  h um an  b o d ies , o rg a n s and  
t is s u e s  from  b oth  th e  living and  d e c e a se d  (i.e . o th e r  th an  g a m e te s  and em b ryos, w hich  are co v e red  by th e  HFEA).
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The UK still has to work hard to keep pace. So for example, to do the 
work that we are doing right now we get a licence from the HFEA 
[Human Fertilisation and Embryology Agency] and, very soon, that is 
going to be complemented by a need for licence from the HTA 
[Human Tissue Authority]. And there is duplication there. What is being 
asked o f individuals, demonstration o f quality assurance standards, etc. is 
basically twice as much work for the people involved, so ultimately we 
need to create a harmonised structure. O n top of that, if you go with 
what the HFEA is concerned about really, is derivation o f cells for 
research. The first version o f the licence that I hold is titled ‘Enabling 
technologies for human embryo stem cell derivation’. But now the 
development is towards therapeutic-grade cells. At some point there 
needs to be recognition that what we are doing, the licence that we are 
seeking is not for research but it is actually for production o f a
therapeutic product. And there are nuances that I think then need to be
addressed.
(NC, PI/CSO/Founder o f Spin-out, 2007)
NC is describing the challenge of the transition from ‘research-grade’ to ‘clinical-grade’ 
work under what he perceives as confusing, overlapping and non-harmonised 
guidelines. The current licence he holds is for derivation of research-grade lines, but as 
his company changes focus he will need to go to ‘yet another regulatory authority’ and 
demonstrate ‘once again’ the necessary quality assurance standards.
The concern over ‘duplication’ o f work revealed by NC (in 2007), had also been 
reported in the media and in commentaries (published in scientific journals) by many 
stakeholders at the time, and had been very controversial. In fact, in December 2006, 
the UK Government published a White Paper under the title 'Review of the Human
Fertilisation and Embryology A c t f x in which it set out its plan for the HFEA and the
HTA to merge and form a single regulatory body, the Regulatory Authority for Tissues 
and Embryos (RATE), covering the whole o f reproduction technology, pathology, 
anatomy, transplantation and the use and storage of human tissue. The arguments that
151 R eview  o f  th e  H um an Fertilisation  and  Em bryology Act: P roposa ls for rev ised  leg isla tion  (includ ing e s ta b lish m e n t o f  th e  
R egulatory A uth ority  for  T issue and  Em bryos). D ep artm en t o f  H ealth (DoH), London: S tation ary  O ffice, 2 0 0 6 .
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had been put forward in support o f the merger had been political (for example, 
reducing the number of regulatory bodies by one) and financial.152
Curiously, the proposed ‘RATE’ merger surfaces in the narratives of many informants 
with another interviewee commenting even more explicidy on it:
They were going to merge the HFEA [Human Fertilisation and 
Embryology Authority] and the HTA [Human Tissue Authority]. But 
that’s been stopped, which is probably a good idea. I don’t think it was 
going to work how it was. Because the HFEA really governs all the 
patients attending IVF [In-Vitro Fertilisation] clinics, mainly. They do 
cover the research, but it is really quite a small aspect of what they do, in 
a way. I mean it is important because they regulate all embryo research, 
but the HFEA come from a way o f protecting patients who are going to 
IVF units. So a lot o f the governance is related to that, which is a bit 
different to the HTA. So I am not sure it would have come together very 
well. But on the other hand, having lots o f different agencies is not 
particularly useful either. W e’ve also had ongoing discussions with the 
MHRA for about three years but they haven’t really come to any 
decision, so this has been a problem.
(GL, PI/C linical Involvem ent/Co-founder o f Spin-out, 2007)
As GL suggests, the problem with the merger is the different ‘concerns’ o f the two 
bodies, with HFEA’s main concern being the protection of IVF patients who donate 
the embryos (from which the embryonic stem cells are subsequendy derived). From 
GL’s reflection, it is clear that he, like other respondents, is facing the dilemma 
between having to deal with reducing the ‘arms length bodies’ by one, but running the 
risk o f not having ‘enough expertise in the central authority to appropriately regulate 
the difficult areas it would have to address’. As another interviewee puts it: ‘It might, 
actually, lead to a more expensive and less efficient system’.
Institutional hybrids such as RATE have proven to be important objects o f social 
science critique before. Brown and Michael (2004), for example, examine the
152 A lth ough  it has b een  argu ed  th a t  eq u a l financial sav in gs cou ld  b e m a d e  by o th e r  ch a n g es  sh o r t o f  m erg in g  th e  b o d ies .
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establishment o f such an institutional hybrid body — the UK Xenotransplantation 
Interim Regulatory Authority (UKXIRA) -  for regulating transpecies transplantation 
and discuss the scope and limitations of its ‘hybridity’. In their analysis, Brown and 
Michael suggest that hybrid institutions are ‘risky creatures’ as they face many risks 
such as ‘whether or not their terms o f reference are adequate to cover the kinds o f new 
combinations arising in bioscience, whether they are sufficiently representative o f all 
the relevant regulatory bodies’ (Brown & Michael, 2004: 209). Their analysis seems to 
agree with the concerns of bioentrepreneurs (and others) whether the establishment of 
RATE would have been an appropriate and effective solution to the ‘duplication of 
work’ concerns at the time.
Summary
The regulatory landscape is changing and the bioentrepreneurs are attempting to make 
sense o f the changes. There are frequent calls for harmonisation and more 
‘straightforward’ regulation. One of the main problems identified by bioentrepreneurs 
is the difficulty o f classifying their products. As mentioned earlier, the category under 
which a product is classified has large implications for the way a product is 
subsequently tested and approved. Up until late 2007, in the absence o f a coherent 
European regulatory framework, similar cell-based products could potentially be 
subjected to different regulatory regimes and decisions, even in the same country (if 
evaluated at a different time), leading to confusion and frustration — especially in view 
of the positive relationship between a clear, regulatory route and investment potential 
for a product/company. To emphasise the need for advance knowledge o f the 
potential regulatory (and commercialisation) route, many informants mentioned how 
grant applications require the inclusion of the relevant information in order to allocate 
funding.
In the narratives o f bioentrepreneurs, uncertainty over regulatory route is coupled with 
uncertainty over the work and regulatory jurisdiction o f the main UK competent 
authorities for RM research and development such as the HTA, the MHRA and the 
HFEA. O ut o f the three agencies, the work o f the HFEA is perceived by the 
entrepreneurs as the most ‘clear-cut’ with responsibilities ending at the point of 
embryo destruction. The HTA and the MHRA on the other hand are ‘uncertain’
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actors, perceived by many interviewees as ‘duplicating’ work and frustratingly wasting 
investigators’ and companies’ precious time and resources. Interestingly, the current (at 
the time) proposal for merging the HTA and HFEA surfaced in many interviews but 
discussion with the informants revealed mixed feelings and there was no consensus on 
whether merging the bodies would facilitate or hamper activity in the field.
Bioentrepreneurs interested in pursuing the production o f clinical-grade cell lines have 
also spoken about the difficulty o f making the transition from research-grade to 
clinical-grade lines under the current regulation. The concerns raised highlight the 
impact o f regulatory uncertainty on innovation and commercialisation. The finding 
also points to another interesting change in the regulatory landscape: the focus o f the 
regulation is no longer on the source o f the cell lines, as this is an issue in the 
embryonic debate that appears to have been ‘solved’. The focus o f the (downstream) 
regulation is on assuring the ‘quality’ o f the hESC lines especially when they are 
destined for therapeutic application and must be o f ‘clinical-grade’.
Co-Shaping the Regulatory Landscape
It would be easy to form the impression from the preceding section that 
bioentrepreneurs are involved as passive actors in the regulatory time and space. 
However, in addition to the narratives and the framing o f the regulatory ‘hurdles’, 
there are also parallel stories about the way many o f these challenges have been 
handled in order to realise the translational objectives.
Intrigued about the way they deal with this uncertainty at the practical level (when they 
are asking for examination o f a product for example), I asked the informants about 
their interaction with the regulatory authorities. A bioentrepreneur replies below and 
explains his belief that regulatory uncertainty stems from the fact that regulators 
themselves are uncertain and inexperienced when it comes to ‘evaluating’ this new kind 
of ‘entities’:
So the regulators ask loads of questions. You know, it went from drugs 
and devices, then biologies, and then what? The move from drugs to 
biologies was a big move when they did it, because you’re talking about
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proteins and synthesised products. But the move from biologies to cells 
is even bigger. Biologies are a single molecular entity, they’re one thing 
and they’re not changing. Once it’s made, it’s made. It just sits there 
slowly degrading, but sits there. Cells are dynamic things, changing by 
the moment.
(NJ, PI/C SO /F ounder o f Start-up, 2007)
NJ attributes the ‘state o f confusion’ to the fact that cell therapies, especially stem cell- 
based therapies, are very different to medical devices, biologies and drugs, which is 
what the regulators are ‘used to’ so far. Thus, traditional approaches to regulation that 
have proven effective for the latter are not well suited to the ‘novel biological products’ 
where the mechanism o f action is still poorly understood; where most products are 
used as a component o f a complex therapeutic strategy in which it is difficult to isolate 
and access its contribution (for example in a conventional clinical trial); and, finally, 
where the field is advancing at a rapid pace that is incompatible with the time frame for 
the approval o f traditional medical products (Gee, 2002). This ‘novelty’ is the reason, 
he later explains, that regulators default on ‘I wonder what i f  type o f questions. His 
comments were mostly applied to the EU regulatory landscape, as he seemed to be 
more convinced by the approach followed by the US Food and Drug Administration 
(FDA). Still, from his perspective, the confusion in the regulatory system is 
‘understandable’. He continues:
I t’s a dual-edged sword at the moment. The confusion in the regulatory 
system is understandable, it’s not that they’re doing anything wrong. You 
can play it to your advantage in a way because in industries like ours you 
can actually, direct it. So you can influence it. I f  we were a start-up drug 
manufacturer now, we would just have to follow the rules. We wouldn’t 
have any chance of changing the rules. Whereas, [in the new area] we 
have chances you know, and they [regulators] come and seek advice all 
the time.
(NJ, CSO /Founder of Start-up, 2007)
NJ seems to believe that the uncertainty that dominates the regulatory landscape in the 
UK (as well as the EU) is a ‘dual-edged’ sword and could also work to the advantage of
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the scientists and ultimately the field. In contrast to having to comply with an already 
established regulatory framework, as would be case for a company entering the 
pharmaceutical industry and drug development field, in the cell therapy field, 
investigators and small companies have the opportunity to influence and perhaps even, 
‘direct’ the work o f the regulatory agencies. To illustrate this work-in-progress 
participatory attitude that, he believes, is also encouraged by the regulators, he provides 
an example from his own company:
And I’ll show you, you talk [about] automation; I ’ll show you in a minute 
because we’re actively in consultation with the MHRA [Medicines and 
Healthcare Product Regulatory Agency] at the moment about this 
automation. Because it’s a robot that we developed for one purpose and 
we’re using it to try and see if we can do it for another purpose. And 
we’re doing this in consultation with the MHRA.
(NJ, P I/C SO /F ounder of Start-up, 2007)
In other words, according to NJ, it might be the case that embarking upon early 
consultations with the appropriate regulatory authority is not only a way to avoid 
committing precious time and funds on the ‘wrong’ innovation process but is also a 
way to be involved in the formulation of the policies. By filtering the regulatory 
guidelines through their personal, first-hand experience o f developing cell therapy 
products and by providing input to the relevant agencies, RM investigators and 
budding companies, are in way shaping expectations o f these agencies and might be 
actually lowering the barriers for their own future commercial product candidates.
The bioentrepreneurs’ ‘claim’ of co-shaping regulation with regulators has been 
recently confirmed by the ‘other side’ (albeit in the medicines field). In a 2010 Nature 
article,153 regulatory experts from the European Medicines Agency (EMA) commenting 
on the drug approval success rates in Europe, have mentioned interaction between 
regulators and sponsor companies as a way to ‘remedy’ the gap between regulatory 
expectations and product development strategies and hence increase the regulatory 
success rates. The experts highlight the fact that such interaction is not mandatory in 
the EU and only 60% of the Marketing Authorisation Applications (MAAs) are
153 (Eichler e t  al., 20 1 0 ).
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currently preceded by scientific advice from the EMA’s Committee for Medicinal 
Products for Human Use (CHMP). The importance o f such ‘dialogue’ early on and 
repeatedly at major transition points, as well as compliance with advice given by the 
CHMP seemed to be a predictor o f positive MAAs outcomes (Regnstrom et al., 2010).
NJ’s account also resonates with scholars’ suggestions in the social science literature 
that there is a shift toward a more ‘participative ethos’ in ‘building’ regulation as well as 
changes in the relationships between science, industry and state regulation. For 
example, Salter and Jones (2002) argue that in the field o f genetics ethical concerns and 
the role of the consumer citizen are becoming increasingly influential, deflecting the 
attention from the promotion of innovation and industrial development, which used to 
be the first priority. Additionally, Kent and Faulkner in their 2006 analysis o f the 
regulation of human implant (breast and hip) technologies argue that we may be 
witnessing (at least in the UK) ‘a move towards a more user-oriented shaping of 
regulation’ (Kent & Faulkner, 2002: 205).
In the case o f the nascent RegenMed industry, the bioentrepreneur can also be 
considered as a type of ‘user’154 who is increasingly gaining ‘power’. N ot yet m em bers. 
of an established industry (such as pharma and biotech), the founders and (often) 
Chief Scientific Officers of small RM companies are collaborating with the regulatory 
authorities and help to ‘co-shape’ the emerging regulation. This collaboration makes 
sense, as both the ‘know-how’ and the ‘maturing’ (bioprocessing) infrastructure are 
‘constructed’ and, at least for the time being, ‘monopolised’ by these small companies 
that are the lifeblood o f the RM field.
N J’s perception, on the other hand, over the rigidness o f the pharmaceutical industry 
and its ‘set’ regulatory framework is not groundless. Abraham and Lewis (2002), for 
example, argue that in the area o f pharmaceutical regulation, despite consumers’ 
growing activism and the associated challenges to medical autonomy and dominance 
(by questioning the social viability o f medical expertise in industry and the regulatory 
state), ‘the evidence that these challenges have been accompanied by societal changes, 
such as increased power for consumers of medicines in terms o f citizenship rights or a
154 A lth ou gh , tech n ica lly , b io en tre p r en eu rs  are n o t u sers o f  RM p rod u cts, in th e  s e n s e  th a t  p a tien ts  and  clin icians are, 
b ec a u se  o f  th e  early  s ta g e  o f  th e  R egen M ed  industry, its r e p r ese n ta tio n  p red om in an tly  th rou gh  SMEs and th e  m u ltifa c eted  
n ature o f  th e  b io en tre p r en eu rs  (o ften  sc ie n tist , clin ician  and m an ager) w h o  are lead in g  th e  fie ld , I argu e th a t th e y  can be  
co n s id ered  a s  a ty p e  o f  'user' w ith  regard  to  th e  regu la tion .
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significant decline in medical authority within the regulatory state, is limited’ (2002:82). 
In other words, the long-established pharmaceutical regulation — shielded behind the 
medical authority and the interests o f the producers (industry) -  is perceived as being 
‘immune’ to the ‘user’ (patient) interests. It is not surprising then that in the face of 
such a scenario, where small RM companies are entering an already established 
industry (much like pharma), NJ perceives his group (i.e. bioentrepreneurs) as having 
much less ‘power’ and fewer opportunities to co-shape the regulation that will 
inevitably define their businesses’ future. In short, it could be said that unlike Abraham 
and Lewis’ ‘active citizenship’ in pharma that is dampened by the ‘biased’ regulatory 
state, ‘active entrepreneurship’ in RegenMed instead seems to be more ‘influential’ and 
‘productive’, facilitated by the early stage o f the science, the early stage of the industry 
and hence the early stage o f the regulation itself.
Another interviewee, LM, reflects on her experience with regulators and comments on 
her perception of their attempts to create ‘a third pillar’ o f regulation in order to 
accommodate the tissue-engineered and other combination products that did not seem 
to ‘fit’ either the medical device or the drug category. More specifically, she describes 
how regulators, challenged by the ‘novelty’ of the emerging RM technologies, default 
on ‘lifting the safety bar higher and higher and higher’ hence running the risk of 
producing something ‘so difficult’ that will discourage investigators from clinically 
translating their findings. She notes:
Because the conundrum for regulators is that they can only regulate 
things they know about — that they have been around for a while. And 
then, how do we ever bring [forward] something new that doesn’t quite 
fit...? I do appreciate it from a regulator’s point of view, but I think that 
if the regulation goes to always lifting the safety bar higher and higher 
and higher, we will end up with something so difficult. I know many o f 
my academic colleagues in the UK would not think o f doing TE research 
that went to the clinic because they view it as too difficult.
I think we’ve got to say this [regulation] is something we hope [...] will 
succeed, but we hope it will succeed and end up with something that is 
sensible, rather than something that is so prohibiting that nobody can do
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anything. Something that recognises that we need to develop products in 
the area. You have to support innovation while also making sure that 
everything that goes forward is safe. What we really want is some sort o f 
“light-touch” regulation while we are developing products.
(LM, PI/Founder o f Spin-out, 2007)
LM appears to share NJ‘s understanding of the regulators’ attitude towards novel 
technologies that challenge the existing guidelines and expertise. In addition, she 
emphasises the need to create a framework that balances the requirements for safety 
and quality with the need for progress and innovation in the Regenerative Medicine 
field. Unreasonably high safety standards and too-restrictive regulations will end up 
stifling, if not completely ‘killing’ the field. She sums up a view held by most 
interviewees, when she says ‘what we really want is some sort o f “ light-touch” regulation 
while we are developing products’.
The term ‘light-touch’ regulation can theoretically be employed in both a narrow 
context — such as the development of a specific therapy/product — and in a broader 
context, such as a whole discipline/field (for example Regenerative Medicine) or 
indeed the whole biotech sector. As LM uses the term, it seems to imply a call for 
flexibility and open-mindedness toward the emerging technologies (and their risks), 
plus a call for a kind of continuous, investigator-friendly guidance from the regulators. 
In other words, the term conveys the image of a constant, back-and-forth 
communication between the product developers/manufacturers and the regulators so 
as to produce an outcome that is ‘in accordance’ and ‘approved’.
In general, the term ‘light-touch’ regulation as employed by LM is useful for 
highlighting the challenges associated with restrictive and inflexible legislation, and 
emphasising the need for regulatory guidelines that allow a rapid response to scientific 
advances — especially in rapidly progressing scientific or technological fields such as 
RM. Indeed, the significance of this mode o f regulation (‘light-touch’) becomes 
obvious in view of recent advances in the stem cell research field, such as induced 
pluripotent stem cells (iPSCs), inter-species somatic cell nuclear transfer (iSCNT), and 
embryonic stem cells derived from parthenogenetic embryos and from embryos
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generated from isolated blastomeres.155 All these techniques were not even 
contemplated during the political and scientific debates that led to the current 
regulation.
The discussion o f the challenge o f regulating rapidly changing science has also been 
raised recently by a group o f stem-cell biologists and law scholars from the University 
of Toronto, Canada (Rugg-Gunn, Ogbogu, Rossant and Caulfield), who are using stem 
cell legislation in Canada as a model and who attempt to demonstrate how broad- 
based prohibitive legislation can unintentionally restrict research direction.156 They 
note:
The law is also often a terribly blunt and clumsy tool. It not only lags 
behind the advances of science but can create unintended hurdles in 
front o f it. Legislation can quickly become an anachronism, no longer 
reflecting the social mood or scientific realities. If  scientific legislation is 
crafted without careful attention to the underlying science, it may run 
aground when faced new scientific realities [...] whether one advocates a 
cautious or permissive approach to regulation, it is important to craft 
legislative provisions that retain the ability to capture the nuances and 
unpredictable turns inevitably associated with scientific progress.
(Rugg-Gunn et al., 2009: 285 and 288)
In other words, there is a call for regulators to strike the difficult balance between 
appropriate guarantees on the safety and quality o f therapies, while at the same time 
allowing for a certain degree o f flexibility in order to keep pace with the technological 
innovation.
For many of my informants, part o f the ‘toughness’ of the regulations was also the 
endless paperwork that accompanied the regulations. Indeed, the multifaceted role of 
bioentrepreneurs as principal investigators, often as heads o f experimental (sometimes 
even clinical) trials, and as company ‘managers’ assigns them the unfortunate task of
155 For an o v er v iew  o f  th e  legal s ta tu s  o f  n ovel cell t e c h n o lo g ie s /te c h n iq u e s  such a s  iPSCs, in ter -sp ec ies  so m a tic  cell n uclear  
tran sfer  (iSCNT), and o th ers  (in C anada) s e e :  (O gbogu  & Rugg-G unn, 2 0 0 8 ) .
156 T he g rou p 's  (i.e . Rugg e t  al.) in ter est in 'proh ib itive' and 'lagg in g-b eh in d ' regu lation  s e e m s  to  h ave b een  raised  by th e  fact  
th a t, in C anada, th e  rep rod u ctive  te c h n o lo g ie s  leg isla tion  th a t a lso  g o v e r n s  em b ryon ic  s tem  cell (hESC) research  c a m e  in to  
fo rce  a d e c a d e  a fter  th e  p ub lication  o f  th e  Royal C om m ission  th a t ca lled  for  its en a c tm e n t.
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arranging for licences, filing in endless forms and preparing all sorts o f applications. 
The interviewee HR is principal investigator and clinician in orthopaedics157 
specialising in autologous chondrocyte implantation (ACI). Like other 
bioentrepreneurs, he recognises that the ‘novelty’ o f most cell-based treatments is 
undeniably contributing to the ‘over-regulation’ and the bureaucracy, but he also thinks 
that better management of the situation could avoid a lot of ‘red tape’.
We have so much bureaucracy now. One o f the problems has been that 
it is a new treatment so it is quite difficult for the regulators/authorities 
to know what to do. Because they don’t know if  there are problems with 
it [the new therapy] or not. Now fortunately this new treatment hasn’t 
ever killed anyone or caused much trouble and a lot o f people are very 
happy with it [...] so the regulatory authorities still want to provide a 
framework. And the EU TCD [Tissue and Cells Directive] came up with 
some quite good suggestions. But these are being interpreted by each 
country in Europe in a different way, and in the UK they’ve become very 
burdensome. There is a lot o f bureaucracy [...] so this is bad 
management. So I think we need to invite people from Singapore to 
come and run licensing in the UK. Because they [regulators in Singapore] 
have managed to arrange things efficiently and cost effectively.
(HR, P l/C lin ician/C o-founder o f Manufacturing Facility, 2009)
HR is frustrated by the bureaucracy. On the one hand, he recognises the regulations as 
necessary and well intentioned, and on the other he expresses his disapproval o f how 
the guidelines have been set up and interpreted in the UK. He perceives the 
‘burdensome’ regulation as a result o f ‘bad management’ (through equally bad 
interpretation), and suggests that the UK could solve the ‘problem’ by inviting people 
from ‘Singapore to come and run licensing in the UK ’ because ‘they have managed to 
arrange things efficiently and cost effectively’.
In addition to discouraging academic researchers from clinically translating their bench 
findings, there is the impression from many interviewees that burdensome regulations
157 O rth op aed ics  is th e  field  prim arily c o n ce rn ed  w ith  th e  tr e a tm e n t  and  correction  o f  d is e a s e s  and injuries o f  th e  
m u scu losk e le ta l sy ste m .
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are perhaps even more critical in the case o f companies who are attempting to enter 
the field. The quote below is from a scientist also working in orthopaedics.
We are aware of the complex problems o f working with a cell-based 
strategy compared to a device. From an industry perspective, they are 
much more interested in a device than a cell-based product, because of 
the regulatory authority requirements [for cell-based products] — and 
working with these dreams of paperwork — that will have to be met and 
approved. GMP facilities, category 2, HTA [Human Tissue Authority] 
licences and MHRA [Medicines & Healthcare Products Regulatory 
Agency]. So we are aware of all that, and from my perspective [i.e. 
academia] it doesn’t change my research programme. I think if  we were a 
commercial entity, it will probably focus quite dramatically what we try to 
do. But based here at the university, it doesn’t affect my programme.
(Q N , PI/Founder of Spin-out, 2009)
In the quote above, QN is well aware o f the expensive regulatory compliance and the 
associated ‘bureaucracy’ when it comes to cell therapies. Regulations need not only to 
be formulated but, to be meaningful, must also be enforced. This unavoidable 
involvement with the bureaucratic apparatus — these ‘dreams o f paperwork that will 
have to be met and approved’ is, he claims, the reason behind the preference158 o f the 
industry for developing devices (implants) as opposed to cell-based approaches. 
Although he admits that such regulatory concerns do not direct his own academic 
work, in the sense that he would not change the product therapy his group is working 
on, he points out that for a company (spin-out or start up) the effect would be 
different. His comments suggest that stringent regulatory requirements impose 
additional costs on industry (companies) thus stifling innovation. This is presumably 
caused by redirection o f funds and efforts towards compliance with regulations, 
instead of towards commercially oriented innovation. In short, what QN suggests, is 
that although burdensome regulations might not determine the science agenda of a
158 Interestin gly , a lth ou gh  RO's v ie w  on  th e  p r e fer en ce  o f  industry  for  d e v ic e s  in stea d  o f  c e ll-b a sed  a p p r o a ch es  h o ld s  tru e  
for m o st o f  R egen era tive  M ed icin es  su b fie ld s , it d o e s  n o t a g re e  w ith  re c e n t  m ark et rep orts th a t  c o n s id er  th e  d e v e lo p m e n t  
o f  stem  cell th era p ie s  to  trea t o r th o p a ed ic  d isord ers to  b e  ad van cin g  a t a rapid p a ce . T h e p ro m ise  o f  b ein g  a b le  to  
r e g en era te  m u ltip le t is s u e  ty p e s  critical to  p rop er m u scu lo sk e le ta l fu n c tio n  h as lead  industry  fo r e c a ste r s  to  pred ict th a t  th e  
m ark et for o r th o p a ed ic -fo cu ssed  s te m  cell th era p ie s  w ill g ro w  from  its cu rren t (2 0 1 0 )  size  o f  $ 1 1 0  m illion to  £ 9 5 0  m illion  by 
2 0 1 2 . Espicom  H ealthcare In te lligen ce  is a provider o f  b u s in e ss  in te llig e n c e  serv ice s  (h t tp : / /w w w .e s p ic o m .c o m ). S ee:  
(E spicom , 2 0 0 8 ).
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predominantly publicly funded academic group (like his own group), it could be a 
seriously limiting factor to the commercialisation strategy o f a small RM company with 
limited resources (financial, administrative, etc.) looking to develop Regenerative 
Medicine products.
In short, it could be said that tough regulatory R&D requirements and bureaucracy 
steer R&D strategy for commercial entities away from ‘high regulatory requirements’ 
products (i.e. cell-based) towards ‘low regulatory requirements’ products (i.e. medical 
devices). This steering activity makes sense as it supports the idea o f a product 
commercialisation trajectory that needs to be ‘easy to the eye o f regulation’ at early 
development stages (when scientific/technical challenges are plenty).
Another interviewee talked about a similar problem he faced in the bioentrepreneur 
(developer)/regulator partnership and that, he believes, stems from regulatory 
authorities recruiting the wrong expert to act as advisor (on the agency’s behalf). LK 
explains:
In the UK the MHRA are extremely helpful now. They have certainly 
changed their position over the last five years and we have excellent 
relationships with the MHRA. I think the problem is more at the 
European level and the complexity o f the CHMP [Committee for 
Medicinal Products for Human Use]159 interactions. Everybody is 
learning, and certainly one example I can think o f [is] where I was asked 
by a company to work with them — and go with them to their 
presentation with the EMA, to be an external adviser with an expertise in 
a particular field — and the person, the expert that the CHMP had 
identified is someone I know very well, [and who] certainly no one in the 
field [would] identify [...] as an expert; and yet to CHMP he was an 
expert. And his lack o f understanding and lack o f knowledge o f the field 
was whoooofL. But he had been identified because o f a particular status
159 The CHMP plays a vital role in th e  m arketing  p ro ced u res  for  m ed ic in es  in th e  E uropean  U nion. For ex a m p le , in th e  
'C o m m u n ity  or 'cen tra lised ' p roced u re , th e  CHMP is re sp o n sib le  for  co n d u c tin g  th e  initial a s se s s m e n t  o f  m ed ic in al p rod u cts  
for w hich  a C om m u n ity -w id e m arketing au th or isa tion  is so u g h t. T he CHMP o p e r a te s  by es ta b lish in g  a n u m b er o f  w ork in g  
p arties at th e  b eg in n in g  o f  each  th ree -y e a r  m a n d a te . T h ese  w orking p arties h ave e x p er tise  in a particular sc ien tific  f ie ld , and  
are c o m p o se d  o f  m em b ers  s e le c te d  from  th e  E uropean ex p er ts  list m a in ta in ed  by th e  EMEA. T h e CHMP co n su lts  its w orking  
p arties on  sc ien tific  is su e s  relating to  th eir  particular fie ld  o f  e x p er tise , and  d e le g a te s  certa in  ta sk s to  th e m  a sso c ia ted  w ith  
th e  sc ien tific  eva lu a tion  o f  m arketing au th or isa tion  a p p lica tion s or draftin g  and revision  o f  sc ien tific  g u id a n ce  d o cu m en ts .
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he held at the tim e...he was the chairman o f an international body...he 
was appointed because he was chairman, so he had absolutely no idea 
[about] the specifics, and he actually clouded the issues. So there will be 
issues there where regulators aren’t sufficiently informed to get the 
appropriate expert to represent them in discussions in a field 
which...som e o f these [fields] are very, very narrow, so the field o f 
expertise is [also] very narrow and tight, and you only ever have a small 
number o f experts that are true experts. So that, I think, was the only 
time where we had a real problem with knowledge.
(LK, PI/C linical Involvem ent/Founder o f Start-up, 2009)
In this quotation, LK emphasises the ‘excellent’ working relationship with the MHRA 
and explains how problems he encountered had not been with the UK regulatory 
agency, but rather with the Committee for Medicinal Products for Human Use 
(CHMP) — that is the European body responsible for the scientific assessment of 
products and for granting marketing authorisations. LK describes how he was asked 
to be an external advisor to a company and join their presentation and subsequent 
negotiations with EMA (European Medicines Agency). He then expresses dismay at 
CHMP’s choice of expert to conduct the specific evaluation. In his view, EMA 
inappropriately chose someone based on their current high-profile status and not, as 
they claim to do, according to the ‘strength of their qualifications and expertise with 
regard to the evaluation of medicinal products’. Interestingly, he points out that he 
personally knows that person and he believes ‘no one in the field [would] identify that 
person as an expert’.
LK repeatedly referred to his example as ‘a knowledge barrier’ case, emphasising the 
complete ignorance o f the so-called ‘expert’ and his ability to ‘cloud’ the issues instead 
of clarifying them. In other words, he seems to imply that, although the scientific 
assessment work conducted by the CHMP is subject to an internal peer-review system, 
the system will only be as good as the choice o f reviewers it recruits. According to LK, 
the danger of regulatory agencies to ‘mis-recruit’ experts increases when fields are 
relatively new and narrow, as is the case with cell therapeutics. ‘True experts’, as he 
calls them, are few.
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As a last point, a few informants brought up the theme of ‘difficult’ regulation of 
Translation in the UK compared to more ‘appealing’ overseas regulation. As founders 
of companies that need to not only survive financially but also ‘turn a profit’, it makes 
sense that bioentrepreneurs will look for successful cases and draw lessons from their 
experience. In the following quote, SP suggests that large UK companies could avoid 
regulatory uncertainties by moving their operations to the United States or wherever a 
system might be more accommodating to their development and commercialisation 
strategies.
The UK could quite rapidly lose out depending on the regulatory 
decisions. All the hard work could be blocked if you find out that you 
cannot move things forward to get things to the clinic. Now if you are a 
company with deep enough pockets you could take the view “Well we 
are not going to develop for the UK market we are going to develop 
things for the States”. So if you are really big company you can say ‘W e 
are not worried about getting to the clinic or the market in the UK, we 
will look at the world stage”. But small companies cannot afford to do 
that. You will find when you talk about Intercytex and Renovo that they 
have strong connections with the States which is how they manage most 
of their funding.
(SP, PI/Founder of Spin-out, 2007)
According to SP, small RM companies do not have many options when it comes to 
regulation and compliance. In contrast, he mentions the case of two large, fairly 
established UK RM companies with ‘connections’, as he points out, in the States. 
Ironically though, in early 2009, Intercytex suffered a potentially damaging setback 
following the failure o f a key product in the latter stages o f clinical trials.160 The 
Cambridge company (which has another UK base in Manchester and a US facility in 
Boston) announced that the Phase III study o f its treatment for venous leg ulcers — 
Cyzact — failed to meet its primary endpoint. As a result o f that ‘failure’ the company 
did not manage to raise the necessary funds to continue operation and ceased all 
activities.161 The Intercytex story proves how critical ‘science’ still is in the development 
of RM products, a view that contrasts with comments some interviewees have made,
160 T he 3 9 6 -p a tie n t  P h ase III trial w a s  a th ree-arm  stu d y  co n d u c ted  in th e  US, th e  UK and C anada.
161 h t tp ; / /w w w .b u sin essw eek ly .co .u k /life -sc ie n c es-a rch iv e /in terc y tex -h it-b y -p ro d u ct-fa ilu re .h tm l
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stating: ‘it just may be that science is the least o f our problems’ in order to highlight 
their view that regulation is ‘what is stifling innovation and progress’.
Summary
The majority o f bioentrepreneurs attribute part o f the uncertainty over classification to 
the novelty o f the emerging Regenerative Medicine products and the inexperience of 
the regulators. A few perceive the uncertainty as a ‘dual-edged’ sword with 
bioentrepreneurs casting themselves as crucial ‘shapers’ influencing the expectations of 
the regulatory authorities, instead o f being passive recipients o f regulatory guidelines. 
This ‘co-shaping’ is encouraged by the regulators, with early and frequent collaboration 
between developers and regulators being cited as a factor that increases the chances of 
successful regulatory approval. This kind of active participation in the creation of 
regulation is perceived as possible because of the early-stage o f the RegenMed industry 
and the fact that regulatory guidelines have to be concurrently produced along with the 
RM science. Interviewees have also emphasised the importance o f ‘light-touch’ 
regulation when it comes to uncertain technologies such as cell-based therapies, as a 
balance needs to be struck between safety and the need for innovation and progress.
Bioentrepreneurs at the helm both o f academic and corporate research groups and 
companies trying to translate their research findings into the clinical setting, feel 
overwhelmed by the apparently ‘endless’ regulatory requirements that apply. Tough 
regulatory requirements and related bureaucracy were perceived as ‘discouraging’ and 
burdensome for academic groups/companies, although not to the point of decisively 
changing the research agenda. However, in the case o f purely commercial entities, 
bioentrepreneurs were more concerned, suggesting that regulation might steer the 
research agenda away from cell-based therapeutics and towards less complex 
technologies such as medical devices. In general, regulatory bureaucracy was criticised 
for discouraging many principal investigators from entering the clinical Translation 
arena altogether.
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The Effects o f Compliance
O n the basis of the ongoing conundrums reported by bioentrepreneurs in the previous 
sections, it can be concluded that the importance o f standardising regulations for 
Regenerative Medicine developers has become increasingly obvious, yet also more 
complicated. All the interviewees for this study agreed that normalisation through 
regulatory standards is imperative across the field. The pressure to meet heightened 
regulatory compliance in such a fast-changing field is felt especially urgently by 
bioentrepreneurs, since they are the ones responsible for the task, and also the first to 
see their circumstances benefit or decline as a result of regulatory set-backs or delays.
The following section addresses the attempts o f the interviewed bioentrepreneurs to 
comply with various regulations, including the new ATMP guidelines. Many 
bioentrepreneurs talk about the challenges and ‘cost’ o f compliance. They disclose 
their feelings about the pressure they feel to comply with the ever-changing regulations 
and also criticise the lack o f guidance and support from the government (and the 
relevant agencies). In the absence of adequate help and infrastructure, several 
informants raise concerns about ‘wastage’ o f time and resources as well as the 
consequent impact on people’s careers. With regard to the ATMP specifically, a few 
respondents point to the ‘still-work-in-progress’ status o f the regulation (despite being 
in effect from December 2008), and highlight the significance o f a ‘careful’ 
interpretation, and hence implementation, o f the ATMP-based harmonisation during 
the transition period.
Below, LM shares her experience of trying to deliver a cell therapy, initially from an 
academic and, subsequently, from a spin-out company setting. LM is a principal 
investigator (PI) who leads her own group in a research institute. Her team’s research 
has a strong translational interest in developing skin tissue engineering which will 
benefit patients, alongside fundamental work to develop new understanding and tools 
in the area of wound healing, burns and various skin conditions. LM is also a founder 
of a RM company that has at least one product in the market, available for use by 
medical professionals. Below, she describes attempts, both o f hers and others’ 
laboratories, to set up ‘clean rooms’ for aseptic manufacturing:
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When the Department of Health made it clear that if you were going to 
deliver cells to patients they had to be from clean rooms I think we were 
one of the first [research] groups and companies to have clean rooms up 
and running. So we set up clean rooms in 2003 and our first product — 
[Product] — was available commercially from about 2004 from clean 
rooms. Other colleagues o f mine also set up clean rooms around the 
same time. It was a very clumsy operation. The Department o f Health 
said “Here is how it must be, do it”. We all got together and said “We 
can’t do it overnight! You mean we have to stop treating burns 
patients?” . "No", they said, “we do not mean that. We will give you 
another year” . So they gave us another year to find the funding and set 
up the clean rooms. To be quite blunt, it caused enormous stress to the 
groups that took it on. People have lost jobs, it has impacted on careers, 
and it’s been really difficult.
(LM, PI/Founder o f Spin-out, 2007)
It is interesting to note here that compliance attempts described by LM precede the 
adoption not only o f the EU TCD Directive which came into force on 7 April 2004, 
but also of the Human Tissue Act (HTA) of 2004. Yet, her account echoes those of 
other bioentrepreneurs who aimed to comply with the subsequent EU Tissue and Cells 
Directive (TCD) and with the more recent ATMP regulation.
Now, both the HTA (2004) and the EU TCD (2007) require that production of 
tissues and cells, either in clinical studies or patient therapy, must be manufactured 
under observance o f strict GMP (Good Manufacturing Practice) conditions in the so- 
called ‘clean rooms’.162 This is because, the culture of cells (in this case skin cells) and 
many other cell types involves their exposure to the atmosphere, for instance during 
feeding. Hence, measures must be taken to prevent the risk of particulate or 
microbiological contamination. The costs o f building or refurbishing existing 
laboratories are substantial and are followed by major costs associated with monitoring 
and restocking of the clean-room and employment o f trained personnel.
162 GMP facilities or 'd e a n  room s' are re lied  on  to  con tro l en v iron m en ta l co n ta m in a tio n  and  th e r e b y  g e n e r a te  a s ter ile  
p roduct. As p o st-p ro c ess  ster ilisa tion  is largely in com p atib le  w ith  m a in ten a n ce  o f  ce ll th era p y  p rod uct p o ten cy , a sep tic  
t e ch n iq u es  are u sed  th ro u g h o u t p rod u ct m an u factu re  to  con tro l co n ta m in a tio n . M aintain ing a sep tic  te c h n iq u e  is w h a t  
drives th e  d esig n , co n stru ction  and fu n c tion  o f  GMP facilities.
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From the interviewee’s description it is obvious that the ‘GMP-compliance’ process 
was uncharted territory for her and her colleagues. She admits that their attempts to 
comply have been ‘clumsy’ and they were not supported financially nor guided by the 
Department o f Health. She also notes the impact the whole process had on the careers 
o f people who were involved as, she implies, compliance took a lot o f extra time and 
effort that had to be directed away from the research work and the treatment of 
patients.
Equally interesting is how LM views regulatory compliance as far more hindering than 
any scientific and technical challenges in her field:
Where we are right now, the scientific challenge o f developing new 
products is actually the attractive and somewhat easier bit. People have 
been culturing adult skin cells since 1995. They have been using skin cells 
therapeutically since 1982, so compared to the stem cell world this is a 
fairly mature technology. To develop new products in the area is entirely 
possible. We could develop many more products than we could afford to 
take down the line. The biggest challenge to us in developing new 
products is actually the regulatory issues and the ever-changing regulatory 
environment.
(LM, PI/Founder of Spin-out, 2007)
LM explains how the science part o f her work is the ‘attractive’ and ‘somewhat easier 
bit’. She refers to the long and established science of her field and contrasts it to the 
very ‘novel’ science of stem cells, characterised by uncertainty and unpredictability. 
Admittedly, LM is working in a scientific arena where there are far fewer scientific and 
technical uncertainties than those faced by hESC researchers. Still, novel biomaterials 
(e.g. for scaffolds) and novel combination products have their own risks and it is 
impossible to say that all ‘technological’ risks can be eliminated. LM notes that, given 
the relatively well established science, to develop ‘new products is entirely possible’ and 
that they could actually ‘develop many more’ if it was not for the ‘unattractive’ part of 
her work, which is the regulation.
199
LM’s suggestion that it is the ever-changing regulation and the pressure to comply that 
are actually hampering innovation in the RM field is matched by other UK 
bioentrepreneurs as well as other investigators. More specifically, D r Julie Daniels, 
reader in stem cell biology and Director o f ‘Cells for Sight Tissue Bank’, Moorfields 
Eye Hospital (London, UK), in an article she published with colleagues, describes their 
experience of trying to comply with the Directives (in this case the EU TCD) and 
gaining regulatory approval, in the hope that it ‘may help colleagues who are 
developing innovative academic research-driven stem cell therapies regarding donor 
consent, raw materials, quality assurance, laboratory specification, indemnity and 
funding’ (Daniels et al., 2006: 715). Their account and long list o f requirements is a 
proof o f the time and effort required for regulatory compliance. In a different quote 
that sums up the views of many o f my respondents the authors state: ‘In our 
experience, gaining regulatory approval has been as great a hurdle as surmounting the 
scientific challenges of stem cell therapy’ and at the end of the article they conclude: 
‘No doubt, the loss of some activities will have prevented the delivery of poor quality 
cell and tissue products to patients, and this can only be a good thing. However, we are 
left to wonder how many innovative new therapy programs borne out of government- 
and charity-funded research in UK universities may have been abandoned owing to the 
pressures of an ever-changing regulatory environment and lack o f infrastructure to 
support it’(2006:718).
Along with the pressure felt and the difficulties o f compliance, a few interviewees 
highlighted the ‘expected’ differences in the interpretation o f regulations across 
Member States and discussed the impact these differences might have on the overall 
attempt for normalisation. GL’s statement is simple but characteristic:
The EU Directive is quite reasonably clear actually, but how do you
implement it? Maybe open to interpretation really.
(GL, P i/C lin ical Involvem ent/Founder o f Spin-out, 2007)
According to Article 29 o f the ATMP regulation, all ATMPs that are on the 
Community market in accordance with national or Community legislation will have to 
comply with the new legislation by December 2011 (ATMPs other than tissue- 
engineered products) or 30 December 2012 (tissue-engineered products). LK, who is
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well versed in the regulations through a number of key positions he holds in national 
and international oversight committees, explains how the regulation o f ATMPs across 
the EU is becoming clearer, but no less arduous in terms of compliance at the level of 
delivery.
The regulations for 1394 [ATMP regulations] were enacted in the UK 
law on the 7th of January this year [2009] but the implementation 
guidelines only came out from the MHRA in July [2009] and the closing 
date for discussion o f those was the 16th of September [2009]. And only 
now [November 2009] I am having conversations with the MHRA about 
interpreting those opinions. And I suspect it will be decided early next 
year how they are going to deal with them in the UK. But they m il be 
different to every Member State [emphasis added]
(LK, P i/C lin ica l Involvem ent/Founder of Start-up, 2009)
Almost a year after the regulation became effective, LK implies that it is still too early 
to determine how the new regulation works, because much depends on the details of 
its implementation — in other words how each country ‘interprets’ the regulations in 
their attempt to ‘adopt’ them through national laws and guidelines. Below, LK draws 
attention to problems that he has experienced during the ‘implementation phase’ of 
the new ATMP regulation because of different interpretations o f the regulation by 
different countries:
So, for example, the Hospital Exemption Scheme (HES) in the 1394163 in 
the UK you are going to have to apply for an MHRA production licence 
for your HES licence or use the currently existing “specials” licence. Well 
I know for a fact that the Dutch are not going to implement it in that 
way. And it will be very difficult for us to import products that are made 
under HES. Well for one, you can’t export products made under the 
HES and yet many cell therapies, particularly transplantation cell 
therapies, we currently ship them all over the world. So, I am using 
mesenchymal stem cells (MSCs) as an example. One o f my colleagues in 
London needed an MSC product for one of their patients and we didn’t
163 '1 3 9 4 ' refers to  th e  ATMP R egulation
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have one. No one else in London had one. The only one we could 
identify was in Utrecht. Now Utrecht then shipped it over. They would 
not be able to do that if they are manufacturing under a HES, they 
couldn’t send it to the UK. So equally, if the lab in the UK was making 
their MSCs under the HES they couldn’t receive MSCs from somewhere 
else. So you have to have a “specials” licence. And that means that the 
manufacturer has to have a “specials” licence.164 And in academia at the 
moment there is only one academic that I am aware of in the UK that 
has an MHRA IMP manufacturing licence165 and the “MHRA specials” 
licence. They just don’t exist [...] so those are the sort o f barriers that I 
have been around, and will be increasingly raised if we are not careful.
(LK, P i/C lin ica l Involvem ent/Founder o f Start-up, 2009)
LK describes a situation where the ‘new regulation’, specifically the HES, would have 
blocked the application of an ATMP, rather than facilitate it. His perspective is 
informed by personal communication and discussions on the implementation o f the 
new regulation with various experts from Holland, who are interpreting it in a different 
way. He explains how cell transplantation therapies such as MSCs — that, so far, have 
been routinely transported from one country to another, based on need — will now, if 
classified under the HES, be prevented from being imported and exported.
As mentioned in the introduction to this chapter, once a product is classified as an 
ATMP, the procurement o f the starting material and the subsequent storage o f the 
product are regulated by the HTA (under the Tissues and Cells Directive), but the 
production is regulated by the MHRA and requires one or more of three licences 
depending on the intended use of the ATMP. The options available include: the 
Hospital Exemption Scheme (HES) manufacturing licence; the ‘specials’ 
manufacturing licence; and the manufacturing licence for Investigational Medicinal
164 A 'sp ecia ls ' m an ufacturin g  licen ce  a llo w s  th e  m an u fac tu re  o f  ATMPs for  tr e a tm e n t  o f  p a tien ts  w ith  clinical n e e d  w hich  
ca n n o t b e  a d d r esse d  by any licen sed  m ed ica l prod uct. In th is  c a se  th e  p rod uct can  b e  re le a se d  for  u se  by th e  q uality  con tro l 
p erson  o f  th e  lab.
165 MA-IMP (M anufacturing L icence for  Investigation a l M edicinal P roducts) -  th is  lic en ce  is required  if th e  ap p lican t is 
planning to  u se  th e  ATMP as part o f  a clinical trial. ATMPs p rod u ced  u n d er an IMP licen ce  requ ire a c o m p reh en s iv e  'p ro d u ct  
sp ec ifica tio n  file' w hich  d eta ils  th e  m an ufacturin g p ro ce ss , th e  q u a lity -con tro l a ssa y s  a sso c ia te d  w ith  th e  m an u fac tu re , and  
a p rod uct d efin ition  a g a in st w hich  ea c h  p rod u ct can b e  a c c e sse d  to  d e te r m in e  w h e th e r  it is fit for  r e le a se  (for in fu sion ). The 
IMP licen ce  a llo w s th e  im p ort and ex p o rt o f  ATMPs. In ad d ition , ATMPs th a t  h a v e  b e e n  m an u factu red  a s IMPs can , u pon  
co m p le tio n  o f  su ccessfu l clinical tria ls, b e c o m e  a licen sed  m ed ic in a l p rod u ct and  can b e  co m m erc ia lised .
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Products (MA-IMP). All three licensing options also require full cGMP compliance 
(Lowdell, 2009).
O ut of the three newly introduced licences, the hospital exemption scheme (HES) 
licence has been in the centre of a debate166 since the draft version o f the ATMP 
regulation with companies (SMEs) claiming that, because o f the rule, they face ‘unfair 
competition’ from hospitals. According to the HES, hospitals will not be Subject to the 
regulation where they prepare advanced therapies in-house, and where these therapies 
are developed ‘on a non-routine basis according to specific quality standards, and used 
within the same Member State in a hospital under the professional responsibility o f a 
medical practitioner, in order to comply with an individual medical prescription for a 
custom-made product for an individual patient’.167 In other words, these ‘one-off 
patient-specific treatments will be exempted from applying for the central EU 
marketing product Marketing Authorisation. Instead, the regulation stipulates that 
ATMPs ‘manufactured under the HES must be authorised by the Member State’ — that 
is the MHRA in the UK.
Although the HES rule appears to enjoy clinical acceptance, according to LK’s 
narrative there is ‘catch’: ATMPs manufactured under the HES licence cannot be 
imported or exported. If  a situation was to unfold like in the case described by LK, the 
turn of events would be ironic, if one considers the objective of the ATMP regulation 
which is to allow free movement of products around Europe, whilst guaranteeing an 
equally high level of safety for patients. As a last comment, LK implies that, 
increasingly, as researchers and agencies recognise the need for importing and 
exporting ATMPs, the value of the HES within the regulations will diminish 
substantially. In short, LK’s example confirms the need for careful implementation of
166 Industry s ta k e h o ld e rs  h ave raised  c o n ce rn s  a b o u t HES and th e  s u b s e q u e n t crea tio n  o f  a tw o -t ie r  sy ste m  favou rin g  
h osp ita ls  and a n eed  to  'level th e  p laying fie ld '. W hile p rod u cts p rod u ced  by p rivate co m p a n ie s  will b e  su b jec ted  to  rigorou s  
ex p er t sc ien tific  eva lu a tio n , h osp ita ls  cou ld  m a n u fa c tu re  th e  sa m e  ty p e  o f  p rod u ct w ith  m uch  le ss  ev a lu a tio n . A ccord ing to  
industry  in sid ers th e  HES rule n o t on ly  le a d s  t o  a situ a tion  o f  unfair co m p etitio n  b e tw e e n  p rivate e n terp r ise s  and h osp ita ls , 
but it a lso  p o se s  risks in term s o f  p rod u ct reliability  and sa fety . On th e  o th e r  h and , clin icians a rg u e  th a t th e  HES will 
m in im ise  th e  im p act o f  th e  n ew  ATMP regu la tion s in hosp ita ls , provid e fr e e d o m  o f  activ ity  and p ro m o te  in n ova tion  
(B revignon-D odin  & Singh, 2 0 0 9 ). For ex a m p le , accord in g  to  Paul H atton a t th e  C entre fo r  B iom ateria ls  and T issue  
E ngineering (U niversity  o f  S heffield  S ch oo l o f  D entistry) th e  ex e m p tio n  o ffers  an op p o r tu n ity  for  h o sp ita ls  to  co n tr ib u te  to  
th e  d e v e lo p m e n t o f  com m ercia l th era p ie s . He s ta tes: 'I can s e e  w h y  industry m igh t f e e l th a t h o sp ita ls  m igh t h ave an unfair 
a d v a n ta g e  in th e  d e v e lo p m e n t o f  ad v a n ced  th era p ie s , b ut c u s to m /n a m e d  p a tien t e x e m p tio n  for h osp ita ls  is n o t a n ew  
c o n c e p t  and  th e  ty p e s  o f  th era p ie s  d e v e lo p e d  in th is  w ay  will, in th e  m ain , b e  d iffer en t to  th o s e  d e v e lo p e d  by industry' 
(Sheridan, 20 0 6 : 4 8 0 ).
167 'ATMP G u id an ce (2 0  April 2 0 1 0 )' d o c u m e n t  (th e  d o cu m en t in clu d es g u id a n ce  on  th e  UK's a rr a n g e m e n ts  u n d er  th e  
H ospital E xem ption  S ch e m e  (HES). A ccessed  o n  M ay 2 0 1 0  at:
h ttp ://w w w .m h ra .g o v .U k /H o w w e reg u la te /A d v a n ced th era p y m ed ic in a lp ro d u cts /A b o u ta d v a n c ed th e ra p y m ed ic in a lp r o d u cts /i
n d ex .h tm
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the ‘new regulations’ through ‘trial and error’. The majority o f interviewees suggested 
that ‘application and practice’ is the only way to test, refine and ultimately improve the 
regulation.
The importance o f Member State ‘interpretation’ for successful harmonisation, 
underscored by bioentrepreneurs, is not new in the EU. Commenting on a report168 
about the effect o f harmonisation on innovation in the European medical devices 
industry (published in 2000), Steg and Thumm (2001) note:
It must be noted that although the basic prerequisites are in place today, 
the positive effects have not yet developed to their full potential. At 
present companies are still greatly influenced by the negative effect of 
transition. Further actions appear to be necessary so that a 
comprehensive harmonisation of the interpretation, practical application, 
and enforcement of the new institutional framework at the level of 
different member states and players can be achieved and that the 
expected positive effects o f the new institutional framework can be 
realised fully.
(Steg & Thumm, 2001: 430)
In short, according to Steg and Thumm, the successful harmonisation that will assist 
the innovation and commercialisation process is not enough in itself. After the 
establishment o f universal and ‘appropriate’ rules and guidelines, innovators and 
companies have to endure a difficult transition period that appears to have negative 
effects. As the authors highlight, harmonisation needs to be followed by ‘further 
actions’ crucially supporting the interpretation, practical application and ultimately, the 
enforcement of the ‘harmonised’ guidelines/legislation. Only then will the positive 
effects o f the harmonisation be ‘realised fully’.
168 R eport co m p iled  in April 2 0 0 0  by VDI/VDE-IT (T eltow , G erm any), T ech n op o lis , (B righton , UK) and  th e  Institu te for  
P rosp ec tive  S tu d ies  (Seville, Spain) for  th e  E uropean C om m ission 's D irectorate G eneral E nterprise.
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Summary
To sum up, it is through use that regulations get revised and refined.169 Regulators 
must therefore work together with bioentrepreneurs/developers to ensure that the 
new regulation in place is practicable. The bioentrepreneurs in my sample admit to 
feeling increasingly pressured because o f the need to comply with ever-changing 
standards and protocols, and describe the impact o f regulatory compliance on their 
time and energy, and subsequendy on their careers. Although they all agree that 
harmonisation is critical for the growth o f the field, the majority also believe that better 
guidance and support on behalf o f the competent authorities would benefit the process 
immensely and hence help the small but innovation-intensive RM firms (like the ones 
they have founded). All interviewees feel that ‘proper’ interpretation o f guidelines is as 
important as harmonisation itself, and a few describe facing interpretation-introduced 
hurdles after the new ATMP regulation became effective. However, they all seem to be 
aware that this is, once again, a transition period and that by the end o f the EC full- 
implementation deadlines, most o f the ‘thorny’ places in the EU regulatory landscape 
will have been smoothed out through regulator/ developer collaboration. For this kind 
of collaboration to be effective, though, authorities must ensure that they are advised 
by suitably qualified members. A few bioentrepreneurs have voiced concerns over an 
apparent shortage o f people with expertise and experience in the emerging 
technologies, implying conflicts o f interests and competition issues (possibly coming 
from relevant fields such as pharma or medical devices). According to 
bioentrepreneurs, these kinds o f interactions would only further complicate an already 
complex and difficult task.
The Cells, the Process and the Models
As noted earlier, the word ‘autologous’ raises particular issues in the context of 
Translation. A key factor mentioned by many of the bioentrepreneurs interviewed for 
this study, and perceived to profoundly influence product regulation during Clinical 
Translation, is whether the cells are patient-specific (autologous) or universal 
(allogeneic). In autologous therapies stem cells are sourced from the patient, 
manipulated, and then returned to the patient. In contrast, in allogeneic therapies stem 
cells are harvested from a donor (or donors), manipulated, expanded and may be
169 Interestin g ly , th e  p ro ce ss  for  US regu lation  fo r  tis s u e -b a s e d  p rod u cts h as b e e n  u n d erw ay  for  a lm o st 1 0  years.
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stored in a tissue bank or as a stem cell line, in order to form the basis o f ‘off-the-shelf 
products and treat a large number of recipients (patients). Both autologous and 
allogeneic products may be combined with manufactured biomaterials to form a 
‘combination’ technology.
Below is a quote from an academic bioentrepreneur who is using autologous products 
(living skin equivalent) to treat ulcers and burns. LM gives her opinion on the different 
‘treatment’ autologous and allogeneic cells receive from regulatory agencies.
I would say that until recendy the UK regulatory environment was one 
where you could hold a sensible dialogue and certainly with respect to 
getting autologous products to patients, entirely possible. Where I think 
the UK regulatory environment is so difficult is when you start to talk 
about allogeneic products.
(LM, PI/Founder o f Spin-out, 2007)
In LM’s experience, investigators like herself can ‘hold a sensible dialogue’ as far as 
autologous products are concerned. This ‘easy’ and ‘sensible’ attitude shown by 
regulators, presumably originates from the fact that LM is using autologous products 
that have less rigorous requirements for testing170 and on a small scale.
Yet, another interviewee’s response seems to up-end the whole impression that 
autologous products are easier to regulate and thus more attractive to develop. 
Interestingly, he is a non-academic bioentrepreneur, founder and Chief Scientific 
Officer (CSO) of a RM start-up (corporate). He states:
In [Company Name] we are developing both autologous and allogeneic 
products and the regulatory issues are somewhat different. The main 
issue with autologous [products and therapies] is the fact that you are 
growing cells from more than one patient at the same time in the same 
facility, so there is the theoretical risk that you could be infecting patient 
A with some virus that patient B has got. So process controls are- critical 
to ensure that this cannot take place [...] With autologous, it’s every day
170 A u to lo g o u s  p rod u cts are g en er a lly  regard ed  as le ss  risky, in te r m s  o f  public h ea lth , com p ared  to  a llo g en e ic  p rod u cts  
b e c a u se  th e  p ro ce ss  on ly  in vo lves  o n e  p a tien t, w h o  is b oth  th e  d o n o r  and re cip ien t o f  th e  cells.
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is a new day. You don’t know what’s coming in. So not only have we got 
to protect ourselves, we’ve got to protect all the other patients from 
contaminating patients. So we assume everyone is contaminating. We 
don’t wait to find out if they are. We just assume they are. [...] The 
concerns are more addressable with allogeneic products because it is 
standard to produce huge cell banks and test them extensively to ensure 
that they are virus free.
(NJ, P I/C SO /F ounder of Start-up, 2007)
In the quote above, NJ explains the different regulatory concerns that his company has 
to address during the production o f autologous and allogeneic cells. According to NJ, 
managing the logistics o f autologous therapies is challenging for his company as every 
patient effectively constitutes their own ‘batch’. In view o f the fact that the company’s 
facilities are processing material (cells) from more than one patient, rigorous Good 
Manufacturing Practice (GMP) standards need to be in place, to ensure that patient 
samples are kept apart in the clean room in order to prevent cross-contamination. As 
NJ later explains, implementing and running a quality control system is more difficult if 
the process is autologous. Processes such as in-process-control, sterility assays, 
endotoxin, mycoplasma, viability and potency all come as standard requirements from 
a regulatory perspective. None of these are cheap and, if the product is autologous, 
they all need to be performed on a patient-by-patient basis. W hat this means is that 
both the manufacturing and the quality control process are extremely space- and 
labour-intensive. Overall, economies of scale and reductions of costs are difficult to 
implement in autologous production, with the overall consequence of having high (per 
patient) cost o f goods. Allogeneic products, in contrast, seem to carry great benefits 
for his company’s manufacturing and commercialisation strategy. Despite their 
requirement for cell expansion, allogeneic products are more amenable to automation, 
can be quality controlled en masse, and thus the costs o f manufacturing are easier to
171recover.
The two preceding statements illustrate different conceptions of the regulatory 
experience for the approval of Regenerative Medicine therapeutics. The former, 
reflects the conception o f an academic-based bioentrepreneur with a relatively small
171 For a co m p reh en s iv e  rev iew  o f  th e  a d v a n ta g e s  and d isa d v a n ta g es  o f  a u to lo g o u s  and  a llo g en e ic  ce lls  in R egen era tive  
M ed icin e  ap p lica tion s s e e  (M ason  & Dunnill, 20 0 9 ).
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academic team/spin-out seeking to take her product towards the clinic. In LM’s case, it 
makes sense to go for autologous products as she is operating on a small (academic) 
scale and she feels she can hold a ‘sensible dialogue’ with regulators in terms o f having 
them approved. Also, given the low (individual) risk o f infection associated with 
autologous therapies, ‘strict’ manufacturing procedures are not critical in her case. The 
second account reflects a rather conventional corporate start-up view from the RM 
industry. In NJ’s industrial setting, the high standards required by regulatory approval 
are ‘easier’ and more cost effective to achieve through the production o f allogeneic 
products.
Two social science studies have made relevant findings, and each partly echoes my 
informant’s perceptions. First, Faulkner et al. (2008) have made a similar finding 
regarding the relationship between the type of TE therapy to be developed and the 
type o f organisation involved. The perceptions noted in their study are those of 
research and clinical scientists in the RM field. The authors write: ‘larger companies 
tend to fund both kind o f research activity [...] potential profitability o f allogeneic is 
one primary motivation in the TE  sector [...] the autologous, service-based model may 
be seen as commercially weak in the longer term, more suited to small scale activity by 
academics in partnership with clinicians and industry’ (Faulkner, et al., 2008: 209). In 
short, there is the perception among their informants that the marketplace was 
structured along the lines of academic groups producing autologous therapies and 
commercial groups focussing on allogeneic, off-the-shelf products.
The second social science study to have partly similar findings is by sociologist Julie 
Kent and colleagues (2006) who, although they make no reference to the type of 
therapy under production (i.e. allogeneic or autologous), describe a two-culture 
perception regarding the setting of production (academic/industrial) and the strict 
management and control of the manufacturing processes. They write:
There are two quite diverse characterisations o f the production o f tissue 
engineered products. One is that it is a relatively low tech activity, which 
can be carried out with minimal resources and in an uncontrolled 
environment. In contrast, the same activities are sometimes characterised 
as highly technical, specialised and requiring strict controls, risk
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management, safety standards and quality assurance procedures. We see 
what has become custom and practice, on the one hand in the social 
world o f the clinic and tissue bank, and, on the other, in the regulated 
industrial setting [...] Manufacturers downplay any role o f standards and 
protocols in the clinic and tissue bank while emphasising the ‘cleaner’ and 
more rigorous procedures embodied in manufacturing practices. O f 
course such a distinction is far from straightforward but it does point to a 
feature o f the two cultures (Kent, et al., 2006: 8).
Kent et al. (2006) point to a ‘two-culture’ representation o f producing Regenerative 
Medicine products. One representation involves the academic/clinic setting (like the 
one LM is operating) with ‘minimal resources’ and a relatively ‘uncontrolled 
environment’. The other representation involves the industrial setting (like the one NJ 
is operating), where the standards and protocols appear to play a pivotal role 
(presumably to achieve the much desired ‘reproducibility’) and the manufacturing 
processes are ‘rigorous’ (to ensure safety and quality of products).
The following narrative by LK seems to nicely complement the previous accounts by 
LM and NJ, by being ‘somewhere in the middle’. More specifically, although LK works 
on autologous stem cell therapies in the field o f cancer Regenerative Medicine he is 
beginning to move his service from an academic small scale to a larger-scale operation. 
In the following extract he talks about issues that arise from the complexity of the cell 
therapy development process, and how they have an impact on the work o f his 
company — especially now that they are looking to expand their service.
Most o f the products that I intend to make over the next ten years will 
always be focussed on a single donor, single patient. So they will be 
directed products. Now at the moment we are restricted in terms of the 
number o f directed products we can make because the processes are 
complex. So, for example, my Technology and Strategy Award for the 
moment will be used to take a complex process that makes a patient- 
specific product and engineer that down to a less complex process. [This] 
still makes a patient-specific product, but [it] does it in a more 
streamlined fashion, so you can produce more. So that’s a scale-up, but
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it’s not industrial scale-up, as [in] single donor—multiple patients — like a 
chondrocyte product or “off-the-shelf’ product. We are not ever going 
to go down the route o f the “off-the-shelf’ [product].
(LK, P i/C lin ica l Involvem ent/Founder o f Start-up, 2009)
As LK explains, his interest lies in simplifying the complex manufacturing process that 
he currendy operates to a ‘less complex’ one that makes the same type and amount of 
product but ‘in a more streamlined fashion’. This will enable his company to ‘service’ 
more patients, but still on a ‘same donor—same recipient’ (autologous) basis.172 He 
mentions the translational award that he has secured in order to fund the project, and 
points out the difference between his approach and that of scaling-up allogeneic 
therapies, where the challenge is to expand the donor’s cells to as large quantities as 
possible (in order to be able to service a large population with the same ‘type’ product).
LK’s kind o f translational work is, in a sense, at the centre o f the Regenerative 
Medicine debate over the lack o f a commercially viable business model and whether 
the (autologous) service-based model will ever be profitable. It is also directly related 
to the popular conceptualisation circulating in the cell therapies field that ‘the product 
is the process’. This conceptualisation, which is based on the solid interdependency 
between a cell-based product and the process through which it has been developed 
and produced, has unique consequences for all parts o f its development and 
commercialisation process. In other words, unlike pharmaceuticals and biologies, a 
cell-based product is in the ‘making’ from the time the cells are sourced up to the point 
of application to the patient. From harvesting conditions, culture conditions, 
manipulation (isolation, differentiation), scale-up/automation (expansion), storage, 
transportation, delivery/application to interaction with the host, are all key 
components. Careful selection and quality assurance o f every component at every step 
is crucial to ensure the safety and effectiveness of the process and, ultimately, the 
product in the clinical setting.
In addition to their allogeneic/autologous concerns and how they affect the process of 
Translation from their perspective, a few interviewees brought up the issue of animal 
models in RM. Below, I present the views of bioentrepreneurs on the reliability of
172 This ap proach  is a s so c ia ted  w ith  a u to lo g o u s  th era p ie s , and is o ften  re ferred  to  in s o m e  co m m e n ta r ie s  and scien tific  
articles a s 'sca le -o u t' (as o p p o s e d  t o  sca le -u p  o f  a llo g en e ic  th era p ie s).
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animal models as a basis for RM clinical Translation, and their opinions on the 
‘changing order’ of future early clinical human experimentation.
As the field of stem cell research and Regenerative Medicine is rapidly moving towards 
translation to the clinical setting, it is no surprise that it becomes dependent on animal 
hosts for assaying the safety and potential therapeutic efficacy in models o f the disease. 
However, judging by the bioentrepreneurs accounts, their validity and hence usefulness 
in the case o f Regenerative Medicine therapeutics is contentious.
The following quote is from a scientist working in the area o f cancer stem cell 
research.
And traditionally once [their use is] proven there are [antibodies] in 
animal models. But increasingly in Regenerative Medicine there is not a 
valid animal model and the EU has understood that.
(LK, PI/C linical involvem ent/Founder o f Start-up, 2009)
LK’s view is shared by principal investigator RG who cites animal models as one of 
the ‘technical challenges’ of translating cell-based products. According to RG, animal 
models cannot be o f use in Regenerative Medicine because RM therapeutics are 
crucially dependent on the environment in which they end up.
I would also point out another technical challenge which is particularly 
true of translating human cells. Which is — the animal models don’t work. 
Because if you put some human cells into an animal, you have to 
immuno-suppress the animal. If  you put them into a human you might 
not — depending on if you have done your work correctly — there are 
autologous cells. So you can’t really test them under the same conditions.
[...] The immuno-suppressants are very, very active molecules, we have 
done some work on this. The same is true for the patch things.173 Animal 
models are now all wrong. You need something with the structure and 
size of the human heart. So you have to move to large animal models 
very quickly, which is difficult. So the scale is wrong for small animal
173 Cardiac p a tch es  th a t are b ein g  d e v e lo p e d  by her tea m .
211
models, and you’ve got all the immune challenges that are wrong for 
human cells. It is a bit like the monoclonal antibody story. You can’t 
really test your actual product in an animal. You could test the concept, 
but you can’t test the product under the same circumstances in an animal.
(RG, PI, 2009)
RG mentions her own experience of trying to develop cell-based cardiac patches for 
the regeneration o f the heart after cardiac disease. She explains how ‘wrong’ the animal 
models are in this case, both in term of ‘context’ and ‘structure’. Immuno-suppressing 
the animal model in order to test the cells, ‘de-natures’ it in a way, as it creates a safe 
but at the same time ‘unrealistic’ context. The animal model, is also ‘structurally 
wrong’, as finding a model with a heart similar in size to a human heart becomes, 
logistically and ethically, more problematic. RG mentions the ‘antibody story’ which is 
discussed below in more detail by LK in his discussion about how regulatory agencies 
are starting to come to terms with the preclinical data and the ‘animal model reality’ in 
Regenerative Medicine product development.
I mean one of the great things to come out of the C28 scandal up at 
Northwick Park was that all of the assays that the regulators wanted were 
done on that antibody. And I was one o f three people that were asked by 
different regulatory authorities to comment on that trial, from different 
EU countries. All three o f us, independently said: “The animal model 
doesn’t test the safety of the antibody in any way, shape or form” . And o f 
course we had the disaster at Northwick Park. Now that has led the EU 
and the FDA to question their traditional acceptance o f pharmaco- 
toxicology studies on biologies. And they are beginning to realise, and we 
have realised, that animal models are not always appropriate. Certainly in 
one of my trials, which is running in the UK at the moment and is about 
to open in the US, both the FDA [Food and Drug Administration, US] 
and the MHRA [Medicines and Healthcare Products Agency, UK] have 
accepted that the preclinical data is all basic laboratory data, there is no 
animal model. So it is straight to human, because there is no animal 
model for that particular product. And we are going to see a lot more o f 
that. (LK, P i/C lin ica l Involvem ent/Founder o f Start-up, 2009)
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In his comments, LK is making reference to the events at the Parexel Clinical 
Pharmacology Unit (housed at the Northwick Park Hospital) in London, where six 
volunteers were left seriously ill after taking part in the first trial in humans o f the drug 
TGN1412.174175 LK mentions the adverse effects associated with the TGN1412 Phase- 
1 trial to highlight the fact that the predictive value of animal models is limited and that 
regulatory agencies will increasingly have to recognise that. He emphasises the fact that 
despite the use o f a series of murine, nonhuman primate studies and even ex-vivo 
human cell assays, the immunological models used in TGN1412 preclinal testing were 
of insufficient predictive power to anticipate the serious adverse events in humans. 
Interestingly, the MHRA, has since said that an ‘unpredicted biological action’ and not 
the manufacture or administration o f the drug was to blame for the adverse reactions 
seen (BMJ, 2006; 332: 1290, 3 June).
In LK’s view, in biologies and cell therapies (as it is also the case with drug 
development programs), moving from preclinical animal testing to human clinical trials 
is a critical juncture. Hence, when extrapolating preclinical testing results to the clinical 
setting, it is important to recognise and appreciate both the relevant attributes and the 
limitations o f a selected animal model of disease/injury. According to LK, events like 
the Northwick Park scandal have prompted regulatory agencies to ‘question their 
traditional acceptance o f pharmaco-toxicology studies on biologies’ and realise that 
‘animal models are not always appropriate’. As cell therapies are becoming more 
common and are starting to be tested across the globe, regulatory, as well as scientific, 
principles for cell therapy development and approval o f clinical trials require re- 
evaluation. The informant implied that the number o f ‘straight-to-human’ trials will 
increase in the future and that regulators and other stakeholders will have to 
implement other modes of regulatory oversight, perhaps, in the absence of appropriate 
animal models, by the identification o f surrogate markers that are more predictive o f 
risk factors in human volunteers.
174 T G N 1412 is a fu lly h u m a n ised  m on oclon a l an tib od y  d esig n ed  to  bind to  C D28, a cell su r face  m o le c u le  on  T ce lls  w hich  
play a ro le in a variety  o f  cell m ed ia te d  im m u n e reaction s.
175 On 13 M arch 2 0 0 6 , e ig h t h ea lth y  v o lu n teers  w e r e  a d m itted  to  th e  Parexel U nit as th e  first o f  fo u r  co h o rts  in ord er  to  b e  
ad m in istered  w ith  esca la tin g  d o s e s  o f  th e  drug. W ithin o n e  hour o f  b ein g  g iven  th e  T G N 1412 in traven ou sly , six o f  th e  
p artic ip ants s ta r ted  reportin g in creasin g ly  se v e r e  m a n ifes ta tio n s  o f  cy to k in e  r e le a s e  sy n d ro m e an d  by m id n igh t o f  th a t day, 
all six v o lu n teer s  d e v e lo p e d  m u lti-organ  failure and w e r e  a d m itted  to  th e  h o sp ita l's  in ten s iv e  care  unit. The tw o  o u t  o f  th e  
eig h t m en  w h o  w e r e  g iven  p la ce b o  sh o w e d  no sign o f  illn ess (S un th aralin gam  e t  al., 2 0 0 6 ). T he drug w a s  b e in g  d e v e lo p e d  
for th e  tr e a tm e n t  o f  a u to im m u n e  and  in flam m atory  d ise a se s  and  leu k aem ia  by th e  G erm an co m p a n y  T eG en ero  and  th e  
trial had b e e n  ap p roved  by th e  M ed ic in es  and H ealthcare Products R egu latory A gen cy  (MHRA) an d  a local e th ic s  c o m m itte e  
(N ada & S om b erg , 2 0 0 7 ).
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My findings on the views of bioentrepreneurs on animal models echo findings of other 
social science studies which also focus on aspects o f the TR process. For example, 
Steven Wainwright, Clare Williams, Mike Michael, Bobbie Farsides and Alan Cribb 
(from King’s College London) and Mike Michael (from Goldsmith’s) (2006) in their 
study o f biomedical scientists expectation in the field o f stem cell research for diabetes 
report and examine similar concerns o f their interviewees about the transfer of 
rigorous experimental studies in animals to clinical studies in humans. According to the 
authors, in the views of biomedical scientists a boundary is drawn between 
interviewees who support rigorous animal modelling and those who question whether 
animal studies will ever lead to similar and thus more clinically relevant studies with 
human cells. Wainwright and colleagues (2006) conclude that ‘the tension between the 
relevance of “human studies” and the rigour of “animal experiments” colours 
expectations for future cell transplant therapies. Our scientists see the target o f ES 
[embryonic stem cell]-driven cell therapies as something that may be unachievable, 
except in very specific and limited areas. In contrast, they see the prospects for 
significant scientific breakthroughs from stem cells in understanding basic cell and 
developmental biology as achievable’ (Wainwright, et al., 2006: 2061).
The animal models controversy, although increasingly prominent, is not unique to the 
RM field (Pound et al., 2004).176 In fact, human clinical trials are essential and 
mandatory because animal studies do not predict with sufficient certainty what would 
be the outcome in humans. Hackam and Redelmeier (2006) clinicians at the 
Department of Medicine, University of Toronto, set out to understand why animal 
experiments often fail to replicate when tested in rigorous human trials. In a review o f 
animal studies (studies that were published in seven leading scientific journals o f high 
impact), they found that only about a third of the highly cited animal research 
translated at the level o f human randomised trials, and only one-tenth o f the 
interventions were finally approved for use in patients. In another systematic review 
that was published in the British Medical Journal a year later, Perel and colleagues (2007)
176 T he au th ors  o f  th is  p ap er in clu d e o n e  so c io lo g is t  (P ou n d, D ep artm en t o f  Social M ed ic in e , Bristol U niversity) and  th r e e  
e p id em io lo g is ts . A ccord ing to  th e  au th ors, th e  id eas  in th is  p ap er h a v e  d e v e lo p e d  th rou gh  th e  au th ors' in v o lv e m en t in 
con d u ctin g  sy ste m a tic  rev iew s and  clinical trials, in rev iew in g  an im al s tu d ie s  b e fo re  trials, an d  in ex am in in g  th e  r e a so n s  
b eh in d  th e ir  failure to  find su c cess fu l tr e a tm e n ts  for strok e and brain injury. T he au th ors  q u e stio n  th e  va lid ity  o f  an im al 
s tu d ie s , h igh light th a t m an y an im al trials h ave b een  o f  p o o r  m e th o d o lo g ic a l q uality  and  call for s y ste m a tic  r e v iew s  to  
b e c o m e  rou tin e  in ord er to  en su r e  th e  b es t  u se  o f  ex istin g  anim al d ata  as w ell a s  im p rove th e  e s t im a te s  o f  e f fe c t  from  
anim al ex p er im en ts .
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compared treatment effects and found that the therapeutic efficacy in animals does not 
always translate into the clinical domain .
The literature on the value of animal disease models in reliably informing human 
studies provides a number of reasons that may explain the disparity between the results 
o f animal models and human clinical trials.177 One o f the most obvious reasons also 
mentioned by my informants is what scientists call the ‘lack of external validity’ or 
‘generalisability’ o f most animal models. In short, both terms refer to the fact that 
animal models to do not sufficiently reflect disease in humans simply because they do 
not adequately mimic human pathophysiology. From the age, size and lifespan o f an 
animal to the workings o f the immune system, all models present a partial-only match 
with the human organism. The ‘lack o f external validity’ is o f special significance in the 
case of Regenerative Medicine, where the ‘product is the process’. In other words, 
given that in RM the ‘process’ refers to the whole journey o f the cells from their 
sourcing to their application on /in  the patient, it makes sense that the final step o f the 
biological interaction between implant and host is crucial in determining the outcome. 
Therefore, according to the bioentrepreneurs, the only ‘adequate’ model to test RM 
cell-based therapeutics is humans themselves.
Summary
To summarise, there is evidence o f a ‘two cultures’ mentality in the RM Translation 
field. The bioentrepreneurs in my sample that are based in academia and clinic show a 
preference for small-scale autologous therapies. In contrast, bioentrepreneurs who are 
involved in start-up companies (considered as an industrial setting) are ‘favouring’ the 
production of universal (allogeneic) products. Interestingly though, each group 
perceives their choice as the ‘easier’ to manage in terms o f regulatory compliance and 
thus approval. The issue of animal models has also surfaced in the narratives and 
appears to be o f special significance to my informants. In fact, a few of them, having 
already completed the ‘necessary’ animal studies, have now moved into the early 
clinical experimentation arena and can talk comparatively about the performance of 
their product in both animal models and humans. Overall, the general perception (as 
confirmed by informants from at least four different disease areas) is that animal
177 For a d iscu ssion  s e e  (Van d er W orp  e t  al., 2 0 1 0 ).
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models are not a reliable model for most RM therapies and more support and guidance 
must be directed toward encouraging investigators to pursue early human 
experimentation (i.e. FIH) and Phase I clinical trials.
Chapter Conclusion
In this chapter I have explored the views of 14 UK bioentrepreneurs in relation to 
regulation during Translation of Regenerative Medicine therapeutics (cell- and tissue- 
based). I have used the concepts o f regulation, uncertainty, innovation, harmonisation, 
interpretation and compliance to develop this analysis.
As a first finding, I identified three sources o f uncertainty for RM UK 
bioentrepreneurs: the classification o f their products; the regulatory route during 
development; and finally, the regulatory authority overseeing each part o f the 
development process. How do bioentrepreneurs overcome this product classification 
uncertainty? What roles do the relevant regulatory agencies such as HFEA, MHRA and 
HTA play in the RM Translation process? I conclude the following:
Before the drafting and the subsequent introduction o f the ATMP regulation, 
bioentrepreneurs working on cell-based and tissue-engineered products in the UK had 
to interact with regulators on a product-by-product basis. The result o f the interaction 
would be an agreement over the characteristics of the product (classification) and, in 
the frequent case of not being able to categorise the product under the existing 
regulations, an agreement on the conditions and the methods/protocols under which 
the therapies ought to be produced in order to secure future regulatory approval. The 
overall impression from the respondents’ narratives is that uncertainty, combined with 
a pressure to comply with an influx of guidelines (often without adequate guidance and 
infrastructure to support it), means that regulation is not a means to ‘control’ 
innovation, but rather another hurdle in Translation that has to be overcome.
In terms of the uncertainty surrounding the regulatory agencies, it seems to be more 
prevalent in the accounts o f the interviews I conducted in 2007 compared to those of 
the 2009 informants. In late 2009, the issue of the HTA-HFEA that surfaced in many 
of the 2007 interviews had already been resolved (by the merger not going ahead) and
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the ATMP regulation was already well into the implementation phase. The 
introduction of the ATMP regulation meant not only clear and comprehensive 
definitions for the classification o f the novel RM technologies but, more importantly, a 
clearly defined regulatory route for each type of product comprising the distinct 
jurisdiction of the HTA, the MHRA and the European Medicines Agency (EMA).
The second finding is that RM bioentrepreneurs present themselves as active shapers 
o f regulations. According to their testimonies, through early and close engagement 
with the regulatory authorities, they have the opportunity to raise their concerns, 
negotiate standards, outcomes and timelines, and most importantly, ‘link’ the 
regulators with the realities o f science and product development as a means to ‘ground’ 
their expectations and hence assist them in producing stringent but also practical 
regulatory guidelines. This is consistent with bioentrepreneurs’ perception o f an ideal 
mode of regulation, accurately described by a term several respondents used — ‘light- 
touch’ regulation. The use of this term endorses a continuous collaboration with the 
regulators who will advise and gradually guide (and apparently be guided by) the 
developers through a consistent yet flexible system.
In so far as bioentrepreneurs‘ (developers) manufacturing input is sought and included 
in the drawing-up of regulatory guidelines (and consequently in policy decisions), the 
evidence for a ‘participative ethos’ (to borrow the Salter and Jones 2002 concept) is 
strong. This strong direct involvement that is revealed in respondents’ accounts also 
agrees with cases discussed by Kent and Faulkner (2002) and Kent (2003) where a 
consumer movement grew up around breast implant use which contributed to calls for 
revision o f the Medical Devices Directive (MDD) and provided some evidence o f a 
more ‘user-oriented’ approach to regulation. Given the nascent state o f the RegenMed 
industry and the limited availability o f research, development and manufacturing 
expertise, as well as necessary infrastructure (for example automation, manufacturing 
equipment), it is not surprising that the feedback o f RM bioentrepreneurs in the 
forefront o f cell therapy production is considered important, allowing them to display 
a form o f ‘active (bio)entrepreneurship’ similar to the what Abraham and Lewis have 
called ‘active citizenship’ (Abraham & Lewis, 2002).
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Also, from a policy perspective, this second finding raises a number o f questions 
regarding the extent to which emerging RM regulatory policy is shaped by 
bioentrepreneurs in the UK. At the moment the bioentrepreneurs’ input and the ‘co­
shaping’ process appear to have an ‘informal’ character, but perhaps in the light o f 
future research, a more ‘formal’ part could be established. This part would benefit 
from the multifaceted role o f the bioentrepreneur and his/her participation in, and 
coordination of, all aspects o f the Translation process.
A third finding is that according to the type o f cells (autologous or allogeneic) used in 
the development of the product, bioentrepreneurs seem to anticipate an ‘easy’ or 
‘difficult’ regulatory approval. However, this anticipation is not straightforward, as it 
appears to depend on whether the bioentrepreneur is operating from an academic or 
industrial setting. Academia-based respondents perceive the autologous regulatory 
approval as ‘requiring comparatively lower production standards’ and hence is more 
‘manageable’, while informants who founded corporate start-ups and manufacture 
products on a comparatively larger scale, think that the ‘high’ safety and quality 
standards necessary in an industrial setting for regulatory approval are easier to address 
in the case of allogeneic products. This point compares intriguingly with recent 
findings reported by Kent et al. (2006), indicating that there is a two-culture perception 
associated with the setting of production (academic/industrial) and the management 
and control of the manufacturing processes.
A fourth and final finding o f this chapter is that many respondents have openly 
questioned the value o f animal models in Regenerative Medicine Translational 
Research. The development, use and interpretation of data from preclinical models 
remain a complex challenge and an imperfect science, and available animal models are 
generally considered deficient (according to the scientific literature) in accurately 
predicting the clinical performance o f a product in humans. My findings however lead 
me to suggest that this ‘liability’ in clinical Translation is perceived by bioentrepreneurs 
to be increasingly worse in RM clinical Translation, because o f the special dependency 
between the product, the process, and the final therapeutic outcome. In fact, several 
respondents instead of advocating ‘a need for innovation in model system’, suggest 
that the only way to really advance the Regenerative Medicine field is to direct clinical 
experimentation to human subjects, as this is the optimal way to test and refine the
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therapies. However, it should be noted that the sample o f interviewees, as chosen from 
the UK bioentrepreneur community, is in a way narrowly focussed in terms o f disease 
areas and types o f product. Thus, it is difficult to generalise beyond the respondent’s 
research areas in deciding whether this ‘dissatisfaction’ with the animal models is true 
for other disease areas at the forefront of RM science.
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Chapter 6
The Art o f Collaboration
Introduction
Guided by Hollander’s description o f the first in the world stem cell transplantation 
and the powerful messages that have been unveiled regarding successful translational 
outcomes, Chapters 4 and 5 have explored the views o f UK bioentrepreneurs with 
regard to the themes of funding and regulation of Regenerative Medicine Translation. 
This chapter will examine the last of the ‘emerging’ key elements credited for 
breakthrough outcomes and necessary to realise the potential o f Regenerative 
Medicine: cross-disciplinary collaboration.
In the context o f Claudia Castillo’s transplantation, cross-disciplinary collaboration 
meant efficient integration of expertise among the different teams from different 
countries, in order to successfully treat the patient using novel technology. This type of 
cross-disciplinarity requires collaboration among ‘actors’ from various science 
disciplines such as stem cell biologists, bioengineers and clinicians in order to translate 
the technology efficiently and successfully. I call this type o f cross-disciplinarity 
‘scientific cross-disciplinarity’. In general, collaborations that are based on ‘scientific 
cross-disciplinarity’ are effective in achieving high-impact developments on national 
and international scales because o f their speed in producing innovative high-quality 
data and combining them, at a level no single discipline or team could have done by 
itself. The crucial importance of this type of collaboration, which requires a 
considerable degree of carefully timed, large-scale recombinant expertise, is a factor 
identified by participants in this study as critical to successful clinical Translation in the 
context o f RM.
Despite the importance of collaborative Translational Research in accelerating 
Regenerative Medicine research benefits, up until recently there were no official 
funding streams in the UK to support such endeavours. Similarly, at the international 
level, there have been relatively few funding bodies prepared to support international
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collaborations between multiple and widely dispersed public and private teams; for 
example, the European Framework Programme has launched a few such collaborative 
initiatives and in the US the National Institutes of Health (NIH). Unfortunately, in 
addition to being limited in number, these initiatives have been fiercely competitive 
and not specifically targeted to provide the support necessary for Translational 
Research (and, presumably, even fewer funding opportunities available specifically for 
Regenerative Medicine (RM) Translational Research).
In fact, it is only in 2008 that the spirit o f international collaborations in Regenerative 
Medicine research and Translation has begun to take hold, as nations realised they 
have much to gain by working together. As a result, cross-border research relationships 
have begun to be forged with participating nations aiming to connect to the global 
supply o f ideas, contribute, adopt and adapt to important innovations. For example, a 
pioneer in setting up international collaboration agreements to co-fund stem cell 
research is the California Institute for Regenerative Medicine (CIRM), which in 2008 
began to sign agreements with various US states and nations across the world.178 The 
aim o f the CIRM strategy is to accelerate the path from research bench to the clinic by 
enabling scientists from different nations to jointly submit research team applications 
and hence foster global academic—industry collaborations that are, according to CIRM 
strategists including their President, Alan Trounson, ‘structured in a manner that is 
more focussed than these relationships have been in the past’ (Trounson et al., 2010: 
513). In the context of such agreements, CIRM awarded 14 Disease Team Awards 
(involving some level o f academic—industry partnership) in October 2009 to the 
average value o f $16 million each. The aim for these ‘disease teams’ is to achieve the 
completion of an Investigational New Drug (IND) application within four years and 
begin a clinical trial.
The objectives o f the CIRM collaborative awards confirm that a new set o f initiatives 
to boost international collaborations extending beyond what Claudia’s case has 
achieved is now well under way. While Claudia’s case was a ‘one-off success which
178 N ation s w h o  h ave s ign ed  such  a g r e e m e n ts  w ith  CIRM in clude A ustralia (S ta te  o f  V ictoria), C anada (th rou gh  t h e  C anadian  
C ancer S tem  Cell C onsortium  (CCSC), th e  Spanish  M inistry o f  S cien ce  and Inn ovation , th e  G erm an M inistry o f  E ducation  and  
R esearch , th e  C hinese M inistry o f  S c ie n c e  and  T ech n o logy , th e  J a p a n ese  S c ie n c e  and  T ech n o lo g y  (JST) O rgan isation , th e  US 
s ta te  o f  M aryland and  th e  N ew  York S tem  Cell Fou n d ation  (Sornberger, 2 0 0 9 ) . Finally, in th e  UK, th e  M edical R esearch  
Council (MRC) h as a lso  s ign ed  a co llab ora tive  a g r e e m e n t  w ith  th e  CIRM, sim ilar to  th e  C anadian d ea l. For m o re  d eta ils  on  
th e  California-UK co llab ora tive  o p p or tu n ity  in tran sla tion a l stem  cell research  s e e  th e  fo llow in g :  
h ttp ://w w w .m rc .ac .u k /F u n d in gop p ortu n ities/C a lls/M R C _C IR M /M R C 005564 .
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involved only scientific and clinical teams and sought the treatment o f a single patient, 
the CIRM initiative has also enlisted the support of the industry, ethicists, government, 
and patient groups in order to bring therapies to the market — that is, to commercially 
translate them. This in turn suggests that in the case o f commercial Translation, the 
need for successful integration o f knowledge domains extends further than just the 
scientific expertise often involved in Regenerative Medicine basic research, to domains 
such as regulation and business. This type o f cross-disciplinarity, which I call 
‘commerciaT cross-disciplinarity, relies upon successful integration of scientific, clinical 
and subsequendy business expertise, and is necessary for commercially exploiting a 
novel regenerative technology. I further suggest below that there is a need for 
‘scientific’ and ‘commercial’ cross-disciplinarity to emerge at distinct time-points during 
the process o f Translation, while the former (scientific cross-disciplinarity) still appears 
to be a prerequisite for the latter (commercial cross-disciplinarity).
Identifying a successful model for commercial cross-disciplinarity, and successful 
Translation, however, is different from actually achieving it. In the sections that follow, 
I explore a number o f issues related to collaboration that emerged out o f the 
bioentrepreneurs’ accounts of Translation collected for this study. These ‘collaboration 
factors’ include: the role(s) of the bioentrepreneurs in the absence of adequate support 
for Translation; the parts played by the university and the Technology Transfer Office 
and their impact on Translation partnerships and collaborations; the value derived 
from the ‘evolving’ composition o f the entrepreneurial team; and finally, the unique 
contribution of clinical input in achieving timely and relevant RM therapy development 
and production.
More specifically, in the next (second) section, I discuss the perception o f the 
bioentrepreneurs that there is a dearth of people appropriately trained and qualified to 
perform ‘knowledge broker’ duties, despite the desperate need identified by various 
stakeholders in the field for support of this kind. I also provide evidence that in the 
absence o f ‘official’ Research Translators, ‘knowledge and research brokering’ activity 
must be performed by bio entrepreneurs themselves, almost always in a ‘trial-and-error’ 
fashion. In other words, bioentrepreneurs must assume the roles o f the ‘Knowledge 
Translator’ and the ‘Boundary-Crosser’ in order to ‘sail’ the company ‘through a sea of 
translational challenges’. In the meantime, these nascent entrepreneurs are not only
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‘forced’ to acquire new expertise (for example business, regulatory, IP, market 
awareness) but they also have to re-direct resources, energy and time away from their 
‘normal’ activities (such as teaching, basic or clinical research) in order to ‘fill the shoes’ 
of the (non-existant) Translators. Although most o f the time this role is taken on 
voluntarily, I present a range o f views regarding the ‘new-found’ role and various levels 
o f commitment to serving it. In the third section, I explore the role o f the university 
and the Technology Transfer Offices as it unfolds though the interviewees’ narratives, 
shedding light on the murky area of technology transfer activities, and their effects on 
translational collaborations in the Regenerative Medicine field. In the fourth section, I 
argue that — in the absence o f adequate and robust funding for Translation, well- 
established, long-term national and /or international collaborations, and well-defined 
regulatory requirements (as seen in Chapter 5) — it is essential to integrate sufficiently 
diverse and innovative expertise in the ‘entrepreneurial team’ to address the challenges 
o f the Translation process (and its missing staff). In the fifth section, I delve into the 
one kind o f collaboration that has emerged as the most decisive in the process o f RM 
Translation — the collaboration between the bioentrepreneurs/developers and the 
clinical community. Drawing from my data, I identify three elements /conditions that 
need to converge in order for RM Translation to successfully occur and use them to 
construct a ‘braided translational model’. In the final section, I discuss my findings, 
draw my conclusions and say how this research contributes to previous work.
Bioentrepreneurs as ‘Research Translators’: A Layer Missing?
In 2007, the Medical Research Council launched a small Translational Research (TR) 
pilot scheme.179 The scheme involved the dissemination o f a small number of research 
funds through institutions in the UK and appointed three Translational Research 
facilitators. Their job was to ease the exploitation o f basic research findings into 
health-related applications that would one day provide tangible benefits. One of the
179 The p ilo t s c h e m e  w a s d es ig n ed  to  run a lon g  m assively  fu n d ed , h ighly acc la im ed  c e n tre s  fu n d ed  by th e  N ational In stitu tes  
for H ealth  R esearch  (NIHR) and w a s  p lan n ed  to  b e  critically ev a lu a te d  a fter  tw o  years. N ow ad ays, accord in g  to  th e  MRC 
w e b s ite  a n ew  cad re o f  'research  tran sla tors' ex ists , 'w h o  h ave th e  skills and  ex p er tise  to  h elp  sc ie n tists  exp lo it th e ir  
research  fin d in gs'. The role o f  th e s e  tran sla tors is to  fa c ilita te  k n o w le d g e  tran sfer  across  all s ta g e s  o f  th e  research  p ip elin e  
and  in a rea s  w h e re  th e  p o ten tia l for  com m ercia l ex p lo ita tion  is n o t ap p aren t. A ccord ing to  th e  MRC, 'th ey  will ta k e  a 
p roactive  ap proach  seek in g  o u t id ea s  for  fu rth er tran sla tion  and brokering links w ith  o th e r  re sea rch ers , industry and  
h ea lth ca re  organ isa tion s. T hey w ill w ork  a t all le v e ls  o f  th e  tran sla tion a l p ro ce ss  from  b asic  research  to  p olicy, practice or 
h ea lth ca re  d e l iv e r / .
(h t tp : //w w w .m rc .a c .u k /O u rresea r ch /ln d u stry /in d ex .h tm ). (A ccessed  M ay 2 0 1 0 ).
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three ‘Research Translators’ was Julie Lotharius who was based at Kings College 
London.
In a statement she contributed to a Nature network forum in June 2008, Lotharius 
identifies one o f the key factors mentioned by many o f the bioentrepreneurs 
interviewed for this study, namely that of defining what ‘Translation’ is, exactly. This 
difficulty — paradoxically o f translating Translation — underscores a fundamental 
confusion among investigators (as described and discussed in Chapter 4) and indeed 
among sponsors of Translational Research about what makes Translation translational. 
In the following statement, Lotharius highlights the need for more ‘Knowledge 
Broker’ positions like hers, in order for Translation to get the critical support that it 
needs for prom pt and successful transfer of research breakthroughs to the clinical 
setting. In her statement, Lotharius asks why more baseline support is not available to 
provide, in effect, a new kind of translational infrastructure:
I do not exaggerate when I say 90% of my applicants still ask me what 
Translational Research is, and giving them a one-line explanation is just 
not possible. Translational Research is a continuum, a fuzzy transition 
from basic research to proof-of-concept trials in man, to clinical 
application, to routine health practice. How do we expect people to do 
something that they don’t understand? So why not invest a little more of 
the £1.7 billion earmarked for Translational Research (TR) in the UK for 
people like me, willing to work on the sidelines, dealing with scientists on 
a day-to-day basis, reading applications, providing feedback, helping
them find resources no one at the university seems to have time to help
them find, searching funding databases, establishing industry links, 
providing intellectual property advice, and sometimes just a few words o f 
encouragement.. .or maybe the directors can do that.
(Julie Lotharius, June 2008)
However, additional infrastructure alone is also not enough — especially since it 
remains unclear to many in the translational sector what exactly it involves (Lotharius 
points out the fact that the majority of the investigators (biomedical and clinical) who
are pursuing ‘translational’ grants are not even certain themselves o f what exactly
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Translational Research actually is). She explains how she spends m ost o f her time 
telling researchers that what they are proposing to do ‘is not really translational’ simply 
‘because the application includes a few buzzwords such as “disease prevention”, “risk” 
and “biomarkers’”. Lotharius appeals for the creation o f more positions like hers that 
have the task o f helping basic and clinical investigators translate their findings. 
According to her description o f the role, Research Translators facilitate Translation 
through helping investigators to integrate various components o f the process such as 
funding guidance, IP advice, and providing networking help to establish university— 
industry collaborations. All of these tasks, although critical and decisive for a successful 
outcome, clearly require special training and expertise and they can be far too time 
consuming to be performed by principal investigators themselves in addition to their 
busy research and /or clinical schedule.
To highlight the challenging nature of her task, which involves having to give face-to- 
face feedback to the ‘rejected’ researchers, Lotharius explains how ‘sometimes just a 
few words o f encouragement’ could also prove useful. Her ironic comment referring 
to the Directors’ ‘words of encouragement’, reveals a deeply held belief among many 
o f the stakeholders I have spoken to (including many o f my interviewees), that the 
process o f Translation is perhaps better managed by people who are personally 
involved in the process and have a ‘sense of it’. Directors and generally people in high 
administrative/managerial posts are considered by principal investigators to be 
disengaged from translational activity and thus ill-suited to give advice and allocate 
money (which they often do).
However, it is not only a new translational infrastructure that is needed, according to 
Lotharius: it is also a new translational culture. In addition to drawing attention to the 
poor understanding o f the Translation concept by many Pis, and the failure o f public 
funders to appoint proper and ample ‘facilitators’ to implement this concept in 
practical terms, Lotharius criticises the way the translational system is currently 
conceptualised by commenting on a recent report in Nature Reviews Drug Discovery praising 
large clinical translation networks. The article,180 entitled ‘Building the bridge from 
bench to bedside’ (2008) reports on and praises the creation o f large networks for 
clinical trials, the erection of large clinical centres and the increasing number o f clinical
180 A dam s, J. U. 2 0 0 8  'Building th e  bridge from  b en ch  to  b e d s id e 1, N a tu re  R e v ie w s  D rug D isc o v e ry  7 (6 ): 4 6 3 -4 6 4 .
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scientist posts being opened in the UK. In response to this ‘mis-directed’ investment, 
Lotharius writes: ‘while indeed very laudable, this is Translational Research (TR) at the 
very end o f the spectrum, where millions o f pounds have already been invested and are 
currendy being overseen and locally disseminated by a select group of people in 
government and academia, mosdy directors o f this and that and the other. W hat we 
must not forget, however is that Translational Research involves a change in research 
culture starting form the bottom up, and re-education o f scientists working at the 
bench about what bench to bedside really is’. In short, Lotharius advocates a shift in 
the focus o f the translational system towards a more thoroughly integrated conceptual 
model o f what Translation actually involves. She clearly suggests that such a shift 
would be better achieved by refraining from committing large investments in generic 
infrastructure, and by carefully directing much smaller investments to change the base 
level culture o f biomedical scientists and clinical investigators, including their 
‘education’ on the real meaning of Translational Research.
In the rest of this section, I explore how bioentrepreneurs perceive this lack of 
guidance and support identified by Lotharius who has not only been a part o f the 
‘system’, but as one of the only three MRC ‘Knowledge Brokers’ she is able to reveal a 
unique ‘insider’s’ perspective on the state o f U K  Translational Research. 
Bioentrepreneurs, on the other hand, can be considered to be on the ‘outside’ o f the 
system, though still having a unique perspective o f their own, as determined by their 
multifaceted role.
Lotharius’ call for more ‘Research Translators’ has been matched by many respondents 
in the sample who acknowledge that individuals with these diverse and integrating 
‘entrepreneurial’ skills, although ‘highly essential’, are in short supply in the 
Regenerative Medicine field. As a consequence, several informants described the many 
challenges and hurdles they faced before reaching the stage in the Translation process 
where they are now (some with licensed products and others with established 
companies and/or products in the pipeline, clinic or market). LM, herself a founder 
and principal investigator, explains how she ‘wished’ there were more 
‘entrepreneurially skilled’ people to help her with the process of clinical and 
commercial Translation.
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I f  I had three wishes, my first one would be that the UK had got more 
people with an entrepreneurial interest in doing this. N ot just a 
commercial interest. Now when you get money from a venture capital 
firm their interest is primarily commercial. What I really wish is that the 
UK  had a bigger number of people who are really interested in working 
alongside the scientists to find the best funding route. So that the people 
who have the experience of having done that, work with the academics.
(LM, PI/F ounder of Spin-out, 2007)
Branding the involvement o f more ‘Research Translators’ as her first wish, bears 
evidence of the difficulties LM faced and the importance she assigns to this type of 
translational expertise and the support it could provide to budding bioentrepreneurs. It 
is also interesting how LM distinguishes ‘entrepreneurial interest’ from ‘just a 
commercial interest’ which, she claims, is expressed by venture capitalists and generally 
commercial sponsors. Her preference towards ‘entrepreneurial interest’ implies that the 
expertise should ideally come from governmental sources; for example, from research 
councils like the MRC who are distributing translational grants, or perhaps they could 
be recruited by the universities themselves. Commercially sourced translational 
expertise is, presumably, perceived by LM as more profit-oriented, a feature that could 
potentially clash with the priorities of the principal investigators themselves.
This difference in culture, based on a more- and a less profit-driven Translation has 
also been part of bioentrepreneurs’ narratives on the role o f the Technology Transfer 
Office (TTO) executives. TTO executives are a recendy added force in UK 
Universities and have various responsibilities including alerting scientists on research 
commercialisation opportunities and providing advice and guidance on intellectual 
property (IP) issues. Many interviewees mentioned TTOs (and their representing 
universities) as ‘frustratingly’ profit-driven and have blamed them for various 
translational obstacles including stifling o f external collaborations (e.g. with industry, 
other universities, etc.)
In LM’s view, experience is also very critical for Translational activities and she 
emphasises that the ‘posts’ should be assigned to ‘people who have the experience of 
having done that before’. It is worth noting here that when Julie Lotharius was
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appointed by the MRC as a pilot ‘Research Translator’ she had five years experience in 
the pharmaceutical industry translating newly identified and validated disease targets 
into clinical development. In Lotharius’ own words, she had ‘knowledge few people in 
academia would generally come across’.
LM continues by describing her efforts to create the spin-out and thus establish a 
commercialisation route for her Regenerative Medicine research. Below, she explains 
how a fellow RM company founder held a meeting181 at his University in 2007 and 
invited many UK bioentrepreneurs so they could all discuss their experiences and learn 
from each other.
A colleague of mine, Professor [Name], held a meeting on spin-outs and 
technology transfer earlier this year and, at the end o f it, he invited 
people who had spin-outs to come and talk to say what was their 
experience, etc. And many o f us, who were academic founders o f 
companies, we all said that we felt we had reinvented the wheel in 
starting the spin-out company. That we had made mistakes, that they 
were obvious in hindsight, and that we just didn’t have the skill set to 
make a good job of this. I am not saying that we failed. I think we all got 
there, but we were all aware how clumsy it was. And what I would say is 
that the academics that are doing the spin-outs usually do have a very 
good sense of where they have expertise, know-how. And I do not think 
that we are being arrogant in saying “oh the business bit is easy”; I don’t 
think we are saying that. We are saying “we wish we had help here”. So if 
we had more entrepreneurs who are really interested in working in the 
sector in the UK, who can work alongside the academics with the idea 
that they wish to commercialise, I think things would go much better. I 
think it’s a whole layer of people we are largely missing.
(LM, PI/Founder o f Spin-out, 2007)
LM’s account provides an insight into how the bioentrepreneurs’ experience 
Translation, and how they share this ‘lived experience’ with each other. LM uses the
181 I w a s  very  intrigued to  learn a b o u t th is  m ee tin g  w hich  u n fo r tu n a te ly  had ju st tak en  p la ce  b efo re  m y in ter v iew  w ith  LM. 
N o d o u b t it w ou ld  h ave b een  a very  en rich in g ex p e r ie n c e  for  m e  t o o ,  to  actu a lly  a tten d  an d  o b se rv e  h o w  'le s so n s  learn ed ' 
are co m m u n ica ted  am o n g  b io en trep ren eu rs .
228
analogy of ‘reinventing the wheel’ to describe how she and her colleagues felt when 
they embarked on the creation of their spin-outs. She admits that everyone has made 
mistakes and that the whole ‘spinning out’ process has been, in fact, ‘clumsy’, but that 
she doesn’t feel like she and the others have ‘failed’. In her opinion, it is clear that the 
novice bioentrepreneurs simply did not have the ‘skill set’ to ‘make a good job o f this’. 
LM also believes that people in her position are very aware o f their ‘strengths’ and 
‘weaknesses’ and are not overambitious with their roles and goals. In a way, she 
confirms the impression that I have from talking to bioentrepreneurs that they, in a 
sense, ‘went with the stream’. In other words, upon identifying a clinical or commercial 
opportunity in their research and with the ‘encouragement’ o f the university’s 
administrators, they decided to pursue it. In the absence o f both internal and external 
appropriate help and guidance though, it seems that nascent bioentrepreneurs have 
been improvising, each drawing their own ‘clumsy’ but ‘edifying’ journey. LM admits 
that they ‘needed help’ and had they had been offered some, she believes ‘things would 
have gone much better’. So she calls for this ‘layer o f people’ that she says is missing. 
In short, she calls for people with the interest, willingness and experience to work 
alongside principal investigators like her, to facilitate and speed up Translation of 
research findings to the market.
Yet in the absence of this ‘layer of people’, PIs-turned-bioentrepreneurs that have 
already gone through some stage of Translation, and perhaps even succeeded in 
creating a company, perceive the process to be challenging and time consuming. In 
principle, academic entrepreneurs may bring a strong commitment to the technology in 
the face of hurdles and setbacks that confront the process o f Translation and 
commercialisation. Their involvement may bring scope for greater ‘technical capacity’ 
together with potential benefits arising from a continuing relationship with the 
technology source such as cross-licensing (Radosevich, 1995). On the downside, 
novice bioentrepreneurs often lack the business knowledge and experience necessary 
to initiate the ‘entrepreneurial activity’. In fact, universities have been found to be more 
successful when the entrepreneurs have experience o f transferring products to the 
market. Furthermore, academic-based entrepreneurs (which dominate my sample), 
may have the tendency to focus on the technical aspects of the innovation to the 
detriment of the business aspects (Radosevich, 1995, 2009).
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Thus it is no surprise that, when discussing the level o f involvement and commitment, 
my interviewees expressed a wide range o f ambivalent views and feelings toward the 
challenges o f Translation. In theory, all respondents’ accounts advocate the notion of 
Translation, but after a closer look at the various narratives, the question about degree 
o f involvement and dedication to the various phases o f the Translation process is 
raised. In the following section I provide examples o f the ‘mixed feelings’ and 
consequently mixed attitudes (of my informants) toward translational challenges. I 
have labelled the respondents accordingly and positioned them on a scale ranging from 
the ‘enthusiast’, ‘eager’, ‘keen’, to the ‘uninterested’ or ‘dismissive’ RM 
bioentrepreneur.
(Keen)
‘Keen’ bioentrepreneurs are well aware of the benefits o f Translation and are receptive 
to the advice of universities and the TTOs. Upon recognising a commercial 
opportunity in their research they very keen to explore it further, although they are also 
eager to emphasise that the commercialisation objective is not ‘driving their research 
agenda’.
Indeed, most of the respondents said they were very interested in getting involved in 
the technology transfer and commercialisation route and admitted to making an effort 
to acquire ‘additional skills’ in order to engage with clinicians and industry. Q N  sums 
up the view of most interviewees in relation to commercial Translation (through 
licensing and/or spinning-out a firm):
I think if the opportunity arises we are very, very keen to harness that 
potential, but it is not our sole driver.
(Q N, PI/Founder o f Spin-out, 2009)
(Reluctant or Accidental)
‘Reluctant’ or ‘accidental’ bioentrepreneurs will recognise the opportunity, but it is 
highly unlikely that they will pursue it without the extra help and advice o f the 
university. Frequently lacking the business expertise to induce commercial Translation 
on their own, reluctant bioentrepreneurs display a preference towards the ‘scientific’
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and ‘technical’ part of the innovation and seem more comfortable in the knowledge 
that the business part is being ‘taken care o f  by business professionals.
Indeed, a few bioentrepreneurs admitted to being less enthusiastic about entering the 
product development and commercialisation process and stated that they would have 
preferred to keep a focus on the ‘science-side o f things’. In short, although these 
informants too were interested in seeing their research being translated and willing to 
facilitate, they expressed ‘mild dysphoria’ about having to become involved with the 
‘operationalisation’, in a sense, o f the Translation process. One such scientist and 
founder states:
It depends how much you want to jump into the company as well. 
[Name of co-founder] and I, although we founded the company, we 
remain at the science part. For the moment anyway. We might get more 
involved if [Company] gets properly funded. At the moment it is at a 
difficult phase.. .although we’ve been going for years.
(GL, P i/C lin ica l Involvem ent/Founder o f Spin-out, 2007)
GL could be described as a reluctant or accidental bioentrepreneur. He admits that, 
along with his co-founder, they prefer to remain focussed at the ‘science part’. His 
statement suggests that the availability and nature of external funding his company has 
so far, plays a critical role in his involvement with the commercialisation activities. 
Perhaps this could also be seen as a conundrum: if they are properly funded, they will 
consider becoming more involved with their company and hence with the Translation 
o f their research. But the possibility of reaching that extra financial support is, 
presumably, directly related to the effort they put in fundraising and thus their level of 
involvement with the company beyond what they call the ‘scientific part’.
Indeed, the commitment of the principal investigator/inventor may be particularly 
important in dealing with the uncertainty surrounding the Regenerative Medicine 
technology in its early stage. Normally, in a pure or orthodox spin-out (Nicolaou & 
Birley, 2003) the academic becomes highly committed to the development of the 
venture. However as seen in the case of GL and his co-founder they may not be the 
best candidate or they may not be interested in assuming the role of the commercial
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Translation champion (instead focussing on clinical Translation or their other ‘core’ 
academic activities).
(Eager)
‘Eager’ or ‘enthusiastic’ entrepreneurs are actively involved with the company and also 
seek to interact with ‘entities’ outside their academic environment such as business 
expertise, regulatory professionals, industry and funders. Bioentrepreneur enthusiasts 
embrace their role more than any other category, seek to learn the ‘language’ of other 
stakeholders with the aim of interacting more efficiently, and seem to enjoy actively 
pursuing all avenues o f the Translation process. Their perception o f the Translation 
process is characteristically informed by the broader social and economic benefits o f 
research commercialisation, as opposed to simply following the guidance o f the 
university administrators.
So a few bioentrepreneurs were clearly more eager to be involved with the commercial 
Translation of their findings and the creation o f a company:
So there was seed-corn available for spin-out companies and my 
colleague Professor [Name] was very keen to have the experience of 
developing a spin-out.
(LM, PI/Founder of Spin-out, 2007)
(Enthusiast)
RB is what I would call a bioentrepreneur ‘enthusiast’. Below, he describes how he 
enjoys working at the interface between academia and industry and highlights the need 
for and importance of people who are able to cross disciplines, especially in a field like 
Regenerative Medicine. He notes:
It hasn’t been easy getting to this point and it will not be easy getting to 
the next point at all. It is high risk, it is very challenging, from my 
personal point o f view, I am learning an awful lot. I am happy in doing it 
because I actually think you need individuals who can cross the 
disciplines. And, actually, I get most out of working at the interface 
between the three disciplines [biology, chemistry and engineering]. It is
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one of the reasons why I think the technology we have developed has 
been very successful. We’ve been working at the interface between 
biology, chemistry and engineering, and I have been working at the 
interface between academia and industry. That is very challenging but it’s 
also very exciting [...] I am very lucky working with some very good 
people. For me, the challenge of getting out o f the laboratory, something 
that we have developed on the bench, into the real world — that is a real 
success. To see one of our products, which we have developed, being 
used by others in the field, and is helping them do their research is 
personally inspiring. But it is also great for the economy and job creation, 
business development and so on. So many positive things really.
(RB, PI/Founder o f Spin-out, 2007)
RB acknowledges that it has not been an easy ‘journey’, from 2002 when his company 
was first incorporated to the day o f the interview in 2007, when it was fairly well 
established. As RB explained earlier, the initial basic research behind the firm was 
supported by research council grants and then a Department o f Trade and Industry 
(DTI) Smart grant was awarded to further exemplify the use o f the technology. RB 
spent a couple o f years setting up the spin-out, during which relevant IP was filed by 
the university and licensed to the company, and access to university facilities was 
arranged (at commercial rates). After the first couple of years however, in 2004, a 
reassessment o f the company’s market offering was performed that resulted in the 
introduction of new R&D. The reasons that prompted the reassessment, as RB 
clarified, included: insecure IP (given the European position on stem cell patents); lack 
of defined product; market potential for the product was difficult to identify and not 
clearly defined. Consequently, the risk for investors was seen to be high. In contrast, 
the newly introduced R&D was considered to have clearly defined commercial 
outputs, a demonstrated demand for both technology and products and thus easily 
defined markets. All these, according to RB, meant that he was more likely to secure 
favourable investment propositions.
The years o f transition from a commercially ‘naive’ spin-out to an established firm with 
significant financial offers and ‘deals under consideration’, seem to have been 
educational for RB. Although he finds the Translation (through transition) process
233
risky and challenging, he emphasises the fact that he is ‘learning an awful lot’. He is 
definitely one of the interviewees to relish the ‘bioentrepreneur’ role and to appreciate 
its ‘boundary-crossing’ features. In fact, it is to the cross-disciplinary work between the 
various research and business teams that he attributes the success o f both the 
technology and the company. He refers to the contribution o f three disciplines — stem 
cell biology, chemistry, engineering — as responsible for the innovative and competitive 
product portfolio and then he credits his own work between academia and industry for 
securing access to expertise and, even more importandy, to revenue streams and 
prospects of early licensing deals. RB describes the work as ‘exciting’ and himself as 
‘lucky’ to be able to work with a diverse group o f people and succeed in transferring 
the product from the ‘bench’ to the ‘real world’. The broader implications of 
Translation on the local (and wider) economy are also very important to him.182
It is clear that RB recognises the importance o f both ‘scientific’ and ‘commercial’ 
cross-disciplinarity and he is well versed on the approach he needs to follow to achieve 
it. He, like LM and the colleagues that attended the spin-out workshop, thinks it is also 
very important to communicate to others the ‘lessons learned’ from the cross­
collaboration and Translation experience. Going over a leaflet he gave me during the 
interview — it is actually a print-out of slides from a presentation he had just given (at a 
conference) on the ‘Issues facing a spin-out stem cell company’ — I read:
Our Aims'.
(a) To create innovative methods to enhance the differentiation and 
function of cultured cells and to improve the accuracy and 
representation of assays.
(b) To develop technologies which are versatile and have multiple 
applications.
Our Approach: to form multidisciplinary collaborations that introduce new 
skills and expertise from different fields which bring innovations and new 
ways to solve problems [emphasis added]
The combination o f ‘Aims’ and ‘Approach’ is a testament to RB’s belief that cross- 
disciplinary collaborations and integration o f scientific and commercial expertise build
182 M ost sp in -o u ts  are unlikely to  serv e  nation al m ark ets, y e t  tak en  as a w h o le , u n iversity  v en tu r e s  d o  h ave sign ifican t 
im p lication s for crea tin g  local e m p lo y m e n t and r e v en u e  g en er a tio n  (C larysse e t  al., 2 0 0 5 ) .
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value into the company and encourage the innovation that is necessary to develop 
successful Regenerative Medicine technologies. Another informant, NC, gives his own 
(sceptical) interpretation about the relationship between academia and bio­
entrepreneurship in the field of Regenerative Medicine:
Ultimately it comes down to a grass roots level o f scientists needing to be 
able to get on and engage with each other productively, and that can be 
problematic. Because to be a good scientist, doesn’t necessarily make you 
good at anything else. I think that there are a few individuals that might 
have other talents but for the most part, I think the majority of 
individuals are very, very focussed on the intricacies of, you know, the 
science that they do and they have a very tunnel vision.
(NC, P I/C SO /F ounder o f Spin-out, 2007)
In modern science, being scientifically brilliant is necessary but it is not sufficient. In 
most fields, a scientist who cannot recruit, work with and communicate with colleagues 
or who cannot attract resources and manage them as obtained, is considered a bad 
overall ‘performer’. According to NC, many principal investigators (and potential 
bioentrepreneurs) are so focussed on their scientific work that he judges them to have 
‘a tunnel vision’. The process of clinically and commercially translating basic science 
findings requires skills that NC believes are ‘foreign’ to most academics. These include 
negotiation and business skills, intellectual property awareness, and market knowledge, 
all o f which may be a prerequisite for the scientist’s ability to recognise the commercial 
value o f the new knowledge and therefore to engage in its Translation (Vohora et al., 
2004). In short, in N C’s view, the majority o f Pis are mainly inspired and motivated by 
the science and overlook the commercial side, which is equally important for 
funnelling their Regenerative Medicine inventions to the patients and market.
Finally, ‘uninterested’ bioentrepreneurs might just prefer to concentrate on their ‘core’ 
academic activities and stay outside the Translational arena, or they might have been 
discouraged by the accounts o f others (as in the case o f one of my interviewees) who 
have had trouble or even failed to translate their research findings altogether.
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RG is the only one o f the respondents who turned down the idea o f commercialising 
her Regenerative Medicine product by spinning out a company (despite pressure from 
the university). She admits to have been discouraged by other bioentrepreneurs’ 
stories.
There have been people who have spun-out companies and I know, 
having talked to them, that they are very shocked by the process. 
Particularly with some of the things where they haven’t realised that they 
are personally liable for any losses and things o f that nature. I know 
people who have tried to [spin-out a company] and they have been rather 
overwhelmed by the process.
(RG, PI, 2009)
RG mentions the accounts o f colleagues who have tried to translate their research 
findings commercially through spin-outs and admit they have been ‘overwhelmed by 
the process’.
1Dismissive'
Another possibility that I have encountered involves a bioentrepreneur who is 
dismissive not of the ‘Translation-through-company-creation’ process, but o f what he 
perceives as an interfering and coercive attitude of the university towards commercial 
exploitation o f its research. Instead, this interviewee proposes a more ‘conservative’ 
approach that involves the creation of a company (preferably non-academic) only 
when the technology has sufficiently matured and the appropriate people (mainly 
professional managers) have ‘come on board’. LK, a PI, head o f RM clinical trials and 
founder, laments the pressure of the universities to translate Regenerative Medicine 
research through spin-outs:
There are a lot o f struggling companies out there, a lot of academic spin­
outs. Some o f them, I would think, are just [a result of] the naivety o f the 
universities. Actually, some of them should never have been span-out. 
Judging by things that I read and from the conversations I have with 
people, they are so naive. They want funding for gathering data that they 
could get through an internet search, or ringing up an academic like me
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to answer their questions. I think there is a lot of naivety out there. I 
think there are far too many spin-out companies; most o f them will never 
turn over a profit and most of them should never have been span-out.
(LK, P i/C lin ica l Involvem ent/Founder o f Start-up, 2009)
LK is the founder o f a RM start-up company (non-academic) and talks about the ‘spin­
out mentality’ that dominates universities. He brands the whole strategy, including the 
resulting companies, ‘naive’. In LK’s view, principal investigators in the Regenerative 
Medicine field are rushing — sometimes through their own initiative but more often 
pressured by their academic institutions — to create spin-out companies.183 The result, 
he explains, is the creation o f companies that have no ‘added-value’, will ‘never turn 
over a profit’ and ‘should never have been span-out’ in the first place. In short, LK 
suggests that, while it is relatively easy to create a legal entity, the act o f setting up the 
company does not necessarily mean that it will succeed in generating wealth. LK ’s view 
is in agreement with a report published in the UK at the end of 2003 — the UK 
Treasury-sponsored Lambert Review o f business—university collaboration — which 
considered that too many university spin-outs were being created and that greater 
focus should be placed on identifying whether a spin-out was the most appropriate 
means to exploit technological inventions produced in universities (Lambert Review of 
Business-University Collaboration, 2003).
Summary
As the data for this study and numerous other analyses have shown, there is an urgent 
need for more ‘Research Translators’ (and this need is identified by all the 
bioentrepreneurs interviewed for this study). According to the interviewees, ‘Research 
Translators’ must be adequately trained and experienced in Translation, and willing to 
work alongside the scientists (Pis, potential bioentrepreneurs) to help them translate 
their findings. Currently this critical ‘layer’ of people is seen to be missing from UK 
universities, with the lack certainly being felt in the RM field. In the absence o f this 
‘helping hand’ infrastructure, novice RM bioentrepreneurs must assume the 
responsibilities o f ‘Knowledge Brokers’, although with varying levels of involvement
183 A s tu d y  by British V en tu re  Capital A ssocia tion  sh o w ed  th a t n o le ss  th an  4 3 5  sp in -o u t c o m p a n ies  h ave b een  cr ea ted  from  
u niversity  research  s in ce  1 9 9 9 . T w o-third s o f  th e s e  h ave on ly  a ttracted  s e e d  fu n d in g , w ith  ju st a handful tak in g  th e  n ex t  
s te p s  to  raise sign ificant su m s to  ta k e  th eir p lans fu rth er. M ore d eta ils  can b e  fo u n d  at: 
h ttp:w w w .g r o th b u s in e ss .c o .u k /n e w s/fu n d r a is in g -d e a ls /2 4 3 5 8 /u n iv e r s ity -c h a lle n g e s .h tm l.(A ccessed  February 2 0 1 0 ) .
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and dedication -  and almost always on a trial-and-error basis. This is a situation also 
characterised as under-defined by commentators such as Lotharius. It is not only a 
question o f getting more specialist-trained translational ‘assistants’ into the mix, but 
also inculcating a stronger sense o f what ‘good’ Translation consists of within the 
sector. As a result o f both these gaps — the missing infrastructure and the as-yet 
emergent ‘culture’ o f translation — it is not surprising that bioentrepreneurs, such as 
those interviewed for this study, frequently express frustration and ambivalence about 
the translational challenges they face. Indeed, in some respects it is surprising there is 
any enthusiasm at all for ploughing forward into this morass o f obstacles. I 
nonetheless came across a wide range of attitudes toward translational challenges 
among Regenerative Medicine bioentrepreneurs. I have termed these categories ‘keen’, 
‘reluctant/accidental’, ‘eager/ enthusiastic’, and finally ‘uninterested’ or ‘dismissive’.
From carefully examining the bioentrepreneurs’ narratives, under which ‘category’ a 
bioentrepreneur would be eventually classified has to do with a person’s character (i.e. 
some are simply more entrepreneurial than others), but also with their experience o f 
interacting with the university for the purposes o f Regenerative Medicine Translation. 
In the following section, I explore the role of the university in the process o f RM 
Translation and how this role is perceived by bioentrepreneurs, as the one ‘driving’ the 
Translation process.
The Role o f the University in RM Translation: Help or Hurdle?
I’m a scientist by training and I think scientists will always find a way 
around that and find a way to collaborate internationally. The interesting 
part comes when you start trying to spin out products and intellectual 
property. That’s when it can get, shall we say, interesting.184 
(Dr. Marilyn Robertson, Scottish Stem Cell Network (SCCN) 
Executive Director)
In the quote above, D r Robertson, SSCN Executive Director, talks about the Scottish 
experience o f forging (cross-border) collaborations and implies that collaborations are
184 Q u o te  tak en  from  (Sornberger, 2 0 0 9 :1 8 5 ) .
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‘easier’ at the level o f fundamental research when the issues o f ownership and profit 
are not yet at the forefront. Since enabling collaborations is one o f SSCN’s key aims, it 
is very important that Robertson recognises that the translational system is built in a 
way that encourages not only universities but also nations to pursue Translation for 
their own economic benefit and hence in their own terms.
In the same vein, while discussing the theme o f collaborations, a key point that 
emerged in my interviews is the role o f the university in the process o f RM 
Translation, through the increasing influence of intellectual property rights (IPRs) on 
the creation o f (national and /or international) translational partnerships and 
collaborations. Many o f the interviewees deplored the strategies followed by the 
universities and their Technology Transfer Offices (TTOs).185
Technology Transfer Offices are the intermediaries through which university science is 
commercialised. Recent research suggests that Technology Transfer Offices vary in 
their mandates and capabilities.186 Although TTO s’ primary activity remains licensing, 
they are also often involved in negotiating multi-party research contracts, establishing 
and facilitating the operation of incubator services, and actively investing in and
187managing university spin-outs.
When asked about their relationship with the university /T T O  and the help they have 
received during their RM translational efforts, my respondents were at pains to 
describe the lack o f guidance and support, as well as the barriers the university 
involvement is introducing. Indeed, the majority of informants criticised the stringent 
university IP policies (mainly patents and material transfer agreements) and gave
185 M uch h as b een  w ritten  a b o u t th e  n e e d  in a k n o w le d g e -b a sed  ec o n o m y  to  ex p lo it  u n iversity -or ig in a ted  in n o v a tio n  and  
th e  n eed  to  im p rove th e  p ro cess . As a lso  m e n tio n ed  in C hapter 2 ab o u t th e  orig in s and  g lob al priority o f  T ran slation , th e  
lan d scap e  is ch an gin g , w ith  TTOs gain ing an in creasin gly  im p ortan t p osition  in a ca d em ia , b o th  in term s o f  p o w e r  and  
n u m b ers. In ad d ition , in ter est in sp in -o u ts  has b e e n  driven by le g is la tive  c h a n g es  such  as th e  B ayh-D ole A ct (US). For a 
co llec tio n  o f  artic les  on  th e  ro le o f  TTOs and th e  rise o f  en trep ren eu r ia l activ ity  at u n iv ersitie s  s e e  th e  sp ec ia l is su e  in th e  
Journal o f  Industrial and C orp orate C han ge, V olu m e 16, N um b er 4.
186 T he su b jec t o f  th e  role o f  th e  TTOs in th e  c o n te x t  o f  ch an gin g u n iv ersity -in d u stry  re la tion s an d  co m m er c ia lisa tio n  o f  
aca d em ic  R&D is very  large. In th e  c a se  o f  sp in -o u ts , th e  bulk o f  research  has fo c u sse d  on  firm  crea tion , w ith  le s s  em p h a sis  
on u n d erstan d in g  o f  w h a t is requ ired  to  grow  th e s e  v en tu res  and 'm ak e' th e m  su c cess fu l. For a g o o d  re v iew  (from  th e  
m a n a g e m e n t literatu re) o f  organ isa tion  in teraction s involving u n iversities and firm s th a t  resu lt in t h e  co m m erc ia lisa tio n  o f  
research  and  te ch n o lo g y , s e e  (M arkm an e t  al., 2 0 0 8 ).
187 S o m e tim e s  th e  TTOs h a v e  b e e n  fo u n d  to  e n a c t  a p roactive  role in ch am p io n in g  n ovel (and  o ften  con troversia l)  
te c h n o lo g ie s . For ex a m p le , a s tu d y  by Sanjay Jain (U niversity o f  W isco n sin -M a d iso n , US) and  Gerard G eo rg e  (Im perial 
C ollege B u sin ess S ch oo l, UK) e x a m in e s  th e  ca se  o f  a TTO-WARF taking on  th e  role o f  th e  in stitu tion a l en tr e p r e n e u r  to  
su p p ort th e  d e v e lo p m e n t o f  hESCs tech n o lo g y . The au th ors argu e th at, in c a s e s  like th e  WARF and  hESCs, 'th e  
com m erc ia lisa tion  ch a llen g e  for th e  TTOs can g o  b eyon d  p a ten tin g  and  licen sin g  or crea tin g  s ta rt-u p s and  in v o lv e s  build ing  
leg itim acy  for th e  n ovel t e c h n o lo g y  (Jain & G eorge, 2007 ).
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examples of how these policies affect their (mainly) external collaborations with 
industry, hospitals, and other academic institutions. Below, a bioentrepreneur reflects 
on his experience of founding a spin-out company in order to translate his research.
It has not been a positive experience. It's been a very frustrating 
experience, because these [TTO executives] are people who tend to be 
very pragmatic and see things from a very traditional perspective. So I 
would be lying to you, if I told you that the creation o f [Company] has 
been easy. Primarily because the university has had a very dogmatic view 
that anything that they are involved with — where, for example, the lead 
contribution scientifically is from their organisation — then they [think 
that they] own everything. And if you are talking about trying to merge 
collective interest, that’s not a helpful starting point. They also have this 
desire to control the distribution o f intellectual property. And again there 
is ‘two-sidedness’ here. On the one hand, there is all this verbal 
acknowledgment o f the need to publicly promote, enhance the 
dissemination [of IP] for public benefit, but at the same time there is a 
desire to maximise the financial return to the university. And those two 
are not necessarily consistent if you need multiple partners to deliver on 
an objective.
(NC, P I /  CSO /Founder of Spin-out, 2007)
NC admits that setting up the spin-out company in order to commercially exploit the 
teams’ laboratory ‘know-how’ ‘has not been a positive experience’. He cites the 
‘dogmatic’ attitude o f the university, conveyed through the IP policies, as the main 
reason behind many of the difficulties he encountered in creating the company. He 
also criticises the university for being overprotective of the work done under its 
auspices, which stems from the perception that ‘they own everything’. This rigid 
attitude towards (material and intellectual) ownership, aims to maximise the 
institution’s financial returns but, as NC suggests, this is problematic when ‘you are 
talking about trying to merge collective interest’ (as in the case o f translational 
collaborations and partnerships). NC also points to the ‘two-sidedness’ of the 
university’s ‘behaviour’ regarding the distribution of intellectual property. On the one 
hand, the university is verbally advocating the (free) dissemination of the resulting IP,
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but one the other hand, they are accused by bioentrepreneurs and other scientists o f 
over-patenting and over-protecting the university’s ‘work’. This behaviour is clearly not 
helpful when ‘you need multiple partners to deliver on an objective’, and many o f my 
interviewees feel that it discourages external partners from pursuing translational 
collaborations.
Indeed, the distribution o f intellectual property rights (IPRs) within a partnership is 
not trivial since it has the objective o f securing the future development and 
competitive advantage of both parties. Issues such as who gains the right to further 
develop and economically exploit the output, and to what extent the use of the know­
how accumulated in the relationship should be restricted in other business contexts 
need to be addressed in contract negotiations.188 Also, a restrictive contract (from 
either side), might cancel the benefits envisaged by a potential partner, leading to the 
collapse o f the partnership. Therefore, in a sense, the ‘commercial cross-disciplinarity’ 
that is achieved and subsequently displayed through the entrepreneurial effort o f the 
founders and the formation of a commercial entity (like a spin-out company), is at the 
same time undermined by university policies. As read in the quote below, the bulk o f 
the blame is directed towards the technology transfer executives and the senior 
academics who they often consult.
At the risk of being slanderous, I am not convinced that the people who 
are in Technology Transfer Offices (TTOs) have the vision to be the 
most effective in their role. So we are talking, essentially, middle 
management posts that are receiving guidance from senior academics, 
heads of departments, etc. Now these academics may have been good 
scientists, and may have been good academic or clinical leaders, but are 
not necessarily versed in business development.
(NC, P I /  Founder of Spin-out, 2007)
NC is very frank about his opinion of the technology transfer executives and how they 
‘operate’ in the commercialisation trajectory. He typecasts them as ‘middle 
management posts’ which are essentially guided by the advice o f senior academics 
from relevant departments of the university (depending on the product). From N C ’s
188 (Paija, 2003).
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perspective, these senior academics who are (frequendy) not research-active any more 
and who have been reassigned to high-level administrative posts such as heads of 
departments (or research institutes), are not qualified to guide Translation either. In 
other words, the essential business development expertise that NC believes to be 
lacking in nascent academic ventures, cannot be satisfactorily provided by the TTOs, 
neither by the way they are staffed nor by the way they operate. To be fair, my 
interviews do provide evidence o f a few bioentrepreneurs who said they were satisfied 
with the help and advice from the TTO .189 Yet far more common were expressions of 
growing frustration among investigators.
In the same vein, a principal investigator based at a top London university with a very 
‘active’ Technology Transfer Office grumbles:
I just had lots of grief from them mostly. As far as I can tell I am never 
going to get any money out o f anything. All they do is they stop me 
working with people. I wanted to get patents on things but the TTO 
didn’t agree with me. So I didn’t get anything from that. And other things 
I know I am never going to get any money from and I want to just do, in 
terms of patents they are very fussy about the IP then.
(RG, PI, 2009)
RG thinks that the university’s TTO  is hindering her work through its strict IP 
policies. She recalls how she has had disagreements with the Office on what ‘stuff she 
should and should not patent, and blames them for being ‘fussy about the IP ’. Yet, 
more importantly, she feels that the IP policies being followed and the strict 
regulations that are in place to govern the research conduct o f staff, are preventing her 
from pursuing essential collaborations. Like other Pis, she is at odds with her TTO 
and does not see it as enhancing collaboration — or other aspects o f her work. In 
effect, rather than being helpful, the TTO is yet another obstacle.
LK provides a similar but more detailed account of the way intellectual property rights, 
and especially the way they are managed (by the university), create barriers in 
Regenerative Medicine Translation. In this case, both sides o f the ‘potential’
189 It is hard to  tell w h e th e r  th e  rare p ositive  c o m m e n ts  th a t I h ave heard a b o u t  th e  TTO's h elp  and  a d v ice  are tru e, or th e  
resu lt o f  a p olitically  correct a n sw er  a b o u t th e  in stitu tion  in w hich  th e  Pis are b a se d .
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collaboration — university and hospital -  are eager to ensure they ‘harvest the fruit’ in 
the partnership, but ultimately have the opposite effect.
Universities tend to overestimate. Well, they’ve been beaten before and 
theyVe lost a lot o f potential IP through not protecting it. And what 
happened is that there has been a reaction towards the other way and 
they believe that IP is everything. I’ve just had a long discussion over 
access to tissues from patients, and one o f the hospitals that I deal with 
believes that a blood sample or a tissue sample that has been derived 
from a patient in their institution carries with it some intellectual 
property. So if I discover something from it, they want to share the IP.
As far as I am concerned, an inert piece o f tissue can’t have any intellect, 
therefore doesn’t have any intellectual property. I f  I or my colleagues 
think of something from that [piece of tissue], develop something from 
that, that property is with the person who generated the intellect behind 
it [final product] and not with the actual substance. But tissue 
agreements190 are the sort o f thing that ties it [IP] up for a very, very long 
time. The university is not happy to give its IP to the hospital just on the 
basis that the hospital provided a bone marrow biopsy.
(LK, P I /  Founder o f Start-up, 2009)
According to LK, the universities’ increasing trend to overprotect IP is a way to ensure 
that they are ‘making the most’ of the research they are funding and that they do not 
lose out to other universities, hospitals, or industry. This ‘over-protectiveness’, LK 
claims, is a result o f previous losses in revenues that universities have incurred by 
showing a ‘flexible’ attitude towards IPRs. He then describes how he recently had to 
abandon a potential collaboration, because the hospital made IP claims over the 
donated tissue to be used in LK’s experiments. The university, on the other hand, was 
not prepared to ‘share’ the IP. According to LK, the ‘property is with the person who 
generated the intellect behind it [product] and not with the actual substance [tissue]’, 
implying that the hospital’s request to retain IP on the grounds that it performed the 
biopsy and extracted ‘a piece o f tissue’ was illogical.
190 By 'tissu e  a g r e e m e n ts ' LK refers to  M aterial Transfer A g reem e n ts  (MTAs).
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It is worth noting that in his description LK specifically mentions ‘tissue agreements’ 
(Material Transfer Agreements) and how ‘they tie IP up for a very, very long time’. An 
MTA is a contract that governs the transfer/exchange o f material such as human tissue 
(cell lines, plasmids or reagents) from the custodian (provider) to a third party 
(recipient). For the provider, a material transfer agreement (MTA) provides several 
comforts including restricting the use o f the material to non-commercial research, and 
reducing the provider's legal liability for the recipient's use of the material. 
Additionally, the terms o f the MTA can help the provider to gain access to the results 
o f the research, both for information purposes and for commercial exploitation. 
According to legal and social scholars, in the case o f Regenerative Medicine and stem 
cell research in particular, ‘patents do not necessarily pose the greatest hurdles to 
research over time; physical property rights, as controlled and enforced through 
material transfer agreements, are often the most difficult to overcome’ (O'Connor, 
2006: 1052).191 Indeed, there are several empirical surveys where researchers express 
greater frustration with material transfer agreements than patents per se,192 while others 
suggest that these two proprietary means of maintaining control and extracting rents 
are ‘mutually reinforcing’.
The above sample of interviews repeatedly suggest that strict IP policies followed by 
UK universities in the field o f RM research (and presumably in other areas o f 
biomedicine) are creating ‘barriers’ and impede the flow o f materials and information 
between research teams and other RM Translation stakeholders such as clinical centres 
(hospitals) and industry. This overemphasis on academic IP has also been identified 
recently in an independent report to the ‘Funders’ Forum’ o f the Department for 
Innovation Universities and Skills (DUIS).193 The report, titled ‘Streamlining 
University-Business Collaborative Research Negotiations’, was published in August 
2007 and states:
191 S ean  O 'Connor, A sso c ia te  D irector o f  th e  C en tre for A dvan ced  S tu d ies  and  R esearch  on  IP (CASPIP), U niversity  o f  
W ash in g ton  Sch ool o f  Law, exp la ins th e  re la tion sh ip  b e tw e e n  IP and  MTAs, using th e  c a se  o f  th e  con tro l o f  s tem  cell p a te n ts  
and  s te m  cell lines by W iscon sin  A lum ni R esearch  F ou n d ation s (WARF) and its affilia te W iCell R esearch  Institu te. S ee :  
O 'C onnor, S. M. 2 0 0 6  'The U se  o f  MTAs to  C ontrol C om m ercia lization  o f  S tem  Cell D iagn ostics and  T h erap eu tics', B erk e ley  
T e ch n o lo g y  L aw  Jou rn al 21  (3).
192 T he m o st  co m m o n ly  cited  su rveys  w e r e  p erform ed  by W alsh  and  c o lle a g u e s  and  in clu d ed  a ca d em ic  re sea rch ers  w ork in g  
w ith in  th e  life sc ie n c e s  gen era lly . A m o re  re cen t su rvey  co n d u c ted  by T im oth y Caulfield is sp ec ific  to  th e  C anadian s tem  ce ll 
resea rch ers , but e ssen tia lly  rep lica tes  W alsh e t  a l.'s core  find ings. S ee: (W alsh e t  al., 2005 ; W alsh  e t  al., 2 0 0 3 ) and (C aulfield, 
e t a l . ,  2 0 0 8 ).
193 T he D ep artm en t for  Inn ovation , U niversities and  Skills (DIUS) w a s  a UK g o v e r n m e n t d ep a r tm e n t crea ted  on  28  June 2 0 0 7  
to  ta k e  o v er  so m e  o f  th e  fu n c tio n s  o f  th e  D ep a rtm en t o f  Education  and  Skills an d  o f  th e  D ep a rtm en t o f  Trade and Industry  
(DTI). In June 2 0 0 9 , th e  DIUS w a s  m erged  w ith  th e  D ep artm en t for  B u sin ess, Enterprise and  R egulatory R eform  (BERR) in to  
th e  n ew ly  fo rm ed  D ep artm en t for  B u sin ess, Innovation  and Skills (BIS).
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It is important that adequate protection is made for Intellectual Property, 
but we feel that both universities and businesses are guilty on occasions 
o f putting excessive emphasis on ensuring their own ideal outcome from 
the negotiation in relation to IP, when it is often not even the most 
important aspect o f the research collaboration [...] there is confusion as 
to whether the primary aim o f collaborative research should be to 
generate income for universities or to create benefit for the wider 
economy; and it is not always clear what public research funders expect 
to see as an appropriate outcome in relation to IP.
(Funder’s Forum Report, August 2007)194
The above passage again echoes the views o f RM entrepreneurs who seem to believe 
that the strenuous efforts that are made by government and research councils to foster 
collaborations in Regenerative Medicine — for example by establishing RM 
Translational Research collaboration grants195 — might indeed be hindered by strict IP 
policies imposed by universities or the funders themselves.
In short, bioentrepreneurs perceive IP (patents and MTAs) as a major obstacle to 
enhanced collaboration and, consequently, their translational work. From the 
interviewees’ accounts, there is no doubt that the majority think they are on a different 
wavelength from TTOs regarding Translation-related priorities. This divergence of 
views and priorities sometimes ends in tense relations with the TTO representatives, as 
informants feel they are limited by IP and related policies in terms o f collaborations 
and expertise and cannot fulfil their ‘true potential’. The main problem lies behind the 
idea o f enhanced collaboration, which not only includes additional expertise and the 
pursuit o f scientific excellence, but also involves the sharing (or matching) o f funds by 
potential collaborators, which could speed up both research and development. 
However, as exemplified by D r Robertson’s comment in the opening quote, it is the 
same financial contributions and need to protect a collaborator’s investment that 
impedes or completely halts the efforts.
194 F ollow ing on  from  d iscu ssion s at th e  Funders Forum Plenary C o n feren ce in N o v em b er  2 0 0 6  a sm all w ork in g g rou p  draw n  
from  u n iversities  and b u sin ess , led  by P e ter  Saraga, look ed  a t th e  issu e  o f  u n iv e r s ity /b u s in e ss  co lla b o ra tiv e  n eg o tia t io n s .  
The re su lts  w e r e  p ub lished  in A ugu st 2 0 0 7  in a report t it led  'S tream lin ing U n iv ers ity / B u sin ess  C ollab orative R esearch  
N eg o tia tio n s '. The report can b e  a c c e ss e d  at:
h ttp : / /w w w .d iu s .g o v .u k /p o lic ie s /sc ie n c e /sc ie n c e -fu n d in g /fu n d e r s -fo r u m /r e p o r ts
195 For e x a m p le  th e  CIRM-MRC tran sla tion a l s te m  cell re search  co llab oration  gran ts.
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The above discussion also brings into relief an omission in writings about ‘successful’ 
RM Translation definition and understanding, namely, that successful Translation for 
one stakeholder may not proceed in parallel with, or may even be in a collision course 
with, other social worlds and downstream, implicated actors. In other words, it might 
be the case that for the PIs-turned bioentrepreneurs the objective is to enlist the input 
(through collaborations) o f necessary people and ‘get stuff done’. For the TTO it 
might be to protect the universities’ research budgets, secure the highest possible 
return on investment and /o r protect future streams o f revenue. Finally, for the 
government the objective might be to ‘look good’ by promoting itself as the distributor 
o f free knowledge and IP and hence a ‘bottleneck solver’. In short, it could be argued 
that Translation may appear to be under-defined not only because people do not know 
‘what it is’ ‘and what it involves’, but because people have very different ideas about
‘what it is for’ — in other words its main objectives.
To add to the pessimism on collaborations, in a recent comprehensive analysis of the 
Regenerative Medicine and stem cell research field (including proprietary domains) 
three authors — Winickoff, Assistant Professor of Bioethics and Society at the 
University of California, Berkeley, Saha from Whitehead Institute (Cambridge, MA), 
and Graff, Assistant Professor of Economics at Colorado State University (2009) — 
have reached the conclusion that stem cell research is an exploding field that ‘is 
characterised by a lack o f any deeply collaborative architecture, yet it is the field that 
requires more coordination than others due to the particular trajectory of its
development’ (Winickoff et al., 2009: 57 and 58). In order to support their claim, the 
authors describe how ‘in response to dominant patterns o f propertisation, competition, 
and decentralisation in the modern life sciences, new forms o f ‘open and collaborative” 
research have, as if by necessity, recently emerged’ (2009:57). These forms of
collaboration, pooling and sharing can mainly be located in fields like open source 
bioinformatics software, genomic and other databases, and to a lesser extent wet-lab 
biology.196 According to Winickoff and colleagues, however, these important efforts 
emanating from either public or private sector initiatives (or at the interface of the two) 
remain the exception rather than the rule, and broad areas o f biomedical research such 
as RM have yet to experiment with such ‘novel collaborative architectures’. In fact, the
196 Specific  'co llab oration ' ex a m p le s  m en tio n e d  by au th ors  in clu d e th e  H um an G e n o m e  Project and  International H ap lotyp e  
M ap Project and  th e  BioBricks Fou n d ation  a t MIT w hich  seek  to  co o rd in a te  a sy n th e tic  b io logy  'c o m m o n s'. For an overv iew  
o f  s o m e  o f  th e s e  effo rts  s e e  (Rai, 2 0 0 5 ).
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authors suggest that such a collaborative architecture would be most useful to 
regenerative research and industry as it seems that not only proprietary, but also 
technical, regulatory and ethical complications seem to ‘cloud the prospects for stem 
cell R&D to a greater extent than other fields in the life sciences’ (2009:58).
Yet, one interviewee mentioned her involvement in what could be called an ‘antidote’ 
to the lack of coordination in the RM IP field. She states:
Interestingly, a paradigm that I am involved with is the Stem Cells for 
Safer Medicines (SC4SM) paradigm.197 This [initiative] supports that free 
protocols should be generated from its academia—industry collaborations 
and be made available to the Stem Cells for Safer Medicines collaborators 
without charge. So it is a shared IP.
(RG, PI, 2009)
Stem Cells for Safer Medicines (SC4SM) Ltd is a not-for-profit public—private 
collaboration with participation by the UK Government198 and pharmaceutical 
companies.199 SC4SM Ltd, in its Intellectual Property policy statement, has set out the 
principles which govern the relationship between the ‘Company’, its members and 
third parties, with regard to intellectual property (IP) rights. The existence of a ‘cell 
bank’ like SC4SM should, in principle, facilitate the exchange o f materials and data (for 
example by mitigating transaction costs), relative to a world where scientists and 
institutions are left to negotiate the terms and conditions o f transfer on a case-by-case 
basis. The operation of SC4SM is based on what is known in the literature as 
‘protective commons’ (or ‘contractually reconstructed research commons’).200 In short, 
participating members in SC4SM are ‘entitled to utilise the intellectual property
197 T he in itia tive w a s  d ev e lo p e d  as a d irect fo llo w  up to  th e  rep ort o f  th e  UK S tem  Cell Initiative, ch a ired  by Sir John Pattison  
and p u b lish ed  in N o v em b er  2 0 0 5  (SC4SM w e b site , w w w .s c 4 s m .o r g ). Initial research  w o u ld  fo c u s  on  th e  d e v e lo p m e n t o f  
'op en  stan d ard s, m e th o d o lo g ie s  and serv ices  in th e  field  o f  s te m  ce lls '. The lo n g -term  o b jec t iv e  o f  th e  co llab ora tion , 
h o w e v er , is to  d e v e lo p  a bank o f  d ifferen tia ted  h u m an  cell lines to  b e  u sed  in early  drug d isco v ery  to  provid e early  
id en tifica tion  and e lim in ation  o f  p o ten tia l tox ic ity  is su e s  b e fo re  clinical te s tin g .
198 G o v ern m en t partic ipation  in clu d es th e  D ep artm en t o f  H ealth , th e  D ep a rtm en t for  Inn ovation , U n iversities  and Skills, th e  
S cottish  G overn m en t, th e  M edical R esearch  Council (MRC) and  th e  B io tech n o logy  and  B iological S c ie n c es  R esearch  Council 
(BBSRC).
199 A straZ en eca, G laxoSm ithK line and  Hoffm an-La R oche are th e  fou n d in g  p rivate s e c to r  m e m b e r s  o f  th e  con sortiu m .
200 For an in -d ep th  d iscu ssion  o f  th e  c o n c e p t o f  'con tractu a lly  reco n stru cted  research  co m m o n s ' s e e  (R eichm an & Uhlir, 
20 0 3 ).
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contributed by other members as well as any new intellectual property generated as 
research projects unfold’.201
According to Mathew Herder, a legal scholar from Loyola University, Chicago, both 
the (UK-based) SC4SM initiative and the Canadian Stem Cell Consortium (CSCC) 
initiative, are two nascent initiatives that have escaped the study by Winickoff and 
colleagues. In his own study, Herder examines the extent to which initiatives such as 
SC4SM and the (similar) Canadian Stem Cell Consortium (CSCC) initiative ‘are able to 
create conditions conducive to scientific collaboration based upon their (observable) 
approach to stem cell-related data, materials, patenting, and licensing, and in spite of 
the real world constraints they each face’ (Herder, 2009: 18).
In addition to the concerns over academia’s restrictive IP policies and their burden on 
RM translational collaborations, the academic metrics system traditionally used in the 
UK is also criticised. A principal investigator from a prestigious London university 
speaks o f the difficulties the metric system imposes on fostering a culture of 
cooperation, interdependence and shared intellectual efforts, all very im portant for 
Translational Research and even more so for the uniquely cross-disciplinary 
Regenerative Medicine Translational Research. RG states:
One o f the barriers is the metrics system o f academics keeping their jobs.
And the university is very clear on this. You have to publish a certain 
number o f papers in impact journal above 5, and you have to be first or 
last author. Now, many o f these experiments require multidisciplinary 
things, they require lots of collaborations, in fact lots of people. So you 
have a paper with 12 or 15 people on and you can have two first joint or 
two last joint authors or whatever, but a lot of people in the middle they 
don’t get credited. I have a lot o f complaints from my collaborators in 
the Physics or whatever Department because they are never the initiators 
o f the biological question, they are only suppliers of a technique so they 
don’t get that first or last authorship. Everybody is saying that we ought 
to be moving to a model where, like physics, where you can have 20 
people on paper and they all get credit.[...] So if you are going to start
201 Entities th a t  are n o t p artic ip ants in th e  SC4SM m ay b e  a llo w ed  a c c e ss  to  re so u rces, but th e y  are n o t  e n titled  to  th o s e  p er  
se .
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throwing people out on the basis that they were not first author then you 
are very much discouraging them from interacting. And this particular 
thing [Regenerative Medicine Translational Research] needs interaction.
(RG, PI, 2009)
RG comments on the ‘academic outcomes’ required and evaluated by the university 
for career progression, and how the current metrics system is hindering collaborative 
Translational Research. As RG explains, bioengineers and materials scientists, although 
absolutely essential for the realisation of many RM projects, are rarely the ‘initiators’ of 
the ‘biological question’. Therefore, according to the current system, they are ‘seen’ as 
mere providers o f a technique and are constrained to the ‘less rewarding’ middle 
authorships. In RG ’s view, by following a system that acknowledges only the first and 
last authors o f a publication, potential collaborators are understandably discouraged 
from forging collaborations with lots of participants and in cross-disciplinary projects. 
To overcome this hurdle, RG suggests a shift to models o f publication followed in 
other disciplines such as physics where, she claims, all contributors in a paper are 
credited equally. Such an approach will undoubtedly encourage interactions between 
scientists and foster RM Translation, which by definition is highly cross-disciplinary 
and depends on many people accumulating and integrating their expertise.
Summary
The bioentrepreneurs in my sample perceive the role o f the university and its TTO  as 
predominandy limiting. The two main areas identified as problematic are the IPRs and 
ownership, and the metrics system. Several interviewees criticise the IP policy o f their 
universities as ‘strict’ and ‘over-protective’, suggesting that it erects barriers to forming 
partnerships as all parties would like to have a claim in the patents rights. A few 
informants mentioned tensions between them and the university/TTO, while others 
passed judgement on what they perceive as ‘two-sidedness’ between what the 
university and Government promote and what their IP policies actually embody. My 
results mirror findings reported in a recent study (Funder’s Forum Report, August 
2007) o f IP over-protection as displayed by both academia and business.
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The UK metrics system and its emphasis on publications are also under the 
respondents’ spotlight. Interviewees suggest that the biased authorship credit that is 
allocated in cases of multi-authored scientific publications such as those frequently 
published in the Regenerative Medicine field, is discouraging scientists such as 
bioengineers, materials scientists, chemist and often clinicians, from contributing to 
RM translational projects. .
Cross-disciplinary and cross-border collaborations are, without doubt, o f critical 
importance in RM as they give research teams, spin-outs, and (on a larger scale) 
nations the opportunity to combine their own scientific, technical, regulatory and 
conceptual advances with that o f others, thus facilitating the generation of novel 
insights that could potentially speed up Translation and innovation. Although this 
‘picture’ o f an ideal collaborative climate is (theoretically) promoted by all stakeholders 
in order for RMT to receive the much needed infrastructural support (as defined by 
Julie Lotharius earlier in the chapter), in reality, the university, which is supposed to be 
the main source of that support, is more often an impediment. A further point to have 
emerged is the conviction of bioentrepreneurs that RM Translation is best managed by 
people who are actively involved in the process. This view echoes Lotharius’ statement 
in the previous section, in which she suggests that directors, heads and generally 
people in high managerial and administrative posts are not the ideal people to advise 
on, design, or allocate funds to translational strategies. Instead, people who are more 
similar to the bioentrepreneurs themselves, on the boundaries o f science, medicine, 
academia and business, are perhaps better suited to guide RM Translation.
In short, according to the bioentrepreneurs who are first in the line of the ‘IP wars’, it 
is often a case of under-definition o f what RM TR involves and how it could best be 
achieved -  that is, through collaborative and cross-disciplinary work. From the 
accounts of the informants it is difficult to avoid wondering whether it is ‘naive’ to 
think the sector will ever be that ‘joined up’. Perhaps this is also what really 
distinguishes bioentrepreneurs from all other stakeholders. They are truly very 
unusually dedicated people with unique communicative and collaborative skills and, 
equally important, they are willing to get into the fray.
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In the following section, I examine the views of bioentrepreneurs on skills, 
accumulation o f expertise, composition of the enterpreneurial team and collaborations. 
What is the importance o f those factors in the Translation process? Which of these 
factors facilitate and which impede the Translation process and how?
The Value o f a Cross-Disciplinary Team
Translational support officers, government programmes, TTOs and University 
research support offices may all be more or less o f use to the RMT bioentrepreneur. 
But at the end o f the day, it is often the immediate team with which such individuals 
work that most profoundly determines their success or failure. Excellent cross- 
disciplinary teamwork can overcome numerous externally imposed barriers. But lack of 
such teamwork cannot be compensated for by any external supports. In this sense, a 
strong team is the true kernel o f successful RM Translation.
This theme is reflected in the interviews, which contain frequent references to teams 
and teamwork. The theme of collaborations in relation to the composition and 
expertise of the translational team surfaced several times when participants were asked 
about the strengths o f their research and company (with regard to Translation). In this 
section, the crucial issue of teamwork is examined with a view to identifying the key 
factors bioentrepreneurs themselves prioritised.
As one interviewee describes her experience of collaboration between stem cell 
biologists, bioengineers and clinicians, it is clear that an emphasis on the significance of 
cross-disciplinary collaboration during RM Translation is both constant and cumulative 
— extending from the early project planning to its successful completion, and 
encompassing everything from basic problem solving to long-term strategy along the 
way:
We start [collaborating] from when we prepare a project proposal and go 
to someone to get funded. We have initial talks about what’s the best 
strategy, what each [team] can bring to the table and then we put it in a 
project proposal, which may or may not be funded. And then, if we have 
it funded, we have regular meetings to try and work out the details [of the
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translational project]. For example, “The rat heart is this size; can you 
trim your material to that size? Can you make it stiffer?” You know, these 
kinds of questions. So, we all take the experience from each experiment 
and carry it forward to the next experiment.
(RG, PI, 2009)
RG describes how she and her team of stem cell biologists collaborate with a number 
of teams from different disciplines including bioengineers, biomaterials scientists, and 
clinicians, initially to write a comprehensive and ‘viable’ translational proposal and, 
subsequently, if funding is secured, to perform experimental work (i.e. animal studies 
and pilot human experimentation). RG explains how the collaborators have meetings 
to discuss everyone’s contribution and how each contribution fits into the overall 
progress. Her narrative about ‘regular meetings’, ‘working out details’ and generally 
back-and-forth questions and answers between the various teams is proof o f the 
degree o f cross-disciplinary, efficient communication and work that must occur in 
order for Regenerative Medicine translational projects to come to fruition.
As she emphasises, there are several benefits that follow from having many
collaborators. First and foremost, with expertise on major developmental pathways, 
stem cell biology, chemical and biomaterial know-how, and ‘eyes’ on clinical 
applications, the group covers a lot o f territory. This scientific synergy makes it 
possible to deal quickly with any particular challenge that may appear. In addition, each 
scientist ‘brings to the table’ a different portfolio o f IP, which is useful if the research 
moves to the phase of commercial Translation. N ot surprisingly, the breadth o f the 
interaction inspires new ways of thinking that can ultimately strengthen the academic 
pathway that each of the collaborating scientists is following. This type of
collaboration could be classified under what I have termed in the introduction to this 
chapter: ‘scientific cross-disciplinarity’. ‘Scientific’ cross-disciplinarity involves
collaboration only among scientists (of various disciplines) and clinicians (as is the case 
with RG’s team), and in order to engage in it, bioentrepreneurs need not have acquired 
neither business skills nor market knowledge (as opposed to ‘commercial’ cross- 
disciplinarity which involves business skills and market knowledge).
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While discussing his experience o f making the transition to the clinic, another spin-out 
founder links the evolution o f the composition o f the enterpreneurial team behind the 
venture to the challenge of securing early-stage funding. He notes:
Establishing the company was really made possible by the merger o f two 
abilities, provided by myself and my co-founder. So on the one hand, 
there needs to be an appreciation o f the science, there needs to be an 
experience with the regulatory process, which is essentially what I 
provide. At the same time, I was struggling to secure funding for this 
work because the research councils, which traditionally would have been 
the first stop for shopping, were not seeing this as a priority or within 
their remit. So it was becoming necessary to present the work and the 
prospect not as a research proposal, but as a business opportunity. At 
that point then, I was rapidly getting out o f my depth. Although I did 
certainly make an effort to engage with both venture capital and the 
regional development agency (RDA), really, I only was successful with 
the latter, when I brought onboard my co-founder who has background 
in accountancy and in business development.
(NC, P I/C SO /F ounder o f Spin-out, 2007)
NC describes his attempt to found a spin-out company in order to move from small- 
scale production of research-grade human embryonic stem cell (hESC) lines to large- 
scale manufacturing o f clinical-grade lines.202 The short-term aim o f N C ’s company is 
to commercially supply these lines as research tools to other academic institutions 
and/or private companies. According to NC, securing research council funding (such 
as he had already received in the academic setting to create the research-grade lines) 
proved highly problematic when he decided to move towards ‘clinical-grade’ work and 
the creation o f a spin-out. As NC explains, funding was eventually secured from the 
Regional Development Agency, but only after the additional (business) expertise was 
brought into the team. N C’s account would be an example o f what I have called
202 W hile re search -grad e hESC lines are a v a lu ab le  re so u rce  for  fu n d a m en ta l s te m  cell research , th e ir  u se  in d ev e lo p in g  
clinical th era p ie s  is co m p ro m ised  by th e  fa ct th a t  th ey  w e r e  d erived  using an im al fe e d e r  ce lls  or  in m ed ia  c o n ta in in g  an im al 
co m p o n en ts , w hich  p resen ts  a risk o f  x e n o g e n e ic  con ta m in a tio n . T here is th e r e fo r e  a clear  im p era tive  to  g e n e r a te  clin ical- 
grad e (or GMP) hum an em b ryon ic  s tem  cell lin es  for th era p eu tic  ap p lica tion s. T h e ear ly  e s ta b lish m e n t o f  b an k ed  clinical- 
grad e lines w ill a lso  en a b le  d ev e lo p m e n ta l an d  preclin ical w ork  to  b e  u n d ertak en  on  ex a c tly  th e  sa m e  s tock  o f  ce lls  th a t  
m ight ev en tu a lly  b e  u sed  in clinical trials and th erap y .
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‘commercial cross-disciplinarity’, as it is the addition of ‘business knowledge’ in the 
team’s ‘knowledge pool’ that seems to give credibility to the new commercial venture.
In the same vein, LK expresses his disapproval o f the universities’ strategy to ‘roll out’ 
companies when technologies are ‘premature’ and the venture team is not adequately 
staffed to deal with the commercialisation requirements.
So many SMEs are being rolled out from the universities with insufficient 
capital, with no expertise [i.e. commercial/business expertise], with a 
really academic approach that everything can be done on a shoestring by 
everyone working a little bit longer, rather that saying “No, we need a 
professional team here and then we really can do it” .
(LK, P i/C lin ica l involvem ent/Founder o f Start-up, 2009)
LK criticises what he calls ‘the academic approach’ to commercial Translation which 
seems to require ‘everyone working a little bit longer’ instead o f recruiting business and 
regulatory professionals. He continues and reflects on the development trajectory of 
the company he co-founded, a start-up, explaining the reasons behind its ‘prosperity’.
And that is why [Company’s Name] is working, because it was not a spin­
out, it was a company in its own right that was set up by businessmen, to 
take [to the market] initially one product that had already gone through 
thirty patients. It wasn’t first-in-man, proof-of-principle; it was thirty 
patients. And they could go out and say “Look, that works, because 
we’ve got the clinical data to show that it works!” And that’s not true of 
every other RegenMed product that has gone out into the market.
(LK, P i/C lin ica l involvem ent/Founder o f Start-up, 2009)
LK credits the involvement o f professional business expertise as well as the advanced 
development stage o f the product for the company’s success. He clearly suggests that 
when a product successfully passes the first-in-human (FIH) stage and there are the 
clinical data to ‘show that it works’, it then automatically becomes more ‘viable’ as the 
foundation o f an SME that will be attractive to external investors. This trajectory, he 
says, is hardly the case for the majority of the RegenMed products, which are spun-out
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from  academia without the necessary expertise, and are usually in a too-early 
development stage to be attractive to investors. Securing the available funds and 
facilities for FIH experimental trials does not, however, guarantee successful 
Translation. If  the principal investigators are to become bioentrepreneurs and devote 
their time to the commercial Translation process, they must also be ‘reviewed in a 
different way’ in terms of their ‘academic performance’. This last point resonates with 
the respondents’ views reported earlier on the publication bias and its damaging effect 
on translational collaborations.
RB reveals a similar understanding to NC and LK, of the importance o f acquiring 
business skills and expertise in order to further the Translation process.
The thing is that the company has developed its technology and it got to 
the point — and I realised this earlier this year — where it needed the 
commercial expertise to go into the real world and spin-out into real 
business. And to do that you require a skill set which comes with people 
that have commercial expertise, who can network, who know how to 
strike a deal. Since the placement o f these two individuals the company 
has changed dramatically. We have now investors knocking on our door 
to give us money rather than the other way around. Word has spread 
very quickly. We are also now talking to a multinational company to 
strike a licensing deal in the US for our technology. There is a very strong 
possibility that an early-stage deal can be negotiated.
(RB, PI/Founder o f Spin-out, 2007)
According to RB, moving his research from the bench to the ‘real world’ in the form 
of a ‘real business’, requires the engagement of business people who are well versed in 
networking and closing deals. As a result o f their recruitment, the company’s financial 
state o f affairs has started to improve, with RB revealing that the company has now 
investors ‘knocking on its door’ and expressing an interest instead o f the other way 
around (which had been the case until that point). He also mentions the possibility of 
negotiating an early-stage deal with a US company, implying that the business expertise 
has significantly boosted the team’s translational efforts.
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Indeed, one of the key issues o f concern at the early phase of the Translation process 
when the decision has been made to proceed and test the application of a laboratory 
findings into the clinic, is the issue o f leveraging the necessary human resources for the 
successful launch o f the venture. Many scholars in the literature o f university- industry 
relations have already emphasized the different rules and norms that prevail in business 
and academic or research environments (Van Dierdonck et al., 1990) while others 
have shown that human and financial resources of spinouts tend to be closely 
interrelated (Heirman & Clarysse, 2004). Additionally, in the venture capital literature, 
Muzyka et al. (1996) provide evidence that when new ventures apply for early-stage 
venture capital funds, the question o f a well balanced team203 with sufficient business 
experience is often raised by the potential investors in order to evaluate a project.
Many bioentrepreneurs in the sample have also stressed the importance o f ‘common 
language’ in the collaborative translational efforts (both for raising financial capital and 
initiating Translation towards the clinic). Indeed, in the organisational literature, 
specialisation and the existence of discipline boundaries are associated with the 
evolution of local norms, values and ‘languages’ tailored to the requirements of the 
disciplines’ work (March & Simon, 1993). Communicating across disciplinary (or 
organisational) boundaries requires learning the local coding schemes and ‘languages’ 
as well as the specialised conceptual frameworks in order to achieve effective 
processing of information (Tushman & Scanlan, 1981). This need for a common 
language is illustrated in the following two quotes:
Essentially we were able to couch the initiative [founding proposal for 
RM company] in terms that the business people could relate to.
(NC, PI/C SO /F ounder o f Spin-out, 2007)
NC explains how he and his ‘business savvy’ co-founder managed to secure capital. RB 
shares N C ’s view:
And that’s when the company is a real business in a sense. And what is 
very interesting is that we are very lucky and we got the right [business]
203 The q u e st io n , n o w , o f  w h a t exactly  is m e a n t by an 'en trep ren eu ria l tea m ' h as b e e n  th e  m a tter  o f  a c o n s id era b le  d e b a te  
and m an y  sch o lars h ave p ub lished  th e ir  ow n  d e fin itio n s  (G artner e t  al., 2 0 0 4 ) . A ccord ing to  V an ae lst e t  al. (2 0 0 6 ) th is  
con fu sion  is re la ted  to  th e  fact th a t en trep ren eu r ia l t e a m s  are to o  o ften  in v estig a te d  w ith in  a s ta tic  fram ew ork  an d  n eg le c t  
th e  ev o lu tio n a ry  a sp e c ts  o f  en trep ren eu r ia l te a m  form a tio n  and d ev e lo p m e n t.
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people in and involved and they know how to speak to the appropriate 
partners and make it happen.
(RB, PI/Founder o f Spin-out, 2007)
RB credits the transition o f his team’s research work into a ‘real business’ to the ‘right 
people’ who got involved and they ‘know how to speak to the appropriate partners and 
make it happen’. According to another interviewee, who has been working in the 
interface of Regenerative Medicine, chemistry and materials, ‘talking the same 
language’ is very important and needs time and effort in order to work. He states:
Especially when you are dealing with people from different backgrounds.
You have to be able to talk the same language and be able to engage — 
and that requires a learning process from both sides.
(MF, PI/Founder o f Spin-out, 2007)
Learning each other’s ‘language’ is, obviously, a crucial ‘activity’ in order for what I 
have termed ‘commercial cross-disciplinarity’ to succeed. The scientists from various 
disciplines, as well as the ‘business’ or ‘industry people’, might have to study at least 
parts o f the other’s field to understand not only the ‘words’ but also the other’s 
motivation, thoughts and impact on value creation. This is, o f course, a two-way 
process and thus, according to MF, requires time and effort from both sides. In  fact, 
all the bioentrepreneurs I have interviewed have admitted to being gradually building- 
up these ‘language’ skills through the various collaborations and interactions with 
diverse communities, all necessary for Translation to succeed.
Summary
All respondents acknowledged the importance o f accumulating and integrating diverse 
expertise for their translational efforts. Each collaborator (scientist, clinician, business 
professional) brings a different type of ‘knowledge’ and only through successful 
integration (via frequent communication and meetings) can RM projects be fully 
realised. Several bioentrepreneurs report that invoking business expertise has made 
their RM ventures more attractive to investors. Finally, bioentrepreneurs spoke of the 
need o f ‘forming’ common language with collaborators — either clinicians, investors, or
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industry — seeking to communicate better with the ‘other side’, induce the creation of 
jointly formed ideas and consequendy be in a better position to invite the other side’s 
support.
Although engaging business expertise is perceived as a crucial step for commercial 
Translation, by far the most important type o f collaboration, as confirmed by all 
interviewees, is collaboration with clinicians. The bioentrepreneurs I interviewed seem 
conscious o f the need to produce clinically relevant results (products/therapies) and 
stress the importance o f early and close collaboration with the future ‘users’ o f the 
technologies under development. The next section explores the dynamic relationship 
between PIs-turned-bioentrepreneurs and clinicians, and draws on empirical data to 
generate a Regenerative Medicine Translational model that has both ‘longitudinal’ and 
‘current’ features.
Collaboration with Clinicians
According to all interviewees, the involvement o f clinical collaborators is o f unrivalled 
importance in Regenerative Medicine Translation. In the following passage, NC 
explains how collaboration with clinical services and integration of clinical experience 
contributes in setting up an attractive investment opportunity that might help secure 
(private and /o r public) capital. NC notes:
I think the clinical interface is very important. I mean clinical translation 
is a really big header. The fact that we have not sorted out translation 
yet...To do so, I would argue that we need to take the [Company] 
paradigm and raise it up a couple o f notches. We need to see that type o f 
integration between the academic centre, the clinical service and private 
investment. This is something that myself and others [in the RM field] 
are working on. What I am hoping [Company] will be able to do is to 
position itself in a way that private companies will come in and see; see 
the elite contributions o f an academic pipeline and clinical experience as a 
desirable setting' to make an investment. Perhaps by acquiring the 
product in the first instance, but then in the second instance, to assist in
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actually ‘taking’ the product to the clinic. (NC, P I / Founder of Spin­
out, 2007)
NC is the founder and Chief Scientific Officer (CSO) o f a Regenerative Medicine 
company that isolates hESCs to the standards required for clinical applications and 
makes them available, either for the development of cell therapies for clinical 
applications or for drug discovery research. His company is unique in that it is 
operating as a partner o f a larger network which includes the university (from which 
the company has spun-out) and an NHS specialist provider. The latter is providing the 
clinical and regulatory expertise and ensures that the cells produced by the spin-out 
company comply with Good Manufacturing Practice standards (required for the cells 
to be o f ‘clinical grade’).
NC refers to Translation as a ‘big header’ implying that it is difficult to solve and that 
the failure to do attracts much attention (because it is recognised unanimously by all 
stakeholders as a priority). He believes that the translational strategy that his company 
is following, which is characterised by integration of the academic centre, the spin-out 
and the clinical service is an attractive proposition for investors who, NC hopes, will 
recognise the ‘elite contributions o f an academic pipeline and clinical experience as a 
desirable setting to make an investment’. In other words, in N C’s opinion, 
demonstrating collaboration between physicians, who can argue from first-hand 
experience that a need for a product/therapy exists, and a biomedical scientist who can 
devise an effective biotechnological solution can be very powerful, especially when a 
spin-out is trying to convince an investor that an idea is both technically and 
economically sound.
Another informant expresses a similar appreciation for the clinician’s input in the 
Translation process:
We have clinicians embedded in the projects, often working on the 
animal work as well, and thinking about it in terms o f what they see 
clinically. In addition, the heads o f most of the divisions in the Medical 
School are clinicians and they are often working at the bedside so we 
have a lot o f clinical input, you know, embedded in the whole process.
(RG, PI, 2009)
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RG highlights the fact of ‘having clinicians embedded in the projects’ and ‘in the whole 
process’ of developing the products. The dominant conception among interviewees is 
that clinicians are familiar with the patients’ needs — from ‘working at the bedside’ — 
and they are also the ones that will eventually deliver (‘use’) the therapy. Hence, 
consulting clinicians increases the chances o f the product being correctly designed and 
developed, and consequently adopted for use, if commercial Translation is also 
successful. In the same vein, a founder talks about what she considers to be the 
strengths of the team behind the company which help boost translational efforts:
We have got strengths in surface technology, in skin cell culture, and in 
wound management. And a particular strength of the company is that we 
have worked very, very closely with clinicians to develop our product and 
our next products.
(LM, PI/Founder o f Spin-out, 2007)
The timing of initiating clinical collaborations is also considered important. For 
example, early communication with clinicians has been mentioned by many 
interviewees as a success factor. GL states:
[...] maybe academically we can push more for translation. I think also 
more active collaborative research with the clinicians who will deliver 
whatever we are going to do. For instance, for the work on the eye that 
we are doing with Professor [Name] at [University]: we have a project in 
collaboration with his group. The [Spin-out] and the [Academic Centre] 
are involved too. They got the surgeons and the downstream [clinical 
work] and we are doing the upstream [fundamental research]. I think it is 
very important you marry that up as early as possible if you are going to 
get it to work [Translation].
(GL, P l/C Iinician involvem ent/Founder o f Spin-out, 2007)
GL describes his first-hand experience of working with clinicians on a cell-based 
product. GL’s team is responsible for what he calls the ‘upstream’ part, while the 
collaborating surgeons are addressing the ‘downstream’ challenges — that is, the ones 
closer to the actual delivery o f the therapy. In GL’s opinion it is important to ‘marry’
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basic research with clinical work ‘as early as possible’ to increase the chances o f a 
product’s success. Clearly, the input from the clinicians and surgeons who are familiar 
with the medical needs o f patients and will be applying the therapy is considered 
critical.
In the case o f one bioentrepreneur, geographical distance between the department o f 
biomedical research located in the university campus and the clinical department 
located approximately 20 miles away, added an additional degree o f complexity which 
eventually led to a termination of the bioentrepreneur/clinic synergy.
We worked with some clinicians in [Region] but we found it frustrating.
For one, it was geographically difficult and, o f course, their [clinicians’] 
interests are the patients. And we were getting tissues which were very 
inconsistent. It [collaboration] didn’t work at all, so we quickly dropped 
that. What you need to do is to have your clinician next door.
(RB, PI/Founder o f Spin-out, 2007)
RB admits that he found working with clinicians ‘frustrating’ for two main reasons: 
firstly, because o f the geographic distance and secondly, because o f a kind of ‘cultural 
distance’, suggesting that the clinicians have different priorities to the Pis and that the 
clinicians’ focus on patients needs was ‘interfering’ with P is’ priority o f getting 
consistent tissues necessary for research and subsequent product development. In 
other words, RB views ‘clinician culture’ as a barrier to the cross-disciplinary work, as 
he highlights the different interests o f his team and those of the clinical practitioners. 
His account echoes other social science studies o f RM Translational Research by 
Wainwright et al. (2006), who have explored some o f the key institutional differences 
that stem cell scientists perceive as affecting their interactions with clinicians. 
According to the authors ‘the scientists’ views o f clinicians reflect the scientific pursuit 
o f rigorous experimental research, and the more “black box” approach o f medicine, 
where improving patient outcomes is often seen as more important than unravelling 
mechanisms’ (Wainwright, et al., 2006: 2057). Yet despite underscoring these different 
‘cultures’ between clinicians and basic scientists (including Pis) RB goes on to mention 
the value of having the ‘clinician next door’ for ‘easy’ and timely feedback.
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The perception of a positive relationship between clinical input and the enhanced 
chance o f therapy adoption is further strengthened by the comments o f one 
bioentrepreneur active in the field of regenerative orthopaedics. QN  notes:
I think it has to make a difference for the clinicians. They are busy, and 
speaking from an orthopaedic perspective there are a number o f things 
that already work really well. In terms of what we are trying to do, it has 
to provide added value whether it’s quicker application, greater longevity 
or enhanced efficacy.
(Q N , PI/Founder o f spin-out, 2009)
For the clinician deciding to change the therapeutic product s/he is using and 
therefore the current practice, there must be a strong incentive present, such as better 
outcomes for patients or significant savings in terms o f cost. In certain disease areas, 
such as the one QN is working on, there are a number o f products and therapeutic 
strategies that are considered to ‘work really well’, hence the new candidate product 
must provide ‘added value’ and make a difference for both the patient and the 
clinician. The same investigator continues:
When you have a hip replacement it is usually — I should stress — not a 
life or death situation, so in that respect, yes, you want to make sure that 
if you are advocating a cell-based strategy that is certainly doing no harm.
There are lots of wonderful hip implants that work. So it’s not life 
threatening in that respect. So you have to be sure that there is really no 
harm and it is real added efficacy. And that informs what we do.
(Q N , PI/Founder o f Spin-out, 2009)
According to all my respondents, the majority of clinicians with whom they collaborate 
would be highly reluctant to adopt the emerging cell-based therapeutics unless their 
safety and efficacy have been sufficiendy proven. This is especially true for areas, as 
QN explains, where there are already a number of products that have been used for 
years and thus their safety and efficacy have been firmly established. This aversion to 
‘novelty’ and ‘uncertainty’, however, is normally less evident in disease areas and /o r 
patient cases where there traditional approaches have had a poor outcome.
262
Overall, collaboration with clinicians has been mentioned by all interviewees as being 
crucial to the product development process and providing unique competitive 
advantage. By closely examining the accounts of the bioentrepreneurs specifically on 
the theme o f bioentrepreneur (developer)/clinician interactions, I was able to observe 
three necessary ‘conditions’ in order for Regenerative Medicine Translation to occur.
As a first condition, the therapy/product must ‘fit’ into the current clinical practice. In 
other words, the application o f the ‘emerging product’ will usually be dependent upon 
an array o f complementary treatments which must have reached a point in their 
progress that allows the new product to be integrated in the ‘overall therapy’, ideally in 
a seamless fashion. If  the product is radically innovative there is the possibility (as in 
the case o f Dermagraft described later on) that it will be ‘ahead o f its time’ and 
consequently its adoption will be delayed until a better ‘match’ is achieved with the 
complementary therapeutic interventions. This ‘matching’ (or ‘treatment 
harmonisation’) process appears to be a longitudinal one as therapeutic interventions 
vary in their pace of progress and degree of innovativeness. This first ‘condition’ is also 
relevant to the notion o f individual clinician practice, as the more often the surgeon is 
applying the product the better he/she becomes at using it, the better the integration 
with the complementary treatments and thus the better the overall outcome. I term 
this condition ‘best performance practice’.
A second ‘condition’, closely related to the first, is that the product must be optimally 
designed in terms of meeting both the physical needs of the treatment (and therefore 
the patient) and the needs of the ‘users’ (physicians/surgeons/nurses) by becoming 
increasingly user-friendly through repeated redesigning and redevelopment. I have 
termed this ‘condition’ ‘best performance design’.
The third and final condition is related to what I have called ‘best performance timing’. 
For all autologous products and allogeneic products with a shelf-life (i.e. not 
cryopreserved)204, the application of the therapy must be perfectly coordinated with the 
health state o f the patient, which in many cases might change unexpectedly, hence 
rending the treatment unusable. Finally, by using the words ‘best performance’ I mean
204 C ryopreservation  is th e  m a in ten a n ce  o f  th e  viab ility  o f  ce lls , t is s u e s  and organ s by th e  p ro ce ss  o f  co n tro lled  co o lin g  and  
storin g at very  low  tem p e r a tu r e s  and  su b se q u e n t re-w arm ing.
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to show that there might be cases where two of the ‘conditions’ are fully satisfied and 
one is ‘underperforming’. In such cases the treatment might still go ahead but 
presumably the chances o f clinical success are lower compared to the scenario where 
all the conditions are fully met.
In the following section, I explore the bioentrepreneur narratives to reveal the 
interdependent nature o f these three ‘conditions’ and how they must all ‘converge’ in 
order for the cell-based treatment to be realised. At the end o f this, I construct a 
theoretical ‘braid’ model o f Translation which is specifically based on bioentrepreneur 
(developer)/clinician interaction.
A ‘Braid’ Model for Cell-therapy Translation?
Best Performance Practice’
A principal investigator, active in the wound-healing and burns field, is commenting on 
the importance of collaborating with surgeons to design and develop a product that is 
compatible with current clinical practice.
W ithout naming products, there have been tissue engineered products 
that were designed in the lab that were works o f art, but when you come 
to take them into the clinic it would have meant that clinicians had to 
change how they normally treated the patient, alter their practice. It was 
obvious that there wasn’t any clinical input into what sort o f product was 
needed. You got to have that user interface. If you make something that 
is a Rolls Royce but the clinician can, really, only handle a Mini, it is no 
good.
(LM, PI/Founder of Spin-out, 2007)
LM explains how crucial it is for the RM product under development to ‘fit’ with the 
way clinicians are used to working and the protocols they follow. Application of 
complex therapies such as RM therapies, require long and intense training so a product 
incompatible with the rest of the practice or significantly different from what clinicians 
have been using (even if more effective) will still meet resistance from the ‘users’.
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In addition to LM’s account above, a product example from the literature — 
Dermagraft — could also demonstrate the dynamics between product complexity and 
current clinical practice. Dermagraft, is a cryo-preserved human fibroblast dermal 
substitute approved for the treatment o f diabetic foot ulcers, once considered the 
poster child for failure in tissue engineering. Dermagraft was initially developed by a 
US company — Advanced Tissue Sciences (ATS) which, in the absence o f significant 
sales in 2001, started to cave in under the costs o f manufacturing and supporting its 
products. In 2002, ATS filed for bankruptcy and transferred all rights for Dermagraft 
to Smith & Nephew. Three years later, in 2005, when Smith & Nephew failed to gain 
FDA approval for the additional indication o f venous leg ulcers, Dermagraft, which 
had also been deemed very expensive and difficult to reimburse, was once again 
dropped. In June 2006, the product was acquired by a small company, Advanced 
BioHealing, who also bought the former ATS manufacturing facility and equipment, 
and employed most o f the former ATS employees. The company, who changed 
nothing from the manufacturing process (which was both GMP and FDA approved), 
managed to ship its first product to customers in February 2007.
According to David Armstrong, an American podiatric surgeon and researcher, most 
widely known for his work in the diabetic foot, amputation prevention and wound 
healing, Dermagraft has had so many ‘troubles’ simply because it has been ‘a product 
ahead of its time’. In the February 2008 issue o f Start-up magazine, and in a review 
article on Dermagraft,205 Armstrong was quoted on the reason why Dermagraft had 
not been able, during the ‘troubled’ times described above, to reach its clinical 
potential and its true market. He states:
Ten years ago, when this product was emerging, the standard of care was 
to put gauze on wounds, an unchanged practise for the last three 
hundred years. When this product and a couple o f others like it came on 
the market, it was a big change for a lot o f clinicians. But now there are 
basic tenets of care, like appropriate surgical intervention, appropriate 
relief of pressure and protection that are now being married with 
technology (David Armstrong, renown podiatric surgeon, 2008)
205 (Stuart, 2008).
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Therefore, in Armstrong’s view, it is the progress in the general standards o f wound 
bed preparation and consequent changes in clinical practice that are now fostering the 
uptake of products like Dermagraft and lead to their adoption by physicians and their 
commercial success.
A relevant key point emerging from respondents’ narratives, is that the efficacy of 
Regenerative Medicine therapies, in addition to being dependent on current standards 
o f care and routine clinical practice, depends heavily on the surgeons’ ‘surgical 
expertise’ (many interviewees, in fact, referred to the new successful therapies being 
transplanted as ‘regenerative surgery’). Indeed, Regenerative Medicine therapeutics 
famously differ from previous medicines such as biopharmaceuticals and small 
molecules in two ways: first, they involve living cells or tissue and, second, there is a 
closer connection between the clinical practitioner harvesting or administering the cells 
and the patients. As one interviewee points out, ‘the clinical application of these 
products is not science anymore, it is engineering’. In other words, because of the 
unique nature o f cell-based therapeutics, the more experienced clinicians and surgeons 
become on delivering them, the more successful the therapies will start to be. Notes a 
founder and Chief Scientific Officer:
First example o f cell therapies is organ transplantation. It works, it’s been 
around for 50 years now and it’s saved many, many lives. For example 
even this morning on the radio, you know, [Hospital Name] stopped 
doing heart transplants because the death rate’s gone up from one in ten 
to seven in 20. Hearts are still the same you know, the success rate of 
heart transplants is not because people have been getting better hearts.
It’s because people [clinicians] have been getting better at using 
[transplanting] them. And it’s the same in all cell therapies and it’s going 
to get more and more, that reiterative loop.
(NJ, C SO /Founder o f Start-up)
NJ uses the example o f organ transplantation to underline the crucial relationship 
between product and clinical delivery (application) in the case of cell and tissue-based 
therapeutics. Unlike pills and medical devices which are mass produced and ‘used’ 
(consumed) roughly the same way, RM therapeutics and their associated benefits
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depend highly on the skills and knowledge o f the person — clinician, nurse, or surgeon 
— who delivers them. This means that even in the case o f automating the entire 
production, possible with many types of RM therapeutics (albeit not all), there will 
often be the ‘variable’, ‘manual’ application.
This surgical expertise-dependent ‘variability’ is added to the risk-laden and provisional 
nature of cell therapies for whom the key to clinical utility lies in the ability (of 
scientists and clinicians) to proliferate cells (hESCs) down a specific differentiation 
path and retain control over that complex process in clinical applications. This is, as 
sociologists Eriksson and Webster (2008) from York University have argued, an 
attempt to deal with the ‘unknown unknowns’. According to Webster and Errikson 
(2008), differentiation down a pathway with known clinical utility is a different matter 
to standardising biomarkers (which they call ‘known unknowns’), it involves ‘dealing 
with uncertainties in vivo and will require considerable input from clinical scientists in 
monitoring as yet unknown effects o f the use o f hESC implants’ (Webster & Eriksson, 
2008: 108). In other words, the authors argue that ‘what goes on in the lab is never 
closed off, or finished even when encased in a black-boxed process or product’ and 
conclude that ‘the basic science in these cases o f differentiations and engraftment is in 
a sense unfinished and can only come to some sort o f closure by hanging on the coat 
tails of its applications’ (2008:109).
Best Performance (Product) Design
A second point that has emerged from the bioentrepreneurs’ narratives is the ‘value’ of 
a carefully thought-out, designed and ‘constructed’ cell-based product. The following 
interview extract provides a detailed account o f the series o f incremental innovations 
that take place while the product is being developed, clinically tested, and then re­
designed/re-developed to fit the patient’s needs and the requirements o f the surgeons:
[Product], our chronic wound care product, has gone through four 
iterations now. It’s still the same product as far as the regulators are 
concerned, which is amazing because it wouldn’t happen with a drug. It 
started out as little, little disks because for chronic wounds, surgeons take 
pinch grafts. I don't know if you know, they pinch the skin up and just 
cut it off. They take this little sliver o f skin and then pepper it all over
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the wound and hope that the skin grows out and covers it; and it works 
fine. So we thought we’ll make synthetic pinch grafts in a way. A little 
pot o f them [synthetic pinch grafts] and you can just pop them on [the 
wound]. That was the first one [design] and the problem was when you 
did that, they all fell off. So you had to dress it. You had to put them 
[synthetic pinch grafts] on and hold them horizontal while you put the 
dressing on which was awkward. So instead, we made just one big one 
[synthetic skin graft] in a big disk, put that on and it stays on. You can 
turn your hand upside down and the [Product] is stuck — it was too big. It 
was seven centimetres in diameter and they had to cut o ff some, so it was 
expensive and they [surgeons] were already thinking: “W e’re throwing all 
this really expensive stuff away”. So the next generation was five 
centimetres. It was in a flat pack so that the pack could hold it because 
it’s not solid, it’s jelly-like. If  it was in a tube, it would all wash up, 
because you’ve got to wash it and you’ve got to peel it out; and that again 
would be awkward. So it sits on the backing o f foil. The surgeon just 
opens it up, pops it on. That [design version] was really good. But when 
you would turn it upside down and you would be looking at foil, and 
you’ve got to try and remember where the wound is, and then all you see 
is foil. So the third generation is a clear, transparent thing.
(NJ, CSO /Founder of Start-up, 2007)
NJ describes in detail the way his company has been using the clinicians’ feedback to 
‘evolve’ their wound care product. His narrative is a fascinating example o f the process 
of refining a cell therapy in a mode not previously envisaged in the pharma and biotech 
industry. The step-by-step re-designing of the ‘physical’ product — although as he 
explains the actual properties remain fundamentally the same — is evidence of the 
clinical concerns and innovation being systematically incorporated towards a more 
user-friendly and ultimately more successful therapy. His account also proves that 
Regenerative Medicine product developers are very concerned about the various 
features of the product that can contribute to clinical uptake and therefore its success 
on the market.
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A similar ‘evolutionary’ process, echoing many o f the considerations addressed in N J’s 
description, has been responsible for the development of Dermagraft (Mansbridge, 
2006). Dermagraft has been developed and approved as a medical device. From the 
beginning, the design concept was to be an allogeneic, viable dermal replacement 
product with a long shelf-life (approximately 6 months). In addition to the standard 
cell and tissue-engineered considerations (such as pH  control, changing medium, and 
gas exchange) the designers o f Dermagraft also considered factors to make the product 
safe and easy to use by the treating physicians. Perhaps the most significant decision 
concerning these two aims, was the decision to make the bioreactor (i.e. the vessel in 
which the cells are grown) part of the final packaging thus avoiding post-growth 
handling of the product and minimising contamination. In addition to meeting all o f 
the clinician’s aseptic conditions requirements, the bioreactor ensures user convenience 
by opening in such a way that the product is well exposed and can be easily rinsed 
prior to application. Finally, as a further assistance to practitioners, the individual 
bioreactor pockets are translucent and accept ink, which means that an outline can be 
traced on them and a suitably sized piece o f the unit may be cut out. As a consequence 
o f its design concept, Dermagraft has also the potential for scale-up production and 
automation which are crucially important for commercial viability.
Both NJ’s account detailing the step-by-step development of his company’s wound 
care product and the Dermagraft ‘story’ as reported in the scientific literature, illustrate 
the same type o f process. A process o f constant communication between developers 
and surgeons, leading to a gradual readjustment o f the product’s physical dimensions 
and packaging until the ‘ideal’ design is attained.
Yet, as one would think that such a degree o f communication and ‘productive’ 
collaboration between UK developers and UK surgeons would be enough to translate 
the product to the market, in reality the Regenerative Medicine market presents further 
challenges. Indeed, as different countries follow different practical approaches to 
therapy for the same type o f problem, it is necessary for companies (and the founders 
and R&D groups behind them) that have international market aspirations, to tap into a 
diverse pool of clinical guidance and advice. This is the only way to create products 
that will satisfy a wide range o f therapeutic approaches and clinical protocols.
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From conversations with various stakeholders (as well as from my respondents) I 
reached the understanding that bioentrepreneurs engaged in academic clinical 
Translation will receive feedback and advice from their collaborating clinic (or 
clinicians embedded in the project as mentioned earlier). Non-academic RM 
companies, in turn, will usually have either a standard clinical advisory board or would 
seek to assemble ad-hoc, product- and /or region-specific clinical panels. One 
respondent explains the strategy followed by his (non-academic) RM start-up company 
when it comes to seeking clinical input for the design o f the product:
And it’s not just with the UK. We do it with Americans and U K  people 
and non-UK Europeans because medical practice is very different in kind 
o f those three areas. For example, I just met with someone yesterday, a 
surgeon, burns surgeon, for our [Product Name], the skin product. W e’re 
looking to use that for basal cell carcinoma removal. The standard 
practice in the UK is you cut it out and you let it go, just leave it. You 
know, it just contracts and heals up. Standard practice in Europe is to use 
flaps and try and close it. In the US they use grafts and flaps but they 
don’t just leave it. So if we just took the UK view of the world, we’d be 
producing a product that everyone else said: “W e don’t do it that way”.
So yes, we get a lot of feedback in from doctors, we have panels o f them.
We don’t have standard medical panels because we don’t want to. We 
want to keep going out in different areas, for different products and at 
different times, in order to get more input around what’s needed. And 
[this is how] the product changes.
(NJ, CSO /Founder of Start-up, 2007)
NJ explains how critical it is to have knowledge of the market (users) for whom the 
products are being developed. W hat is ‘standard practice’ in one European country is 
not necessarily followed in another. Therefore, it is crucial to engage with ‘users’ 
repeatedly, at ‘different areas’ (markets) and ‘at different times’ to ensure capitalising 
on the best knowledge available and targeting innovation.
Indeed, innovation is increasingly being viewed as a complex and iterative process of 
direct producer-user interaction, and users who have so far been confined to passive
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recipients of products are also being increasingly appreciated as reflexive actors, 
actively involved in the evaluation, modification, and sometimes even invention of 
products. In recent years scholars from many disciplines have emphasised the role of 
users in innovation processes in general, and in the biomedical innovation field in 
particular.206
Best-Performance Timing’
Even with the creation o f a product that is carefully designed to fit the ‘physical’ needs 
o f the clinical problem, be user-friendly and compatible with current clinical practice, 
RM therapy success is still not guaranteed. In addition to being dependent on the 
‘environment’ (i.e. current practice, clinicians’/surgeons’ skills, product design), many 
RM products, mainly autologous, are also time-dependent. In other words, autologous 
products must be delivered promptly and in perfect coordination with the patient and 
clinician needs (unlike the majority o f allogeneic products that can be stored, usually 
cryopreserved).
In the following quotation, a bioentrepreneur who is working on autologous epithelial 
grafts (autografts) describes the difficulties of working with them because o f their 
inflexible delivery schedule:
How we you used to do this is we take a small biopsy from the patient, 
we would grow the cells and then we would wait until they form an 
integrated sheet o f cells and then we detach the sheet enzymatically, put 
it on some backing dressing and deliver it to the patient. Now we could 
not deliver the cells until all the cells were joined together and formed a 
sheet and that took a minimum of 9 days. But then we had to use the 
cells within 3 days otherwise they would not attach to the patients. So in 
terms o f their useful shelf life it was a very, very difficult product to
206 The e n g a g e m e n t  o f  u sers (stak eh o ld ers) in m ark et-o r ien ted  sec to rs , su ch  as th e  p harm aceu tica l and m ed ica l d ev ic e  
industry, h as b een  sh o w n  in th e  literatu re to  h a v e  a ran ge o f  p ositive  e f fe c ts  for c o m p a n ies  and th eir  fu tu res . For ex a m p le , 
th e  ab ility  o f  co m p a n ies  to  k eep  track o f  th e  n e e d s  and  w is h e s  o f  u sers n o t  on ly  cou ld  e n h a n c e  th e  a d o p tio n  ra te  o f  th eir  
p rod ucts, but it cou ld  a lso  lead to  sign ificant m o d ific a tio n s  and im p ro v e m en ts , if th e y  m ak e u se  o f  th e  u ser's  'exp erien tia l 
k n o w led g e ' (C aron-Flinterm an e t  al., 2 0 0 5 ). C hatterji an d  co lle a g u e s  (2 0 0 8 ) , in turn , p rov id e  ev id e n c e  th a t  p h ysic ian s  
co n tr ib u te  to  m ed ica l d ev ic e  in n ovation . As th e  au th o r s  n o te , p ractising  clin icians re p r e se n t  an im p ortan t so u r c e  o f  
'extern al' k n o w le d g e  and in n ovation  as th e y  h ave th e  b e s t  insights regard ing u n m e t clinical n e e d s  and th e  c le a r e s t  s e n s e  o f  
th e  m o st fe a s ib le  so lu tion  to  a particular p rob lem . In v o lv em en t in activ itie s  such  a s  clinical trials and p rod u ct te s t in g  is o n e  
o f  th e  m ea n s  by w hich  clin icians can learn a b o u t th e  n e w  te ch n o lo g y . Their k n o w le d g e  is d erived  from  using th e  d e v ic e  -  
th e y  k n ow  w h a t is p rob lem atic , w hich  im p ro v e m en t w o u ld  b e  m o st critical, and w hich  so lu tio n s  are  p refer a b le  from  th e  
p ersp ec tiv e  o f  th e  en d  u ser  (i.e . p hysician s or p a tien ts  d ep e n d in g  on th e  ty p e  o f  th e  d ev ice ).
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manage. Because you had to fine-tune the production o f the cell sheets to 
be just right to the needs of the patient. And what used to happen is that 
we would make a plan...and I worked very, very closely with burn 
surgeons in [Hospital] for whom we were delivering the cells... and we 
would make a plan and we would set off to deliver cells to an agreed 
time-point. And then the patient’s condition would change and instead of 
the patient going to theatre Wednesday they would say “The patient has 
developed a fever, we cannot take him on Wednesday, we might take 
them on Friday, and is that ok? And I have to say, “N o it’s not ok, 
because the cells are now past the point at which they detach and there 
was not sufficient time for us to start again”. So basically, how we used to 
deliver the cells was very inflexible in terms o f the timing. Everything was 
about getting the cells to the right possible condition, but it was not a 
very good fit with the needs o f this critically ill group of patients whose 
condition could change day by day. So it became clear that we could not 
change the patients, so we had to change the product.
(LM, PI/Founder of Spin-out, 2007)
LM narrates in detail the process of producing autografts — from the mom ent o f the 
initial biopsy to the application o f the product. As mentioned earlier in the thesis, 
autologous therapies are based on the same donor—same recipient approach —meaning 
that a sample (biopsy) o f healthy cells are sourced from the patient, then expanded for 
a certain period (depending on the quantity of tissue/cells needed in each case) and 
then when ‘ready’, re-introduced to the same individual. The whole process, however, 
is crucially time-dependent and this is a feature that is ‘incompatible’ with some o f the 
conditions bioentrepreneurs seek to treat such as burns. The usual problem, as noted 
by LM, being an unpredictable deterioration o f a burn patient’s condition that may 
require rearranging the time o f surgery (application), and hence rendering the whole 
cell product unusable. N ot being able to guarantee a perfect fit between the 
state/quality o f the cells and the condition of the patients deems the whole approach 
‘inflexible’ and ineffective. Therefore the search continues for LM’s team to ‘change’ 
and improve the product as ‘it became clear that we could not change the patients’ and 
the unpredictable nature o f burns.
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LM’s account perfectly illustrates the critical relationship between a cell therapy 
product and the timing o f its delivery. In addition to being provided in a convenient 
format, autologous cells or autologous engineered tissue must be available to a 
schedule workable to the physician or surgeon. Sometimes it might be possible for the 
surgical team to access the status o f a patient’s bioprocessed material, and to try and 
schedule the application so as to gain maximum efficiency. In other cases, it might be 
possible for the bioprocess team to ‘slow down’ (e.g. by lowering the temperature) the 
growth of the cells in order to match the surgical team’s schedule or, more 
importandy, the patient’s condition. In cases where none of the above ‘time 
adjustments’ is possible, the autologous bioprocessed material exceeds its shelf-life and 
can no longer be used for treatment. A new biopsy will have to be taken and the 
bioprocessing will have to be repeated. Hernon et al. (2006) undertook a clinical audit 
o f cultured epithelial autografts (CEA) use in a burns unit in Sheffield and have shown 
that the extent of wastage between CEA production and delivery to patients was nearly 
fifty percent (Hernon et al., 2006).
Allogeneic therapies are subject to time restrictions too. With the exception o f cryo- 
preserved cell products that can be employed at a very short notice and be applied 
again soon after they thawed, most allogeneic therapies that have a shelf-life are subject 
to similar time limitations as autologous products. During a presentation o f his 
company’s translational milestones Geoff MacKay, President and Chief Executive 
Officer of Organogenesis, describes the challenges they faced in order to be able to 
ship their flagship allogeneic wound care product (Apligraf) to customers (clinics). 
Although, MacKay speaks on behalf o f a large RM company which has shipped more 
than 200,000 treatments so far, the process of reaching that stage does not differ much 
from LM’s account who is working in a small-scale academic setting. Both stories 
begin with a ‘time-dependent’ product and narrate the challenge o f fitting cell therapy 
supply around an unpredictable demand. Said MacKay:
And, you know, some o f the mundane things like “How do you get it 
from A to B in a reliable way?”, are things that we really had to get our 
heads around. Initially, we were shipping our product with 3 to 5 days 
shelf-life. So it would get to the clinic, but by the time it got to the clinic 
if the patient did not show up, if there was a snowstorm, if the doctor
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just chose not to treat because the wound wasn’t ready, it created anxiety 
on the side o f the customer. So what we wanted to do is we wanted to 
lengthen our shelf-life to go from 3-5 days to 10-15 days. But the issue is 
that the fixed variable is our release criteria. We can’t go to FDA and say 
we’ve decided that we want to have 90% • survivability instead o f 95%. 
Something had to change. [But] that is [release criteria] in stone. And so 
it’s really by getting a much better handle on controlling the environment 
that we can enhance the shelf-life of the product. And we looked at many 
different temperature ranges for the products and we were able to 
establish an exact temperature range where the shelf-life, the viability of 
the cells and the histology o f the cells would remain intact for 15 days, 
instead o f 5 days. The challenge was [that] there can only be a + / -  2 
degrees Celsius variation or that [cell viability] doesn’t hold [.. .]And so 
with that as a challenge, our process engineers were able to put together a 
really neat technology package. We went to NASA and we got really 
space-age technology — so we were able to accomplish that. And then the 
next challenge is “How you do it in an environmentally friendly 
manner?” And we’ve done the best that we could there. And also “How 
do you make it as small as possible?” because weight equals money and 
that [cost] just gets passed on. We want to become standard-of-care, so 
we have to drive down costs. So, you know, something as banal as a 
shipper has actually been a priority project for us. We are very pleased 
that we‘ve been able to demonstrate that you can get this [Apligraf] 
around the world.
(Geoff MacKay, Organogenesis, LRM N, 2008)
Like LM, MacKay explains the need to ‘p roo f product supply from unpredictable 
changes such as the fluctuating condition of the patient, the schedule o f the surgeon or 
even the weather. According to MacKay, the one thing in the production process that 
is ‘written in stone’ and has to remain stable is the release criteria, as approved by the 
Food and Drug Administration (FDA). The ‘fixed’ released criteria leave the 
developers with the challenge o f ‘adjusting’ the rest o f the product’s features to 
withstand delays. MacKay describes how Organogenesis’ process engineers 
experimented with different temperatures and how they sought advice and state-of-
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the-art ‘shipping technology’ from NASA in order to maintain a ‘target’ temperature 
that safeguards the cells’ viability to the point of delivery. Yet, all these adjustments 
must also be made in an environment-friendly and cost effective way. This way 
Organogenesis not only sustains a profile o f a ‘socially responsible corporation’, but 
also paves the way to become the standard-of-care by lowering production costs and 
establishing itself as an attractive option to healthcare payers. Both NJ’s description 
and MacKay’s account attest to the existence o f the third condition that has to be met 
in order for cell-based therapies ‘to perform their best’.
The challenge in Regenerative Medicine Translation lies in converting ideas and 
inventions into products that will eventually lead to improvements in patient care. 
However, as has been demonstrated by the many attempts to convert laboratory 
findings into Regenerative Medicine products, scientific strategies will not be 
effectively translated unless they agree with clinical practice and patient care. In other 
words, scientific and clinical strategies must be woven together in terms o f both 
specific outcomes and timelines. Drawing on the narratives o f bioentrepreneurs with 
regard to clinical collaborations and input in the phase o f product (prototype) 
development, I have shown that there are there three conditions that must converge in 
order for the therapy to succeed: ‘best-performance practice’, ‘best-performance 
design’ and ‘best-performance timing’. In cases where one of these conditions is absent 
or underperforms, the chances of therapy success are significantly lower and the whole 
Translation process is endangered.
Chapter Conclusion
This chapter provides a number of findings that contribute to a more textured 
understanding o f the role o f successful collaboration in RMT. While the factors 
influencing successful and unsuccessful collaboration identified by the 
bioentrepreneurs interviewed for this study do not point to any one single model of 
translation, they do help us to understand the priority issues in developing successful 
translational ‘culture’ from the point of view of those who are currently most 
intimately involved with the challenges defining this sector o f bio-innovation. 
Moreover, while many o f the themes in this chapter overlap with those o f other
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chapters, the theme of collaboration is revealed to have many specific features that 
would repay further qualitative study.
First, drawing on bioentrepreneurs’ narratives, I have identified a profound lack of 
people appropriately trained to support scientists, clinicians and budding 
bioentrepreneurs in their translational efforts. The need for this ‘layer’ of 
entrepreneurial people is clearly articulated in the narratives o f most interviewees, who 
also express their wish to ‘source’ these people from non-commercial entities to avoid 
any possible conflicts between what are perceived as the ‘profit-driven’ commercial 
approach to Translation and the more ‘outcome-driven’ approach followed by 
academia-based bioentrepreneurs.
My data also suggest that some bioentrepreneurs are more committed to the 
‘commercial’ part of Regenerative Medicine Translation than others. Although all 
interviewees were highly supportive o f the notion o f Translation the narratives reveal 
fairly different levels of commitment towards the practical activities involved and the 
‘additional’ skills that have to be acquired.
Another suggestion that emerges is that bioentrepreneurs are resentful of the way 
universities and TTOs manage intellectual property rights, which has a significant 
(negative) impact on RM translational collaborations. This ‘bad management’ is 
frequently linked (in the respondents’ accounts) to the fact that the ‘wrong’ and 
‘unqualified’ people are designing and guiding university policies. These people, who 
act from high-level administrative posts, are by definition disengaged from the actual 
Translation process and thus have no real sense o f how it should be promoted and 
facilitated. Such findings prompt a rethinking o f the way patents and material transfer 
agreements (MTAs) are managed, and at the same time provide recommendations 
about the way Translation might be better guided by ‘actors’ such as bioentrepreneurs 
who have been involved in all aspects o f the process and have displayed the necessary 
‘boundary-crossing’ skills which are critical for accumulating and successfully 
integrating all kinds of expertise.
It is also worth reiterating at this point why I have called my model ‘the braid model of 
Translation’: Drawing on the empirical data I identified three conditions that must all
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‘converge’ in order for RM to succeed: the first condition, which I called ‘best- 
performance practice’; the second condition called, ‘best-performance design’; and the 
third and final condition, ‘best-performance timing’. Ideally all three conditions would 
converge so that a cell-based product has the ‘optimum’ design, is compatible with the 
clinical practice and is also delivered in a timely fashion perfectly suiting the patient 
condition. It is important to note that the ‘model’ I have identified is not uniformly 
found across all RM therapies and products. The application o f the model is clearly 
most highly pronounced in disease areas where the patient’s condition is unstable and 
unpredictable and is limited to RM products/therapies that are autologous or 
allogeneic with a limited shelf-life.
Finally, caution is needed here: my research has explored the perspective of one group 
o f ‘stakeholders’ which, although central and critical, cannot fully capture or represent 
the entire ‘phenomenon’ of Translation. More specifically, the research cannot said to 
document all types o f interactions and collaborations between basic biomedical 
scientists, principal investigators, clinicians, and business professionals involved in the 
various phases of clinical and commercial Regenerative Medicine Translation. What it 
does provide, however, is a picture of the bioentrepreneurial ‘logics’ that characterise 
small Regenerative Medicine companies in the UK and the founders and the teams 
behind them.
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Chapter 7
Thesis Conclusion
Introduction
Understanding the process o f Translation is crucial to understanding Regenerative 
Medicine (RM) innovation. This research has explored the process of Regenerative 
Medicine Translation in the UK through the perspective o f bioentrepreneurs. It has 
addressed issues o f funding (Chapter 4), regulation (Chapter 5) and collaboration 
(Chapter 6) and related these to successful (or not successful) translational RM 
outcomes. Such matters are central to discussion about the development, application 
and commercialisation o f RM products and therapies both in the U K  and global arena. 
This thesis has also demonstrated how bioentrepreneurs in the UK  perceive and 
respond to the translational challenges and how they comprehend, negotiate and 
‘evolve’ their own role in the translational landscape.
Aim o f Chapter
In this final chapter, I first briefly summarise the contents o f the thesis. I then revisit 
the aims and objectives of this study as presented in chapter 1 (‘research questions’) 
and through briefly summarising the empirical findings I discuss the contributions of 
this PhD research to sociological research in the field of translational RM and to ideas 
and concepts of sociology in general. Afterwards, I reflect on the strengths and 
weaknesses of this study. In the two final sections, I highlight the implications of the 
study for future research as well as the implications for policy along with some 
tentative recommendations.
Brief Summary o f Thesis
This thesis began with the story of the first in the world stem cell-based tissue- 
engineered organ replacement as narrated by one of the scientists that took part in the 
‘breakthrough experiment’- Professor Anthony Hollander, a stem cell biologist from
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Bristol University, UK. Hollander’s presentation was accurately tided ‘Claudia’s 
Trachea: Lessons Learned for Future Regenerative Medicine Strategies’, a title which 
inspired me to do exactly what the professor’s presentation called for: use ‘Claudia’ 
story’ to identify and investigate the factors that appear to play the most critical role in 
the successful Translation o f RM technology. Indeed, three factors emerged from 
Hollander’s narrative — funding, regulation, and collaboration. These factors (which 
were also confirmed later on by the empirical data) served as the three ‘lenses’ through 
which my interviewees were asked to view Translation and share their experiences.
An explanation for my choice o f actors to study, namely RM bioentrepreneurs was 
provided in chapter 1. There are two main reasons behind this choice. First, in view of 
previous relevant research where I had the opportunity to interview other types o f RM 
stakeholder (including clinicians, basic scientists, bioengineers and industry 
representatives) I gained the impression that bioentrepreneurs are in possession o f the 
most wide ranging knowledge and skills on RMT. Second, their unique position and 
responsibilities between the laboratory, the clinic, a spinout company, and the industry, 
requires them to work across the ‘boundaries’ between disciplines and specialisations 
‘where most innovation happens’ (Leonard- Barton, 1995).
The importance of Regenerative Medicine as the new and promising treatment 
paradigm has been established in chapter 2. Indeed, RM is widely seen as the next 
major source of innovation in healthcare and it is applicable to numerous diseases and 
conditions, many of them currently incurable. They include genetic diseases, cancer, 
various autoimmune conditions, diabetes, renal failure, and spinal injury. In addition, as 
the population ages, age-related conditions such as stroke, cardiovascular and 
neurodegenerative conditions (Alzheimer’s, Parkinson’s disease), bone degeneration 
and type-2 diabetes become more common. As organs fail they need to be repaired or 
replaced and the potential for new medical breakthroughs that could improve the lives 
o f individuals is huge. Furthermore, as the result o f successful RM would be new 
therapies that offer a short course or a one-off treatment, the overall impact of 
decreasing the prevalence and the current treatment costs o f these diseases is 
potentially extremely large.
279
The UK has so far been considered to have a leading position in the RM fundamental 
research mainly attributed to the informed and open approach towards RM work that 
combines a strong ethical basis with informed regulatory policies as well as substantial 
basic research funding. However, as recendy identified in the Cooksey Review, the 
Translation o f major advances in laboratory science to successful healthcare 
innovations and consequently patient benefits remains problematic. In response to this 
‘diagnosis’, increasing amounts o f budgets and political willpower were dedicated to 
expanding the RM innovation field. The process of Translation became a significant 
component in this ambition.
In the second half of chapter 2, I have provided a detailed explanation o f the 
phenomenon o f Translational Research including the ‘meaning’ of the term and how it 
has been used in various health-related disciplines, its emerging status as a global 
priority, the inherent difficulty in quantifying it (rate), the numerous definitions and the 
frequent use of inconsistent nomenclature (in different contexts), as well as the barriers 
to TR that have been reported in the scientific, social and other relevant literature. 
Finally, I briefly described two related characteristic features of TR- complexity and 
non-linearity- that were important for understanding the empirical chapters, and 
introduced RM translational research which, according to many, rightfully holds the 
tide of ‘poster child’ for the phenomenon of TR.
In chapter 3 ,1 have provided a review o f the relevant social science literature and have 
positioned my own research and contribution. The chapter has two main sections: the 
first section I described sociological research in the area o f RM in general. Considering 
the large volume of research in the field of RM, I had to carefully choose to include 
those works that are meaningfully-related to my own research and would by some 
means offer a helpful insight into issues and themes relevant to my work. All these 
social science studies, although not direcdy addressing the phenomenon o f RM 
Translation, are nonetheless very important as both a source and clarification of 
sociological concepts and contexts that are useful when exploring the more narrow 
area o f RM TR.
The second section comprises a review of the social studies o f RM translational 
research (the so-called paradigm from ‘bench to bedside’). As both RM and TR are
280
considered nascent paradigm shifts in medicine it is no surprise that so far there are 
only a few social science studies that have sought to explore them. These studies have 
drawn on a variety o f concepts from various research traditions such as the sociology 
o f expectations, boundary work, regulation and standards, and ethics. To complement 
the sociological research described above I review recently emergent literature on what 
scholars have called ‘translational ethos’. The last area of sociological literature that I 
review (in Chapter 3) is the literature on ‘sociotechnical networks and heterogeneous 
engineering’ and is the research area where this study aims to contribute the most.
Chapters four, five and six present the empirical findings o f the research. The thesis 
concludes with chapter seven where theoretical arguments and empirical findings are 
weaved together to provide the answers to the research questions presented in chapter 
one and thus satisfy the objectives of this study.
Research Questions Revisited
As explained in chapter 3, the process of RM Translation has been at the forefront of 
sociological research since the development o f the first cell therapies and tissue 
engineering products. In most cases, the phenomenon o f Translation has been studied 
and understood in terms of various stakeholders’ perspectives including biomedical 
scientists, clinical practitioners, regulators and individuals working in the biotechnology 
or pharmaceutical industry. However, as it has been observed in the relevant literature, 
Translation is not a phenomenon that just happens. Against this background, this 
thesis set out to investigate the role of a specific group o f stakeholders- 
bioentrepreneurs- in the Translation process with a view o f understanding the 
phenomenon through the eyes of these very ‘central’ actors and identifying best 
practices that could assist in facilitating their work and hence the process o f 
Translation.
In order to clearly spell out the contribution of the study to ‘sociological research’ it is 
useful to restate the research questions and use them as a ‘scaffold’ on which to 
organise and present the empirical findings. The following four questions (and their 
sub-questions) constituted the focus of this research:
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1. H ow  is Translation being conceptualised and practised by 
bioentrepreneurs in the Regenerative M edicine field in the UK?
a. W hat are the key challenges (problems) that need to be overcome and 
at which stage of the Translation process?
b. How do bioentrepreneurs address each challenge?
2. What are the translational models that bioentrepreneurs identify?
(e.g. funding models, IP models, regulatory governance models, collaboration 
models)
3. What is the importance of the bioentrepreneurs* contribution?
a. What are the resources bioentrepreneurs need to employ (financial, 
human, etc) in order to lead the products/therapies through clinical 
and commercial Translation?
b. D o they relish their ‘coordinating’ role?
In order to answer the above questions, the thesis took as its starting point a 
‘sociotechnical network’ and ‘heterogeneous engineering’ approach on the RM spinout 
creation process that is integrating the social, individual, technical and economic 
dimensions. By bringing the theoretical arguments (Chapter 3) and empirical findings 
(Chapter 4, 5, and 6) together, answers to the research questions can now be put 
forward.
The Challenge o f Funding
One o f the main barriers identified by bioentrepreneurs as hindering RM Translation is 
the funding deficit for translational projects. As a response, my research has sought to 
unravel the origin and dimensions of this deficit as perceived by RM bioentrepreneurs 
who have made attempts to clinically and /or commercially translate promising 
laboratory outcomes. The main finding is that bioentrepreneurs attribute the profound 
lack o f translational funds to an incorrect understanding on behalf of public funders of 
what TR really involves and the subsequent misallocation o f supposedly ‘translational 
funds’ to what bioentrepreneurs claim to be basic (fundamental) RM research.
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In the absence o f successful public funding strategies and in light o f the widely shared 
feeling of TR funding uncertainty, I sought to explore the views of my informants with 
regard to the other two alternative sources of capital, namely venture capital and 
industry investments. My findings suggest that informants perceive venture capital as 
the least likely funding source for their RM translational activities. According to the 
majority o f the bioentrepreneurs in this study, venture capitalists have ‘closed their 
minds’ to early-stage investing (required by RM spinouts and small start-ups) and are 
looking for low risk and short-term investments (again not a feature compatible with 
the long-term development trajectory involved in RM therapeutics).
For few o f the informants the fall in the number o f available VC funding opportunities 
is a logical and expected consequence of a dent in the early RM companies track 
records caused by poor returns and the consequent bursting of the RM technology 
‘bubble’. In short, the perception that dominates amongst the informants in this study 
is that there is a serious shortage o f risk capital that can be accessed by RM spinouts 
planning commercial Translation. This restricts growth and hence threatens to 
undermine the UK’s position in the RM field compared to other countries (such as the 
US) where VC early-stage investing is a dynamic and strong part o f the economy.
Perhaps this profound lack o f risk capital is one reason why more ‘non traditional’ 
sources o f capital who are not so concerned with historic performance indicators, but 
can recognise the technology’s potential, have emerged and are being considered; for 
example, big pharma and, to a lesser extent, the biotechnology industry. Indeed, 
according to interviewees, the drug industry ‘is keener on stem-cell technologies than 
ever before’. Pharma’s interest however is not in using stem cell for developing 
replacement tissues. Instead, the wave of new partnerships recendy announced by big 
pharmaceutical firms aim to use stem cells as tools for the screening o f drug 
candidates.
The use of stem cell-based tools in conventional drug discovery programs is varied, 
but is based on the reproducibility of deriving clinically relevant cell types (as diverse as 
cardiac myocytes, sensory neurons, pancreatic progenitors, and so on) and using them 
to test the safety and effectiveness of candidate drug substances. The approach is often 
referred to as ‘disease in a dish’ model of Translation and it applies the pharmaceutical
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strength in the R&D o f small or large molecule projects to find novel therapeutics that 
modify endogenous stem /progenitor cell fate. Given the fact that the ‘disease in a 
dish’ paradigm is able to profit from the strength o f biopharmaceutical companies, the 
commitment to Regenerative Medicine based on combining drug discovery and stem 
cell platforms that is taking hold across the industry, appears not to be a surprise to 
bioentrepreneurs. However, the majority seem to believe that ultimately cell 
replacement therapies will start to become of particular relevance, as bio­
pharmaceutical companies move away from a focus on palliative treatment and seek 
opportunities in disease modifications and eventually personalised, custom-made 
replacement RM therapy.
At present, however, pharma’s involvement appears to be obscured, especially with 
regard to small academic spinouts, with significant factors comprising insufficient 
demonstration of efficacy, regulatory and safety concerns as well as lack o f familiarity 
with the complexity o f developing a cell-based product and the business model for 
commercialising it (including the ‘downstream’ challenges o f distribution, delivery, 
reimbursement).
It may well be that the funding strategies followed by UK research councils and 
biomedical research charities need reassessment. Indeed, it is probably a lack of 
understanding from both sides- the funders and the technology developers- about 
what translational research really involves and consequently how it could best be 
funded.
H ow  is the Funding Challenge Addressed?
Respondents admit to following a variety of funding strategies in order to transfer their 
findings from the laboratory to the clinic. These include trying to persuade public 
sponsors that their work is in the realm o f TR and creating the ‘right’ heterogeneous 
entrepreneurial team that will inspire trust to private funders and will attract the 
necessary resources. A few interviewees have admitted to considering the possibility o f 
changing their research agendas and focussing on the creation o f what they perceive as 
‘attractive’ products favoured by public (cell therapies) or private sponsors (e.g. cell 
based drug discovery tools).
284
W hat are the Translational Models that Bioentrepreneurs Identify?
Even in the presence o f abundant funding, it has proved difficult to translate the 
concepts and paradigms of RM into clinically successful procedures and, even more 
importandy, into commercially viable products or processes. Indeed, it is well known 
in the RM sector that after a great deal o f promise and hype in the early 1990’s (back 
then the TE industry), the industry failed to provide the anticipated novel products. 
Much o f the blame for this failure has been directed towards the business models and 
their slow response to the changing conditions including a product development 
trajectory that was far longer than originally envisaged. Even at this stage, no 
universally applicable business model has been identified for RM and as noted earlier 
in the thesis, this uncertainty has been partly blamed for many o f the difficulties still 
faced by the RegenMed industry. In the respondents’ accounts we can see a divergence 
o f views and practices with regards to business models.
First, there is a divergence of views dependent upon whether a venture should 
concentrate on cell therapeutics and follow a long-term Translation trajectory or 
whether it should focus on short-term (quick economics returns) business models such 
as those based on the development o f stem cell-based drug discovery tools. Informants 
mentioned various reasons to justify their choices including the preference shown by 
public funders for cell therapies, the potential for bigger returns and the importance 
for concentrating on a technology instead o f diversifying and risking becoming 
diffused. Overall however, no consensus could be reached among the 
bioentrepreneurs, which lends credence to my claim that there is probably no ideal 
business model for RM- at least at this stage- and that it makes sense for RM teams 
and companies to operate business models as diverse as the products they are 
developing and labouring to bring to the market.
Second, even among those who chose to develop cell therapeutics there was a 
divergence o f views dependent upon whether the future o f RM will be in the 
(allogeneic) product-based or (autologous) service-based industry. In the former case, 
allogeneic (universal) products could be supplied to healthcare facilities in a way similar 
to that for drugs or devices. In the later, we could imagine the commercial RM service 
operating within the healthcare facility, deriving cells from patients, expanding them, 
combining them with scaffolds (matrices, growth factors or other biomaterials and
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substances) in order to provide a customised service. Again there is no obvious 
consensus that emerges from the narratives. Some interviewees seem to be convinced 
that the allogeneic, off-the-shelf approaches will dominate as they represent 
technologies that are more comparable to molecular pharmaceuticals, hence is possible 
to envisage a similar production, quality assurance process and commercialisation. 
Others however are more convinced by the autologous, service based approach and 
doubt that in certain areas RM will ever survive commercially if it based on selling a 
product.
However, despite their beliefs about which business model is going to dominate, they 
all seem to be aware o f the ‘volatility’ of the sector and they also appear willing to 
‘change and adapt’. Indeed, bioentrepreneurs seem to be aware that changing business 
models, extending or often limiting their range o f candidate products, changing and 
expanding their scientific and technical expertise and even changing the content and 
direction of their research are all plausible scenarios that might become reality in light 
o f necessary ‘survival decisions’.
This pronounced divergence o f views seems to cut to the very heart o f the complexity 
and techno-scientific uncertainty that characterises RM science at this stage. Perhaps it 
is through further scientific and technical progress and breakthroughs that some o f the 
current challenges will be met and a few distinct, ‘safe’ and ‘tested’ business models 
will start to emerge from the hazy commercial landscape. It is perhaps then that 
sponsors will also become less cautious and more will eventually step in to support the 
ventures, Translation and hence the sector.
The Challenge o f IP
As commercial RM remains a paradigm in search of product success, one way to clear- 
up the ‘cloudy’ commercial landscape is to clarify issues of intellectual property rights 
and ownership. At the end o f Chapter 4, I have shown how bioentrepreneurs 
understand and approach intellectual property rights (IPRs) in the context o f research, 
product development and commercialisation.
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The two main IP-related issues that have emerged from the narratives include the 
freedom to operate in the RM field and the ability to protect their own work and 
exploit their ‘market exclusivities’. As it is the case with other types of small high-tech 
ventures, RM spinouts are based and centred on the development o f proprietary 
technology or know-how protected by patents which makes IP one of the key 
components in attracting finance.
Once more, informants’ views diverged depending on the type o f product under 
development and the type o f company through which they operate. In general, 
submitting ‘expensive’ patent applications and ‘eating’ from the spinout’s limited 
financial resources is perceived as problematic by academic-based founders, although 
views are different when it comes to larger RM start-ups (these can afford to submit 
patent application ‘as a precaution’ even for developments that are considered o f 
relatively litde importance in the current context of business goals). A few interviewees 
perceive the field- especially hESCs- to be particularly vulnerable to patent thickets, 
potentially ‘slowing down’ and skewing the overall development o f new products, in 
addition to dampening investor interest in commercialisation.
H ow  is the Challenge o f IP Addressed?
To avoid the high costs associated with patenting, respondents stressed the need to 
prioritize which patents are ‘critical’ for product development and must be protected 
and which patents will have to be ‘dropped’. Clearly, this is not an easy decision to 
make especially when the product is at the very early stages o f Translation and neither 
scientific nor technical aspects have been ‘stabilised’. One informant claimed to have 
avoided the ‘IP hurdle’ by avoiding the markets were the relevant patents hold.
W hat are the Translational Models that Bioentrepreneurs Identify?
The respondents mentioned two IP access systems that they think would facilitate 
access to IP by reducing the costs and inefficiencies identified above: patent pools and 
the already established (in the UK) SC4SM model. As described earlier (chapter 4), a 
patent pool is an arrangement between two or more patent holders in which the 
relevant patents are licensed jointly as a ‘package’. Obtaining a single license from the
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pool means that the licensee has access to all the IP covered by the patents in the pool. 
The UK-based SC4SM model described by one o f the participants, operates in a very 
similar way to patent pools based on managing the collectives rights o f all of its 
members, thus avoiding potential coordination failure among its members (and other 
‘external’ IP owners) and minimising high transaction costs usually associated with 
upstream/downstream licensing.
The Challenge o f Regulation
In Chapter 5 ,1 have shown how RM bioentrepreneurs deal with regulatory uncertainty 
during development and Translation of their products, how they actively contribute to 
the building o f regulatory infrastructure and finally what they perceive as the biggest 
regulation-related obstacles that need to be overcome before successful RM 
Translation is realised. In addition, the fact that I collected my empirical data in two 
different time points (before and after the seminal ATMP regulation) gave me the 
opportunity to compare perceptions and attitudes among the participants and how 
these have evolved during this very important period o f transition for the RM field. A 
number o f significant concluding points have emerged and are discussed below.
For the majority of the interviewees before the ATMP regulation came into force, the 
regulatory picture was cloudy. Informants were primarily concerned with the 
classification o f their products/therapies and appeared frustrated by arbitrary product 
classification and lack of harmonisation. This frustration and uncertainty apparently 
spilled over into regulatory authority jurisdiction and the perceived ‘duplication’ of 
work that seemed to burden and discourage translational efforts. All informants 
stressed the need for harmonisation and looked forward (albeit with caution) to the 
new (ATMP) regulations that were expected to clarify the classification criteria and 
streamline the route to approval.
I have also shown that regulatory compliance without guidance and appropriate 
infrastructure to support it is a significant burden to the bioentrepreneur community 
and the teams behind the ventures. With numerous new ‘discoveries’ every day the 
pressure to control them and safeguard the public has lead to an influx o f guidelines. 
Overall, the pressure to comply with the ever-changing regulation is sometimes seen as
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distorting the necessary balance between necessary regulation and the need for 
progress and innovation. It is not an exaggeration to say that regulation was seen by 
the (first round) interviewees, as yet another hurdle to overcome in addition to the 
scientific and technical challenges of product development.
How is the Challenge o f Regulation Addressed?
In a significant departure from other studies and other fields (e.g. pharma industry), 
bioentrepreneurs/developers in RM claim to play a decisive role in the shaping of the 
emerging regulatory landscape. Either through being involved in discussions and 
negotiations with regulators over the classification o f their candidate products (mainly 
before the introduction o f ATMP regulation) or providing input on the use, safety and 
effectiveness of manufacturing/automation equipment and protocols, the informants 
present themselves as ‘active shapers’ o f what is seen as ‘work-in-progress’ regulation.
In other words, the bioentrepreneurs in this study clearly confirm that they are far 
from passive recipients o f guidelines and protocols. On the contrary, they describe 
how they seek early collaboration with the regulators and how they ‘educate’ the 
regulators on the novel technologies. This kind o f ‘synergy’ between the ‘regulating’ 
and the ‘regulated’ (stakeholder) communities is perhaps unavoidable in such a 
scientifically and technologically revolutionary paradigm where the notion of expertise 
is virtually redefined everyday.207 In short, this co-shaping o f regulation that is 
welcomed by bioentrepreneur/developers and encouraged by regulators, indicates a 
more participatory approach and signals perhaps an age where bioentrepreneurs will 
have a more formal role in the regulation and, consequently, the regulatory policy 
formation process.
In the context o f RM Translation as a ‘network’, even the regulators are important 
suppliers of problems, knowledge and skills. On the one hand, product developers 
seek early communication with regulatory agencies and on the other hand, agencies 
send their teams to learn from developers in order to try and produce practical
207 Ind eed , in form an ts h a v e  draw n a tten tio n  to  occasion a l 'm istak es' o f  regu la tory  au th o r itie s  in a p p o in tin g  ad v isers- on  th e  
basis o f  th eir  p ro fess ion a l s ta tu s- b ut w h o  w ou ld  n o t b e regarded  as 'true exp er ts ' in f ie ld . T he overa ll p erc ep tio n  is th a t  th e  
recru itm en t o f  non e x p er ts  c lou d s th e  d ev e lo p e r-reg u la to r  com m u n ica tio n  and h e n c e  d e la y s  and  ev e n  e n d a n g e rs  th e  RM 
field .
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guidelines. Consequently, regulatory guidelines are ‘constructed’ as a collaborative 
effort in which ‘heterogeneous engineers’ from the RM company and regulators 
negotiate, experiment, and design. Since the respective competences o f RM developers 
and regulators are complementary, their collaboration represents a proper example of 
how heterogeneity may be achieved through institutional arrangements. Judging from 
the respondents’ narratives this ‘co-shaping’ o f regulation is no simple process of 
knowledge integration. Instead, it is presented as a series o f problem-solving 
negotiations in which different kinds o f knowledge are debated and checked and where 
the outcome also depends on the persuasive ability o f the ‘heterogeneous engineers’ 
(bioentrepreneurs) involved. As noted by one interviewee, in these early stages o f the 
RM science and industry the artifacts (in this case an automated manufacturing 
machine) which are being built are characterised by a substantial level o f flexible 
interpretation. In other words, in many cases, although the physical design of a 
technology may be stabilised (in the sense that there is a more or less fixed technical 
design), the applications may be negotiable. This flexible interpretation o f the fixed 
design means that ‘problems’ (standards, technical guidelines, reagents) will keep 
changing and what counts as relevant expertise and equipment is rather open.
W hat are the Translational Models that Bioentrepreneurs Identify?
Another important point to have emerged from this part o f the study is the existence 
o f a complex relationship between the type of product under development and the 
perception of a future regulatory approval that is either ‘easy’ or ‘difficult’ to achieve. I 
have shown that informant perceptions of an ‘easy’ or ‘difficult’ regulatory route are 
not straightforward- that is they are not simply related to the type of cells autologous 
or allogeneic used and the therapeutic approach followed but are also dependant upon 
the setting o f therapy production such as academia or industry. In short, academia- 
based bioentrepreneurs perceive autologous approaches as more manageable in terms 
of standard compliance and regulatory approval, while start-up founders who operate 
on a larger scale seemed to believe that because o f their ‘logistics’, allogeneic products 
‘make more sense’.
One more repeating theme to have emerged from the fieldwork and the only case 
where all informant views seem to have converged is the predictability o f animal
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models in RM TR. Indeed, although in other biomedical fields the debate is still raging 
about methods to evaluate the clinical relevance o f basic animal studies and whether 
and to what extent animal models can predict with sufficient certainty what will 
happen in humans, in the case o f the RM bioentrepreneur community, the verdict is 
unanimous. Animal models simply do not work. The disparity between animal models 
and human clinical trials in the RM field is perceived as insurmountable because of the 
‘special’ relationship between the cells, the host and the therapeutic outcome. 
Interviewees called for more guidelines and support in pursuing FIH experimentation, 
which they perceive as the only useful way to evaluate the cell-based therapies.
The Challenge o f (Effective) Collaboration
Bioentrepreneurs in this study expressed dismay .on stringent IP policies and claimed 
that universities, research sponsors and other translational entities such as hospitals, 
are increasingly seen to overestimate their IP assets. This, in turn appears to distort 
business decisions which nowadays are inextricably linked to decisions o f cross- 
departmental, cross-institutional and, perhaps m ost importandy, international 
collaborations. Therefore, one of the main conclusions to be drawn here is that the 
existing IP policies operated by many UK universities (as well as public research 
funders) are inhibiting valuable translational collaborations. Although it is legitimate 
for academic institutions to seek to capture some o f the economic value associated 
with an innovation (in the creation of which they have invested), it is equally important 
to be aware o f other issues too and evaluate them in a balanced way.
In the context of RM Translation as a sociotechnical system, the reverse salient 
(Hughes, 1983) is a useful concept for analysing overreaching IP policies. Although 
not a technical element (in line with the sociotechnical standpoint), IP policy is a factor 
(subsystem) of the system that appears to hamper the progress o f the system (through 
hindering translational collaborations, and hence Translation). Given the fact that 
reverse salients limit system development, the further progress o f the system lies in the 
correction o f the reverse salient, where correction can be attained through either 
incremental or radical innovation- in this case a review o f the IP policies. In the case or 
RM IP, the reverse salient refers to an extremely complex situation where individuals 
(biomedical researchers, patent holders, TTO executives), material forces (patents,
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material transfer agreements) and other factors, all have distinctive, causal forces and 
play their part in the process.
In addition to the IP-related hurdles, the different ‘cultures’ of biomedical researchers, 
clinicians and industry have also been mentioned by a few interviewees as a barrier to 
successful collaborations. For example, clinical practitioners work in different 
timescales to basic researchers and appear to have different (more patient focussed) 
objectives, whereas commercial sponsors such as venture capitalists and industry show 
a more risk averse funding attitude and a clear orientation towards products and route 
that will ensure lower costs and ‘quick- returns’.
How is the Challenge o f (Effective) Collaboration Addressed?
To overcome the hurdles placed by stringent and ‘unrealistic’ university IP policies, 
bioentrepreneurs feel they have to ‘argue’ the with university technology transfer 
offices about IP, potential collaborations and rules o f research contact. As informants 
claim, this is often a frustrating process and more often than not results in the 
cancellation of the collaboration.
Despite admitting to the ‘different culture’ hurdles, respondents emphasize that there 
are certain types of collaborations that lend credibility to the venture such as the 
involvement of business and clinical expertise. Especially clinical expertise are 
considered as the only way to ensure that the product under development is clinically 
relevant, which increases the possibility that it will be adopted by the clinical 
community. Additionally, many interviewees have suggested that the involvement of 
clinicians in the innovation team, makes it ‘easier to secure financial and other 
resources. N ot surprisingly then, bioentrepreneurs have sought strategies to ensure that 
communication/collaboration with RM clinical investigators is arranged early on in the 
therapy development process and that clinical advice is incorporated in the ‘design’ of 
the therapy. In short, as with the cases of successful ‘societal embedding’ (of a 
biotechnology product) where societal actors are given an early on constructive role, in 
RM ‘concurrent engineering’ is encouraged between product developers 
(bioentrepreneurs) and clinicians. In other words, clinicians are given a constructive 
role and hence the chance to contribute (early on) to the product development
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process; this includes contributions which signal difficulties and may lead to shifts in 
the design o f the product/therapy, up to decisions to halt the development altogether.
W hat are the Translational Models that Bioentrepreneurs Identify?
My findings suggest that there is some basis to the fear, often voiced by the critics of 
university industry relations, that salient IP-related obstacles impede translational 
collaboration in the RM field. Furthermore, like any large and diffuse organisation, it is 
difficult to identify (let alone intervene and change) how decisions are made within a 
university and this, according to interviewees, makes IP negotiations a time consuming, 
unpredictable and often frustrating process. Thus, a key message emanating from the 
informants’ accounts is that less emphasis must be given to monetary returns and more 
emphasis on operating an IP system that does not ‘frighten o ff  potential collaborators 
and, therefore, weakens future prospects of the bioentrepreneurs’ efforts.
At the last section of the chapter six (‘The Art of Collaboration’), I contemplate a 
translational model based on what is perceived as the most important type of 
collaboration for Translation- that is the collaboration o f bioentrepreneurs/developers 
with clinicians. Drawing on data from the interviews and the literature it is not difficult 
to see that a number o f ‘conditions’ must converge in order for clinical Translation to 
be realised. To some extent the ‘translational model’ I identify de-privileges the 
‘empowered’ position o f bioentrepreneurs in the Translation process by involving a 
level of external and uncontrollable factors. In short, according to the model, apart 
from the optimal product design and the optimal product delivery, there is one more 
condition to be met- the product must ‘agree’ with current clinical practice. This 
condition is largely out o f the product developers’ control. I t is perhaps what happens 
in the case o f radical innovations in biomedical practice where it may take some time 
before they are adopted by clinicians and their benefits realised.
W hat is the importance o f the bioentrepreneurs’ contribution? (Research 
Question 3)
W hat are the resources bioentrepreneurs need to employ (financial, human, etc) in 
order to lead the products/therapies through clinical and commercial Translation?
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Chapter 6 commences with the perceived lack o f ‘Research Translators’ currently 
available in the UK and in the RM field in particular. Research Translators are defined 
by the Medical Research Council (MRC) who created both the post and the term, as 
cross-disciplinary individuals with experience and skills in ‘facilitating the Translation 
o f basic research finding into tangible health benefits’. The suggestion that emerges 
from my data is that, in the absence o f such qualified individuals, RM bioentrepreneurs 
like the ones interviewed for this study, are ‘encouraged’ to assume the ‘knowledge 
broker’ role that is so critical in achieving successful Translation outcomes.
If  the process o f RM Translation can, in fact, be depicted as a sociotechnical network 
(as described by Hughes and Law), then bioentrepreneurs are the creators o f this 
network- the system builders and the heterogeneous engineers. The concept o f 
‘heterogeneous engineering’ has been coined by John Law (who was inspired by the 
work of Michel Callon and Bruno Latour in actor-network theory ANT). While the 
term ‘engineering’ as it is used in (ANT) may be best described as ‘getting to work’, the 
adjective heterogeneous emphasises that this ‘getting to work’ takes hybrid manoeuvres 
mixing and coordinating people and things.
As stated earlier, RM bioentrepreneurs (often) assume voluntarily the role o f 
‘heterogeneous engineer’ in order to steer their findings through the process o f 
Translation. According to MacKenzie (1996) and his discussion of Seymour Cray as 
the ‘charismatic engineer’, invention is the bringing together of many resources and 
building of heterogeneous networks. Brilliance, charisma or great leadership is in 
placing oneself at the front of these networks.
RM bioentrepreneurs are builders of Translation networks and do ‘heterogeneous 
engineering’. It must be emphasised, however, that (in this case), the outcome o f 
heterogeneous engineering is not only the RM product that is developed. Even more 
importantly, it is the creation of the ‘Translation network’ itself. In other words, for 
successful (therapy) Translation bioentrepreneurs must simultaneously build artifacts 
and the environments in which those artefacts can function. In fact, (at least) in the 
case o f RM Translation neither of these activities can be done on their own.
Law’s networks and Hughes’s (sociotechnical) systems bundle many different actors 
and resources together. System builders need scientific and technical knowledge but
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they also need financial, material, and social resources. For network creators, nothing 
can be reduced to only one dimension and technology requires heterogeneous 
engineering of a dramatic diversity of elements (Bucciarelli, 1994; Law, 1987). In  the 
same way, successful RM Translation draws on multiple types o f resources and 
simultaneously addresses multiple domains. The scientist-turned-entrepreneur faces 
scientific, technical, social (legal, regulatory) and economic obstacles all at once and has 
to bind solutions to these problems together in a configuration that ‘works’. To do this 
s /he  must also enrol any number o f actors, not all o f whom may be immediately 
compatible (with the rest of the network).
N ot surprisingly, large-scale heterogeneous engineering (like the one necessary for 
Translation) is difficult (Law, 1987). Law’s network approach stresses this by noting 
that ‘there is almost always some degree of divergence between what the elements o f a 
system would do if left to their own devices and what they are obliged, encouraged, or 
forced to do when they are enrolled within the network’ (Law, 1987: 114). In short, in 
Law’s scenario, ‘the environment within which a network is build may be treated as 
hostile, and heterogeneous engineering may be treated as the association o f unhelpful 
elements’ (1987:114). This description fits well with the narratives of bioentrepreneurs 
who have mentioned the interaction with actors who have different cultures (e.g. 
clinicians), different objectives (e.g. universities seeking to maximize return on 
investment), different reward structures (e.g. VCs attracted by short term returns), and 
regulators (interested in maintaining public trust in the regulatory system).
Given that heterogeneous engineering is a difficult task it is interesting to have 
unravelled a variety of attitudes towards performing it. Indeed, my data suggest that 
some bioentrepreneurs are more committed to this ‘operational part’ of Translation 
than others. Indeed, a variety of different commitment levels have emerged ranging 
from what I have termed bioentrepreneur ‘enthusiast’ to the expression o f a very 
hesitant or even dismissive attitude toward translational endeavours, especially those 
that involve the creation of commercial entities such as academic spinouts or small RM 
start-ups. However, even when including the cases o f the few informants that 
expressed their reluctance toward creating a company, the founders that I have 
interviewed, are indeed what I would call ‘above the average’ entrepreneurial, 
displaying ‘networking’, ‘organising’ and ‘integrating’ skills.
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The Contribution o f the Thesis to Concepts and Theories in Sociology 
In the previous sections, I drew the main threads from approaches (theories) on 
sociotechnical systems (Hughes, Law, Callon, MacKenzie) and applied them to the 
study o f RM Translation. This is not to say however that all concepts and ideas from 
these approaches have been utilised. Only those that seemed to provide the most 
fruitful analysis for comparison and insights for the study of RM Translation were 
chosen. In this section, I summarise the findings from the comparison and spell out 
the contribution of my work to concepts and theories in Sociology (particularly the 
social study of networks/sociotechnical systems).
As I have already mentioned in chapter 3 (in the description o f the theoretical 
framework), I consider the process of RM Translation as an example of what Thomas 
Hughes calls a sociotechnical system. The core ‘element’ of the system is the RM 
product/therapy under development as well as the network itself. Five more ‘elements’ 
o f the network exist around this core element namely- regulation/regulatory bodies, 
public sponsors (research councils, charities), commercial sponsors (VCs, industry), 
academia/biomedical researchers, clinic/physicians.
Similarly to technological systems that can be hampered by reverse salients, Translation 
networks are also plagued by them. Drawing on the respondents’ narratives a number 
o f reverse salients can be identified: for instance, stringent university and sponsor IP 
policies which hinder translational collaborations and increase the cost of research and 
development. By maintaining these policies as part of the network, the whole system’s 
output performance is compromised. A similar threat may be seen in the case o f the 
ever-changing regulatory guidelines. The continuous effort to comply with the 
guidelines consumes valuable resources and holds the system back from attaining that 
higher output performance.
In this study, the creators o f the network- the heterogeneous engineers and the system 
builders- are the scientists-become- entrepreneurs. The main argument of the thesis is 
that there would be no successful clinical or commercial RM Translation if it was not 
for the ‘weaving’ and mobilising o f bioentrepreneurs and the subsequent creation of 
their heterogeneous networks. So, in this view, the task o f sociology is to characterise 
these networks in their heterogeneity, examine the interactions between the various
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actors (and if and how these interactions are mediated) and finally, explore how it is 
that they come to be patterned to generate effects like organisations, standards, 
legislation, alliances, patents and therapies.
Overall, the thesis aimed to make a contribution to our understanding o f the work of 
the bioentrepreneurs as key actors in the Translation process and the ‘heterogeneous’ 
factors that critically shape the Translation process itself. The study is unique in 
integrating a story about these factors into a single narrative and it highlights a number 
o f important policy lessons that could help further refine the process o f Translation in 
this promising area of biomedicine.
Implications o f Research for Policy
Several policy implications of this study have been identified. In the following 
paragraphs, I summarise the views of respondents on what they perceive as the biggest 
hurdles for RM Translation in the UK and I make a few recommendations for 
overcoming them.
Increasing Dedicated Funding for RM TR
From the interviewees accounts there is no question that the UK biomedical science 
excels in basic RM research. Inside the community o f bioentrepreneurs there is a 
strong conviction, however, that greater levels of funding have to be dedicated 
translational research especially for the support o f animal studies, early-stage human 
experimentation and clinical trials. Moving their work from the lab bench towards 
prototypes, to a larger and faster scale and ultimately patients is proving extremely 
difficult hence discouraging many scientists from entering the field altogether.
One possible solution, would involve funding agencies across the discovery- product 
development continuum expanding existing interagency partnerships and establishing 
new ones. Given the different priorities (and missions) o f research (e.g. councils, 
charities) versus application sponsors (NHS), limited resources are available from all 
parties. Hence collaborative development of investment priorities (in the field of TR) 
and pooling resources may be the only way to ensure that an adequate investment is
297
made in the critical area o f RM TR. In other words, setting aside what is currendy been 
seen (by bioentrepreneurs) as competing agendas will enable biomedical research 
sponsors and service funding agencies to develop coordinated translation programs 
thus integrating research with practice. Furthermore, such funding 
arrangements/schemes will ensure that the novel products being developed are actually 
informed by lessons learned from basic research as well as medical practice.
Changes in University and Funder Intellectual Property (IP) Policy 
Although all respondents agree that patents are important in attracting private sector 
investment, the majority have also drawn attention to the negative impact university 
and sponsor IP policy can have o n , building research and industry translational 
collaborations in the field o f RM. More specifically, bioentrepreneurs have criticised 
the emphasis given by universities and funders on legal contractual agreements for the 
exchange/sharing o f scientific materials and reagents and believe that they are slowing 
down the pace o f Translation, discouraging researchers from collaborating, and 
constraining the freedom o f small enterprises (such as university spinouts) from 
operating.
The need to improve the management o f IP by both universities and sponsors has 
been identified by all informants. Universities, research funders and clinical services 
providers (NHS) must address the issue by collaboratively drawing guidelines that will 
both ensure acknowledgement in downstream research and protection o f the 
inventors’ rights but at the same time avoid excessive rights of ownership in research 
results and /o r demanding agreements that are overreaching and overprotecting (based 
on the fear o f losing financial returns even when perceived as improbable by 
inventors/bioentrepreneurs themselves). This way, all relevant parties (universities, 
hospitals, firms) will save time and resources and will be able to concentrate on the 
development of much needed therapies.
Addressing Regulatory Uncertainty
Prior to the introduction of the ATMP regulation, regulatory uncertainty both in terms 
of regulatory agency jurisdiction and product development guidelines was identified as 
one o f the main hurdles for RM Translation. Bioentrepreneurs reported a desire within
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their community for greater overall clarity regarding the current legislation, guidance 
and standards to be used. The interviewees felt that there was a need for greater 
standardization and harmonisation in scientific and technical areas that would endure 
fair classification o f products and avoid unnecessary delays and costs in the 
development and approval o f products. Apart from the perceived lack o f standards 
and manufacturing guidelines, part o f the uncertainty was also based on the role of 
regulatory agencies such as the HTA, HFEA, MHRA, and EMA and the overlap of 
their regulatory jurisdictions.
Development and introduction of the ATMP was welcomed by these key members of 
the RM community and it was anticipated to make researchers and developers feel 
more reassured about the clinical and commercial Translation o f RM therapeutics. 
However, bioentrepreneurs interviewed after the ATMP regulation came into force, 
although satisfied with the introduction of formal and comprehensive guidelines they 
admitted to being concerned about the potential differences in interpretation of the 
guidelines as well as the enormous effort required to comply with the new regulation.
In order to address the concerns of bioentrepreneurs (and other stakeholders), 
regulatory agencies such as MHRA, HTA, HFEA and EMA must provide clear 
guidance to the RM community across the whole spectrum including the process of 
research, development, trials and commercialisation/approval o f cell therapy products. 
This not only requires to identify regulations and guidelines and link them to the 
corresponding stage o f therapy production but to provide the bioentrepreneur 
community with the essential resources (documents, financial resources, personnel) 
that will expedite the Translation process.
Fostering Collaborations between RM TR Stakeholders
All respondents acknowledged the importance of fostering effective collaborations 
between the various ‘spaces’ of Translation- academia, clinic, industry, regulators. As 
mentioned previously this could be facilitated through establishing collaboration 
schemes with shared/combine funding and by more efficient management of 
university IP.
299
All bioentrepreneurs agreed that collaboration with clinicians is especially important 
as it increase the chances of the product being correctly designed and developed hence 
minimising costs and increasing the possibility that it will be adopted for use when 
finalised (that is its efficacy and safety proven). Thus, early on collaboration with 
clinicians should be encouraged through schemes that cross institution and national 
borders with the aim to acquire the most relevant and up-to-date clinical input.
Employing ‘Research Translators’
Crucial to fostering collaboration during Translation is the role o f ‘research translators’ 
as piloted by the MRC. According to bioentrepreneurs, research translators that are 
adequately trained and experienced in the process could promote the understanding o f 
what TR really is, therefore changing the various cultures across the Translation 
spectrum, and could also be the crucial link between TR funders, basic researchers and 
product developers. This will not only take the ‘knowledge brokering’ load o f the 
shoulders of bioentrepreneurs but it will also speed up the process and avoid costly 
R&D and commercialisation errors. These research translators which would (ideally) 
be appointed in common by sponsors, academia and the clinical community, could 
create ‘Knowledge Brokering Networks’ (or Networks of Translation’) that will 
enhance communications and collaboration between UK universities, spinout 
companies, NHS and the industry.
Formalising the Role o f Bio entrepreneurs in Policy Shaping 
Bioentrepreneurs are at the forefront o f Translation and have the skills and knowledge 
to facilitate the process. According to their accounts, their role is critical for successful 
translational outcomes especially through what they see as ‘active shaping of relevant 
regulation’. Policy makers should seek to exploit this valuable resource o f expertise by 
formalising the role o f bioentrepreneurs in building regulatory guidelines. This is 
especially important in the short term as the introduction and training o f the ‘research 
translators’ will take time and the call o f the RM community for help in this area is 
rather urgent. Furthermore, the importance of having the ‘right’ people at the right 
‘post’ has been noted by many participants who have also claimed that it is often the
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case that non-experts are employed and instead of facilitating the process they ‘end up 
clouding the regulatory issues even more’.
Strengths and Limitations o f Thesis
The previous sections identified key factors that promote or prevent the progress of 
RM Translation in the UK and explored the dynamics o f the Translation ‘network’ 
aiming to promote the development and commercialisation of RM therapies. It 
concluded by outlining some policy recommendations.
Against the general lack of systematic data analysis supporting theoretical arguments 
about the area of RM Translation in general, this thesis succeeded in putting forward a 
conceptual framework substantiated by empirical evidence for describing and analysing 
the process o f RM Translation in the UK. Its focus on bioentrepreneurs provided a 
perspective that has not been fully explored before.
Following on from the thesis strengths above, it could be seen as limitation that only a 
small-scale theory was developed. A PhD thesis does not provide the scope or 
resources to raise this very specific theory to a more generalised level such as for 
example a formal grounded theory. This conceptual framework also remains to be 
validated by other researchers working in other contexts (e.g. other countries). These 
new contexts would also provide opportunities to refine the methodological approach 
adopted by this study and to assert its trustworthiness.
As mentioned earlier, the findings and analysis o f this study are based on a limited 
number of respondents. Teams o f researchers, as opposed to a single one, would be 
able to engage with more participants, collect more data and engage in a more ‘varied’ 
and perhaps precise analysis and interpretation. The additional data resulting form such 
studies would indeed enrich the corpus of narratives and would enable the 
development of a more robust substantive theory.
Finally it needs to be remarked that the author of this study was relatively new to using 
grounded theory methodology when conducting this research project. Thus, it could 
be seen as a limitation that considerable time and resources were spend on reading
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literature about GT methodology and learning how to analyse data. Nevertheless, the 
research process- data collection and analysis- has been a very valuable experience that 
will be o f assistance in carrying out similar future projects.
Directions For Future Research
As the work for this thesis progressed, a number o f areas deserving future research 
revealed themselves. In particular, one way to extend the research would be to look 
into the similarities and differences between the two main empirical sources used in 
this study- that is the 14 interviews and the three observations o f talks from the 
LRMN. Additionally, the LRMN provides an archive o f its presentations throughout 
the years (in audio format) so there is the possibility for further data collection. More 
could also be made from the various informal discussions that I have had over the 
years at this LRMN meetings and the notes that I have kept regarding bioentrepreneur 
and other stakeholder statements.
One way to explore these data would be to ‘use’ Hilgartner’s ‘Science on Stage’ study208 
which provides an insightful and useful approach to understanding the production of 
science advice by bodies like the American National Academy of Science. In his study, 
Stephen Hilgartner employs Goffman’s dramaturgical theory as the framework for his 
analysis o f three National Academy Committee reports on diet and health. In short, ‘by 
creative use of the metaphor of the theatre, Hilgartner examines the production of 
science and advice and reveals the social machinery involved in its production. He 
views science advice as a form of drama, and reports, recommendations and criticisms 
o f science advice as performances. He makes the case that expert authority is 
constituted through strategic impression management and very deliberate control over 
what is displayed publicly and what is concealed from the audience’ (Dersken, 2001 :pgs 
n/a).
Hilgartner’s methodological approach and the metaphor o f frontstage and backstage 
could prove very useful as RM is a nascent biomedical field (and nascent industry) and 
as such it is especially dependent on expert advice. Exploring the process by which the 
advice is produced, contested and maintained would shed light into decision processes
208 H ilgartner, S. (2 0 0 0 ). S cien ce  on S ta g e :  E xpert A d v ice  a s  Public D ram a. S tand ford , CA: S tandford  U niversity  Press.
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that often remain deliberately hidden from view and are thus little understood. 
Comparing the personal account of bioentrepreneurs given at the interviews with talks 
or presentations (of the same individuals) at a LRMN (or other Translation-relevant) 
meetings, would provide social science with an insight about the degree (if any) of 
enclosure and disclosure o f information in the RM field and the role that it plays in the 
shaping o f knowledge and advice, and subsequently the effect in the shaping o f the 
trajectory o f the RM field (including scientific, technological, economic, social, ethical 
and legal aspects).
Another way to examine the data could utilise the literature on the dynamics of 
Translation as examined by several authors including Alberto Cambrosio and Bourret 
and colleagues in the context o f oncology and cancer genetics. In particular, Pascale 
Bourret and colleagues (2006) examine the founding and development o f a French 
bioclinical collective- the Groupe Genetique et Cancer (GGC)- that coordinates and 
structures the activities of most French actors in cancer genetics and operates 
simultaneously in the clinical, research, and regulatory domains. The authors are 
interested in understanding the development o f hybrid biomedical collectives (such as 
GGC) whose activities bridge the research, clinical, and regulatory domains, thus 
raising epistemic issues that are intimately connected to the evolving material and 
organisational arrangements that characterise these collectives. ‘Within these collectives 
a heterogeneous set o f actors interacts in a number o f ways by establishing flexible 
collaborative arrangements at the national and international level. These interactions 
give rise to novel practices, engendering and regulating the human [...] and nonhuman 
[...] entities mobilised by bioclinical activities’ (Bourret et al., 2006: 432).
According to Bouret et al (2006), ‘collaborative networks offer a strategic empirical 
starting point for the investigation of new biomedical developments that avoids the 
twin pitfalls of focussing only on research, strictly defined, or on clinical work, looking 
instead at the alignment between these activities and at the role played by regulation in 
this respect’ (Bourret, et al., 2006: 457). As the authors emphasize, when they speak of 
new biomedical collectives they refer to more than simply team work within hospitals. 
In their view, biomedical collectives (such as the GGC in their article) ‘cannot be 
equated to a mere lobbying institution or a learned society since it obviously engages in 
collaborative research activities leading to joint publications, nor can it be reduced to a
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research network since its activities bridge clinical and laboratory work; the GGC has, 
moreover, become a policy actor by producing guidelines and regulations that have 
been officially endorsed. The group, in other words, structures and channels its 
members’ activities by simultaneously producing the (regulatory) environment within 
which it acts’ (2006:457) .The notions of biomedical collectives and collaborative 
networks as described by Bourret et al. (2006) fit well with the phenomenon o f RM 
Translation and might be useful in examining the emerging role o f bioentrepreneurs as 
‘co-shapers’ o f regulation.
Although heterogeneous maps allow Bourret and colleagues (2006) to inspect the 
constitutive dynamics o f the GGC as a sociotechnical network, there is at least one 
im portant way in which it differs from my analysis and that is scale. Single RM 
spinouts and start-ups navigating the Translation process do not have the scale of the 
GGC. Perhaps as a next stage the analysis presented in this study could be expanded 
to include the activities o f national networks and consortia focussing on RM 
Translation and commercialisation such as the LRMN which in essence brings all types 
o f stakeholders in contact with one another and thus gives the opportunity to 
bioentrepreneurs to form their own (so far mainly) informal networks.
Apart from the above research directions, many o f which will require additional data 
collection and further examination of the relevant literature, a short term plan to build 
onto this study would be to create an executive summary of the thesis and request the 
feedback o f the study’s participants. How do participants think o f the questions and 
their own answers now? What do they think about the answers o f other respondents 
and were they what they expected them to be? Have they been through important 
changes (for example: does the company still exist, have their roles evolved, and have 
they managed to clinically or commercially translate any products/therapies, etc.). Such 
an approach will give me the opportunity to identify which issues examined in this 
thesis are still at the forefront of UK RM Translation (as experienced by 
bioentrepreneurs), which issues have been ‘solved’ and which are those key issues that 
have started to emerge and would require immediate addressing by all stakeholders 
including sociologists studying the field o f RM.
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Concluding Words
This research concludes that at present in the UK, in the absence o f adequate 
institutional support, bio entrepreneurs are central to the ‘mission’ o f Regenerative 
Medicine Translation and that they have assumed the critical role of weaving the 
translational ‘web’. In other words, bioentrepreneurs are seen to use a variety of 
means, routes and ‘combinations’, which according to them are the most appropriate, 
for achieving the desired translational outcomes. These bioentrepreneurial ‘strategies’ 
involve getting therapies to the clinic in an uncertain economic and regulatory climate, 
providing therapy development and manufacture input and helping shape the emerging 
regulatory infrastructure, and creating small companies that have the potential to be 
the vanguards in the ‘art’ of RM Translation.
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Appendix 1
List of Interviewees
Coded
Initials Brief D escription of Role(s)
S i- i  t4'- 2007 1
1 NC PI/CSO/Founder of Spinout, 2007
2 M PI/CSO/Founder of Start-up, 2007
3 GL Pi/Clinical Involvement/Co-founder of Spinout, 2007
4 RB PI/Founder of Spinout, 2007
5 LM PI/Founder of Spinout, 2007
6 ME
U fM
'mS^KSSBS^m
Pl/Co-founder of Spinout, 2007
7 QN PI/Founder of Spinout, 2009
8 HR
Pl/Clinician/Co-founder of Manufacturing Facility, 
2009
9 EJ Pl/Co-founder of Manufacturing Facility, 2009
10 RG PI, 2009
11 MF PI/Clinician/Founder of Spinout, 2009
12 XB PI/CEO/Founder of Start-up, 2009
13 LK PI/Clinical involvement/Founder of Start-up, 2009
14 ZL
PI/Clinician/Licensor of RM technology through an 
independent Start-Up, 2009
Appendix 2
LSE
London School o f Economics and Political Science 
BIOS Centre for the Study of Bioscience, Biomedicine, Biotechnology
and Society
Informed Consent to Participate in a Research Study:
"Regenerative Medicine Translation:
The UK Bioentrepreneur Experience"
A. PURPOSE AND BACKGROUND
R e g en e ra t iv e  m ed ic ine ,  t is sue  engineering ,  and  stern cell te ch n o lo g ie s  a re  e m erg in g  as 
po ten t ia l ly  revo lu t ionary  n e w  w ays to  t r e a t  d isease  and  injury, w ith  w ide  ranging  medical 
bene f i ts .  Successful o u tc o m e s  of  this re se a rch  d e p e n d  n o t  only on  clinical viability a n d  
sa fe ty ,  b u t  also on  com m ercia lisa t ion .  H ow ever,  co m m erc ia l  r e g e n e ra t iv e  m ed ic ine  (with 
t h e  e x c ep t io n  of  a few  t i s su e -e n g in e e re d  p roducts)  is still in an early  y e t  critical phase .  In 
th e i r  e f fo r ts  to  deve lop ,  p ro d u c e  and  d is t r ibu te  th e ir  p ro d u c ts  b o th  in s t i tu tions  an d  
p r iva te  b io tech  c o m p a n ie s  s tu m b le  across  f ru s t ra t ing  and  po ten tia l ly  crippling o b s ta c le s  
t h a t  ref lec t  b o th  t h e  con trovers ia l  n a tu re  of  this  r esea rch  a n d  th e  u n d e r d e v e lo p e d  n a tu re  
o f  t h e  T ransla t ion  p rocess  itself.
W hile  a g re a t  dea l of  a t te n t io n  has b ee n  o r ie n ta te d  to w a r d s  'e th ica l '  issues, th e  ro u te  to  
successfu l  t r an s la t io n  involves m any  o th e r  a re a s  such as funding, regu la t ion  an d  quality  
con tro l .  This s tu d y  a im s to  identify  th e  key fac to rs  t h a t  a ffec t  t h e  p ro ce ss  of T ransla tion  
a n d  com m erc ia l isa t ion  of  R egene ra t ive  M edicine  p roduc ts .  The re se a rc h  will be  a s tu d y  
b e t w e e n  UK universi ties and  th e i r  RM com m erc ia lisa t ion  e f fo rts  an d  will be  d o n e  mainly 
by in te rv iew s w ith  RM b io n e n t r e p r e n e u r s  to  gain an  u n d e r s ta n d in g  of  t h e  T ransla tion ,  to  
d e t e r m in e  c u r r e n t  prac tices  in th is  a re a  and  also to  d o c u m e n t  th e i r  e x p e r ie n c e s  of  th e  
jo u r n e y / t r a n s f e r  o f  ce ll-based  re sea rch  f rom  th e  bench  to  t h e  m a rk e t .
The r e se a rc h e r ,  Lamprini Kaftantzi,  is a doc to ra l  s tu d e n t  a t  BIOS.
B. PROCEDURES
If you  a g re e  to  pa r t ic ipa te  in th is  s tudy, t h e  following will occur:
1. You will be  in te rv iew ed  for app rox im ate ly  1 h o u r  by th e  p ro jec t  r e s e a r c h e r  a b o u t
th e  th e m e (s )  desc r ib ed  in Section A of th is  form.
2. The in te rv iew  will be reco rded  with a digital voice r e c o rd e r  to  e n s u re  accuracy
in rep o r t in g  yo u r  s ta te m e n ts .
3. The in te rv iew  will ta k e  place a t  a t im e  and  place c o n v e n ie n t  to  you.
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4. You will be sent a copy of the transcript to correct or modify.
5. The researcher may contact you later by e-mail to clarify any interview answers.
C. CONFIDENTIALITY
The research data will be kept in a secure location and only the researcher will have 
access. Upon the agreement of the participants the researcher would prefer not to 
anonymise the data as it will make the research findings more informative and valuable to  
the target audience. However, in the case of a participant wishing to preserve his/her 
anonymity, all identifying information will be removed.
D. QUESTIONS
You have spoken with the researcher about this study and have had you questions
answered. If you have any further questions about the study, you may contact the
researcher by e-mail at l.kaftantzi@lse.ac.uk.
E. CONSENT
You have been given a copy of this consent form to keep. The signed consent in this study 
will confirm that you agree:
1. To be interviewed by the project researcher at a time and place of your choosing;
2. To allow the researcher to transcribe the interview and to copy relevant 
documents or other material that you may provide her/him  with;
3. To use these materials in publications subject to the following conditions (please 
add or delete as appropriate):
A. That during the interview you may indicate any topics on which you 
do not wish to be publicly quoted or transcribed;
B. That you will be sent a transcript of the interview to correct or modify 
before it is used for any research purposes;
C. That you retain the right to restrain access to all of the materials you 
provide, in whatever manner you see fit;
D. That you can withdraw portions from the interview at any time;
E. That you may terminate the interview at any time.
Subject to the above conditions, I give my consent to points 1-3.
Signature of Participant: Date:
Signature of Researcher: Date:
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A ppendix 3
List o f Interview Questions 
-BACKGROUND-
1. If you could please tell me briefly about your positions and background
Basic Researcher/ Clinician/ Head of trials/ Translational Investigator/ 
Bioentrepreneur/ Founder
2. What do you understand by the term Regenerative M edicine ‘Translation* 
and how do you relate your work to that?
3. What are the projects/ applications that you are currently developing?
(allogeneic/ autologous, limitations, process)
-Focus on TRANSLATION-
4. What would you say are the main challenges in product/therapy  
development? (or in other words, the Translational challenges o f the 
field?)
Scientific/ Technical Challenges — including manufacturing and scale-up 
Regulatory Challenges/ Business Challenges in Product D evelopm ent/ IP Challenges 
(ownership issues)
5. What do you think the UK needs to do in order to improve the process of 
Regenerative Medicine Translation?
(for example, what kind of policy interventions would improve the general outcome 
for the field?)
-FUNDING-
6. What kind of funding is most important for your work during the R&D and 
Translation phase?
NHS /  Research Council (Research grant)/ Regional Development Agency/ Venture 
capital/ Industry investments/ Combination
7. H ow  did you ‘go about* raising the capital?
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-COLLABORATIONS-
8. RM is a very cross-disciplinary field. What collaborations do you have 
and what form do these collaborations take?
Academic/ Industry collaborations (Pharma, biotech)
Clinical/ Regulatory, National/International collaborations
9. D o you feel that there are any barriers in these types o f collaborations?
(knowledge, culture, ethics, IP)
-REGULATION-
10. H ow  would you describe the current RM regulation in the UK?
D o you think it facilitates or impedes innovation?
11. H ow  would you describe your experience with regulatory requirements? 
Have encountered any specific issues? If so what kind o f issues?
12. Which regulatory agencies do you communicate with?
13. D o you have the chance to give feedback to the agencies on the 
Regulation? (panels, committees, etc.)
14. What is your opinion about the EU  attempts o f standardisation and 
harmonis ation?
15. What is your experience with G M P/A T M P/E U  TCD compliance? D id you 
find it challenging?
-IP-
16. What is your opinion on patenting in RM? D o you think it enhances or 
inhibits innovation?
-COMPANY-
17. H ow  would you describe your role in the creation o f the company?
-UNIVERSITY/TTOs-
18. Have you had any contact/collaboration with the T echnology Transfer 
Office (for the purposes of translation)? If yes, what is your 
experience?
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